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Background: The National Institute for Health and Care Excellence recommends the use of generic
preference-based measures (GPBMs) of health for its Health Technology Assessments (HTAs). However,
these data may not be available or appropriate for all health conditions.
Objectives: To determine whether GPBMs are appropriate for some key conditions and to explore
alternative methods of utility estimation when data from GPBMs are unavailable or inappropriate.
Design: The project was conducted in three stages: (1) A systematic review of the psychometric properties
of three commonly used GPBMs [EQ-5D, SF-6D and Health Utilities Index Mark 3 (HUI3)] in four broadly
deﬁned conditions: visual impairment, hearing impairment, cancer and skin conditions. (2) Potential
modelling approaches to ‘map’ EQ-5D values from condition-speciﬁc and clinical measures of health
[European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30
(EORTC QLQ-C30) and Functional Assessment of Cancer Therapy – General Scale (FACT-G)] are compared
for predictive ability and goodness of ﬁt using two separate data sets. (3) Three potential extensions to the
EQ-5D are developed as ‘bolt-on’ items relating to hearing, tiredness and vision. They are valued using the
time trade-off method. A second valuation study is conducted to fully value the EQ-5D with and without
the vision bolt-on item in an additional sample of 300 people.
Setting: The valuation surveys were conducted using face-to-face interviews in the respondents’ homes.
Participants: Two representative samples of the UK general population from Yorkshire (n = 600).
Interventions: None.
Main outcome measures: Comparisons of EQ-5D, SF-6D and HUI3 in four conditions with various
generic and condition-speciﬁc measures. Mapping functions were estimated between EORTC QLQ-C30
and FACT-G with EQ-5D. Three bolt-ons to the EQ-5D were developed: EQ + hearing/vision/tiredness.
A full valuation study was conducted for the EQ + vision.
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Results: (1) EQ-5D was valid and responsive for skin conditions and most cancers; in vision, its
performance varied according to aetiology; and performance was poor for hearing impairments. The HUI3
performed well for hearing and vision disorders. It also performed well in cancers although evidence was
limited and there was no evidence in skin conditions. There were limited data for SF-6D in all four
conditions and limited evidence on reliability of all instruments. (2) Mapping algorithms were estimated to
predict EQ-5D values from alternative cancer-speciﬁc measures of health. Response mapping using all the
domain scores was the best performing model for the EORTC QLQ-C30. In an exploratory analysis, a
limited dependent variable mixture model performed better than an equivalent linear model. In the full
analysis for the FACT-G, linear regression using ordinary least squares gave the best predictions followed
by the tobit model. (3) The exploratory valuation study found that bolt-on items for vision, hearing and
tiredness had a signiﬁcant impact on values of the health states, but the direction and magnitude of
differences depended on the severity of the health state. The vision bolt-on item had a statistically
signiﬁcant impact on EQ-5D health state values and a full valuation model was estimated.
Conclusions: EQ-5D performs well in studies of cancer and skin conditions. Mapping techniques
provide a solution to predict EQ-5D values where EQ-5D has not been administered. For conditions
where EQ-5D was found to be inappropriate, including some vision disorders and for hearing, bolt-ons
provide a promising solution. More primary research into the psychometric properties of the generic
preference-based measures is required, particularly in cancer and for the assessment of reliability.
Further research is needed for the development and valuation of bolt-ons to EQ-5D.
Funding: This project was funded by the UK Medical Research Council (MRC) as part of the MRC-NIHR
methodology research programme (reference G0901486) and will be published in full in Health Technology
Assessment; Vol. 18, No. 9. See the NIHR Journals Library website for further project information.
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Scientiﬁc summary
Background
Generic preference-based measures (GPBMs) of health-related quality of life (HRQL) are commonly used in
the economic evaluation of health interventions. They provide a multidimensional description of health
that is combined with survival to generate quality-adjusted life-years (QALYs). To enhance comparability,
the National Institute for Health and Care Excellence (NICE) prefers the use of one of the GPBMs, EQ-5D,
for measuring HRQL. This report addresses a number of important methodological issues arising from the
use of GPBMs in NICE decision-making. It describes a series of studies undertaken to address the key
questions of how to determine whether a GPBM is valid for use in calculating QALYs, what to do when
the GPBM is not available (and speciﬁcally the use of ‘mapping’ or ‘cross-walking’ techniques to predict
EQ-5D values) and what to do when the GPBM is found to miss important components of HRQL for a
speciﬁc condition through the use of a new approach using ‘bolt-on’ dimensions.
Objectives
l To examine the appropriateness of three GPBMs of HRQL [EQ-5D, Health Utilities Index Mark 3 (HUI3)
and SF-6D] for vision loss, hearing loss, skin disorders and cancer.
l To compare alternative methods for mapping from condition-speciﬁc or clinical measures onto EQ-5D,
and to conduct exploratory analysis of the incorporation of uncertainty in the predicted estimates.
l To estimate mapping functions for use by researchers and policy-makers in conditions in which the
EQ-5D has been found to be appropriate.
l To explore a new method for measuring HRQL in patient groups in which a generic measure has been
shown to miss important dimensions (‘bolt-ons’).
l To estimate the impact of three ‘bolt-on’ dimensions on the value of EQ-5D health states.
l To estimate a new value set containing one of the EQ-5D bolt-ons and compare it with a value set
without the EQ-5D bolt-ons.
Methods and results
Study 1: a systematic review of the performance of generic
preference-based measures of health in four disease areas – visual disorders,
hearing impairments, skin conditions and cancer
Methods
A systematic review of the literature was conducted for three GPBMs of HRQL: EQ-5D, HUI3 and SF-6D.
Search strategies included free text and controlled terms. The following electronic databases were
searched: BIOSIS (1969 to 2010), Cumulative Index to Nursing and Allied Health (CINAHL) (1982 to 2010),
Cochrane Library comprising the Cochrane Database of Systematic Reviews (CDSR), Cochrane Central
Register of Controlled Trials (CENTRAL), Cochrane Methodology Register, NHS Economic Evaluations
Database (NHS EED) (1991 to 2010), EMBASE (1980 to 2010), MEDLINE (in process and non-indexed to
2010), PsycINFO (1806 to 2010) and Web of Science (1900 to 2010). Relevant websites were also
searched. For inclusion, the studies had to report dimensions and/or index values and another measure of
HRQL or clinical severity to allow an assessment of validity. Searching was completed in August 2010.
Performance was assessed in terms of (1) construct validity, the extent to which the measure differentiated
between groups deﬁned according to severity (known group) or a weaker test of differences between
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people with and without the condition (case–control); (2) convergent validity, the strength of association
between the EQ-5D and other measures of HRQL or clinical severity assessed using correlation coefﬁcients
or statistical signiﬁcance and regression methods; (3) responsiveness, the extent (size and statistical
signiﬁcance) to which EQ-5D shows change where change has been observed using other HRQL or clinical
measures; and (4) reliability, the extent to which the EQ-5D shows no change where no change in health
has been observed using other measures.
Results
Visual disorders
Most of the 31 studies considered in this review found a worsening of utility values as visual impairment
increases. Most evidence was found for the EQ-5D. Nearly all studies found signiﬁcant differences between
patients with the condition and a control group without it. Studies comparing EQ-5D scores across severity
groups were more mixed, with most ﬁnding little or no difference between groups deﬁned by clinical
measures of visual impairment. No studies reported evidence on reliability for any of the measures.
Three studies only allowed assessment of responsiveness and these identiﬁed changes consistent with an
effective intervention, but differences were statistically signiﬁcant in only two of three studies. The
assessment of convergent validity was more concerning, with several studies not demonstrating a
statistically signiﬁcant correlation with clinical measures. While there was less evidence for the HUI3, all but
one study demonstrated good validity and no studies assessed responsiveness. There was very limited
evidence on the SF-6D.
Hearing impairment
Of the 18 studies found in the review, the HUI3 was the most commonly used measure. In all six cases
that used the HUI3, this measure detected differences between groups deﬁned by their severity and
statistically signiﬁcant changes were detected in ﬁve out of six cases as a result of intervention. Differences
picked up by the HUI3 were driven by the hearing dimensions, and, in some cases, the speech and
emotion dimensions. The ﬁndings suggested relatively poor responsiveness of EQ-5D in this condition as in
four out of ﬁve cases it failed to detect change. A study suggested it only had weak ability to discriminate
differences between severity groups. Only one study involved the SF-6D; thus, the information is too
limited to conclude on its performance. No studies reported evidence to allow an assessment of reliability
for any of the measures.
Skin diseases
Out of the 16 papers found, there was evidence to suggest the EQ-5D has good construct and convergent
validity and responsiveness in skin disorders. All six studies reporting data for groups deﬁned according to
severity showed EQ-5D was able to reﬂect differences between groups and only one was not signiﬁcant.
EQ-5D was able to signiﬁcantly differentiate patient and general populations in four case–control
studies (one study did not report statistical tests), as well as groups deﬁned by non-severity. Moderate to
strong correlations were found between EQ-5D and other measures. Nine out of ten studies demonstrated
that the EQ-5D measure was able to detect change appropriately over time, and, among them, only one
study was not statistically signiﬁcant. Most of the studies included patients with psoriasis or psoriatic
arthritis. No studies reported evidence for HUI3 and SF-6D, and no studies reported evidence on reliability
for any of the measures.
Cancer
Ninety-eight studies were found across 20 different types of cancer. Most evidence was found for the
EQ-5D and the results were, overall, satisfactory. The majority of studies found signiﬁcant differences in
EQ-5D values between patients with various cancers and a control group. In most cases, the EQ-5D
differentiated between severity groups, although the differences were not always statistically signiﬁcant.
Correlations between EQ-5D and other measures were mixed. In terms of responsiveness, overall EQ-5D
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scores or dimensions were able to detect appropriate change over time points, but sometimes the change
in scores was small or not statistically signiﬁcant. Evidence on the performance of EQ-5D varied in different
types of cancer. There was some limited evidence of reliability for the EQ-5D, but most studies had not
been speciﬁcally designed to assess reliability. There was evidence to support the ability of the HUI3 to
differentiate between severity groups and between patients with or without cancer. The responsiveness
of the HUI3 was also found to be satisfactory but evidence of reliability was mainly limited to assessments
of inter-rater reliability. Few studies reported evidence to allow a judgement to be made on the validity,
reliability or responsiveness of the SF-6D.
Study 2: mapping from cancer-specific measures to EQ-5D – a comparison
of methods
Methods
The aims of this study were to estimate mapping functions from two cancer-speciﬁc HRQL measures, the
European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30
(EORTC QLQ-C30) and Functional Assessment of Cancer Therapy – General Scale (FACT-G), for estimating
EQ-5D and to test the applicability of different mapping approaches that have been used in the literature.
In particular, the analysis aimed to provide comprehensive information on how to select the mapping
function and incorporate information on uncertainties around the predictions. Ordinary least squares (OLS),
tobit model, two-part models (TPMs), splining models and response mapping models were used and an
illustrative analysis using a limited dependent mixture model for a selected FACT-G model was also
conducted. We used a range of criteria to identify the most appropriate mapping functions including mean
absolute error (MAE), severity groups and shrinkage. Analysis for the FACT-G instrument was based on
530 patients with various cancers and the EORTC QLQ-C30 was based on 771 patients with multiple
myeloma (MM), breast cancer and lung cancer.
Results
The mean observed EQ-5D value for the FACT-G data set was 0.722 [standard deviation (SD) = 0.224],
ranging from –0.135 to 1, with 17% of participants reporting full health. For the sample with EORTC
QLQ-C30 data, the mean, range and per cent in full health was 0.57 (SD = 0.35), –0.594 to 1 and
11% respectively.
Based on the range of criteria used, response mapping using all the domain scores was the
best-performing model for the EORTC QLQ-C30. This was followed by OLS and tobit model, both of which
were based on signiﬁcant item-level models. Results for the FACT-G showed OLS gave the best
predictions, followed by tobit model, with both based on item-level models. Response mapping and TPMs
gave the poorest predictions. The limited dependent variable mixture model (LDVMM) performed better
than an equivalent linear model in an exploratory analysis.
Generally, both OLS and tobit models using item levels gave some of the best estimates for EORTC
QLQ-C30 and, for FACT-G, produced the most reliable models. Response mapping worked best for the
EORTC QLQ-C30 functions but did not perform well for the FACT-G. This is because the FACT-G data set
did not cover the full range of severity on both the EQ-5D scale and FACT-G; therefore, the mapping
functions for this measure should be used only in non-severe populations.
Different selection methods for choosing the best model are currently used in mapping studies and can
result in selecting different models therefore a range of criteria should be considered. We used criteria that
were common across the different modelling techniques to select the best models. Further work is
required on the most appropriate criteria to use in model selection.
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Study 3: a new approach to dealing with inappropriateness – developing
‘bolt-on’ items to EQ-5D
Study 3a: testing the impact of three ‘bolt-ons’ to the EQ-5D methods
Three ‘bolt-on’ dimensions were developed following the systematic review of the performance of the
EQ-5D. Two were developed in conditions in which EQ-5D was shown to be problematic: hearing and
vision. A third was developed in fatigue, since this has been raised as a problem area in cancer (although,
overall, EQ-5D was found to be satisfactory for cases of cancer). The description of levels follows the
approach used for EQ-5D (‘no problems’ as level 1, ‘some problems’ as level 2 and ‘extreme problems’ as
level 3). Three core EQ-5D health states were selected for valuation covering a range of severity: a mild
state, a moderate state and a severe state. To each of these states, three levels of the extra dimension
(with severity levels of 1, 2 or 3) were added, resulting in nine EQ-5D states for each bolt-on. The three
core EQ-5D states without the bolt-ons were also valued, plus another six EQ-5D states. A valuation survey
was undertaken using a sample of the general public in South Yorkshire, UK, using face-to-face interviews
and the time trade-off (TTO) method. Individuals were allocated into four groups – three groups each
valued one of the bolt-on variants and one group valued EQ-5D with no bolt-ons.
Mean values for each bolt-on health state were compared with the corresponding core EQ-5D state using
paired t-tests. Regression analyses were used to further examine whether any differences between the
groups could explain any potential differences between the values for the bolt-on states. Random effects
(RE) models were used to take account of the clustering of data by respondents.
Results
Three hundred interviews were successfully completed, evenly split (n = 75) across three groups valuing
each of the three bolt-ons and a group valuing EQ-5D alone. The characteristics of the groups were well
balanced with the exception of fewer people in the group allocated to valuing the EQ + vision reporting
current problems with vision.
Each of the bolt-on items had a signiﬁcant impact on at least one EQ-5D health state. The extent and
direction of the impact of the bolt-on varied according to the severity of the bolt-on and the state to
which it was added. Adding a level 1 bolt-on to a mild state had no impact, but adding more severe levels
led to lower values. Adding a level 1 or 2 bolt-on to the moderate state led to higher values, but was only
statistically signiﬁcant for the level 1 hearing bolt-on. Adding a level 3 bolt-on to the moderate state led
to statistically signiﬁcant lower values for the vision bolt-on. Adding a level 1 or 2 to the severe state
has little impact or increased the health state values, though not signiﬁcantly. Adding level 3 to the severe
state reduced the value, but not signiﬁcantly. The severe state had the highest SDs associated with the
mean values and so the comparisons had the lowest power. The regression analysis conﬁrmed that
the differences in characteristics did not have a signiﬁcant impact upon the valuations.
Study 3b: estimating the impact of a vision bolt-on to EQ-5D valuation model
Methods
The aim was to examine the impact of the vision bolt-on on EQ-5D health state values and the overall
model parameters. A valuation study was undertaken using face-to-face interviews to obtain TTO values
from members of the general public in South Yorkshire, UK. Half of respondents valued health states
described using the EQ-5D plus vision bolt-on (EQ-5D + vision), and for comparative purposes, half of
respondents valued EQ-5D states without the bolt-on. An orthogonal design of a six-dimension three-level
instrument included 18 states, most of which were severe. Starting from these, 20 health states each for
EQ-5D + vision and EQ-5D were selected for valuation, including two mild states. The set of EQ-5D states
consisted of the same EQ-5D + vision states but without the vision bolt-on item. Two RE models were
estimated for both instruments separately. TTO values were regressed on dimension or level models and
coefﬁcients for each of the ﬁve EQ-5D dimensions were compared for the two models using z-values.
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Results
Three hundred people completed the interviews and 3120 TTO values were obtained. The two groups
valuing EQ-5D and EQ-5D + vision were comparable in terms of age, gender, education, and health status.
The results indicate that the inclusion of a vision bolt-on has a statistically signiﬁcant impact on the
valuation of EQ-5D health states. As with the exploratory analysis, the results suggest a somewhat complex
relationship between the bolt-on and EQ-5D. Health states with a level 3 (extreme) vision problems
included are unsurprisingly lower than the corresponding EQ-5D health state; however, the values given to
severe EQ-5D states are higher if ‘no problems’ on vision are explicitly mentioned (EQ + vision) compared
with if vision is not mentioned at all (EQ-5D only). There was also a suggestion that the coefﬁcients on
usual activity and anxiety and depression dimensions were lower with the introduction of the vision
bolt-on; however, this difference did not quite reach the 5% level of signiﬁcance.
Conclusion
This report has presented three substantial pieces of research.
The reviews of performance of the GPBMs were limited by the amount of evidence available, particularly
for HUI3 and SF-6D. It is also difﬁcult to prove the validity or otherwise of EQ-5D given the absence of a
gold standard. However, the systematic review established that EQ-5D was a valid and responsive method
for cases of cancer and some skin conditions, performance varied according to aetiology for vision, and
performance was poor for hearing disorders. The HUI3 performed well for hearing and vision disorders and
it also performed well in cases of cancer, although evidence was limited and there was no evidence for
skin-related conditions. There were limited data for the SF-6D in all four conditions. There was very little
evidence on reliability of all the instruments in all four conditions.
Mapping algorithms were estimated to predict EQ-5D values from alternative cancer-speciﬁc measures of
health (FACT-G and EORTC QLQ-C30). While some differences were found in performance between
models examined and some models did perform noticeably better across most criteria, conclusions about
the best method are hard to draw owing to small sample sizes and the limited coverage of the patient
groups. Further work is needed to determine the most important criteria for model selection. Ideally, all
the mapping functions would be estimated in bigger data sets spanning the full spectrum of disease and
then validated against an external, but similar, sample. Such data sets were not available for us to conduct
this analysis but would be useful for further research.
The exploratory valuation study found that bolt-on items for vision, hearing and tiredness signiﬁcantly
impacted on values of the health states. The direction and magnitude of differences depended on the
severity of the health state. A full model to obtain values for all EQ-5D + vision health states was
estimated. The vision bolt-on item had a statistically signiﬁcant impact on EQ-5D health state values, but
the impact was not simply additive. The results from the vision study suggest that it may be necessary to
estimate new models for some bolt-ons where there is an impact on the coefﬁcients of the ﬁve core
dimensions. The development of bolt-ons is a signiﬁcant development for researchers and policy-makers
using GPBMs in their evaluations. A proliferation of bolt-ons could be problematic if they reduce lead to
many different value sets and the research to develop them is not conducted appropriately. However,
bolt-ons could be very useful by improving on the performance of EQ-5D in speciﬁc conditions where
there may be speciﬁc concerns.
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Recommendations for further research
l Extend the reviews of the psychometric literature to more conditions.
l Undertake more primary research or analyses of primary data sets into the psychometric properties
of GPBM particularly in cancer.
l Compare alternative statistical models in larger data sets, including those for EORTC QLQ-C30
and FACT-G.
l Develop a systematic programme of research into bolt-ons for EQ-5D.
Funding
This project was funded by the UK Medical Research Council (MRC) as part of the MRC-NIHR
methodology research programme (ref: G0901486) and will be published in full in Health Technology
Assessment; Vol. 18, No. 9. See the NIHR Journals Library website for further project information.
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Chapter 1 Introduction
This report addresses a range of important methodological issues arising from the use of generic andcondition speciﬁc measures of health-related quality of life (HRQL) in the decision-making of the
National Institute for Health and Care Excellence (NICE). It describes a series of studies undertaken to
address the key questions of how to determine whether a generic measure of HRQL is valid for use in
calculating quality-adjusted life-years (QALYs), what to do when the generic measure is not available (and
speciﬁcally the use of ‘mapping’ techniques) and examines a new approach to dealing with situations
where the generic measure is found to miss important components of HRQL for speciﬁc conditions (i.e. the
use of ‘bolt-on’ dimensions). The rest of this chapter describes the rationale for looking at these questions
and presents the key objectives of the research.
Background
Generic preference-based measures (GPBMs) of HRQL are commonly used in the economic evaluation of
health interventions. These instruments have many advantages, including that they can incorporate the
impact of treatment or ill health on a multidimensional scale and can be combined with data on survival in
the form of QALYs. Furthermore, they facilitate comparisons between interventions and across conditions,
which is important if there is a need for consistency in decision-making between interventions or if there
is a need to compare with a common benchmark or cost-effectiveness threshold. The questionnaires can
usually be easily administered to patients for self-completion and the data can incorporate a reﬂection
of the value associated with different levels of health (usually based on values from members of the
general population).
In the UK, NICE has speciﬁed that Health Technology Assessments (HTAs) submitted to its Technology
Appraisal programme should be based on an incremental cost per QALY framework and recommends the
use of the EQ-5D as the preferred GPBM.1 The EQ-5D descriptive classiﬁcation consists of ﬁve dimensions
of health: mobility, self-care, usual activities, anxiety/depression, and pain/discomfort.2 In the older and
most commonly used version, each dimension of health has three levels of severity; however, a new
ﬁve-level version has recently been published.3 The 3-level version can describe 243 unique health states,
to which a preference value can be assigned based on a set of values obtained from a large UK general
population survey.4
The decision by NICE to recommend the EQ-5D was, in part, a pragmatic decision.5 It is now widely
recognised that the various GPBMs produce different values,6–8 and this can be problematic for an
organisation wanting to make consistent, transparent and predictable decisions. The GPBMs, including
EQ-5D, have been criticised for being insensitive or failing to capture important aspects of health.9,10 While
NICE recommends the use of the EQ-5D for its HTAs, in its Guide to the methods of technology appraisal,1
it recognises that the EQ-5D may not be an appropriate measure for all conditions.1 NICE requests
evidence to show that EQ-5D is inappropriate for the condition of interest; however, it does not specify
areas where EQ-5D is inappropriate, nor does it provide criteria to determine when a measure is
appropriate for a particular condition or treatment.
The ﬁrst section of this report will describe a systematic assessment of the appropriateness of the EQ-5D
and other commonly used GPBMs in four broadly deﬁned health conditions using the criteria of reliability,
validity and responsiveness. This assessment uses established psychometric methods but is complicated
by the absence of a gold standard measure of HRQL with which to compare the GPBMs. It is not possible
to deﬁnitively determine whether the generic measures are inappropriate; it still requires an element of
judgement. A generic measure may legitimately show no overall change in HRQL in contrast with a
disease-speciﬁc measure because they are measuring different constructs. For example, a condition-speciﬁc
measure may show improvements in some symptoms, but the overall impact on HRQL may be weakened
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as a result of new symptoms or side effects from treatment. However, judgements can be made
transparently and systematically based on the totality of the evidence available. The reviews presented
here draw on published research and established psychometric methods to establish the performance of
the GPBMs.
In addition to acknowledging that the EQ-5D may not always be appropriate, the NICE Guide to the
methods of technology appraisal1 also acknowledges that EQ-5D data may not always be available. This
may be for a variety of reasons, such as planning the economic evaluation after the trial design, concerns
about obtaining data directly from patients and concerns about the views of regulators regarding
non-signiﬁcant differences in HRQL between treatments. In these circumstances NICE suggests
incorporating data from other measures of health through the use of ‘mapping’. ‘Mapping’ (sometimes
referred to as ‘cross-walking’) describes a method by which values obtained from GPBMs, such as EQ-5D,
can be predicted from other measures or indicators of health.11,12 No speciﬁc guidance is provided on the
best methods of mapping other than to state that it must be based on empirical analysis and the methods
must be clearly described. In 2013, recommendations on the use of mapping were described;13 however,
these acknowledge that there is limited evidence to provide clear guidelines on many aspects of mapping,
in particular the most appropriate model speciﬁcations. A recent review of mapping functions showed use
of a range of different models including linear models, tobit models, censored least absolute deviation
(CLAD), two-part models (TPMs) and response mapping to predict quality of life (QoL).11 Studies also report
a variety of methods to assess model and predictive performance including predicted mean and standard
deviation (SD), median, Akaike information criterion (AIC), Bayesian information criterion (BIC), R2,
pseudo-R2, mean estimates across severity groups, root-mean-square error (RMSE) and mean square error.
A further issue in mapping is uncertainty, which is typically ignored. There is uncertainty in utility
measure weights, the mapping coefﬁcients, the choice of coefﬁcients and the choice of model and these
have not been addressed in the literature.
The second section of this report aims to establish the most appropriate model speciﬁcations for mapping
based on two separate data sets. The analysis draws on the results of the systematic reviews reported in
Chapter 2 and focuses on conditions where the EQ-5D measure has been found to be appropriate based
on the published evidence. An exploratory analysis demonstrates how the uncertainty in the estimates can
be better incorporated into analyses.
The third section of the report examines an alternative method for dealing with the situations when the
EQ-5D has been demonstrated to be inappropriate for a given condition owing to insensitivity or failing to
cover an important dimension of HRQL. One option could be to use alternative GPBMs, but, as discussed
above, this leads to a lack of comparability in the estimates compared with the standard EQ-5D approach
and also may not cover missing dimension(s). Recently, there has been growing interest to explore
an alternative approach by developing preference-based measures from existing and validated
condition-speciﬁc measures of HRQL (for a full review of this approach, see the HTA monograph by
Brazier et al.14 and for recent examples, see papers by Yang et al.15,16). This approach can offer a useful
solution in some situations. There have, however, been concerns raised that these condition-speciﬁc
preference-based measures also produce very different values to the GPBMs and so may compromise
comparability17 and these differences may continue to arise even when the methods of valuation
are designed to be similar with GPBMs.14
One possible solution to this problem is to not use comparable methods of valuation only, but also to keep
the health state classiﬁcation systems as similar as possible through the development of ‘bolt-on’ items to
the EQ-5D or the GPBM of interest. Bolt-ons are dimensions that can be appended to another instrument
and to which utility values can be attributed to the health states described by the instrument with the
bolt-on. Previous research has examined the impact of modifying the EQ-5D descriptive system to include
additional dimensions of health.18,19 Krabbe et al.18 valued EQ-5D health states including a ‘cognition’
dimension of health and found that it signiﬁcantly impacted upon health state values.18 More recently,
Yang et al.19 developed a ‘sleep’ dimension to add to the EQ-5D but found that it did not signiﬁcantly
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impact on values.19 The value of any potential ‘bolt-on’ dimension to EQ-5D depends crucially on whether
its inclusion signiﬁcantly impacts on the values given to the EQ-5D health states. The design and
complexity of ‘bolt-on’ valuation studies will depend on how the values of the bolt-on levels are affected
by the EQ-5D states accompanying it and whether the inclusion of the bolt-on items has a signiﬁcant
impact on the values given to the EQ-5D dimensions. Furthermore, the methods of bolt-on development
and valuation are not well developed. Two studies are described in this report to develop potential
bolt-ons to the EQ-5D, to quantify the impact they have on EQ-5D values and to assess the implications of
this for future bolt-on developments. In undertaking this, a full valuation model is provided for one of the
EQ-5D bolt-ons.
Aims and objectives of the report
The overall aim of the study was to develop methods for systematically incorporating information from
condition-speciﬁc measures into the NICE decision-making framework. Speciﬁcally, the project had three
related objectives:
1. To examine whether the EQ-5D and other commonly used generic HRQL measures are appropriate for
use in calculating QALYs for NICE decision-making in selected speciﬁc conditions.
2. To develop mapping functions to predict EQ-5D data from condition-speciﬁc or clinical measures, to
compare alternative model speciﬁcations and to conduct an exploratory analysis around the
incorporation of uncertainty in the predicted estimates.
3. To investigate the development and valuation of bolt-ons to expand the EQ-5D descriptive system for
those conditions in which the EQ-5D is not appropriate.
The results from the analysis to meet the ﬁrst objective are used to inform the second and third objectives.
Mapping will not be successful if the measure to be predicted does not adequately capture HRQL;
therefore, only those conditions where the EQ-5D is found to be appropriate (objective 1) are considered
to inform the mapping analyses (objective 2). Conversely, those conditions found to be not adequately
captured by EQ-5D (objective 1) are the focus of the analyses of bolt-on measures (objective 3).
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Chapter 2 A systematic review of the
psychometric properties of generic preference-based
measures of health in four conditions
Introduction
The aim of the review reported in this chapter was to assess the reliability, validity and responsiveness of
the EQ-5D, Health Utilities Index Mark 3 (HUI3) and SF-6D for measuring HRQL in four broadly deﬁned
conditions: visual disorders, hearing disorders, skin conditions and cancer.
The three GPBMs focused on (EQ-5D, HUI3 and SF-6D) were chosen to represent commonly used GPBMs
of HRQL in NICE Technology Appraisals.20 Speciﬁcally, as noted previously, the EQ-5D is recommended
as the preferred measure by NICE and is the most commonly used measure in its Technology Appraisals.1,20
The HUI3 was chosen as it is commonly used internationally and is the second most frequently used in
NICE Technology Appraisals.20 The SF-6D was also chosen as it has properties considered important
by NICE (as a validated and generic measure of HRQL that also has a set of UK general population values
elicited using a choice based method). In addition, the SF-6D questionnaire was derived from the short
form questionnaire-36 dimensions (SF-36), which is widely used in clinical trials.
The four conditions were chosen to represent areas where the EQ-5D measure may not be appropriate
based on previous published research21–24 or concerns reported during the development of NICE
Technology Appraisals.25,26 Previous research has reported that the generic instruments, particularly the
EQ-5D, do not adequately capture changes in health as a result of visual or hearing loss, but ﬁndings are
mixed.21–23,24 In addition, the measurement of HRQL in these conditions has been the subject of debate
within NICE Technology Appraisals of treatments for these conditions.25,26 The appraisals of treatments for
skin conditions by NICE have frequently relied upon data from condition-speciﬁc measures in analyses
rather than directly using generic measures of HRQL. Finally, the condition for which treatments are most
frequently appraised by NICE is cancer. There have been suggestions that generic measures, such as the
EQ-5D, may not adequately reﬂect the effects of cancer and related treatments that are considered
important to patients (e.g. fatigue); however, a comprehensive review of the evidence has not been
previously reported. A similar review has been conducted to examine the appropriateness of the EQ-5D in
mental health as part of another Medical Research Council (MRC) funded project.27,28
The rest of this chapter discusses the methods used for the systematic literature reviews, the ﬁndings and results
for the four conditions, each discussed separately, and ﬁnally a brief discussion and conclusion is provided.
Methods
The generic preference-based measures
EQ-5D
The EQ-5D describes HRQL in terms of ﬁve dimensions: mobility, self-care, usual activities, pain/discomfort
and anxiety/depression.2 Each dimension is usually described in terms of three levels of severity, although a
version with ﬁve levels has recently been published.3 The health classiﬁcation system for the three-level
version describes 243 health states and a tariff of values for each health state is available for several
countries, including the UK. The UK value set was obtained from valuations provided by 3395 members of
the general population using the time trade-off (TTO) valuation method.4,29
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SF-6D
Derived from the SF-36 and Short Form questionnaire-12 dimensions (SF-12) health questionnaires, the
SF-6D has six dimensions (physical functioning, role limitation, social functioning, bodily pain, mental
health and vitality) and each dimension has four to six severity levels.6,30 Any patient who completes the
SF-36 or the SF-12 can be uniquely classiﬁed according to the SF-6D. The health classiﬁcation system of
SF-6D describes a total of 18,000 health states and a tariff of values for each health state is available
for several countries, including the UK. The UK value set was obtained from valuations provided by
611 members of the general population using the standard gamble (SG) valuation method.30
Health Utilities Index Mark 3
Health Utilities Index is a group of GPBMs for measuring comprehensive health status and HRQL,
including Health Utilities Index Mark 1(HUI1), Health Utilities Index Mark 2 (HUI2) and HUI3. HUI3 has nine
dimensions (vision, hearing, speech, ambulation/mobility, pain, dexterity, self-care, emotion and cognition)
and each dimension has three to six levels. The health classiﬁcation system of HUI3 describes almost a
million unique health states and a tariff of values for each health state is available for Canada. The
Canadian value set was obtained from valuations provided by 504 members of the general population
using the visual analogue scale (VAS) and SG valuation methods.31
Search strategy and data identification
The search strategy aimed to identify relevant journal papers providing evidence on the reliability, validity
and responsiveness of EQ-5D, HUI3 or SF-6D in the following four clinical conditions: vision disorders,
hearing impairments, skin disorders and cancer.
Four separate search strategies were developed, one for each of the conditions. The search strategies were
developed following consultation with experts in information resources and health economics. An iterative
approach to the searches was adopted. The strategies consisted of a broad search to identify studies
reporting the use of the GPBMs in patients with each of the four clinical conditions. The search included
both free text and controlled terms. Free text words included ‘euroqol’, ‘hui3’, ‘sf6d’ (all with alternative
spellings). Condition-speciﬁc terms were also included (see Appendix 2 for the full searches used). The
following electronic databases were searched: BIOSIS (1969 to 2010), Cumulative Index to Nursing and
Allied Health (CINAHL) (1982 to 2010), Cochrane Library comprising the Cochrane Database of Systematic
Reviews (CDSR), Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Methodology
Register, NHS Economic Evaluations Database (NHS EED) (1991 to 2010), EMBASE (1980 to 2010),
MEDLINE (in process and non-indexed to 2010), PsycINFO (1806 to 2010) and Web of Science
(1900 to 2010).
In addition, a database of studies held on the website of the EuroQol Group32 was searched to check for
any missing papers reporting EQ-5D and to check that the search strategies were identifying relevant
papers. Comparable databases for the SF-6D and HUI3 are not available. The search strategies are
presented in Appendix 2.
The inclusion criteria were that (1) the study reported dimensions and/or index values for at least one of
the generic instruments EQ-5D, HUI3 or SF-6D and (2) the study reported another measure of QoL
[including VAS or EuroQol VAS (EQ-VAS), TTO, SG direct valuation of QoL or another utility measure]
or a measure of clinical severity/symptoms that would enable an assessment of validity, responsiveness
or reliability.
The condition-speciﬁc inclusion criteria were that the studies reported the above data for people with one
of the following conditions: vision disorders, hearing disorders, skin disorders or cancer.
There was no restriction relating to the type of study or type of condition within the overall deﬁnitions.
Owing to resource limitations, only English language studies were reviewed.
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Data extraction
Data were extracted from the studies using a standardised set of forms developed for this study after
reviewing forms used for similar studies in other disease areas.27 The data extracted included general
characteristics of the study and participants, instruments used in the study, methods and results used in
the study for assessment of reliability, construct validity and responsiveness. Data extraction for the
different clinical conditions was undertaken by one member of the research team and summarised using
items presented in Table 1.
Data analysis
Assessment of quality and relevance
For the review, of most importance was the relevance of the study in terms of the patient population and
inclusion of evidence to establish the psychometric performance of the generic measures. Studies including
a mixed population of patients (i.e. with various conditions) were only included if they reported
health-related utility values or dimension responses for subgroups of patients with one of the four speciﬁc
conditions being evaluated. Nevertheless, a judgment regarding the risk of bias for each study was
TABLE 1 Information extracted from included papers
General Author name, year
Country where the study took place
Type of disease/disorder
Disease/treatment stage
Treatment (if any)
Study design
Participant characteristics Number of participants
Age (mean and range)
Gender (percentage of males)
Ethnicity
Missing data, including reasons for non-completion if given
Valuation and descriptive methods Descriptive systems
Tariff or source of value sets
Mean values (SD, range)
Direct valuations used
Condition-speciﬁc HRQL measures used
Clinical measures used
Qualitative questions asked
Missing data of measures completion
Reliability Methods
Results
Validity Methods
Results
Responsiveness Methods
Results
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determined by reviewing the methods of patient recruitment and noting any missing data reported
(either study drop-outs or incomplete questionnaires). Studies were not required to be speciﬁcally designed
to assess validity, responsiveness or reliability, provided that they reported data in sufﬁcient detail to allow
an assessment of these traits. The intention of the assessment of quality was not to exclude relevant
studies, but to highlight any concerns about quality when ﬁndings were interpreted.
Assessment of reliability
The reliability of a measure is deﬁned as its ability to reproduce results when measurements are repeated
on an unchanged population,33 or the comparability of responses across different assessors (for example,
patient and proxy report). Reliability can be measured by retesting and reporting either the correlation or
difference between estimates. In some circumstances, no change in health status may be expected over
time and, subsequently, the values obtained using the measures may be stable. These results were
interpreted as evidence of the reliability and stability of instruments. Other assessments of reliability
included assessments of inter-rater reliability based on a comparison of responses given by multiple people
completing the questionnaire on the patients' behalf. When considering the results of inter-rater
comparisons, it is important to note that all of the GPBMs have been designed for self-completion and to
report self-assessed HRQL. Therefore, perfect agreement between the intended respondents and their
proxies may not be expected. Finally studies reporting internal consistency were also included as assessed
through multitrait analysis.
Assessment of construct validity
Validity is deﬁned as how well an instrument measures what it was intended to measure. More speciﬁcally,
for the GPBMs, whether the dimensions adequately cover the key determinants of health-related utility.
Criterion validity is determined by comparing an instrument to an established gold standard; however,
a gold standard with which to benchmark HRQL measures against does not exist. Therefore, it is necessary
to assess the validity of measures of health-related utility using measures that have evidence of construct
validity for that condition, which establishes if patterns in scores conﬁrm constructs or hypotheses about
expected patterns.
We assessed the construct validity of the GPBMs using the ‘known-group’ method. The known-group
method compares the values obtained from the GPBMs between groups of patients who are expected to
differ [qualitatively or statistically using t-test or analysis of variance (ANOVA)] in the construct measured by
the indicator used to deﬁne the groups. The known groups in this context are often deﬁned according to
clinical severity using other measures. It should be noted that the usefulness of these comparisons can be
limited by sample size, particularly as studies are usually not powered to detect differences according to
preference-based measures. In addition, consideration must be given to the appropriateness of the clinical
measure and the groups deﬁned by it, and exogenous factors that may inﬂuence HRQL. For instance,
groups deﬁned solely by the presence of a biomarker may have no impact on HRQL. If patients have a
number of comorbidities, then these may have a greater impact on HRQL than the condition of interest.
Known groups can also be deﬁned using a case–control analysis in which comparison is between
patient and general public population, or deﬁned on the basis of other aspects such as age, gender or
countries. However, a more stringent test is to deﬁne known groups based on different levels of condition
severity (for example, by using a clinical indicator).
We also examined convergent validity, which is a type of construct validity. Convergent validity is deﬁned
as the extent to which one measure correlates with another measure of the same or similar concept. In
this review, we examined the extent to which the EQ-5D, SF-6D or HUI3 correlate with other measures of
QoL or clinical severity. Correlation was deﬁned as ‘low’ if correlation coefﬁcient was < 0.3, ‘moderate’ if
between 0.3 and 0.5 and ‘strong’ if > 0.5. Correlations need to be interpreted with caution as it is not
always clear how strong the relationship between the generic and condition-speciﬁc indicators should be.
Furthermore, we interpreted estimation of regression between GPBMs and other measures as another
indication of a correlation, focusing on whether some measures were signiﬁcant predictors of others.
8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
PSYCHOMETRIC PROPERTIES OF GENERIC PREFERENCE-BASED MEASURES OF HEALTH
Assessment of responsiveness
Responsiveness assesses the ability of an instrument to measure a change in health-related utility over
time. As with construct validity, the measurement of responsiveness is difﬁcult as there is no gold standard
measure with which to compare. Nevertheless, we assessed the responsiveness of health-related utility
measures by comparing change in health-related utility measured over a period of time in which health
status is expected to change (e.g. before and after an intervention) with the change demonstrated by
another measure of health. For inclusion in the assessment of responsiveness, the comparator measure
must have demonstrated a change in health. We did not review data from studies outside of the review
relating to responsiveness of the comparator measures. Good evidence of responsiveness is considered
where the GPBM shows statistically signiﬁcant change in health (e.g. t-test) shown by other measures or
clinical indicators. Weaker evidence of responsiveness is considered where the same trend of change is
shown but the change is not statistically signiﬁcant. When responsiveness indices for estimates of
health-related utility are reported [e.g. effect size (ES) or standard response mean], they were compared
with other measures. ES is the mean change in score of a measure between two different time points
divided by the SD of the score at baseline. Standardised response mean is the mean change score of a
measure between two different time points divided by the SD of the change score. As for the tests of
validity, it is important to consider whether the measures of health change that are being used to
assess responsiveness are valid. In addition, it is important to consider whether other health changes
not directly related to the condition could have impacted upon health-related utility (e.g. side effects
of treatment).
Presentation and analysis
Data for each of the four conditions are presented separately. Information on the study design, participant
characteristics and the measures included are reported. Within each of the broadly deﬁned conditions,
there is a range of underlying aetiologies with different symptoms. The results for visual disorders, skin
diseases and cancers are therefore presented for subgroups deﬁned according to type of condition.
Subgroups are not presented for hearing impairments as the studies were mainly deﬁned according to the
presence or absence of hearing loss and/or extent of hearing loss. For each condition, a summary table is
presented which reports an overview of the conclusions drawn from each paper for each of the types
of assessment.
Results
Vision
Search results: vision
Bibliographic searching was completed in August 2010 and total of 1025 potentially relevant papers
were identiﬁed. Abstracts and titles for all papers were screened to identify papers meeting the
inclusion criteria; 969 records were excluded and full papers were ordered for the remaining 56 records.
After reviewing the full papers, 25 were excluded and a total of 31 papers were included in the review.
A ﬂow chart of the study selection process is shown in Figure 1.
Quality assessment: vision
A range of recruitment procedures were reported. Some were retrospective analyses of data sets with
predetermined inclusion criteria,34–36 some were case–control analyses,37–39 and the majority were
cross-sectional observational studies.22,34,36,40–52 The only randomised controlled trial (RCT) had well-deﬁned
inclusion criteria.53 Response rates for questionnaires ranged from 33% to 96%, with completion rates of
longitudinal studies > 85% in all but one study50 (range 52–98%). No study was excluded after the
assessment of quality.
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Study design and patients' characteristics: vision
Summary characteristics of the 31 studies are presented in Table 2. Thirty of the 31 studies were
observational studies22,34,36–39,40–52,54–64 and the remaining study was a RCT.53 The studies were
conducted in different countries including the UK, the USA and Canada and some were multicountry
studies. The studies identiﬁed included a wide range of visual disorders. Five studies were in patients
with glaucoma,34,44–46,54 seven studies were in patients with age-related macular degeneration
(AMD),22,43,47–49,55,56 eight studies included patients with cataracts,36–39,53,57–59 two studies were on patients
with diabetic retinopathy,42,50 three were on patients with conjunctivitis51,60,61 and the remaining studies
included people with various other visual conditions.40,41,52,62,63,64
Number of potentially relevant records
(n = 1025)
Number of citations screened
(n = 1025)
Number of full-text articles assessed
(n = 56)
Number of citations excluded
(n = 969)
Number of full-text articles excluded
(n = 25)
Number of studies included in review
(n = 31)
FIGURE 1 Flow diagram showing selection of studies: vision.
TABLE 2 Characteristics of included studies: visual disorders
Study reference
grouped by condition
(author, year) Country Disease/treatment stage
Sample
size Study type
Glaucoma
Aspinall et al., 200844 UK Glaucoma and no other ocular
comorbidity
72 Cross-sectional
Kobelt et al., 200645 Sweden Ocular hypertension or
open-angle glaucoma
109 Cross-sectional
Mittmann et al., 200134 Canada Glaucoma – a subset from a study
on a range of chronic conditions
137 Cross-sectional
Montemayor et al., 200146 Canada Chronic open-angle glaucoma,
normal-pressure glaucoma
or suspected glaucoma
with treatment
224 Cross-sectional
Thygesen et al., 200854 Multiple Late-stage primary open-angle
glaucoma
162 Case review
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TABLE 2 Characteristics of included studies: visual disorders (continued )
Study reference
grouped by condition
(author, year) Country Disease/treatment stage
Sample
size Study type
AMD
Cruess et al., 200747 Canada Neovascular AMD 67 Cross-sectional
Espallargues et al., 200522 UK Wet or dry AMD 209 Cross-sectional
Kim et al., 201055 Korea – 625 Cohort
Lotery et al., 200748 UK Bilateral subfoveal
neovascular-AMD
75 Cross-sectional
Payakachat et al., 200949 Multiple Wet AMD 154 Cross-sectional
Ruiz-Moreno et al., 200856 Spain Bilateral neovascular AMD 89 Prospective
case–control
Soubrane et al., 200743 Multiple Neovascular AMD 401 Cross-sectional
Cataracts
Asakawa et al., 200836 Canada With or without other
comorbidities
911 Cross-sectional
Black et al., 200957 UK First or second eye 860 Prospective
cohort
Conner-Spady et al., 200558 Canada – 253 Cohort
Datta et al., 200853 UK Bilateral cataracts in participants
over 70 years of age
289 Secondary
analysis of RCT
Jayamanne et al., 199959 UK First Eye 144 Prospective
Polack et al., 200737 Kenya – 196 Case–control
Polack et al., 200838 Bangladesh – 217 Case–control
Polack et al., 201039 Philippines Participants over 50 years of age 401 Case–control
Diabetic retinopathy
Lloyd et al., 200842 UK Diabetic retinopathy due to
diabetes
122 Cross-sectional
Smith et al., 200850 USA Type 2 diabetes 401 Cross-sectional
Conjunctivitis
Pitt et al., 200460 UK – 310 Cohort
Rajagopalan et al., 200551 Multiple Non-Sjögren’s keratoconjunctivitis
or Sjögren’s syndrome
210 Cross-sectional
Smith et al., 200561 Spain – 401 Cohort
Other visual disorders
Boulton et al., 200640 UK Vision impairment or
blindness in children
100 Cross-sectional
Clark et al., 200862 Australia Postcataract surgery
endophthalmitis
49 Cohort
Kempen et al., 200363 USA Cytomegalovirus retinitis in
patients with acquired
immunodeﬁciency syndrome
961 Prospective
cohort
Langelaan et al., 200741 Netherlands Low-vision patients 120 Cross-sectional
Quinn et al., 200464 USA Retinopathy of prematurity 244 Cohort
van Nispen et al., 200952 Netherlands Vision impairment in older people 296 Observational
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The inclusion criteria varied across the studies reviewed within each of the speciﬁc conditions. Some
studies reported that patients were identiﬁed through case notes, but no more details are provided. It was
noted whether AMD was bilateral or unilateral and wet or dry, whether cataracts were present in the
ﬁrst or second eye and whether glaucoma was primary or multiple. Sample sizes also varied across studies,
ranging from 4962 to 961.63 One study40 included children with a mean age of 6 years and used HUI3. The
authors reported that the HUI system had been used in a previous study of young children with a range
of impairments similar to those included in their study, although it should be noted that this did not refer
speciﬁcally to the HUI3 at that time. All other studies included adult patients and the AMD studies
included patients over 70 years.
Measures used in studies: vision
Table 3 summarises the measures that have been used in the 31 studies included in the review. For the
three GPBMs of interest, the EQ-5D was reported in 27 studies22,37–39,41–63 and therefore was the most
commonly utility measure, six studies reported the HUI322,34,36,40,42,64 and only one study reported the
SF-6D.22 Ten studies also reported direct valuations of patients' own health states using methods such as
the TTO or VAS.22,44,45,51,58–63 Twenty-three studies reported visual acuity (VA)22,34,37–39,41–50,52–55,58,61,63,64 to
indicate visual severity. In addition, various patient-reported visual-speciﬁc QoL measures were used.
Reliability: vision
No tests of reliability were performed on the generic preference-based measures.
Known-group analysis and convergent validity: vision
Known-group analysis was performed in 24 studies:22,34,36–45,47–51,54,56,60–64 20 for EQ-5D,22,37–39,41–45,47–51,54,
56,60–63
ﬁve for HUI3,34,36,40,42,64 but no studies for SF-6D. In six of the studies, groups were deﬁned by VA,
or by contrast sensitivity, and mean estimates of utility for each deﬁned group were provided.22,41–43,54,61
The remaining 25 studies had either a case–control design, had different conditions or did not deﬁne levels
of severity.
Nine of the 31 studies reviewed provide evidence on correlation or regression between GPBMs with either
each other or with visual measures.22,37,38,44,46,50,52–54 Eight studies report evidence of convergent validity in
EQ-5D compared with a visual measure,37,38,44,46,50,52–54 with Espallargues et al.22 also reporting correlations
across EQ-5D, SF-6D and HUI3. Details of the data are summarised in Appendix 3 and below by type of
vision disorder.
Glaucoma
Known-group analysis Three studies of people with glaucoma allowed a known-group analysis for
EQ-5D where groups were deﬁned by severity of vision problems.44,45,54 The studies by Aspinall et al.44 and
Kobelt et al.45 found that EQ-5D utility values decreased with increasing glaucomatous damage but were
not statistically signiﬁcant. The study by Thygesen et al.54 deﬁned three groups on the basis of the Snellen
score and the ordering of mean utility values were consistent and statistically signiﬁcant. No such data
were available for HUI3 or SF-6D by severity groups. However, one paper reported HUI3 in a case–control
study, which showed an appropriate and signiﬁcant difference in HUI3 values between the cases
and controls.34
Convergent validity Three studies reported correlation statistics for EQ-5D with VA in patients with
glaucoma.44,46,54 Aspinall et al.44 reported moderate and statistically signiﬁcant correlations for the EQ-5D
measure and the mobility, self-care and anxiety dimensions. The study by Thygesen et al.54 also showed
a signiﬁcant correlation between VA and EQ-5D. However, Montemayor et al.46 reported low and
non-signiﬁcant correlations for EQ-5D with VA.
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TABLE 3 Instruments used: vision
Study reference
grouped by condition
(author, year)
GPBM Direct valuation Rating scale Condition speciﬁc HRQL instruments Clinical severity
EQ-5D SF-6D HUI3 TTO VAS VFQ-20/25 VF-14/4D RQLQ VFA IDEEL VA
Glaucoma
Aspinall et al., 200844 ✓ ✓ ✓
Kobelt et al., 200645 ✓ ✓ ✓
Mittmann et al., 200134 ✓ ✓
Montemayor et al., 200146 ✓ ✓ ✓
Thygesen et al., 200854 ✓ ✓
AMD
Cruess et al., 200747 ✓ ✓ ✓
Espallargues et al., 200522 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Kim et al., 201055 ✓ ✓ ✓
Lotery et al., 200748 ✓ ✓ ✓
Payakachat et al., 200949 ✓ ✓ ✓
Ruiz-Moreno et al., 200856 ✓ ✓
Soubrane et al., 200743 ✓ ✓ ✓
Cataracts
Asakawa et al., 200836 ✓
Black et al., 200957 ✓ ✓
Conner-Spady et al., 200558 ✓ ✓ ✓ ✓
Datta et al., 200853 ✓ ✓ ✓
Jayamanne et al., 199959 ✓ ✓ ✓
Polack et al., 200737 ✓ ✓ ✓
Polack et al., 200838 ✓ ✓ ✓
Polack et al., 201039 ✓ ✓ ✓
continued
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TABLE 3 Instruments used: vision (continued )
Study reference
grouped by condition
(author, year)
GPBM Direct valuation Rating scale Condition speciﬁc HRQL instruments Clinical severity
EQ-5D SF-6D HUI3 TTO VAS VFQ-20/25 VF-14/4D RQLQ VFA IDEEL VA
Diabetic retinopathy
Lloyd et al., 200842 ✓ ✓ ✓ ✓
Smith et al., 200850 ✓ ✓
Conjunctivitis
Pitt et al., 200460 ✓ ✓ ✓ ✓
Rajagopalan et al., 200551 ✓ ✓ ✓
Smith et al., 200561 ✓ ✓ ✓ ✓
Other visual disorders
Boulton et al., 200640 ✓
Clark et al., 200862 ✓ ✓ ✓
Kempen et al., 200363 ✓ ✓ ✓
Langelaan et al., 200741 ✓ ✓
Quinn et al., 200464 ✓ ✓
van Nispen et al., 200952 ✓ ✓
IDEEL, impact of dry eyes on everyday life questionnaire; RQLQ, rhinoconjunctivitis; VF-14/4D, Visual Function Questionnaire 14/4 dimension; VFA, Visual Function Assessment;
VFQ-20/25, Visual Function Questionnaire – 20/25.
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Age-related macular degeneration
Known-group analysis In studies of people with AMD, all seven22,43,47–49,55,56 papers provided evidence to
allow an assessment of construct validity of the EQ-5D. Of these, ﬁve22,43,48,49,55 differentiated between
groups based on severity of vision disorder and three43,47,56 included assessments of cases against controls.
Three studies deﬁned visual severity groups: two22,43 in terms of levels of VA and the other55 based on
whether they had unilateral or bilateral AMD. Soubrane et al.43 showed inconsistency with the mean
estimates, with normal VA having a worse mean utility when compared with mild, moderate, severe and
near blind utility values. The anxiety dimension of the Hospital Anxiety and Depression Scale (HADS) was
also inconsistent between the normal and mild VA groups, but this inconsistency was not shown in the
Visual Function Questionnaire-25 (VFQ-25). The study did, however, report a signiﬁcant difference of
utility values between those with neovascular AMD and the control group. Kim et al.55 found a
statistically signiﬁcant difference in EQ-5D values between those with unilateral and bilateral AMD.
Espallargues et al.22 found a consistent relationship between VA and contrast sensitivity with HUI3, SF-6D,
TTO and VAS but not EQ-5D.
Of the three case–control studies, two found that EQ-5D showed an appropriate and statistically
signiﬁcant reduction in HRQL for people with AMD compared with general population controls.43,56 One
reported a difference that was not a statistically signiﬁcant difference, but the difference was in the
appropriate direction.47
Convergent validity Three studies provided correlation statistics between generic and visual measures
in patients with AMD and all showed poor correlation of EQ-5D with other measures.22,47,48 Espallergues
et al.22 found that the VAS, TTO, HUI3 and SF-6D were all signiﬁcantly correlated with both VA
and contrast sensitivity. However, they did not ﬁnd signiﬁcant correlations for EQ-5D with VA or
contrast sensitivity.
Cataracts
Known-group analysis Four36–39 of the seven37–39,53,57–59 studies in patients with cataracts provided
evidence to allow an assessment of the construct validity of the EQ-5D37–39 and HUI3.36 Three case–control
studies conducted in different countries by Polack et al.37–39 found that there were signiﬁcant differences in
EQ-5D between cases and controls, and found that cases were likely to report a signiﬁcant difference
across all dimensions (except pain dimension in Polack et al.38). However, Polack et al.39 reported an
inconsistent association between EQ-5D and VA.
One study reported HUI3 values for cases and controls and identiﬁed a statistically signiﬁcant and
appropriate difference between the two groups.36
Convergent validity Four studies provided evidence of the convergent validity of the EQ-5D with
VA.37–39,53 Polack et al.37–39 tested associations between EQ-5D and VA, with one study ﬁnding that poorer
VA was associated with higher odds of reporting any problem with all EQ-5D dimensions apart from
anxiety.37 The other two studies found no signiﬁcant associations between VA and EQ-5D dimensions,
apart from a borderline association with self-care.38,39 Datta et al.53 did not ﬁnd signiﬁcant correlations for
EQ-5D with VA.
Diabetic retinopathy
Known-group analysis Two studies reported EQ-5D identifying a statistically signiﬁcant difference
between the two extreme groups; however, the differences between neighbouring groups were not
signiﬁcant and frequently inconsistent.42,50 In the study by Lloyd et al.42 the inconsistencies were also
shown in VAS ratings of patients' own health and the HUI3. This may be the result of small sample size or,
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as the authors speculate, it may be the result of a loss of independence of the participants when they
reach that level of severity.42
Convergent validity Smith et al.50 ﬁtted a linear regression and found visual angle to be a predictor
of EQ-5D utility values. They also ﬁtted a non-parametric ordinal logistic regression and this estimated that
any degree of visual impairment would result in an increased likelihood of reporting non-perfect
utility values.
Conjunctivitis
Known-group analysis All three studies allowed an assessment of construct validity of the EQ-5D in
people with conjunctivitis. Two were case–control studies and showed a statistically signiﬁcant difference
between cases and controls.60,61 One study demonstrated a difference between groups deﬁned according
to severity.51 Within the dimensions of the EQ-5D, the study by Pitt et al.60 found the pain dimension to be
the only dimension to show a statistical difference. However, Smith et al.61 reported a signiﬁcant
difference across all dimensions except mobility. No studies provided evidence on the construct validity of
the HUI3 or SF-6D.
Convergent validity No papers reported on convergent validity of the measures in patients
with conjunctivitis.
Other visual conditions
Known-group analysis The remaining six studies were in unique visual conditions.40,41,52,62–64 Three of
these studies allowed an assessment of the construct validity of the EQ-5D41,62,63 and two of the HUI3.40,64
Clark et al.62 and Kempen et al.63 reported an appropriate, but non-signiﬁcant, difference in the EQ-5D
between the control group and those with endophthalmitis and cytomegalovirus, respectively.
Langelaan et al.41 undertook a study on visually impaired patients and identiﬁed an appropriate, but
non-signiﬁcant, difference in the EQ-5D between low and high visual ﬁeld groups, but an inconsistent
and non-signiﬁcant difference in the EQ-5D between low- and high-VA groups.
Boulton et al.40 and Quinn et al.64 found the HUI3 identiﬁed statistically signiﬁcant and appropriate
differences between groups of patients with unspeciﬁed blindness/visual impairment.
Convergent validity A study by van Nispen et al.52 reported a multivariate regression analysis of
data from older patients with visual impairment. They found that worsening VA was a signiﬁcant risk
factor for a lower EQ-5D value.
Responsiveness
Only three studies reported responsiveness of the utility measures in visual disorders (Appendix 4).55,57,58
Kim et al.55 reported a statistically signiﬁcant improvement in both the Visual Function Questionnaire
(4 dimension) (VF-4D) and the EQ-5D after photodynamic therapy in patients with AMD. Black et al.57
reported a statistically signiﬁcant improvement in both the Visual Function Questionnaire (14 item) (VF-14)
and the EQ-5D postcataract surgery, although the latter was relatively small. Conner-Spady et al.58
reported a statistically signiﬁcant improvement in the Visual Function Assessment (VFA) and VA post
cataract surgery, but the subsequent mean improvements in EQ-VAS and EQ-5D were small and not
statistically signiﬁcant. This may suggest that the EQ-5D is not responsive in this population; however, it
should be recognised that the study was not initially powered to identify statistically signiﬁcant changes
and a mean improvement was identiﬁed. In addition, the VAS did not change from pre to post treatment;
therefore, the treatment may not signiﬁcantly impact on HRQL.
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Summary of results for visual review
The 31 studies included in this review show a worsening of utility values as visual impairment
increased in many though not all studies. The magnitude and statistical signiﬁcance of the association
varied between different GPBMs of HRQL. Table 4 shows an overview of performance of utility measures in
visual impairment.
The largest amount of evidence was found for the EQ-5D compared with the other generic measures and
the results were mixed. Nearly all studies showed signiﬁcant differences between patients with the
condition and a control group. Studies comparing EQ-5D scores across severity groups were more mixed,
with the majority of studies showing little or no difference between groups deﬁned by clinical measures of
visual impairment. No studies allowed an assessment of reliability for any of the measures. There were
just three studies on responsiveness. and all were in the form of before-and-after studies of an
intervention.55,57,58 These identiﬁed changes consistent with an effective intervention, but differences were
statistically signiﬁcant in only two of three studies.55,57 The assessment of convergent validity was also
concerning, with half of the studies not demonstrating a statistically signiﬁcant correlation with clinical
measures. While there was less evidence for the HUI3, all but one study42 demonstrated good validity;
no studies assessed responsiveness. There was very limited evidence on the SF-6D in patients with
visual impairment.
Hearing
Search results: hearing impairment
Bibliographic searching was completed in July 2010. The search strategy identiﬁed 119 articles. After
reviewing titles and abstracts, 70 papers were excluded. Forty-nine papers were reviewed in full, and a
further 31 were excluded and 18 papers were included in the ﬁnal review. A ﬂow chart of the study
selection process is shown in Figure 2.
Quality assessment: hearing impairment
A range of study designs was reported in the studies included in the review. Three studies were
cross-sectional65–67 but the majority were prospective or retrospective before-and-after studies.21,23,68–78
Studies had well-deﬁned inclusion/exclusion criteria for recruitment. For longitudinal studies, no study had
extremely high levels of missing data and completion rates for patients in studies ranged from 60%68 to
100%.66 The completion rates for the instruments included were usually high, ranging from 71%67 to
97%.23 The reporting in these papers was reasonably clear. After quality assessment, no studies were
excluded from the review.
Study characteristics: hearing impairment
The main characteristics of the 18 papers included in this review are shown in Table 5. The two papers by
Joore et al.71,72 and the two papers by Joore73,74 reported the results of one speciﬁc study and, similarly,
the two papers by Vuorialho et al.77,78 reported a single study. In total, 14 separate studies were included
in the review. The studies were undertaken in a range of countries, including the UK, the Netherlands, the
USA, Canada and Finland. Some studies recruited patients with speciﬁc hearing problems, e.g. large
vestibular aqueduct syndrome,23 but most were for deﬁned the sample using clinical indicators such as
the better ear unaided pure-tone average (PTA). As shown in Table 5, the level of hearing loss varied
between studies.
The sample sizes of the studies reviewed ranged from 2068 to 3272.65 Most studies had approximately
100 participants, but two studies only had approximately 20 participants.68,79 Five studies included young
children with hearing impairments (the mean age of the samples ranged from 7 to 9 years),66–68,76,80 and
the remaining studies included adults, with most focusing on older adults over 60 years of age. The studies
involving children used parents or caregivers as proxies to assess HRQL of children.
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TABLE 4 Overall performances of EQ-5D, HUI3 and SF-6D in visual disorders
Study reference
grouped by measure
(author, year)
Known group (severity) Known group (case–control) Known group (other) Responsiveness
Conditions
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant Correlation
Consistent
evidence Signiﬁcant Reliability
EQ-5D
Aspinall et al., 200844 Glaucoma ✓ ✗ Moderate
Kobelt et al., 200645 Glaucoma ✓ ✗
Montemayor et al., 200146 Glaucoma ✓ (low)
Thygesen et al., 200854 Glaucoma ✓ ✓ ✓
Cruess et al., 200747 AMD ✓ ✗ ✗
Lotery et al., 200748 AMD ✓ ✓ ✗
Payakachat et al., 200949 AMD ✗ ✗
Ruiz-Moreno et al., 200856 AMD ✓ ✓
Soubrane et al., 200743 AMD ✗ ✗ ✓ ✓
Espallargues et al., 200522 AMD ✗ ✗ Low
Kim et al., 201055 AMD ✓ ✓ ✓ ✓
Datta et al., 200853 Cataracts ✗
Polack et al., 200737 Cataracts ✓ ✓ ✓
Polack et al., 200838 Cataracts ✓ ✓ ✗
Polack et al., 201039 Cataracts ✓ ✓ ✗
Conner-Spady et al., 200558 Cataracts ✓ ✗
Black et al., 200957 Cataracts ✓ ✓
Lloyd et al., 200842 Diabetic
retinopathy
Mixed
evidence
Mixed
evidence
Smith et al., 200850 Diabetic
retinopathy
Mixed
evidence
Mixed
evidence
✓
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Study reference
grouped by measure
(author, year)
Known group (severity) Known group (case–control) Known group (other) Responsiveness
Conditions
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant Correlation
Consistent
evidence Signiﬁcant Reliability
Pitt et al., 200460 Conjunctivitis ✓ ✓
Rajagopalan et al.,
200551
Conjunctivitis ✓ ✓
Smith et al., 200561 Conjunctivitis ✓ ✓
Clark et al., 200862 Other ✓ ✗
Kempen et al., 200363 Other ✓ ✗
Langelaan et al., 200741 Other Mixed
evidence
Mixed
evidence
van Nispen et al., 200952 Other ✓
HUI3
Mittmann et al., 200134 Glaucoma ✓ ✓
Asakawa et al., 200836 Cataracts ✓ ✓
Lloyd et al., 200842 Diabetic
retinopathy
✗ ✗
Boulton et al., 200640 Other ✓ ✓
Quinn et al., 200464 Other ✓ ✓
Espallargues et al., 200522 AMD Low to
moderate
SF-6D
Espallargues et al., 200522 AMD Low to
moderate
1
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Number of potentially relevant records
identified electronically
(n = 119)
Number of citations screened
(n = 119)
Number of full-text articles assessed
(n = 49)
Number of citations excluded
(n = 70)
Number of full-text articles excluded
(n = 31)
Number of papers included in review
(n = 18)
FIGURE 2 Flow diagram showing selection of studies: hearing impairment.
TABLE 5 Characteristics of the studies included in the review: hearing loss
Study reference
(author, year) Country Hearing disorder Treatments
Sample
size (n) Study design
Barton et al., 200521 UK Hearing impaired Hearing aid
(analogue and digital
signal-processing)
609 Prospective
before-and-after
Barton et al., 200665 UK Hearing impaired Cochlear implant 3272 Cross-sectional
Damen et al., 200769 Netherlands Postlingual
deafness
Cochlear implant 83 Prospective
before-and-after
Grutters et al., 200723 Netherlands Hearing impaired Hearing aid 337 Prospective
before-and-after
Hol et al., 200470 Netherlands Conductive or
mixed hearing loss
Bone-anchored
hearing aid
56 Prospective
before-and-after
Joore et al., 2002,71
2002,74 2003,72 200373
Netherlands First-time
hearing-aid users
Hearing aid 126 Prospective
before-and-after
Palmer et al., 199975 Canada and
USA
Severe to profound
hearing impaired
Cochlear implant 62 Prospective
before-and-after
Vuorialho et al.
2006,77 200678
Finland First-time hearing
aid user over 60
Hearing aid 101 Prospective
before-and-after
Lee et al., 200679 South
Korea
Postlingual
deafness
Cochlear implant 26 Retrospective
before-and-after
Bichey et al., 200268 USA Large vestibular
aqueduct syndrome
Cochlear implant and
hearing aid
20 Retrospective
before-and-after
Cheng et al., 200080 USA Profoundly deaf Cochlear implant 140 Retrospective
Sach and Barton,
200776
UK Hearing impaired
children
Unilateral cochlear
implant
222 Retrospective
before-and-after
Lovett et al., 201066 UK Profoundly deaf Cochlear implant
(bilateral and unilateral)
50 Cross-sectional
Smith-Olinde et al.,
200867
USA Permanent
childhood hearing
loss
Cochlear implant 146 Cross-sectional
20
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Measures: hearing impairment
Table 6 summarises the measures used in the 18 papers.21,23,65–80 Eleven papers reported EQ-5D,21,23,70–74,76–79
10 reported HUI321,23,65–69,75,79,80 and one used the SF-6D21 (alongside EQ-5D and HUI3). Among those
studies that used EQ-5D, most reported the EQ-5D index based on the tariff of UK population values. In
two cases, it was unclear which tariff of population values had been used.71,77 Three papers also reported
responses on the EQ-5D dimensions alongside the utility values.72–74 A total of 11 papers reported patients'
rating of own health using VAS66,70–74,76–80 and two used TTO methods.79,80 A total of seven studies
employed self-reported hearing-speciﬁc HRQL measures66,69–71,74,77,78 and seven studies reported clinical
indicators to indicate severity of hearing impairment,23,65,67–69,75,77 including PTA for the best or worst ear
without hearing aid and speech identiﬁcation tests.
Reliability: hearing impairment
The review found little evidence on the reliability assessments of EQ-5D, HUI3 and SF-6D in hearing
impairment. No papers reported test–retest experiments. Although not speciﬁcally for test–retest reliability
purposes, one study71 reported EQ-5D responses and VAS indices at baseline and asked respondents to
recall them 3 months after a hearing aid ﬁtting. The authors did not ﬁnd any signiﬁcant difference
between the baseline assessment and the recalled assessment of baseline health for EQ-5D.
Known-group analysis and convergent validity
Out of the 18 papers included in the review, seven papers provided information to enable an assessment
of the validity of EQ-5D, HUI3 or SF-6D,23,65–68,75,76 although most studies were not designed to examine
the validity of these measures.23,65–68,75,76 The results are summarised in Appendix 5.
Known-group analysis
Seven studies presented data to allow an assessment of known-group differences of HUI3 and EQ-5D
where the groups were deﬁned by the severity of hearing loss.
Assessment for EQ-5D Using ANOVA, the study by Grutters et al.23 demonstrated that EQ-5D failed to
detect signiﬁcant differences by hearing loss severity whereas HUI3 showed a difference. Sach and
Barton76 found that EQ-5D differentiated the group with the most severe hearing loss but not groups
deﬁned by milder levels of deafness.
Assessment for Health Utilities Index Mark 3 Barton et al.65 reported that HUI3 mean scores were
different between moderate, severe, profound and implanted groups but no statistical test was reported.
Palmer et al.75 showed that HUI3 showed signiﬁcant difference between people with and without hearing
aids at two follow-up time points. Similarly, HUI3 discriminated two groups of patients with cochlear
implant and with normal hearing aids where the hearing loss of these two groups was different according
to their PTA.68 In a study comparing HUI3 and the quality of well-being scale (QWB) in hearing loss, both
scores declined with the degree of hearing loss for children who did not have a cochlear implant with a
much greater extent for HUI3 than QWB.67 Another study found that the HUI3 differentiated between
groups deﬁned according to unilateral or bilateral implantation but this was not signiﬁcant as suggested by
the speech measure.66 However, this ﬁnding was also reﬂected in the VAS measure and might reﬂect that
the additional impact of bilateral implantation in this group and the sample size was small.
Convergent validity
Four studies presented data for an assessment of convergent validity of EQ-5D and HUI3.21,23,65,69 HUI3
showed moderate correlation with two speech perception tests, which was consistent with a hearing
speciﬁc QoL measure that also showed similar results.69 Barton et al.65 reported a regression analysis and
showed that for cochlear implant (grouped by age at implantation and duration of use), the average of
pure-tone air-conduction thresholds at different frequencies in the better hearing ear and gender were
signiﬁcant predictors of HUI3 in a large cross-sectional study.65 Grutters et al.23 reported a moderate
correlation between EQ-5D and HUI3 and Barton et al.21 reported strong correlations between EQ-5D,
HUI3 and SF-6D in their study.
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TABLE 6 Measures reported in the papers: hearing loss
Study reference
(author, year)
GPBMs Direct valuation Rating
EQ-5D HUI3 SF-6D TTO VAS Hearing-speciﬁc measures Clinical indicators
Barton et al., 200521 ✓ ✓ ✓
Barton et al., 200665 ✓ AHL
Grutters et al., 200723 ✓ ✓ BEPTA
Lee et al., 200679 ✓ ✓ ✓ ✓
Bichey et al., 200268 ✓ PTA
a
Cheng et al., 200080 ✓ ✓ ✓
Damen et al., 200769 ✓ NCIQ NVA and AN test
Lovett et al., 201066 ✓ ✓ SSQ
Palmer et al., 199975 ✓ NU-6; audiological
mean score for CID
sentence recognition
Smith-Olinde et al., 200867 ✓ BEPTA
Hol et al., 200470 ✓ EQ-VAS HHDI
Joore et al., 200271 Index and responses VAS and EQ-VAS ADPI
Joore et al., 200372 Index and responses VAS and EQ-VAS
Vuorialho et al., 200677 Index and responses ✓ HHIE-S BEHL, SRT, WRS
Joore et al., 200373 ✓ VAS and EQ-VAS
Joore et al., 200274 ✓ VAS and EQ-VAS HHIE-S and hearing
aid satisfaction/use
Sach and Barton, 200776 ✓ EQ-VAS and QoL VAS
Vuorialho et al., 2006b78 ✓ EQ-VAS HHIE-S, hearing
aid satisfaction
ADPI, audiological disabilities preference index; AHL, average hearing level; AN test, Antwerp–Nijmegen hearing test; BEHL, better ear hearing levels; BEPTA, better ear PTA; CID,
central institute for the deaf; HHDI, hearing handicap and disability index; HHIE–S, Hearing Handicap Inventory for the Elderly – Screening; NCIQ, the Nijmegen cochlear implant
questionnaire; NU-6, Northwestern University 6-word test; NVA test, Dutch Audiological Society open speech recognition test; SRT, speech reception thresholds; SSQ, speech, spatial and
qualities of hearing scale for parents; WRS, word reception scores.
a Parents were used as proxies.
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Responsiveness
Twelve papers21,23,66,69–72,74,77–80 involved a total of nine studies that provided adequate information to allow
an assessment of responsiveness of EQ-5D, HUI3 and/or SF-6D (see Appendix 6).
Assessment of EQ-5D
Six studies reported evidence to assess the responsiveness of EQ-5D.21,23,70–72,74,77–79 In most of these studies,
no statistically signiﬁcant changes before and after the hearing intervention were detected23,70–74,77,78 and
the ES where reported were very low. However, for these studies, statistically signiﬁcant improvements
were shown in VAS scores or condition-speciﬁc measures or SF-36 social functioning domain.
Assessment of Health Utilities Index Mark 3 Six studies reported the responsiveness of HUI3.21,23,66,69,79,80
Grutters et al.23 found that HUI2 and HUI3 detected statistically signiﬁcant change after cochlear implant
ﬁtting. The study by Lee et al.77 demonstrated that the increases in EQ-5D, VAS, HUI3 and QWB scores
following cochlear implantation were all statistically signiﬁcant. The results suggest that the EQ-5D
was responsive in capturing larger improvements in hearing, as in the study by Lee et al.,79 but was not
able to capture the smaller levels of improvement shown in the study by Grutters et al.23
Cheng et al.80 found that the change in HUI3 overall score was higher than the change in both VAS and
TTO scores after cochlear implant ﬁtting, but all changes were statistically signiﬁcant. Only the change in
scores on the hearing and speech dimensions of HUI3 were signiﬁcant and the change score was greatest
for the hearing dimension, while scores on other dimensions were stable over time. Moderate correlations
between the change scores of VAS, TTO and HUI3 were found.
Assessment of SF-6D Barton et al.21 detected statistically signiﬁcant differences (p < 0.001) between the
changes in HUI3 and EQ-5D values and between the changes in HUI3 and SF-6D values, but not between
the changes in EQ-5D and SF-6D values.
Summary and conclusion
Overall, the HUI3 was the most commonly used measure in the studies. In all six cases,23,65–68,75 the HUI3
detected a difference between groups deﬁned by their severity of hearing impairment and four23,68,78,79 out
of ﬁve23,66,69,79,80 cases detected statistically signiﬁcant changes as a result of intervention (Table 7).
Differences picked up by the HUI3 were driven by the hearing dimensions and, in some cases, the speech
and emotion dimensions. On the other hand, the ﬁndings of the review suggested relatively poor
responsiveness of EQ-5D in this condition as, in ﬁve23,70–72,74,77,78 out of six cases,23,70–72,74,77–79 EQ-5D failed
to detect change. The studies that allowed an assessment of known groups using the EQ-5D suggested it
had only weak ability to discriminate difference between severity groups. Only one study involved the
SF-6D; thus, the information is too limited to conclude on its performance.21 No studies allowed an
assessment of reliability to be made.
Skin conditions
Search results: skin conditions
The bibliographic search was completed in September 2010. The search of electronic databases identiﬁed
161 records and two additional records were identiﬁed from the EuroQol Group website database.
After reviewing titles and abstracts, 122 records were excluded. Forty-one papers were reviewed in full:
a further 25 papers were excluded and 16 papers were included in the ﬁnal review (Figure 3).
Quality assessment: skin conditions
Three types of study designs were observed in the review. Eleven studies were RCTs,81–91 four studies
were cross-sectional92–95 and one was an uncontrolled before-and-after study.96 The majority of studies
provided clear inclusion and exclusion criteria, but two did not.81,82 Six papers did not report completion
rates82,83,87,88,92,96 and, among the 10 studies reporting this information, completion rates were
reasonable or high (ranging from 70%84 to 97%).94 The completion rates for speciﬁc measures
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TABLE 7 The overall performance of EQ-5D, HUI3 and SF-6D in studies of hearing impairment
Study reference
grouped by measure
(author, year)
Known group (severity) Known group (case–control) Known group (other) Responsiveness
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant Correlation
Consistent
evidence Signiﬁcant Reliability
EQ-5D
Grutters et al., 200723 ✓ ✓ Moderate ✗ ✗
Sach and Barton, 200776 Mixed
evidence
Mixed
evidence
✓ ✓
Lee et al., 200679 ✓ ✓
Hol et al., 200470 ✗ ✗
Joore et al., 2002a,
2002b, 2003a71,72,74
Mixed
evidence
✗
Vuorialho et al., 2006a,
2006b77,78
✗ ✗
Barton et al., 200521 ✓ ✗
HUI 3
Barton et al., 200665 ✓ ✓
Bichey et al., 200268 ✓ N/R
Damen et al., 200769 Moderate ✓ ✓
Grutters et al., 200723 ✓ ✓ Moderate ✓ ✓
Lovett et al., 201066 ✓ ✗ ✓ ✗
Palmer et al., 199975 ✓ ✓
Smith-Olinde et al., 200867 ✓ N/R
Lee et al., 200679 ✓ ✓
Cheng et al., 200080 ✓ ✓
Barton et al., 200521 ✓ ✓
SF-6D
Barton et al., 200521 Strong ✓ ✓
N/R, not reported.
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(e.g. item non-response) were generally high (above 90%).82,91,92,95 No study was excluded after the
assessment of quality.
Study design and patients' characteristics: skin conditions
The main characteristics of the 16 papers included in this review are shown in Table 8.81–96 Studies were
conducted in various European and American countries, with several multinational studies. All but four
studies recruited patients with psoriasis or psoriatic arthritis;82–88,92–96 the remaining studies recruited
patients with acne,81 eczema,90 hidradenitis suppurativa89 or venous leg ulcers.91 All studies included adults
(mean age approximately 43 years), and male respondents accounted for 24–71% of the samples.
Sample sizes ranged from 3291 to 27,994,95 with most studies including between 100 and
200 participants.
Measures used in studies: skin diseases
Table 9 summarises the measures that have been used in the 16 studies included in the review. Of the
three GPBMs of interest, only those studies reporting EQ-5D were identiﬁed and included in the review.
No studies reported data from SF-6D or HUI3. Fourteen studies also reported patients' valuation of their
own health states using VAS.81,82,84–89,90–92,94–96 Clinical indices were reported in studies to indicate severity
of skin problems, including the Psoriasis Area Severity Index (PASI) by eight studies,85–88,92,94–96 Nail Psoriasis
Severity Index (NAPSI) by one study,96 and the Acne Grade by one study.81 Various generic measures
[e.g. SF-36, Health Assessment Questionnaire – Disability Index (HAQ-DI), Health Assessment Questionnaire
(HAQ)], skin-speciﬁc HRQL measures [e.g. Dermatology Life Quality Index (DLQI)], or symptom-speciﬁc
HRQL measures (e.g. HADS, the Depression Inventory) were included in the studies (see Table 9).
Reliability: skin conditions
No study reported data on reliability of the three GPBMs.
Known-group analysis and convergent validity: skin conditions
Thirteen studies of patients with skin conditions provided sufﬁcient evidence to allow assessment of
known-group analysis and convergent validity of EQ-5D81–85,88–93,95,96 including: 12 known-group
analyses82–86,88–93,96 and seven convergent validity analyses.83,87,89–92,95 A summary of the ﬁndings is
presented below. See Appendix 7 for details.
Number of potentially relevant records
identified electronically
(n = 163)
Number of citations screened
(n = 163)
Number of full-text articles assessed
(n = 41)
Number of citations excluded
(n = 122)
Number of full-text articles excluded
(n = 25)
Number of papers included in review
(n = 16)
FIGURE 3 Flow diagram showing selection of studies for skin review.
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Plaque psoriasis and psoriatic arthritis
Known-group analysis Eight studies provided evidence of known-group validity for EQ-5D among people
with psoriasis or psoriatic arthritis.82–85,87,92,93,96 Three studies showed that EQ-5D was able to
discriminate between severity groups on the basis of psoriatic arthritis and psoriasis,93 treatments,84 pain
and nail psoriasis.96 Three case–control studies conﬁrmed that EQ-5D can differentiate between people
TABLE 8 Characteristics of studies included: skin diseases
Study reference
grouped by condition
(author, year) Country Treatment
Sample
size Study type
Plaque psoriasis and psoriatic arthritis
Bansback et al., 200683 UK Methotrexate with and without
ciclosporin A
72 RCT
Brodszky et al., 201092 Hungary None 183 Cross-sectional
Christophers et al., 201093 Multiple None 1660 Cross-sectional
Daudén et al., 200984 Multiple Continuous vs. paused
subcutaneously therapy
720 RCT
Van de Kerkhof 200482 Multiple Two-compound product
(+ ointment vehicle, once daily),
Two-compound product
(twice daily), calcipotriol
(Dovonex®, LEO) (twice daily),
ointment vehicle (twice daily)
828 RCT
Luger et al., 200996 Multiple Continuous and paused
etanercept therapy
130 Before-and-after
Reich et al., 200985 Multiple Etanercept 720 RCT
Revicki et al., 200894 Multiple Adalimumab (Humira®, AbbVie),
methotrexate, placebo
54 Cross-sectional
Shikiar et al., 200695 USA and Canada Subcutaneously administered
adalimumab vs. placebo
27994 Cross-sectional
Shikiar et al., 200786 USA and Canada Subcutaneously administered
adalimumab vs. placebo
142 RCT
Weiss et al. 200287 USA N/R (only baseline data were reported) 271 RCT
Weiss et al. 200688 USA Topical therapy vs. combination
clobetasol solution
147 RCT
Acne
Klassen et al. 200081 UK Isotretinoin or antibiotic, hormonal,
physical and topical treatments
148 RCT
Hidradenitis suppurativa
Matusiak et al. 201089 Poland N/R 233 RCT
Hand eczema
Moberg et al. 200990 Sweden N/R 35 RCT
Venous leg ulcers
Walters et al. 199991 UK Compression bandaging in a
community clinic setting vs.
usual home-based care by
district nursing services
32 RCT
N/R, not reported.
26
NIHR Journals Library www.journalslibrary.nihr.ac.uk
PSYCHOMETRIC PROPERTIES OF GENERIC PREFERENCE-BASED MEASURES OF HEALTH
TABLE 9 Measures used in the studies included in the skin review
Study reference
grouped by condition
(author, year)
GPBMs Direct valuation Rating scale Generic or condition speciﬁc HRQL instruments
EQ-5D SF-6D HUI3 TTO VAS SF-36 DLQI PASI Others
Plaque psoriasis and psoriatic arthritis
Bansback et al., 200683 ✓ HAQ-DI
Brodszky et al., 201092 ✓ ✓ (pain, global
assessment)
✓ PsAQoL, HAQ, PASI, DAS28, BASDAI,
swollen joint count, tender joint count,
EQ-VAS, patient pain VAS, patient global
assessment VAS
Christophers et al., 201093 ✓ BSA, employment disadvantage
questionnaires
Daudén et al., 200984 ✓ ✓ ✓ ✓ HADS, PSS, BSA, PGA
Van de Kerkhof 200482 ✓ ✓ Psoriasis Disability Index
Luger et al., 200996 ✓ ✓ ✓ ✓ ✓ HADS, SGA, PGA, BSA, NAPSI
Reich et al., 200985 ✓ ✓ ✓ ✓ FACIT-F, BSA
Revicki et al., 200894 ✓ ✓ ✓ ✓
Shikiar et al., 200695 ✓ ✓ ✓ ✓ ✓ PGA
Shikiar et al., 200786 ✓ ✓ ✓ ✓ ✓ PGA
Weiss et al., 200287 ✓ ✓ ✓ SAPASI, SWLS
Weiss et al., 200688 ✓ ✓ ✓ ✓ SAPASI, BSA
continued
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TABLE 9 Measures used in the studies included in the skin review (continued )
Study reference
grouped by condition
(author, year)
GPBMs Direct valuation Rating scale Generic or condition speciﬁc HRQL instruments
EQ-5D SF-6D HUI3 TTO VAS SF-36 DLQI PASI Others
Acne
Klassen et al., 200081 ✓ ✓ ✓ Acne grade
Hidradenitis suppurativa
Matusiak et al., 201089 ✓ ✓ ✓ BDI-SF, FACIT-F, QLES-Q, GQ 6-item
scale, Hurley’s classiﬁcation
Hand eczema
Moberg et al., 200990 ✓ ✓
Venous leg ulcers
Walters et al., 199991 ✓ ✓ ✓ FAI, SF-MPQ, self-perceived transition
question (item 2 of SF-36) with three
scales: better, same and worse compared
with 3 months earlier
BASDAI, the Bath Ankylosing Spondylitis Disease Activity Index; BDI-SF, Beck Depression Inventory – short form; DAS28, the 28 joint disease activity score; FACIT-F, Functional Assessment
of Chronic Illness Therapy – Fatigue; FAI, the Frenchay Activities Index; GQ, Global Question index; PGA, Physician Global Assessment; PsAQoL, Psoriatic Arthritis Quality of Life Scale;
PSS, patient satisfaction survey; QLES-Q, Quality of Life Enjoyment and Satisfaction Questionnaire; SAPASI, self-administered PASI; SF-MPQ, Short Form McGill pain questionnaire;
SGA, subject global assessment (for joint pain); SWLS, Satisfaction With Life Scale.
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with psoriasis and the general population.82,85,87 Brodszky et al.92 found that the standard mean difference
between groups measured by EQ-5D were comparably lower than measured with the Psoriatic Arthritis
Quality-of-Life Scale (PsAQoL) or the HAQ; however, the groups were deﬁned not according to
severity aspects, but according to possible surrogate markers of severity such as admission to hospital or
use of devices.92
Convergent validity Good convergent validity of EQ-5D was found among people with psoriasis
or psoriatic arthritis in four studies.83,88,92,95 Three studies showed moderate or strong correlation between
EQ-5D and other generic or skin-speciﬁc measures.87,92,95 Bansback et al.83 suggested that the HAQ
disability index was a signiﬁcant predictor of EQ-5D.
Other skin conditions
Four studies had sufﬁcient information to allow assessment of construct and convergent validity in various
skin conditions.81,89–91
Known-group analysis In a case–control study, Klassen et al.81 found that people with acne reported
more problems on most EQ-5D dimensions than the general population. Among those with hidradenitis
suppurativa, Matusiak et al.89 found that signiﬁcant differences according to the severity groups deﬁned
by Hurley's classiﬁcation groups were suggested by EQ-5D, EQ-VAS, DLQI, the Beck Depression
Inventory-Short Form (BDI-SF) and other measures. Among patients with hand eczema, Moberg90
suggested that EQ-5D and EQ-VAS signiﬁcantly differ between groups deﬁned according to whether they
have hand eczema groups, as well as age and gender. For venous leg ulcer patients, Walters et al.91
reported small ESs for the EQ-5D, EQ-VAS, SF-36 and Frenchay Activities Index (FAI) for patients grouped
on the basis of their initial leg ulcer size, current ulcer duration, maximum ulcer duration and age; however,
the differences were statistically signiﬁcant only for the EQ-5D, EQ-VAS, FAI and ﬁve subscales of the SF-36.
Convergent validity Among those with hidradenitis suppurativa, moderate correlation was reported
between EQ-5D with DLQI and EQ-5D with Functional Assessment of Cancer Therapy – Fatigue module
(FACT-F). Moberg et al.90 found strong correlation between EQ-5D and EQ-VAS among hand eczema
patients, and, similarly, Walters et al.91 found moderate to high correlations with SF-36 subscales.
Responsiveness: skin conditions
A total of 10 studies provided evidence to allow assessment of responsiveness of EQ-5D in skin
diseases.81,82,84–86,88,91,94–96 Among them, eight studies included people with psoriasis or psoriatic
arthritis,82,84–86,88,94–96 one study included people with acne81 and one study focused on venous leg ulcers.91
Ten studies examined changes of scores over time or after treatment,81,82,84–86,88,91,94–96 and two provided
details of ES or standard response mean estimation.81,91 One study checked the correlation between
change scores of health measures with changes in clinical measures95 (see Appendix 8).
Plaque psoriasis or psoriatic arthritis
All eight studies among people with psoriasis or psoriatic arthritis conﬁrmed that EQ-5D was responsive to
change in health over time in these conditions.82,84–86,88,94–96 Daudén et al.84 reported that consistent with
EQ-VAS, DLQI, HADS-anxiety subscale and the SF-36 vitality dimension, EQ-5D values improved
signiﬁcantly and clinically meaningfully from baseline for both treatment groups. Luger et al.96
demonstrated that EQ-5D values improved signiﬁcantly (by 29%), as did scores from the EQ-VAS, DLQI,
the SF-36 vitality dimension, HADS-depression subscale and HADS-anxiety subscale among patients with
joint pain; however, the improvement reported using EQ-5D was not signiﬁcant for patients with nail
psoriasis, whereas improvement using the other measures was signiﬁcant.96 Reich et al.85 reported that, at
both follow-up time points, the group who received active treatment achieved signiﬁcant improvement
compared with placebo, measured using EQ-5D, EQ-VAS, FACT-F and DLQI (both total and domain
scores). Similarly, Revicki et al.94 reported that a statistically signiﬁcant improvement was detected for
treatment groups by EQ-5D, DLQI and PASI and the difference between treatment and placebo groups
was signiﬁcant. Shikiar et al.86,95 also conﬁrmed that the two treatment groups improved signiﬁcantly more
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than placebo, measured using EQ-5D, EQ-VAS, DLQI, and most SF-36 domains. Weissi et al.88
reported that, after 2 weeks of therapy, scores of EQ-5D, EQ-VAS, PASI, body surface area (BSA) and
self-administered PASI (SAPASI) all improved signiﬁcantly. Van de Kerkhof82 showed that a signiﬁcant
improvement was detected by EQ-VAS, Psoriasis Disability Index, and the pain/discomfort and
anxiety/depression dimensions of EQ-5D, although no statistical tests were reported.
Acne
Klassen et al.81 reported that EQ-5D detected a signiﬁcant change after treatment and this was consistent
with SF-36 physical component summary score and DLQI. A moderate ES for EQ-5D was reported.
Venous leg ulcers
Walters et al.91 reported mixed results in a study of compression healing of venous leg ulcers in different
settings. When patients were grouped according to the status of the leg ulcer healing at 3 months, both
EQ-5D and SF-36 showed deterioration in health status, but this conﬂicted with data from the VAS and
the Short Form McGill pain questionnaire (SF-MPQ).
Summary and conclusion: skin conditions
The overall performance of EQ-5D among skin diseases is summarised in Table 10. Overall, there was
evidence to suggest that EQ-5D is appropriate in terms of construct and convergent validity, as well as
responsiveness in some skin conditions. All six studies showed that EQ-5D was able to reﬂect differences
between severity groups84,89–91,93,96 and only one was not signiﬁcant.91 EQ-5D was shown to be able to
signiﬁcantly differentiate between patient and general populations in four case–control studies85,86–88 (one
study did not report statistical tests),82 as well as groups deﬁned by other aspects rather than severity.
Moderate to strong correlations were found between EQ-5D and other measures. Nine81,82,84–86,88,94–96 out
of 10 studies81,82,84–86,88,91,94–96 demonstrated that EQ-5D was able to detect change appropriately over time.
Among these, only one study did not demonstrate a statistically signiﬁcant difference.82 ‘Skin conditions’
were deﬁned in very broad terms for the purpose of the review and incorporate a range of conditions,
each of which can affect different aspects of patients' QoL. Most of the studies identiﬁed were conducted
for patients with psoriasis or psoriatic arthritis. Evidence was limited or unavailable for other skin
conditions; however, the limited data available were generally positive. No studies reported evidence for
HUI3 and SF-6D and no studies allowed an assessment of reliability for any of the measures.
Cancer
Search results: cancer
Bibliographic searching was completed in August 2010. A total of 5223 potentially relevant papers were
identiﬁed. Overall, a total of 5000 papers were excluded following screening of title and abstract. Full
papers were reviewed for the remaining 223 records which met the inclusion criteria. After reviewing the
full papers, 125 were excluded and a total of 98 papers were included in the review. A ﬂow chart of the
study selection process is shown in Figure 4.
The 98 papers were grouped according to 20 different types of cancers. These included 18 papers on
non-speciﬁc cancers,97–114 11 each for colon cancer115–125 and cancer survivors,126–136 10 for breast
cancer,137–146 eight for gastric cancer147–154 and seven for prostate cancer,155–161 and a small number of
papers for brain,162,163 cervical,164–167 kidney,168–171 lung103,172,173 and other cancers101,124,174–188
(Table 11 gives details). As different cancers affect HRQL in different ways, the following sections present
data according to the different types of cancer.
Quality assessment: cancer
A range of study designs were observed in the review. Some were cross-sectional studies,13,97–99,102,103,106–108,
114,115,121,126,128–130,133,137,138,147,148,151,152,156,161,163,164,173,183,184,189 others were before-and-after studies110,112,116,117,120,
123,139,140,145,190 or cohort studies100,141,142,155,157,158,160,162,191 and many were RCTs.118,119,122,125,132,136,143,144,146,149,150,
153,154,159,161,165,166,168–171,176,177,180–182,188,192,193 Most RCTs had clear inclusion and exclusion criteria and
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TABLE 10 Overall performance of EQ-5D in studies of skin diseases (continued )
Study reference
grouped by measure
(author, year)
Known group (severity) Known group (case–control) Known group (other) Responsiveness
Conditions
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant Correlation
Consistent
evidence Signiﬁcant Reliability
Revicki et al., 200894 Plaque
psoriasis
✓ ✓
Shikiar et al., 200695 Psoriasis Moderate
to strong
✓ ✓
Shikiar et al., 200786 Psoriasis ✓ ✓
Weiss et al., 200287 Psoriasis ✓ ✓ Moderate
(signiﬁcant)
✓ ✓
Weiss et al., 200688 Psoriasis
Klassen et al., 200081 Acne ✓ ✓ ✓ ✓
Matusiak et al., 201089 Hidradenitis
Suppurativa
✓ ✓ Moderate
Moberg et al., 200990 Hand
eczema
✓ ✓ ✓ ✓ Strong
Walters et al., 199991 Venous
leg ulcers
✓ N/R ✓ N/R Moderate Mixed
evidence
N/R
N/R, not reported.
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Number of potentially relevant records
(n = 5223)
Number of citations screened
(n = 5223)
Number of full-text articles assessed
(n = 223)
Number of citations excluded
(n = 5000)
Number of full-text articles excluded
(n = 125)
Number of papers included in review
(n = 98)
FIGURE 4 Flow diagram showing selection of studies: cancer.
TABLE 11 Number of papers included in the review by type of cancer
Cancer type Number of papers
Non-speciﬁc 18
Brain 2
Breast 10
Cervical 4
Colon 11
Gastric 8
Hodgkin's lymphoma 2
Kidney 5
Leukaemia and related 3
Liver 3
Lung 2
Lymphoma 3
Lymphoma/leukaemia 2
MM 2
MM/lymphoma 1
Musculoskeletal 1
Pancreatic 1
Prostate 8
Spinal metastases 1
Survivors 11
Total 98
MM, multiple myeloma.
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appropriate and explicit methods of randomisation. In some studies, the inclusion criteria were not clearly
reported, which occurred mainly for studies of non-speciﬁc cancers.97–100
Response rates varied between studies. Completion rates for breast cancer studies ranged from 74%141
to 99%143 and for colon cancer ranged from 67%115 to 90%.120 No study was excluded after the
assessment of quality.
Study characteristics: cancer
General characteristics of the 98 studies are presented in Table 12. These studies were divided into 20
subgroups according to different types of cancer. Thirty-three studies were cross-sectional analyses,97–99,102,
103,106–108,114,115,121,126–130,133,137,138,147,148,151,152,156,161,163,164,173,181–184,189 24 were RCTs,118,119,122,125,143,144,146,149,150,
153,154,159,165,166,168–171,176,177,180,188,192,193 24 were before-and-after or longitudinal studies99,101,105,109,111–113,116,117,
120,123,125,140,145,154,162,167,172,174,178,179,185,187,190 and nine were cohort studies.100,104,141,142,155,157,158,160,191
Most groups included a mixture of study designs, exceptions were kidney cancer168,169,170,171,193 and
lymphoma177,188,192 which were all RCTs and both lung cancer studies103,173 had cross-sectional designs.
The selected studies were conducted in different countries across Europe, Asia and North America and
eight were multinational studies.118,146,157,168–171,193 Various treatments were included in the studies
including types of surgery,117,141 radiotherapy and chemotherapy,100,137,162,175 other medicines and
supportive care interventions or referral.118,143,165,166 Most studies included adults, but some were collected
data from children using HUI including studies of brain cancer,163 Hodgkin's lymphoma,185,190 and a
couple of the studies where recruitment was not limited to a speciﬁc type of cancer.98,99,105,107
The inclusion criteria for recruiting patients varied across the studies reviewed and within each type of
speciﬁc cancer. Some studies recruited patients according to speciﬁc stages of cancer patients, for example
primary tumours,162 stage II and III breast cancer with poor prognosis,140 tumour stage I, II and III breast
cancer144 and advanced colorectal cancer.119 Some studies involved patients after screening, for example
studies of screening for cervical cancer.164–167 For these screening studies, some of the respondents would
be asymptomatic and therefore the GPBMs and other measures may not be expected to reﬂect
differences between patients with and without cancer. Sample size varied across studies, ranging from
18112 to 113,587.99
Measures: cancer
Table 13 summarises the measures that have been used in the 98 studies included in the review. For the
three GPBMs of interest, EQ-5D was the most commonly used and was reported by 71 studies.97,98,100,101,
103–107,110–123,128,129,137–140,145–154,143,144,156–160,164–173,175–177,179–184,186,188,192–194 Twenty-four studies reported
HUI2/HUI399,108,109,126,127,130,131–136,141,142,155,161,162,163,174,178,185–187,190 and only three studies reported
SF-6D.98,147,156 Two studies101,143 used EQ-5D and HUI3 alongside other measures and another three
studies98,147,156 use both EQ-5D and HUI3 alongside other cancer-speciﬁc measures. Fifty-eight studies also
reported patients' ratings of their own health status using VAS97,98,100–104,106–109,111,112,114–118,120–123,129,137–140,
142–145,148,149,151–155,159,164–166,168–172,175,177,179–181,183–185,190,193,194 and valuations of own health were reported in
three studies using TTO101,138,174 and in one study using the SG method.161 Five studies also reported
generic measures SF-12 or SF-36.120,141,164,173,184 A wide range of cancer-speciﬁc measures of health were
used, including the most commonly used European Organization for Research and Treatment of Cancer
Quality-of-life Questionnaire (EORTC QLQ) in 26 studies100,101,111,115–117,121,124,128,129,144,146,147,149–151,153,154,
172,179,180,182,183,188,192,193 and the FACT in 13 studies.102,103,105,106,114,118,120,123,129,143,171,176,190 A range of other
measures were reported, including variations of the previously mentioned cancer-speciﬁc HRQL
measures such as the EORTC QLQ-Core 38 (EORTC QLQ-C38), staging of cancer progression using various
staging systems and other measures of symptoms or aspects of health such as the HADS (see Table 13 for
details). Many studies used multiple measures and did not always give consistent results, which make
conclusions regarding concordance with results from the GBPMs more difﬁcult to interpret.
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TABLE 12 Characteristics of included studies: cancer review
Study reference
grouped by condition
(author, year) Country Sample size Disease stage Treatment Study type
Brain cancer
Le Gales et al., 1999163 France 43 Children with medulloblastoma Standard treatment protocols Cross-sectional
McCarter et al., 2006162 Canada 93 Primary tumours Radiotherapy and/or chemotherapy
and surgery
Prospective
longitudinal
Breast cancer
Chang et al., 2004143 Canada 354 Mildly anaemic (haemoglobin level
≤12g/dl) women with breast cancer
Epoetin alfa (40,000 international units
once weekly) vs. standard of care
RCT
Conner-Spady et al., 2001139 Canada 52 Stage II and III breast cancer High-dose chemotherapy with
autologous blood stem transplantation
Before-and-after
Conner-Spady et al., 2005140 Canada 52 Stage II and III breast cancer with poor
prognosis
High-dose chemotherapy with
autologous blood stem transplantation
Before-and-after
Crott et al., 2010146 5 European countries
including UK
220 Locally advanced Cyclophosphomide, epirubicin and
ﬂuorouracil vs. dose-intensiﬁed
epirubicin and
cyclophosphomide-ﬁlgrastim
RCT
Freedman et al., 2010145 USA 1050 Early stage breast cancer
(stage 0, I, II invasive breast cancer)
Breast conserving surgery and radiation Before-and-after
Jansen et al., 2004137 Netherlands 448 Early stage breast cancer Adjuvant chemotherapy (choice
regarding treatment with adjuvant
chemotherapy)
Cross-sectional
Kimman et al., 2009144 Netherlands 192 Breast cancer (tumour stage I, II, III and
unknown)
Curative treatment: surgery and/or
radiotherapy and/or chemotherapy
RCT
Lidgren et al., 2007138 Sweden 361 Consecutive breast cancer N/R Cross-sectional
Lovrics et al., 2008141 Canada 85 Breast cancer (tumour grade I, II, III) Breast-conservation surgery Cohort
Polsky et al., 2002142 USA 1159 Primary T1 or T2, N0 or N1, or NX
and M0 invasive breast carcinoma.
People aged over 67 years and
community dwelling
Mastectomy, breast conservation with
radiation, breast conservation only.
Choice regarding breast cancer
treatment
Cohort study
continued
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TABLE 12 Characteristics of included studies: cancer review (continued )
Study reference
grouped by condition
(author, year) Country Sample size Disease stage Treatment Study type
Cervical cancer
Korfage et al., 2010164 Netherlands 622 Low grade abnormalities after screening N/R Cross-sectional
Maissi et al., 2005167 UK 1011 Screening tested for either human
papillomavirus (HPV) or abnormal smear
or normal smear
N/R Prospective
longitudinal
Whynes et al., 2008165 UK 3132 Low-grade abnormalities after screening Control: cytological surveillance
Intervention: immediate referral to
colposcopy
RCT
Whynes et al., 2008166 UK 191 Low-grade abnormalities after screening Control: cytological surveillance
Intervention: immediate referral to
colposcopy
RCT
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Study reference
grouped by condition
(author, year) Country Sample size Disease stage Treatment Study type
Colon cancer
Anderson and
Palmer, 1998119
UK 545 Advanced colorectal cancer Raltitrexed (Tomudex®, Hospira) vs.
Standard 5-ﬂuorouracil (5-FU) plus
leucovorin
RCT
Colwell et al., 2010125 USA 391 Metastatic colorectal cancer Panitumumab (Vectibix®, Amgen) plus
best supportive care vs. best supportive
care alone
RCT
Doornebosch et al., 2007115 Netherlands 62 T1 carcinoma after surgery (TEM),
T1 to T3 (35%) (TME)
Total mesorectal excision vs. transanal
endoscopic microsurgery
Cross-sectional
Doornebosch et al., 2008116 Netherlands 47 People with rectal cancer eligible for
TEM
Transanal endoscopic microsurgery Before-and-after
Gosselink et al., 2006121 Netherlands 204 People with rectal cancer in the middle
or low third of the rectum after total
mesorectal excision
Abdominoperineal resection, transanally
double stapled low colorectal anastomosis,
coloanal J-pouch anastomosis
Cross-sectional
Hamashima, 2002117 Japan 110 Rectal cancer patients who had received
surgery as their initial treatment
Surgery Before-and-after
Janson et al., 2007122 Sweden 285 Elective colon cancer patients with
potentially curable cancer best treated
by right or left hemicolectomy or
sigmoid resection
Laparoscopic colon resection vs. open
resection
RCT
Ramsey et al., 2000191 USA 74 (phase 1),
98 (phase 2)
Colon carcinoma survivors with TNM
stage I–IV
Colon cancer related treatment
including surgery, chemotherapy,
radiation therapy, colostomy appliance
Before-and-after
Sharma et al., 2007123 UK 104 Newly diagnosed colorectal cancer
scheduled for elective open resection
Elective open resection Before-and-after
Siena et al., 2007118 Multinational 463 Metastatic colorectal cancer patients
who had progressed on prior
ﬂuoropyrimidine, irinotecan and
oxaliplatin
Panitumumab plus best supportive care
vs. best supportive care alone
RCT
Wilson et al., 2006120 UK 210 Patients undergoing potentially curable
open surgery for colorectal cancer
Surgery Before-and-after
continued
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TABLE 12 Characteristics of included studies: cancer review (continued )
Study reference
grouped by condition
(author, year) Country Sample size Disease stage Treatment Study type
Gastric (and related) cancer
Homs et al., 2004149 Netherlands 209 Patients with dysphagia from inoperable
oesophageal carcinoma
Arm 1: stent placement
Arm 2: single-dose brachytherapy
RCT
Kontodimopoulos et al.,
2009147
Greece 48 N/R Surgery and 2–4 previous chemotherapy
sessions
Cross-sectional
(mapping)
McMillan et al., 1999153 UK 73 Histologically proven advanced or
metastatic gastrointestinal cancer
Arm 1: megestrol acetate (Megace®,
Bristol-Myers Squibb) and ibuprofen
Arm 2: megestrol acetate and placebo
RCT
O’Gorman et al., 1998151 UK 119 Histologically proven advanced or
metastatic gastrointestinal cancer
N/R Cross-sectional
Rogers et al., 2006148 UK 224 Oral and oropharyngeal squamous cell
carcinoma patients
Primary surgery Cross-sectional
Shenﬁne et al., 2009150 UK 215 Patients with dysphagia due to
oesophageal carcinoma
Arm 1: 18mm stent
Arm 2: 24mm stent
Arm 3: rigid stent
Arm 4: non-stent treatments
RCT
Verschuur et al., 2009154 Netherlands 109 Patients after surgery for oesophageal or
gastric cancer
Arm 1: standard follow-up by surgeons
at an outpatient clinic
Arm 2: home visits by specialist nurse
RCT
Wildi et al., 2004152 USA 50 Newly diagnosed adenocarcinoma/
squamous cell carcinoma of the
oesophagus
N/R Cross-sectional
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Study reference
grouped by condition
(author, year) Country Sample size Disease stage Treatment Study type
Hodgkin’s lymphoma (children)
Klaassen et al., 2010185 Canada 49 New presentation of Hodgkin lymphoma First and second course of
chemotherapy and radiation
Longitudinal
Klaassen et al., 2010186 Canada 49 New presentation of Hodgkin lymphoma First and second course of
chemotherapy and radiation
Longitudinal
Kidney cancer
Castellano et al., 2009171 Multinational 304 mRCC Sunitab (Sutent®, Pﬁzer) RCT
Cella et al., 2008169 Multinational 750 mRCC Sunitab RCT
Cella et al., 2010168 Multinational 750 mRCC Sunitab RCT
Sternberg et al., 2010193 Multinational 435 aRCC Oral pazopanib (Votrient®, GSK)
Placebo
RCT
Yang et al., 2010170 Multinational 270 aRCC Temsirolimus (Torisel®, Pﬁzer) RCT
Leukaemia cancer
Barr et al., 1997174 Canada 18 Acute lymphoblastic leukaemia Continuing chemotherapy Prospective
longitudinal
Cox et al., 2005187 USA 27 Acute lymphoblastic leukaemia Frontline protocol Longitudinal
Hahn et al., 2003176 USA 865 Chronic myeloid leukaemia Arm 1: imatinib (Glivec®, Novartis)
Arm 2: interferon alfa plus
low-dose cytarabine
RCT
continued
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TABLE 12 Characteristics of included studies: cancer review (continued )
Study reference
grouped by condition
(author, year) Country Sample size Disease stage Treatment Study type
Liver metastases
Langenhoff et al., 2006180 Netherlands 97 Colorectal liver metastases Arm 1: surgical treatment of liver
metastases
Arm 2: inoperable disease and
underwent exploratory laparotomy only
Arm 3: patients with inoperable disease
who were not scheduled for operation
as were groups 1 and 2
RCT
Mendez Romero et al., 2008172 Netherlands 28 Metastatic liver tumour Stereotactic body radiation therapy Longitudinal
Krabbe et al., 2004179 Netherlands 75 Liver metastases Liver surgery to eradicate metastatic
disease
A: resection
B: local ablative therapy
C: unresectable (so no surgery)
Prospective
longitudinal
Lung cancer
Pickard et al., 2007103 USA 50 Advanced lung cancer At least two cycles of chemotherapy Cross-sectional
Trippoli et al., 2001173 Italy 95 Non-small cell lung cancer Resection, chemotherapy and/or
radiotherapy
Cross-sectional
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Study reference
grouped by condition
(author, year) Country Sample size Disease stage Treatment Study type
Lymphoma cancer
Doorduijn et al., 2005188 Netherlands 132 Patients with newly diagnosed
aggressive non-Hodgkin's lymphoma
Cyclophosphamide, doxorubicin,
vincristine, prednisone chemotherapy
RCT
Van Agthoven et al., 2001177 Netherlands 91
PBSCT: 62
ABMT: 29
Intermediate or high-grade Morbus
Hodgkin or non-Hodgkin's lymphoma
who relapsed after or were refractory to
primary chemotherapy
Arm 1: autologous peripheral blood
stem cell transplantation
Arm 2: autologous bone marrow
transplantation
RCT
Witzens-Harig et al., 2009192 Germany 91
Treatment: 47
Observation:
44
Patients with CD20+ B cell
non-Hodgkin's lymphoma
Arm 1: maintenance therapy with
rituximab (MabThera®, Roche) every
3 months for 2 years
Arm 2: observation
RCT
ML/AML
Banks et al., 2008178 Canada 29 N/R One course of chemotherapy Longitudinal
study of patient
and proxy
report
Slovacek et al., 2007181 Czech Republic Total: 36
ML: 24/AML:
12
N/R Haematopoietic stem cell transplantation Retrospective
cross-sectional
continued
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TABLE 12 Characteristics of included studies: cancer review (continued )
Study reference
grouped by condition
(author, year) Country Sample size Disease stage Treatment Study type
MM
Slovacek et al., 2007182 Czech Republic 32 N/R High-dose chemotherapy followed by
autologous peripheral blood progenitor
cell transplantation
Retrospective
cross-sectional
Uyl-de-Groot et al., 2005124 Netherlands 51 Newly diagnosed MM Tandem transplantation programme Prospective
longitudinal
MM/ML
Slovacek et al., 2007181 Czech Republic 80 recruited.
56 (70%)
returned
questionnaires
N/R Progenitor stem cell transplantation Retrospective
cross-sectional
Musculoskeletal cancer
Lee et al., 2003184 South Korea 49 Patients who had been operated on for
malignant musculoskeletal tumours and
could walk unassisted
Surgery Cross-sectional
Pancreatic cancer
Mueller-Nordhorn et al.,
2006183
Germany 45 First admission to hospital with expected
pancreatic cancer
N/R Cross-sectional
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Study reference
grouped by condition
(author, year) Country Sample size Disease stage Treatment Study type
Prostate cancer
Albertsen et al., 1998155 USA 84 Localised Management Cohort
Krahn et al., 2003161 Canada 235 All prostate cancer stages Prostatectomy
Radiotherapy
Hormonal therapy
Cross-sectional
Krahn et al., 2007160 Canada 248 1: patients undergoing treatment
2: patients with metastatic prostate cancer
3: all other prostate cancers, majority
post treatment
Prostatectomy
Radiation/hormonal therapy (cohort 1)
Cohort
Sandblom et al., 2004158 Sweden 1442 Palliative Full range of palliative treatments Cohort
Shimizu et al., 2008156 Shimizu 330 Localised and advanced Prostatectomy
Radiotherapy
Brachytherapy
Hormonal therapy
Watchful waiting
Cross-sectional
Sullivan et al., 2007157 Multinational 280 Hormone refractory (advanced
or metastatic)
Chemotherapy
Laser ablation
Radiotherapy
Other treatments
Cohort
Weinfurt et al., 2005159 USA 643 Advanced Zoledronic acid vs. placebo RCT
continued
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TABLE 12 Characteristics of included studies: cancer review (continued )
Study reference
grouped by condition
(author, year) Country Sample size Disease stage Treatment Study type
Spinal metastases
Falicov et al., 2006101 Canada 85 Cancer with bony spinal metastases Surgery for spinal metastases Prospective
longitudinal
Non-specific cancer
Barton et al., 200898 UK 2770 N/R N/R Cross-sectional
Bowker et al., 200699 Canada 113,587 N/R N/R Cross-sectional
Capuano et al., 2008107 Italy 164 No previous oncological treatment N/R Cross-sectional
Cheung et al., 2009105 Singapore 558 Various Various (54.7% currently on
chemotherapy/radiotherapy)
Longitudinal
Chow et al., 2010106 Singapore 316 Various Complementary and alternative
medicine
Cross-sectional
Kim et al., 2008113 Korea 42 Various. All experiencing nausea or
insomnia
Mirtazapine Longitudinal
Lathia et al., 2008
(abstract only)102
Canada N/R Various. All experiencing febrile
neutropaenia
N/R Cross-sectional
Mantovani et al., 2004111 Italy 28 Advanced disease Pharmaconutritional support for 16
weeks
Non-randomised
Norum, 1996100 Norway 125 N/R Radiotherapy and/or chemotherapy Cohorts
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Study reference
grouped by condition
(author, year) Country Sample size Disease stage Treatment Study type
Park et al., 2006191 Korea 293 Palliative care Palliative care Cohort study
Pickard et al., 2007114 USA 534 Advanced (stages III and IV) Various Cross-sectional
Pickard et al., 2007190 USA 424 Various N/R Cross-sectional
Ravasco et al., 2003104 Portugal 125 Various Nutritional counselling and radiotherapy Prospective
cohort
Sung et al., 2003108
(children)
Canada 36 Various (child patient, parent
respondent)
Chemotherapy Cross-sectional
Trudel et al., 1998109
(children)
Canada 61 Various (child patient) Assessed during treatment and
follow-up
Longitudinal
Vaghela et al., 2007 112 UK 18 Various ‘Spiritual healing’ Before-and-after
(pilot)
Wang et al., 200897 Germany 38 N/R N/R Cross-sectional
Weze et al., 2004110 UK 35 Various Healing by ‘gentle touch’ Before-and-after
continued
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TABLE 12 Characteristics of included studies: cancer review (continued )
Study reference
grouped by condition
(author, year) Country Sample size Disease stage Treatment Study type
Cancer survivors
Barr et al., 1999127 Canada 44 Survivors of central nervous system
tumours
Operative intervention, radiotherapy and
chemotherapy
Cross-sectional
Barr et al., 2000133 Canada 78 Survivors of Wilm's tumour and
advanced neuroblastoma in childhood
N/R Cross-sectional
Boman et al., 2009134 Sweden 1599 Survivors of CNS tumours N/R N/R
Felder-Puig et al., 2000131 German 142 Survivors of a range of cancers N/R N/R
Fu et al., 2006130 Central America 211 Survivors of a range of cancers Chemotherapy, surgery and radiation Cross-sectional
prospective
(patient and
proxy report)
Grant et al., 2006135 USA 84 Survivors of a range of cancers N/R N/R
Korfage et al., 2009129 Netherlands 640 Survivors of cervical cancers N/R Cross-sectional
Nijdam et al., 2008128 Netherlands 119 Survivors of a range of cancers Brachytherapy or surgery Cross-sectional
Nixon Speechley et al.,
1999136
Canada 244 Survivors of a range of cancers N/R Retrospective
cohort
Pogany et al., 2006132 Canada 4584 Survivors of a range of cancers Operative intervention, radiotherapy and
chemotherapy
Retrospective
cohort
Shimoda et al., 2005126 Brazil 50 Survivors of a range of cancers Chemotherapy, radiotherapy and
surgery
Cross-sectional
AML, acute myeloid leukaemia; aRCC, advanced renal cell carcinoma; ML, malignant lymphoma; MM, multiple myeloma; mRCC, metastatic renal cell carcinoma; N/R, not reported;
TEM, transanal endoscopic microsurgery; TME, total mesorectal excision; TNM, tumour node metastasis.
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TABLE 13 Measures used: cancer review (continued )
Study reference
grouped by condition
(author, year)
GPBMs
Direct
valuation Rating Generic measures Condition speciﬁc measures Clinical index
EQ-5D SF-6D HUI2/HUI3 TTO VAS SF-12 and SF-36 FACT EORTC HAD Others ECOG Stage
Colon cancer
Anderson and Palmer, 1998119 ✓
Doornebosch et al., 2007115 ✓ ✓ ✓
Doornebosch et al., 2008116 ✓ ✓ ✓ ✓
Gosselink et al., 2006121 ✓ ✓ ✓ ✓
Hamashima, 2002117 ✓ ✓ ✓
Janson et al., 2007122 ✓ ✓
Ramsey et al., 1998190 ✓ ✓
Sharma et al., 2007123 ✓ ✓ ✓
Siena et al., 2007118 ✓ ✓ ✓
Wilson et al., 2006120 ✓ ✓ ✓ ✓
Gastric (and related)
Homs et al., 2004149 ✓ ✓ ✓ ✓
Kontodimopoulos et al., 2009147 ✓ ✓ ✓
McMillan et al., 1999153 ✓ ✓
O'Gorman et al., 1998151 ✓ ✓ ✓ ✓
Rogers et al., 2006148 ✓ ✓ ✓
Shenﬁne et al., 2009150 ✓ ✓ ✓
Verschuur et al., 2009154 ✓ ✓ ✓ ✓
Wildi et al., 2004152 ✓ ✓ ✓
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TABLE 13 Measures used: cancer review (continued )
Study reference
grouped by condition
(author, year)
GPBMs
Direct
valuation Rating Generic measures Condition speciﬁc measures Clinical index
EQ-5D SF-6D HUI2/HUI3 TTO VAS SF-12 and SF-36 FACT EORTC HAD Others ECOG Stage
Lymphoma
Doorduijn et al., 2005188 ✓ ✓ ✓
van Agthoven et al., 2001177 ✓ ✓
Witzens-Harig et al., 2009192 ✓ ✓
ML/AML
Banks et al., 2008178 ✓ ✓
Slovacek et al., 2007181 ✓ ✓
MM
Slovacek et al., 2008175 ✓ ✓
Uyl-de-Groot et al., 2005124 ✓ ✓
MM/ML
Slovacek et al., 2007182 ✓ ✓
Musculoskeletal cancer
Lee et al., 2003184 ✓ ✓ ✓ ✓
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TABLE 13 Measures used: cancer review (continued )
Study reference
grouped by condition
(author, year)
GPBMs
Direct
valuation Rating Generic measures Condition speciﬁc measures Clinical index
EQ-5D SF-6D HUI2/HUI3 TTO VAS SF-12 and SF-36 FACT EORTC HAD Others ECOG Stage
Non-specific cancers
Barton et al., 200898 ✓ ✓ ✓
Bowker et al., 200699 ✓
Capuano et al., 2008107 ✓ ✓
Cheung et al., 2009105 ✓ ✓ ✓
Chow et al., 2010106 ✓ ✓ ✓
Kim et al., 2008113 ✓ ✓ ✓
Lathia et al., 2008
(abstract only)102
✓ ✓ ✓
Mantovani et al., 2004111 ✓ ✓ ✓ ✓ ✓
Norum, 1996100 ✓ ✓ ✓
Park et al., 2006192 ✓ ✓ ✓
Pickard et al., 2007103 ✓ ✓ ✓ ✓
Pickard et al., 2007114 ✓ ✓ ✓ ✓
Ravasco et al., 2003104 ✓ ✓ ✓ ✓
Sung et al., 2003108 ✓ ✓ ✓
Trudel et al., 1998109 ✓ ✓ ✓
Vaghela et al., 2007112 ✓ ✓ ✓
Wang et al., 200897 ✓ ✓ ✓
Weze et al., 2004110 ✓ ✓
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Reliability: cancer
Fourteen studies127,130,131,133,134,163,168,174,176–178,184,190,192 reported evidence to allow assessment of reliability of
EQ-5D (ﬁve studies)168,176,177,184,192 and HUI3 (nine studies)127,130,131,133,134,163,174,178,190 in patients with cancer
and results are summarised in Appendix 9. Cella et al.168 examined EQ-5D in patients with kidney/renal
cancer in terms of stability across treatment groups and found that EQ-5D, FACT and VAS scores did not
differ between the different country cohorts. This provided some evidence for the reliability of EQ-5D in
multinational trials. Similarly, Hahn et al.,176 van Agthoven et al.177 and Witzens-Harig et al.192 reported
that no signiﬁcant differences between the treatment groups were found for EQ-5D, as well as EORTC
QLQ-C30, among patients with leukaemia and lymphoma. Two studies examined the internal consistency
of EQ-5D and HUI3 for speciﬁc questions/dimensions and dimensions/overall scores within measures.163,184
One study reported that internal consistency was high for EQ-5D (as was the SF-36)184 and another study
reported consistency for most questions for HUI3.163 Inter-rater reliability of HUI3 was reported in nine
studies.127,130,131,133,134,163,174,178,190 These studies reported completion of HUI3 by multiple respondents and
all studies demonstrated high agreement between different raters' assessments of the dimensions of HUI3.
Although the instruments are designed for self-completion by adults, the agreement between raters
provides some limited evidence of reliability.
Known-group analysis and convergent validity: cancer
Overall, 77 studies97–109,114,115,117,118,120–123,126–138,141,143–153,156–159,161–173,175,176,178,179–185,187,188,190,193 out of 98
provided evidence to allow for known-group analysis and convergent validity. Known-group analysis was
carried out in 54 studies,97–99,103–106,109,114,115,117–122,126,127,130–135,138,148–152,156–159,162–167,169,170,172,173,175,176,179–183,
188,190,193 41 for EQ-5D,97,98,103–106,114,115,117–122,138,148–152,156–159,164–167,169,170,172,173,175,176,179–183,188,193 of which two
also included the SF-6D98,156 and 13 included the HUI3.99,109,126,127,130–135,162,163,190 In most studies, groups
were deﬁned by severity of cancer on the basis of a global heath scale,126,163,179 or disease
status120,127,162,164,195 or by treatment.18,121,128,148,157 Some studies had case–control design comparing
between cancer patients and the general public.97,117,129,149 Several studies deﬁned groups on the basis of
other characteristics such as age and smoking status175 and country.130 The differences in the clinical
deﬁnition of groups, conditions, characteristics of patients and study designs make it difﬁcult to directly
compare the utility values, or to conduct meta-analyses across studies.
Convergent validity testing was carried out in 30 studies, 20 for EQ-5D98,100–103,107,123,137,138,144–146,148,151,156,
164,165,173,184,196 and 10 for HUI3101,108,136,141,143,155,162,178,186,187 and one for SF-6D.156 In most cases, evidence
on the correlation between generic measure of HRQL with either each other or with cancer-speciﬁc
measures was reported.138,141,143–145,162 Regressions between scores of different measures were reported by
several studies.102,122,146,147
Details of the assessments of construct validity of utility measure in different type of cancers are shown in
Appendix 10 and below are brieﬂy summarised by speciﬁc types of cancers. For some types of cancer,
there were only limited studies (fewer than three) for assessment of validity. The ﬁndings of these are
summarised under the heading of ‘other cancers’.
Breast cancer
Known-group analysis One study among people with breast cancer allowed a known-group analysis for
EQ-5D where groups were deﬁned by severity of breast cancer status.138 EQ-5D and TTO can distinguish
between different groups to some extent but the two measures did not always agree with each other in
terms of which groups were different.
Convergent validity Correlation statistics were reported by ﬁve studies for EQ-5D137,138,144–146
(two through regression estimation)137,146 and two studies for HUI3 with other HRQL measures in patients
with breast cancer.141,143 Moderate to high correlations were found between the EQ-5D index with
EQ-VAS or TTO values and the EQ-5D index with EORTC.138,144,145 Signiﬁcant regression coefﬁcients were
found between EORTC QLQ items and EQ-5D146 and EQ-5D index, VAS, HADS-depression or anxiety
54
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demonstrated similar relationships between treatment choice and chemotherapy.137 Strong correlations
were found between HUI3 index and three subscales with Functional Assessment of Cancer
Therapy – Anaemia (FACT-An) and FACT-F,143 and between HUI3 and SF-36.141
Colon cancer
Known-group analysis In studies of patients with colon cancer, six studies for EQ-5D115,117,118,120–122 and
one study for HUI3190 provided evidence to allow an assessment of construct validity. Of those reporting
EQ-5D, ﬁve differentiated between groups based on severity of cancer115,118,120–122 and one included an
assessment of case (people with cancer) against controls (general population without cancer).117 In two
studies, EQ-5D scores demonstrated differences between treatment groups.118,120 In four studies, EQ-5D
index revealed no difference between study groups; the results of one study were consistent with no
difference on EORTC QLQ-C30,122 another was consistent with EQ-VAS among patient with or without
stoma,117 and two were consistent with EORTC QLQ-C30 but not EORTC QLQ-C38 among treatment
groups.115,121 The case–control analysis of the Gosselink et al.121 study found that EQ-5D could differentiate
between some, but not all, treatment groups with the general population. Ramsey et al.190 found that
HUI3 was consistent with the FACT – Colorectal subscale (FACT-C) summary scores and both measures
detected signiﬁcant differences between diagnosis groups.
Convergent validity One study123 found that EQ-5D and EQ-VAS were not signiﬁcantly correlated to the
cancer tumour node metastasis (TNM) stage and the correlation coefﬁcient was low, whereas other
measures (HADS-anxiety subscale, positive and negative affect schedule and the emotional well-being
component of the FACT-C module) had moderate correlations.123
Kidney cancer
Known-group analysis Three studies found that EQ-5D followed the same pattern across the study
follow-up period with VAS, EORTC global health and EORTC global scores.169,170,193 One study showed that
EQ-5D, VAS and FACT scores did not differ between different country cohorts.168
Convergent validity The only study that reported convergent validity and illustrated that EQ-5D and
EQ-VAS were moderately and signiﬁcantly correlated with the Functional Assessment of Cancer Therapy –
General Scale (FACT-G) and FACT-Kidney Symptom Index (FKSI).171
Cancer survivors
Known-group analysis Eight studies allowed known-group analysis for HUI3,126,127,130–135 which
successfully discriminated between cancer severity groups,131 treatment groups,132 global health rating126
and between patients and controls.132 Some HUI3 dimensions also discriminated between groups.133,134
The HUI3 values and HUI3 dimensions were not signiﬁcantly different between diagnosis groups;130,135
however, it is not clear that any difference HRQL would be expected between these groups.
Two studies reported evidence for known-group assessment for EQ-5D.128,129 One study found EQ-5D
consistent with EORTC QLQ-C30 in that EQ-5D did not differ between treatment groups.128 Another study
found that neither EQ-5D nor the majority of dimensions of SF-36 displayed signiﬁcant difference between
survivors and control groups, but this was not consistent with the ﬁnding for the State-Trait Anxiety
Inventory (STAI).129
Convergent validity Only one study reported moderate to high and signiﬁcant correlations between
HUI3 and the child health questionnaire (CHQ).136
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Cervical cancer
Known-group analysis Three studies reported evidence to allow an analysis of known group validity for
EQ-5D and the results were mixed.164,166,167 One study166 found that EQ-5D did not discriminate between
the treatment and control group, which was consistent with HADS-anxiety and HADS-depression but not
with the Multidimensional Health Locus of Control Scale chance dimension. Korfage et al.164 demonstrated
that EQ-5D found non-signiﬁcant worsening of health for borderline mildly dyskaryotic group, but the
increased psychological distress found by the SF-12 mental component summary score, STAI, Psychological
Consequences Questionnaire (PCQ) score was signiﬁcant. In contrast, signiﬁcantly better physical health
was found by the SF-12 physical component summary score. Maissi et al.167 showed that STAI and general
health questionnaire were sensitive to health differences at baseline whereas EQ-5D was not.
Convergent Validity One study165 demonstrated moderate correlation between EQ-5D and
EQ-VAS. Through regression, Korfage et al.164 found that perceived risk of being diagnosed with cervical
cancer was signiﬁcantly associated with EQ-5D and PCQ score but not with mental component summary
score or STAI.
Gastric cancer
Known-group analysis Five studies provided evidence to allow a known-group analysis for EQ-5D and
the ﬁndings were generally mixed.148,149,150–152 Shenﬁne et al.150 and Rogers et al.148 conﬁrmed that EQ-5D
values or the EQ-5D mobility and usual activities dimensions could discriminate between treatment groups.
O'Gorman et al.151 showed that, consistent with EORTC, EQ-5D was signiﬁcantly lower and not
signiﬁcantly different in the weight-losing groups. However Wildi et al.152 reported that the overall
difference measured by EQ-5D between groups deﬁned by cancer stage groups was not as expected or
signiﬁcant, although EQ-5D was higher for patients at cancer stage 0 than patients at stage 1–3. Two
case–control studies148,149 conﬁrmed the ability of EQ-5D to discriminate between cancer patients and the
general population.
Convergent validity Three studies provided evidence to assess convergent validity for EQ-5D,147,148,151 and
one of them also included SF-6D.147 Through regression, Kontodimopoulos et al.147 found that three
EORTC subscales (physical and emotional function and global health status) were signiﬁcant predictors of
EQ-5D, whereas six EORTC subscales (social and emotional functioning, pain, constipation, dyspnoea and
global health status) were signiﬁcant predictors of SF-6D. Rogers et al.148 showed signiﬁcant correlation
between the EQ-5D mobility, usual activities and anxiety dimensions, and the University of Washington
QoL questionnaire overall scores, and between questionnaire subscales scores and speciﬁc
EQ-5D dimensions.
Prostate cancer
Known-group analysis Four studies with prostate cancer patients allowed a known-group analysis of
EQ-5D and the results suggested that EQ-5D discriminated between survival groups,158 symptom-based
severity groups (also shown by SF-6D156), and treatment groups.157,159
Convergent validity Studies reported low or non-signiﬁcant correlations between HUI3 and VAS155 or
HUI3 and SG.160
Non-specific cancers
Known-group analysis Seven studies in groups not deﬁned according to speciﬁc cancers provided
evidence to allow a known-group analysis of the EQ-5D.97,98,103–106,114 Among the six studies, four found
that EQ-5D could discriminate groups deﬁned on the basis of cancer severity such as Eastern Co-operative
Oncology Group (ECOG) and FACT (statistical signiﬁcance not reported),103 high or low risk,104 ECOG105
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and stage of cancer106 (statistical signiﬁcant not reported). For the two case–control studies, one study
showed that a signiﬁcant difference was found by EQ-VAS but not EQ-5D or SF-6D98 and another study
found that cancer patients were more likely to report any problems on the usual activities dimension of
EQ-5D than other patients97 but this was not found by the other dimensions.
Two studies in non-speciﬁc cancers provided evidence to allow known-group analysis for HUI3.99,109 Both
studies found that HUI3 scores were statistically different between groups. One study deﬁned groups
as cancer, cancer and diabetes, and diabetes only groups compared with no cancer or diabetes group;99
another study deﬁned groups on the basis of severity.109
Convergent validity Five studies examined the relationships of EQ-5D with other measures: two
through correlation100,114 and three through regression.102,105,107 Pickard et al.114 found statistically
signiﬁcant and moderate correlations between all EQ-5D dimensions, ECOG and subscales of FACT-G.103
Similarly, Norum100 found high correlations between EQ-5D, EQ-VAS and EORTC QLQ-C30.
Capuano et al.107 found that anaemia and weight loss signiﬁcantly inﬂuenced EQ-5D scores but not
inﬂammation, whereas in study by Lathia et al.102 none of the EQ-5D data were signiﬁcant predictors
of Functional Assessment of Cancer Therapy – Neutropenia (FACT-N).
Two studies provided evidence to examine convergent validity of HUI3.108,109 One study in children with
cancer108 found a moderate but signiﬁcant correlation between HUI3 and the CHQ physical scale and
between the pain, physical activity and emotion dimensions of HUI3 and the corresponding scale of the
CHQ, but not between HUI3 and the psychosocial scale of CHQ. The other study including children
reported by Trudel et al.109 found moderate correlations for HUI3 values and the HUI3 dimensions
compared with the VAS and a cancer-speciﬁc measure.
Liver cancer
Known-group analysis Two studies179,180 found that EQ-5D could discriminate between treatment
groups, which was consistent with the EORTC measure. Another case–control study172 found that both
EQ-5D and EORTC measure were sensitive to differences between a group of patients with liver metastasis
and a group of the general population.
Lung cancer
Known-group analysis Two studies demonstrated that EQ-5D is able to distinguish patients groups on
the basis of FACT quintiles,103 and between patients with and without metastasis.173
Convergent validity Tripploli et al.173 found that there were signiﬁcant correlations between the EQ-5D
index and VAS, and also between EQ-5D and SF-36.
Malignant lymphoma/acute myeloid leukaemia
Known-group analysis Slovacek et al.181 found signiﬁcantly higher EQ-5D scores among malignant
lymphoma (ML) patients, which indicates that EQ-5D can discriminate between ML patients and acute
myeloid leukaemia (AML) patients.
Convergent validity Banks et al.178 demonstrated that there were substantial correlations between proxy
HUI2/HUI3 and the CHQ physical score.
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Other cancers
Known-group analysis Six studies among various cancer patients provided evidence to allow a
known-group analysis for EQ-5D and HUI3. Slovacek175 found that EQ-5D scores were signiﬁcantly
different depending on age and smoking status among patients with multiple myeloma (MM). Slovacek182
demonstrated that the EQ-5D could differentiate between patients with MM and ML, with ML patients
having signiﬁcantly higher scores. One case–control study suggested that EQ-5D was consistent with
EORTC in that it discriminated well between patients with pancreatic cancer and the general population as
well as between gender groups.183
Two studies used the HUI3 in patients with brain cancer.162,163 One study163 found that the number of
impaired HUI3 attributes was lower for children with better health status as reported by physicians, but no
signiﬁcant differences were found according to the level of radiation treatment received. Another study162
found signiﬁcant difference of all HUI3 dimensions (except emotion) between patients and the general
population group, and between tumour groups although no signiﬁcance was reported.
Convergent validity Signiﬁcant correlations were reported between dimensions of the EQ-5D and the
Musculoskeletal Tumour Rating Scale (MSTS) in patients with musculoskeletal cancer.184,185 Klassen et al.81
reported strong correlations between HUI3 and VAS, Pediatric Quality-of-Life Inventory (PedsQL) core and
PedsQL-cancer module among patients with Hodgkin's lymphoma.186 Falicov et al.101 found a low to
moderate correlation between EQ-5D and HUI3 among patients with spinal metastases.
Responsiveness: cancer
A total of 39 out of 98 studies among cancer patients provided sufﬁcient evidence to allow assessment of
responsiveness for EQ-5D (31 studies),104,110–113,116,124,139,140,143,144,147,149,153,154,157–160,165,167–169,170,171,176,
177,179,180,188,192 for HUI3 (six studies)101,141,142,174,178,186 and both EQ-5D and HUI3 (two studies).143,160
Most studies reported mean change of scores over the study period.116,122,123,143,149,153,154,167 Some studies
compared scores or responses at baseline and follow-up.104,110,119,139 Some studies also reported
responsiveness indices including ES or standard response mean,141,169,171,185 or a correlation between
changes of different measures.143,144 Statistical tests such as the t-test, ANOVA and Mann–Whitney U-test
were conducted by some, but not all, studies. The detailed results are summarised below according to type
of cancer. As for validity, cancer types for which only three or fewer studies reporting responsiveness data
were available are grouped as ‘other cancers’. See Appendix 11 for details.
Breast cancer
Three studies of breast cancer patients provided evidence to examine responsiveness of EQ-5D, which was
shown to perform satisfactorily. Conner-Spady et al. (2001)139 found a signiﬁcant change in mean scores
over time for EQ-5D and three of its dimensions, Functional Living Index – Cancer (FLIC) and three of its
subscales and VAS using repeated ANOVA. Large ESs were reported for all measures except for EQ-5D
with a moderate ES for severe cancer according to thyroid hormone level (T3/T4). Another study by
Conner-Spady et al.140 demonstrated that EQ-5D, FLIC and VAS showed a similar pattern of change after
high-dose chemotherapy, and a Friedman test showed signiﬁcant change over time on four of the EQ-5D
dimensions; there was no signiﬁcant change for pain/discomfort. Kimman et al.144 conﬁrmed consistency
between EQ-5D and EQ-VAS in terms of showing signiﬁcant effect in the group that perceived a moderate
and large change of global health but found no effect in the group that perceived no or small change of
global health. Two studies examined the responsiveness of HUI3 in patients with breast cancer and found
that performance was good.141,142 Both Lovrics et al.141 and Polsky et al.142 found signiﬁcant decreases in
HUI3 score shortly after surgery and improvements in longer term, which was consistent with the VAS and
SF-36 subscales.
One study by Chang et al.143 provided evidence for both EQ-5D and HUI3, alongside EQ-VAS, FACT-An
and FACT-F. The results of this study were difﬁcult to interpret as it found that both HUI3 and EQ-VAS
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scores improved in one treatment group but decreased in another, although EQ-5D showed improvement
for both groups. In addition, the difference between changes of scores between the treatment groups
were statistically signiﬁcant for HUI3 and EQ-VAS, but not for EQ-5D.
Cervical cancer
Two studies reported evidence for responsiveness assessment of EQ-5D.165,167 Maissi et al.167 found that
mean change on EQ-5D was small but this was consistent with General Health Questionnaire and STAI.
Whynes165 showed that EQ-5D dimensions and HADS were signiﬁcant predictors of decreasing VAS scores.
Colon cancer
Four studies provided evidence to examine responsiveness of EQ-5D.116,119,122,123 Anderson and Palmer119
found similar patterns over time for all EQ-5D dimensions and most subscales of the Rotterdam Symptom
Checklist (RSCL) and signiﬁcant differences were found between the two treatment groups over time
using both measures. Doornebosch et al.116 found that 6 months after surgery, signiﬁcant improvement
was detected by both the Faecal Incontinence Severity Index and EQ-VAS, but not EQ-5D. Both Janson
et al.122 and Sharma et al.123 found that EQ-5D indicated no signiﬁcant change over time and that this was
not consistent with EORTC QLQ-C30 or the HADS.
Gastric cancer
Three studies provided evidence of responsiveness for EQ-5D.149,153,154 Two studies149,153 found consistent
results with the EORTC, EQ-5D and EQ-VAS and all showed a change in HRQL, but this change was not
signiﬁcant. McMillan et al.153 demonstrated that EQ-5D detected signiﬁcant improvement in the
intervention arm at follow-up.
Kidney cancer
Five studies included evidence to assess responsiveness of EQ-5D.168,170,171,193,194 All ﬁve studies found that
EQ-5D and EQ-VAS could detect differences between treatment groups and two studies169,171 reported
statistically signiﬁcant differences.
Liver cancer
All three studies with responsiveness evidence suggested that EQ-5D was consistent with EORTC.173,179,180
In one study,180 both the EQ-5D and EORTC QLQ showed a response over time following three different
surgical procedures. In another study,172 both measures detected no change and another study179 found
comparable magnitude of change over time in terms of ES.
Prostate cancer
Two studies among the prostate cancer patients reported evidence of responsiveness for EQ-5D157,159 and
another study included both EQ-5D and HUI3.160 Both Sullivan et al.157 and Weinfurt et al.159 conﬁrmed
that EQ-5D was responsive in prostate cancer patients as it detected deterioration in HRQL at follow-up
and showed similar ES to other measures. Krahn et al.160 indicated that EQ-5D and HUI3 were less
responsive to treatment compared with other measures. Using external responsiveness, EQ-5D and
HUI3 were able to discriminate between those whose health had changed and those whose health had
not changed.
Non-specific cancer
Five studies among patients with general cancers provided evidence of responsiveness for EQ-5D and all
studies found satisfactory performance of EQ-5D. Mantovani et al.111 showed that EQ-5D registered a
trend of improvement over time and the improvement at 4 months was statistically signiﬁcant compared
with baseline. Vaghela et al.112 suggested that statistically signiﬁcant improvement was seen on the anxiety
and depression dimension of EQ-5D but was seen by the two ﬁrst stated concerns of Measure Yourself
Concerns and Well-Being Questionnaire (MYCaW), the overall proﬁle and the EQ-VAS but not the
well-being measure. Ravasco et al.104 reported that all EQ-5D dimensions (except for pain/discomfort) and
EQ-VAS improved following radiotherapy but the difference was statistically signiﬁcant only for high-risk
59
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Longworth et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
DOI: 10.3310/hta18090 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 9
patients on the EQ-5D. Weze et al.110 demonstrated that only the anxiety/depression and pain dimensions
of EQ-5D showed statistically signiﬁcant improvement whereas the EQ-VAS and stress, fear, sleep,
relaxation and coping were signiﬁcant. Similarly, Kim et al.113 also reported that they found statistically
signiﬁcant differences in the sum of severity levels on pain/discomfort and anxiety/depression after
treatment.
Other cancers
Five studies of various cancers provided information to allow assessment of responsiveness of the
EQ-5D124,176,177,188,192 and four studies for HUI3.101,174,178,186 Hahn et al.176 suggested that EQ-5D was picking
up differences in mean change over time between the treatment groups in people with leukaemia, and
Uyl-de-Groot et al.124 found a signiﬁcant mean change for EQ-5D and some EORTC QLQ-C30 dimensions
at selected follow-up time points for people with MM. Three studies in patients with lymphoma indicated
that EQ-5D changed over the study period, but this change was not always statistically signiﬁcant.177,188,192
For HUI3, Klaasen et al.186 found consistent change in the HUI3 and other measures between two time
points with large and clinically relevant ES, but not at two other time points. The remaining three studies
indicated good responsiveness of HUI3 across a range of indicators, including similar responsiveness to
CHQ, but lower than PedsQL in terms of size of change. The pain dimension of HUI3 was responsive to
change with EORTC QLQ-C30.
Summary and conclusion: cancer
The overall performance of EQ-5D, HUI3 and SF-6D are summarised in Table 14. Among the 98 studies
included in this review, the EQ-5D97,98,100,101,103–107,110–123,128,129,137–140,143–154,156–160,164–173,175–177,179–184,186,188,192,194
was the most commonly used GPBM, whereas HUI399,108,109,126,127,130–136,141,142,155,161–163,174,178,185–187,190 was the
second most widely used measure. Few studies reported evidence for SF-6D.98,147,156
Overall, the results for EQ-5D compared with the other generic and cancer-speciﬁc measures were
satisfactory. The majority of studies comparing patients with cancers and a control group of people
without cancer showed consistent differences in EQ-5D values.97,117,121,148,149,152,157,172,173,183 Studies
comparing EQ-5D scores across severity groups also showed that, in most cases, EQ-5D differentiated
between groups, although this was not always statistically signiﬁcant.103–106,114,118–120,122,148,156,158,164,173,176,188
Correlations between EQ-5D and other measures were a mixture of low, moderate and strong. In terms of
responsiveness, overall EQ-5D scores or dimensions were able to detect appropriate change-over time
points but sometimes the change of scores was small or not statistically signiﬁcant over all time points. The
assessment of reliability of EQ-5D provided some evidence of good reliability with no change being
observed in EQ-5D responses when other measures conﬁrmed no reported change in health over time;
however, very few of the identiﬁed studies were speciﬁcally designed to assess test–retest reliability.
Evidence on the performance of EQ-5D varied in different types of cancer. EQ-5D showed good
responsiveness and convergent validity in breast cancer137–140,143–146 but known-group evidence was
very limited. For colon cancer studies, the majority of evidence suggested relatively good construct
validity,118–120,122 but the only study available did not support responsiveness of EQ-5D.116 In prostate cancer
studies, EQ-5D appropriately differentiated between groups and detected change over time, but in most
cases the differences or changes were not statistically signiﬁcant.156–160 In studies of non-speciﬁc cancers,
EQ-5D was sensitive to change over time and sensitive to differences between severity groups.103–106,110–114
There was evidence to support HUI3's ability to differentiate between severity groups and between
patients with and without cancers. The ability of HUI3 to detect between groups deﬁned by other
non-severity based aspects was more mixed and the responsiveness of HUI3 was also found to be
satisfactory. Although HUI3 is essentially designed for self-completion by the patient, several studies
examined inter-rater reliability.133,134,163,174,178,186 These studies generally found that inter-rater reliability for
HUI3 was good.
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TABLE 14 Overview of performance of EQ-5D, HUI3 and SF-6D in studies of cancer
Study reference
grouped by
measure
(author, year)
Known group (severity) Known group (case–control) Known group (other) Responsiveness Reliability
Cancer
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant Correlation
Consistent
evidence Signiﬁcant
Consistent
evidence
EQ-5D
Chang et al.,
2004143
Breast cancer ✓ ✓
Conner-Spady et al.,
2001139
Breast cancer ✓ ✓
Conner-Spady et al.,
2005140
Breast cancer ✓ ✓
Crott et al., 2010146 Breast cancer ✓
Freedman et al.,
2010145
Breast cancer Strong
(with
EQ-VAS)
Jansen et al.,
2004137
Breast cancer ✓
Kimman et al.,
2009144
Breast cancer Moderate
to high
✓ ✓
Lidgren et al.,
2007138
Breast cancer Mixed
evidence
Mixed
evidence
Moderate
Korfage et al.,
2010164
Cervical cancer ✓ ✗ ✓
Maissi et al., 2005167 Cervical cancer ✗ ✗ ✓ N/R
Whynes et al.,
2008165
Cervical cancer ✓ ✓ ✓
(moderate)
✓ ✓
Whynes et al.,
2008166
Cervical cancer Mixed
evidence
N/R
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TABLE 14 Overview of performance of EQ-5D, HUI3 and SF-6D in studies of cancer (continued )
Study reference
grouped by
measure
(author, year)
Known group (severity) Known group (case–control) Known group (other) Responsiveness Reliability
Cancer
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant Correlation
Consistent
evidence Signiﬁcant
Consistent
evidence
Anderson and
Palmer, 1998119
Colon cancer ✓ ✓
Doornebosch et al.,
2007115
Colon cancer Mixed
evidence
Mixed
evidence
Doornebosch et al.,
2008116
Colon cancer ✗ ✗
Gosselink et al.,
2006121
Colon cancer ✗ ✗ ✓ ✓
Hamashima, 2002117 Colon cancer ✓ ✓
Janson et al.,
2007122
Colon cancer ✓ ✓
Sharma et al.,
2007123
Colon cancer Low
Siena et al., 2007118 Colon cancer ✓ ✓
Wilson et al.,
2006120
Colon cancer ✓ ✓
Homs et al., 2004149 Gastric cancer ✓ N/R N/R N/R
Wildi et al., 2004152 Gastric cancer ✗ N/R ✓ ✗
O'Gorman et al.,
1998151
Gastric cancer ✓ ✓ Moderate
Shenﬁne et al.,
2009150
Gastric cancer ✓ ✓
Verschuur et al.,
2009154
Gastric cancer ✓ N/R
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Study reference
grouped by
measure
(author, year)
Known group (severity) Known group (case–control) Known group (other) Responsiveness Reliability
Cancer
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant Correlation
Consistent
evidence Signiﬁcant
Consistent
evidence
Kontodimopoulos
et al., 2009147
Gastric cancer ✓
McMillan et al.,
1999153
Gastric cancer ✓ ✓
Rogers et al.,
2006148
Gastric cancer ✓ ✓ ✓ N/R Low to
moderate
Castellano et al.,
2009172
Kidney cancer Moderate ✓ ✓
Cella et al., 2008169 Kidney cancer ✓ N/R ✓ ✓
Cella et al., 2010168 Kidney cancer ✓ N/R ✓
Sternberg et al.,
2010193
Kidney cancer ✓ N/R
Yang et al., 2010170 Kidney cancer ✓ N/R ✓ N/R
Hahn et al., 2003176 Leukaemia
cancer
✓ ✓ ✓ N/R
Langenhoff et al.,
2006180
Liver cancer ✓ N/R ✓ N/R
Mendez Romero
et al., 2008172
Liver cancer ✓ ✓ ✓
Krabbe et al.,
2004179
Liver cancer ✓ N/R ✓ N/R
Basch et al., 2009196 Lung cancer Low to
moderate
Trippoli et al.,
2001173
Lung cancer ✓ ✓ ✓ Moderate
to high
continued
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TABLE 14 Overview of performance of EQ-5D, HUI3 and SF-6D in studies of cancer (continued )
Study reference
grouped by
measure
(author, year)
Known group (severity) Known group (case–control) Known group (other) Responsiveness Reliability
Cancer
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant Correlation
Consistent
evidence Signiﬁcant
Consistent
evidence
Doorduijn et al.,
2005188
Lymphoma ✓ ✓ ✓ ✗
Van Agthoven et al.,
2001177
Lymphoma ✓ N/R ✓
Witzens-Harig et al.,
2009192
Lymphoma ✓ ✓ ✓
Slovacek et al.,
2007181
ML/acute
myeloid
leukaemia
(AML) cancer
✓ ✓
Slovacek et al.,
2008175
MM cancer ✓ ✓
Uyl-de Groot et al.,
2005124
MM cancer ✓ ✓ ✓ ✓
Slovacek et al.,
2007182
MM/ML ✓ ✓
Lee et al., 2003184 Musculoskeletal
cancer
Low to high High
Mueller-Nordhorn
et al., 2006183
Pancreatic
cancer
✓
Krahn et al., 2007160 Prostate cancer ✓ Mixed
evidence
Sandblom et al.,
2004158
Prostate cancer ✓ Mixed
evidence
✓ Mixed
evidence
Shimizu et al.,
2008156
Prostate cancer ✓ Mixed
evidence
✓
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Study reference
grouped by
measure
(author, year)
Known group (severity) Known group (case–control) Known group (other) Responsiveness Reliability
Cancer
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant Correlation
Consistent
evidence Signiﬁcant
Consistent
evidence
Sullivan et al.,
2007157
Prostate cancer ✓ Mixed
evidence
✓ ✓
Weinfurt et al.,
2005159
Prostate cancer ✓ Mixed
evidence
✓ Mixed
evidence
Falicov et al.,
2006101
Spinal
metastases
Moderate
Capuano et al.,
2008107
Non-speciﬁc
cancer
✓
Mantovani et al.,
2004111
Non-speciﬁc
cancer
✓ ✓
Vaghela et al.,
2007112
Non-speciﬁc
cancer
✓ ✓
Park et al., 2006192 Non-speciﬁc
cancer
Pickard et al.,
2007103
Non-speciﬁc
cancer
✓ N/R
Pickard et al.,
2007114
Non-speciﬁc
cancer
✓ ✓ Moderate
Ravasco et al.,
2003104
Non-speciﬁc
cancer
✓ ✓ ✓ Mixed
evidence
continued
continued
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TABLE 14 Overview of performance of EQ-5D, HUI3 and SF-6D in studies of cancer (continued )
Study reference
grouped by
measure
(author, year)
Known group (severity) Known group (case–control) Known group (other) Responsiveness Reliability
Cancer
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant Correlation
Consistent
evidence Signiﬁcant
Consistent
evidence
Wang et al., 200897 Non-speciﬁc
cancer
✓ ✓
Weze et al., 2004110 Non-speciﬁc
cancer
✓ ✓
Barton et al., 200898 Non-speciﬁc
cancer
✗ ✗
Cheung et al.,
2009105
Non-speciﬁc
cancer
✓ N/R ✓
Lathia et al., 2008102 Non-speciﬁc
cancer
✗
Chow et al., 2010106 Non-speciﬁc
cancer
✓ N/R ✓ N/A
Kim et al., 2008113 Non-speciﬁc
cancer
✓ ✓
Norum, 1996 100 Non-speciﬁc
cancer
Moderate
to high
(signiﬁcant)
Korfage et al.,
2009129
Cancer survivors ✗ ✗
Nijdam et al.,
2008128
Cancer survivors ✓
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Study reference
grouped by
measure
(author, year)
Known group (severity) Known group (case–control) Known group (other) Responsiveness Reliability
Cancer
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant Correlation
Consistent
evidence Signiﬁcant
Consistent
evidence
HUI2/HUI3
Le Gales et al.,
1999163
Brain cancer Mixed
evidence
✓ ✓ ✓
McCarter et al.,
2006162
Brain cancer ✓ N/R ✓ ✓ Moderate
to high
Chang et al.,
2004143
Breast cancer ✓ Strong ✓ ✓
Lovrics et al.,
2008141
Breast cancer ✓ Moderate
to strong
✓ ✓
Polsky et al., 2002142 Breast cancer ✓ ✓
Ramsey et al.,
1998190
Colon cancer ✓ N/R ✓ ✓
Klaassen et al.,
2010186
Hodgkin’s
lymphoma
Moderate
to high
✓ ✓
Klaassen et al.,
2010185
Hodgkin’s
lymphoma
Generally
substantial
agreement
Barr et al., 1997174 Leukaemia ✓ Mixed
evidence
✓ (inter-rater
reliability)
Cox et al., 2005187 Leukaemia Reported
accept
ability
continued
continued
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TABLE 14 Overview of performance of EQ-5D, HUI3 and SF-6D in studies of cancer (continued )
Study reference
grouped by
measure
(author, year)
Known group (severity) Known group (case–control) Known group (other) Responsiveness Reliability
Cancer
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant Correlation
Consistent
evidence Signiﬁcant
Consistent
evidence
Banks et al., 2008178 ML/acute
myeloid
leukaemia
(AML)
Low to high
(baseline)
Low to
moderate
(change
scores)
✓ N/R Moderate:
substantial
agreement
Krahn et al., 2007160 Prostate cancer ✓ Mixed
evidence
Krahn et al., 2003161 Prostate cancer ✓
Albertsen et al.,
1998155
Prostate cancer Low
Falicov et al.,
2006101
Spinal
metastases
Moderate ✓
(pain only)
✓
Bowker et al.,
200699
Non-speciﬁc
cancer
✓ ✓
Sung et al., 2003108 Non-speciﬁc
cancer
Low to
moderate
Trudel et al.,
1998109
Non-speciﬁc
cancer
✓ ✓ ✓
Barr et al., 2000133 Cancer survivors ✓ Mixed
evidence
Substantial
agreement
Boman et al.,
2009134
Cancer survivors ✓ ✓ ✓ Mixed
evidence
Moderate:
substantial
agreement
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Study reference
grouped by
measure
(author, year)
Known group (severity) Known group (case–control) Known group (other) Responsiveness Reliability
Cancer
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant
Consistent
evidence Signiﬁcant Correlation
Consistent
evidence Signiﬁcant
Consistent
evidence
Felder-Puig et al.,
2000131
Cancer survivors ✓ ✗ Moderate:
substantial
agreement
Fu et al., 2006130 Cancer survivors ✓ Mixed
evidence
Low:
substantial
agreement
Barr et al., 1999127 Cancer survivors ✓ Mixed
evidence
Substantial
agreement
Pogany et al.,
2006132
Cancer survivors ✓ ✓
Grant et al., 2006135 Cancer survivors Mixed
evidence
Mixed
evidence
Nixon Speechley
et al., 1999136
Cancer survivors Moderate
to high
Shimoda et al.,
2005126
Cancer survivors ✓ ✓ Substantial
agreement
SF-6D
Kontodimopoulos
et al., 2009147
Gastric cancer ✓
Shimizu et al.,
2008156
Prostate cancer ✓ N/R ✓
Barton et al., 200898 Non-speciﬁc
cancer
✗ ✗
N/R, not reported.
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Chapter 3 Mapping to EQ-5D
Introduction
The review of the performance of GPBMs in the previous chapter showed that EQ-5D is a valid and
responsive measure for patients with cancer. Despite these ﬁndings, many cancer studies do not include
the EQ-5D and are more likely to include one of two cancer-speciﬁc questionnaires: the EORTC QLQ-C30
or the FACT-G. Five studies have previously mapped between EORTC QLQ-C30 and EQ-5D.146,147,197–199
Four of these functions are not necessarily applicable to other samples,146,147,197,198 Versteegh et al.197 fail to
provide the mapping function for other researchers to use and the sample used by Crott and Briggs146
includes only female patients. Wu et al.198 require data on both the FACT-G and the EORTC QLQ-C30 to
produce mapped estimates, although studies may not routinely collect both of these together.
Kontodimopoulous et al.147 use a linear regression model to predict EQ-5D scores; however, they state that
the model does not produce reliable predictions and is based on a small sample. Potentially the most
useful mapping function was published by McKenzie and van der Pol,199 who produced two mapping
functions; the ﬁrst used linear regression to estimate EQ-5D index scores and gave reasonable predictions
and the second used ordered probit models to predict EQ-5D dimension levels and gave poor predictions.
Other models such as tobit and TPMs were not explored by any authors but may predict EQ-5D values
more accurately, and this needs to be explored further. Only one mapping function has been published
using FACT-G data to predict EQ-5D values; it ﬁtted ordinary least squares (OLS) and CLAD models at the
domain level and showed that scores were poorly predicted away from the mean.105
The aims of this chapter are (1) to estimate mapping functions using two cancer-speciﬁc HRQL measures,
the EORTC QLQ-C30 and FACT-G, to the EQ-5D for use in future studies and (2) to test the applicability of
different mapping approaches that have been used in the literature in order to provide recommendations
for future mapping studies. In particular, the analysis was aimed at providing comprehensive information
on how to select the mapping function and information on uncertainties around the predictions. We
assessed different modelling techniques that have been applied in the literature and used standard criteria
to identify the most appropriate mapping functions. We also provide information on uncertainty.
Methods
Measures
Target measure: EQ-5D
Our target measure for mapping was the EQ-5D.
Source measures
The cancer data sets included two widely used cancer-speciﬁc measures and these were selected as the
source measures: EORTC QLQ-C30 and the FACT-G.
The EORTC QLQ-C30 is a cancer-speciﬁc HRQL measure that has been found to be valid for many cancer
conditions and has been widely used in cancer clinical trials across Europe and Canada.200 The EORTC
QLQ-C30 has 30 items, 28 with four levels (not at all, a little, quite a bit and very much) and two items
(overall health and overall QoL) with seven levels (ranging from very poor to excellent). The items cover ﬁve
functioning scales (physical, role, social, emotional and cognitive functioning), plus a global QoL scale and
nine symptoms scales (fatigue, nausea and vomiting, pain, dyspnoea, sleep disturbance, appetite loss,
constipation, diarrhoea, ﬁnancial impact). Each summary scale ranges from 0 to 100. Higher scores for the
functioning and global QoL scales indicate higher functioning levels, whereas higher scores for the
DOI: 10.3310/hta18090 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 9
71
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Longworth et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
symptoms scales indicate higher symptom levels. Mapping functions were developed using the dimensions
scores and items.
The FACT-G has been shown to be a reliable and validated HRQL measure.201 The questionnaire consists of
27 items in four subscales (physical well-being, social/family well-being, emotional well-being and
functional well-being). Each item has a range of ﬁve options ranging from not at all (score 0) to very much
(score 4) and item scores are added to form a subscale score and subscale scores are added to form a
global score. Global scores can range from 0 to 108. Mapping functions were developed using the total
score, dimension scores and items.
Data sets
Four data sets were used for the mapping study; three contained the EORTC QLQ-C30 and EQ-5D while
one contained the FACT-G and EQ-5D. The three data sets containing EORTC QLQ-C30 were pooled into
a single data set.
European Organization for Research and Treatment Quality-of-life
Questionnaire Core 30
One EORTC QLQ-C30 data set came from a randomised trial [Velcade as Initial Standard Therapy
(VISTA)]202 while the other two data sets came from a cancer clinic. The VISTA data were collected in a
Phase III randomised open-label trial for patients newly diagnosed with MM. Patients were requested to
complete both the EQ-5D and EORTC QLQ-C30 at their screening visit, day 1 of each of the nine cycles of
treatment, at the end of each treatment visit and during the post-treatment phase (every 6 or 8 weeks)
until disease progression. For the mapping analysis, only responses at screening visit were used. The mean
age of the screening sample was 72 years (SD 5.5 years) and 50% were male. Severity was measured
using the International Staging System for Multiple Myeloma, according to which patients are classed as
having stage I disease if serum beta-2-microglobulin (Sβ2M) is < 3.5 mg/l and serum albumin ≥ 3.5 g/dl
(median survival 62 months). Patients are classed as having stage II disease if they do not meet the criteria
for stages I or III and as having stage III disease if Sβ2M ≥ 5.5 mg/l.
203
The other data were collected at the Vancouver Cancer Clinic. Women diagnosed with breast cancer and
attending an outpatient clinic were asked to complete EQ-5D and EORTC QLQ-C30. The mean age of the
full sample was 68 years (SD 18.2 years). Severity was measured using the stage of disease, with stage I
indicating that the cancer is localised and stage IV indicating that cancer has metastasised or spread to
other areas of the body. Patients diagnosed with lung cancer attending an outpatient clinic were also
asked to complete EQ-5D and EORTC QLQ-C30. The mean age of the full sample was 62 years
(SD 21.1 years) and 48% were male. As with the data set from patients with breast cancer, severity was
measured using the stage of disease.
Functional Assessment of Cancer Therapy – General Scale
The FACT-G data set contained 538 cases from USA of which 530 provided self-reported data on HRQL.
Participants were from a validation survey of different cancer scales and had one of 11 cancers at stage 3
or 4 and had undergone at least two cycles of chemotherapy, for non-cyclical treatments, and had
received treatment for more than 1 month.189 Participants completed the EQ-5D (both the three- and
ﬁve-level versions), FACT-G and ECOG performance measures, cancer and treatment distress scale, FACT-G
cancer disease-speciﬁc add-on questions, the renal cell carcinoma symptom index and the symptom
checklist for depression and anxiety. For the mapping study, we focus on mapping between EQ-5D and
FACT-G and use the ECOG performance status measure as a measure of cancer severity. The sample
consisted of 273 (52%) male patients and 255 (48%) female patients with an average age of 59 years
(SD 11.9 years, range 24–88 years).
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Data analysis
Preliminary analysis
Spearman's rank correlations of the independent variables were used to determine whether any variables
were highly correlated and therefore not recommended for inclusion in the same regression model. A high
correlation was deﬁned as a correlation coefﬁcient > |0.7|.204 Spearman's rank correlations were also used
to determine correlations between the dependent and independent variables to inform model speciﬁcation
and this was undertaken for the EQ-5D utility values and dimension levels and the total scores, dimensions
scores and items of the EORTC QLQ-C30 and the FACT-G. The distribution of the EQ-5D was also
examined to determine the distribution of the scores and whether this differed by data set. This was used
to determine the appropriate model speciﬁcations for the regression equations mapping the two cancer
measures onto EQ-5D.
Specification
The mapping analysis involves using regression techniques to estimate the relationship between the EQ-5D
and the cancer-speciﬁc measures. The relationship can be speciﬁed in different ways. The simplest additive
model regresses the EQ-5D onto the global score of the starting measure, for example, the FACT-G global
score. This speciﬁcation assumes that all the items/dimensions contributing to the global score have equal
weight and response choices to each item lie on a similar interval scale (e.g. the intervals between
‘all of the time’, ‘most of the time’ and ‘some of the time’, etc., are equal). These assumptions can be
relaxed by including dimension scores and item responses as independent variables. We assessed global
scores, dimension scores and item responses for each cancer measure, where appropriate. Global and
dimension scores were treated as continuous variables and item responses were modelled as discrete
dummy variables.
We included squared terms for dimensions that displayed non–linear relationships. We also tested the
inclusion of interaction terms where there was evidence of correlations between dimensions. We tested for
the inclusion of interaction terms for the dimension scores based on high correlations (> ∣0.7∣). Squared
and interaction terms were not included for item models.
Modelling techniques
Models were ﬁtted to the overall EQ-5D score using linear regressions estimated by OLS, tobit models,
TPMs and splining. Further models were ﬁtted to the individual dimensions of the EQ-5D using response
mapping. A limited dependent variable mixture model (LDVMM) was also used in an illustrative analysis.
Ordinary least squares
The most common model used in the literature for mapping between QoL instruments is OLS, which
assumes that the relationship between the dependent variable (EQ-5D index values) and the independent
variable(s) (EORTC QLQ-C30 or FACT-G) can be expressed as a linear function of the parameters.
OLS models are typically able to predict the mean scores but are poor at predicting those in poor health
and full health.
Tobit model
Ordinary least squares does not allow for the fact that the EQ-5D is bounded at –0.594 at the bottom and
1 at the top of the scale and thus predictions could be greater than 1 or less than –0.594. The tobit model
can be used to take into account the upper and lower limits of EQ-5D so predictions are limited to the
credible range.
Two-part model
The TPM uses a combination of two different model types to predict different parts of the distribution of
the data. These have been used in cost analysis to predict whether resource use is incurred (see Lipscomb
et al.205 for example) and in mapping, where logistic regression is applied to model the probability of
whether responders are in full health or not and OLS or another suitable model used to model scores less
DOI: 10.3310/hta18090 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 9
73
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Longworth et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
than full health. The results from the two parts of the model are combined to obtain an overall score. We
ﬁtted a logistic regression model to estimate the probability of being in full health (yes/no) and a truncated
OLS model to predict EQ-5D score if not in full health, where for the truncated OLS model scores cannot
exceed a value of 1.206 Predicted EQ-5D scores were calculated as follows, where FH is full health:
ExpectedðEQ-5DÞ ¼ probabilityðFHÞ þ fpredicted EQ-5D score if not FH  ½1−probabilityðFHÞg ð1Þ
Splining
One of the issues in mapping to EQ-5D scores is that they rarely follow or approximate to the normal
distribution. Transformations can be used to account for this but another option is to use splining to identify
changes (cut points) in the distribution of the data and to model these changes using different
mathematical functions; this approach is also known as fractional polynomials. The ﬁrst stage of the process
is to identify possible cut-off values, which was done using the multivariable fractional polynomials function
in Stata version 12, StataCorp LP, College Station, TX, USA,207 which ﬁts all possible polynomial functions to
the data and identiﬁes the best-ﬁtting model. We applied splining functions to the best-ﬁtting dimension-
based models to test whether splines offered an improvement over including squared terms in our models.
Response mapping
An alternative to modelling the EQ-5D index is to ﬁt models to the dimensions of the EQ-5D using ordinal
or multinomial logistic regression models known in the literature as response mapping.208,209 We ﬁtted
multinomial logistic regression models to each of the ﬁve dimensions of the EQ-5D. Using an approach
previously reported in the response mapping literature,210 the expected value of the EQ-5D was then
calculated by multiplying the probability of being in each response level by the standard UK tariff.4
ExpectedðEQ-5DÞ¼ 1−ðPrmob20.069Þ−ðPrmob30.314Þ−ðPrcare20.104Þ−ðPrcare30.214Þ
−ðPruact20.036Þ−ðPruact30.094Þ−ðPrpain20.123Þ−ðPrpain30.386Þ
−ðPranx20.071Þ−ðPranx30.236Þ−ð1− PrPerfectÞ0.081−PrN30.269
ð2Þ
where Prmob2 is the probability of being in mobility level 2 on EQ-5D, Prmob3 is the probability of being
in mobility level 3 on EQ-5D, Prcare2 is the probability of being in self-care level 2 on EQ-5D, Prcare3 is the
probability of being in self-care level 3 on EQ-5D, Pruact2 is the probability of being in usual activities
level 2 on EQ-5D, Pruact3 is the probability of being in usual activities level 3 on EQ-5D, Prpain2 is the
probability of being in pain or discomfort level 2 on EQ-5D, Prpain3 is the probability of being in pain or
discomfort level 3 on EQ-5D, Pranx2 is the probability of being in anxiety or depression level 2 on EQ-5D
and Pranx3 is the probability of being in anxiety or depression level 3 on EQ-5D. PrN3 is the probability of
any of EQ-5D dimensions being at level 3.
PrPerfect is the probability of being in perfect health
¼Prmob1Prcare1Pruact1Pr pain1Pranx1 and PrN3 is the probability of being
in level 3 ¼1− ð1− Prmob3Þð1− Prcare3Þð1− Pruact3Þð1− Prpain3Þð1− Pranx3Þ
ð3Þ
where Prmob1 is the probability of being in mobility level 1 on EQ-5D, Prcare1 is the probability of being
in self-care level 1 on EQ-5D, Pruact1 is the probability of being in usual activities level 1 on EQ-5D,
Prpain1 is the probability of being in pain or discomfort level 1 on EQ-5D and Pranx1 is the probability of
being in anxiety or depression level 1 on EQ-5D.
Limited dependent variable mixture model
A further model was ﬁtted, the LDVMM. Although the models described in the preceding section for
modelling the index of EQ-5D are widely used in the literature, they have been shown to be inappropriate
in several studies as they are unable to take into account the characteristics of EQ-5D data and their
distribution across individuals.211–213 These characteristics include the bounded nature of the EQ-5D data, a
large proportion of respondents at 1 (full health), a large gap between this top value and the next
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allowable EQ-5D value and the multimodality of the distribution. These are the features that the standard
models are unable to generate and has led to the development of new, more advanced models, one of
which is the LDVMM of Hernández Alava et al.211,212 Finite mixture models provide a very ﬂexible
semiparametric framework in which to model complex nonstandard distributions in cases where standard
models are unable to provide a satisfactory model for all the data. By combining several distributions (also
referred to as components) using probability weights, mixture models can approximate any distribution
arbitrarily well and are able to generate characteristics such as skewness and multimodality. These
probability weights can be functions of any relevant variables. Thus, the covariates in these models can
determine EQ-5D directly by inclusion in the individual components but also indirectly through their effect
in the probability of component membership. This ﬂexibility generates a rich and complex pattern of
relationships between the explanatory variables and EQ-5D where the same variable can be highly
signiﬁcant in certain components but not in others and can also have an independent indirect effect
through its signiﬁcance in the probability of component membership. Insigniﬁcance of variables in
standard models (i.e. models with only one component) may be the result of differing patterns of
signiﬁcance across components and might lead to the erroneous exclusion of variables under usual
practice. The LDVMM combines the ﬂexibility of the mixture model approach with specially designed
components that are limited at 1 (full health) and at –0.594 and have an adjustment to generate the gap
in feasible values of the UK EQ-5D tariff between 1 and 0.883. For a more technical description of this
model, see Hernández Alava et al.211 The LDVMM was ﬁtted to the FACT-G data set using domain level
covariates to illustrate new model developments in this area which take into account the idiosyncrasies of
EQ-5D data.
Model specification
Models were ﬁtted using backwards regression where all possible variables are included in the model and
the least signiﬁcant removed until only signiﬁcant variables remain (p < 0.1), except in the implementation
of the LDVMM. To avoid overﬁtting models, we use the rule of 10 participants per variable for continuous
models and 10 events for the smallest category for response mapping models. When variables were highly
correlated, the variable that was most likely to map to the EQ-5D was selected, based on the analyst’s
judgement. Standard errors (SEs) of regression co-efﬁcents were calculated from bootstrap estimates and
5000 bootstrap samples were run for each model.
Insigniﬁcant variables were not automatically dropped in the LDVMM analysis. This process of data mining
increases the risk of ﬁtting a model to the speciﬁc sample data set being used but that lacks
generalisability. It leads to an estimated model with an improved in-sample ﬁt but tends to perform poorly
out of sample. This is particularly important when the number of observations is relatively small, as in the
present case, since often these data sets present many idiosyncrasies not seen in larger samples. The aim
of the LDVMM analysis was to ﬁt a model that predicted well in sample and that captured the general
characteristics of EQ-5D data sets but at the same time avoided ‘ﬁtting the model to the data’ in excess.
Model goodness of fit
Model goodness of ﬁt was measured using AIC and BIC, where the smaller the value, the better the model
ﬁt. For each model, we also reported the model RMSE and mean absolute error (MAE). For OLS models, we
reported the R2 and adjusted R2 and used the Ramsey Regression Equation Speciﬁcation Error Test (RESET)
to test non-linear combinations of variables in the model. For tobit, logistic regression and Response
mappings, we used the pseudo-R2. Sigma was reported for the tobit and truncated regression models and
the link test was used to check model speciﬁcation. The Hosmer–Lemeshow test was used to assess
goodness of ﬁt for logistic regression models.
Model performance and discrimination
Summary statistics including mean and range were examined to assess overall model predictions. However,
a more stringent test was applied using a severity measure to assess the discriminative performance of the
predicted EQ-5D score. For FACT-G, respondents were asked a variation of the ECOG performance status.
ECOG has ﬁve categories ranging in severity from 0 to 4 (worst)214 and ﬁve response categories: normal
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activity without symptoms, some symptoms but do not require bed rest during the waking day, require
bed rest for less than 50% of the waking day, require bed rest for over 50% of the waking day and
unable to get out of bed. No patients were in the most severe level (unable to get out of bed) and few
patients [n = 21 (4%)] required bed rest for more than 50% of the waking day; therefore, these two
categories are merged with the level do not require bed rest less than 50% of the waking day. The ECOG
responses are included in mapping models as a measure of disease severity and to test the predictive
ability of the mapping models across different severity groups. There was no common severity measure in
the EORTC QLQ-C30 data sets and the item reporting health status was used instead. Response options
ranged from poor (1) to excellent (7). Discriminative ability across severity groups using these measures
was tested using ANOVA. MAEs were reported for each subgroup.
Model performance was also assessed visually by plotting observed and predicted EQ-5D values by health
state. As a further comparison for the LDVMM, EQ-5D data sets were simulated using each model in turn
as the data generating process based on 100 replications per individual in the sample for a total of 53,000
simulated EQ-5D data points. Only one data set per model was generated and, therefore, small variations
for different generated errors can be expected for the individual simulated data points; however, enough
simulations have been generated to ensure an accurate overall distribution. Plots of the observed EQ-5D
distribution in the data were compared with distributional plots of the simulated data sets. A model that
correctly ﬁts the data should generate a distribution of simulated values which displays similar
characteristics to the observed EQ-5D distribution in the data.
Model validation
Internal model validation was carried out using bootstrapping to estimate a shrinkage factor. We used
the bootstrapping techniques reported by Steyerberg et al.215 to assess all models (except in the
implementation of LDVMM) and shrinkage coefﬁcients are reported in order to counter overoptimism of
estimates.215 Five thousand bootstrap estimates were run to calculate shrinkage factors. A shrinkage
coefﬁcient of less than 1 (typical value expected for a shrinkage coefﬁcient) reﬂects an ‘overﬁtting’
of the data.
Model selection
When producing a mapping model, the factors that are important in selecting a model are accuracy of the
predicted mean and SE, MAE, shrinkage and the reproducibility of the model across different severity
states. Mapping and model ﬁtting literature does not suggest a single criteria for use in selecting the
best-ﬁtting model and the criteria that we might focus on when selecting a model may depend on what
we want the mapping function to achieve. For each type of model (OLS, tobit, etc.) we gave equal
weighting to all model selection and performance statistics and ranked across models based on these
statistics, a mean rank per model was then estimated. The model with the best mean ranking was
selected. The best-performing models per model type were then compared and ranked to select the best
overall model. In the event of there being no clear difference between models, we gave priority to models
that best estimated the mean and were able to discriminate across disease severity.
Table 15 presents an overview of the analysis that was carried out. For each modelling technique (with the
exception of LDVMM) we assessed the performance of a series of model speciﬁcations based on overall
cancer instrument score, dimensions scores, dimensions scores plus squared and square root terms,
dimensions scores plus squared, square root terms and interations, item level models and the best ﬁtting
of these models plus patient characteristics.
Mapping models that we ﬁtted between EORTC QLQ-C30 or FACT-G and EQ-5D were:
Model 1 EQ-5D Index = Global Index Score (FACT-G only).
Model 2 EQ-5D Index = All dimensions.
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TABLE 15 Overview of analysis
Dependent
variables Independent variables
Model selection and
speciﬁcation Model type Performance Validation Uncertainty
EQ-5D index
EQ-5D dimension levels
EORTC QLQ-C30
Dimension summary scores
+ interaction terms
+ squared terms
+ square root terms
Item level models
Sociodemographic variables
FACT-G
Total score
Dimension summary scores
+ interaction terms
+ squared terms
+ square root terms
Item level models
Sociodemographic variables
Used standard statistical
techniques to examine the data
prior to mapping estimation
(including frequency tables and
correlations)
Fully described the data set used
to estimate the regression model
including both range of EQ-5D
and plots showing EQ-5D
distribution, to determine
whether unimodal/bimodal/
trimodal or skewed
Linear OLS
Tobit
TPM
SPL
Response
mapping
LDVMM
(FACT-G
dimension
summary
scores only)
Goodness of fit
Statistical
signiﬁcance, sign
and size of
coefﬁcients
R2, adjusted R2 and
pseudo-R2
AIC and BIC
Further tests of
model ﬁt such as
Ramsey RESET
Predictive ability
MAE, MAE by
subset of severity
range of EQ-5D
and/or predictive
measure(s)
Plots of observed
and predicted
EQ-5D scores
Application and
assessment of
mapping
algorithm was
validated using
bootstrapping
Estimate for best performing
model using probabilistic
sensitivity analysis (based
on regression estimates and
correlation matrix)
SPL, splining.
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Model 3 EQ-5D Index = Signiﬁcant dimensions only.
Model 4 EQ-5D Index = Signiﬁcant dimensions, squared and square root terms.
Model 5 EQ-5D index = Signiﬁcant dimensions, squared, square root and interaction terms.
Model 6 EQ-5D index = Signiﬁcant items.
Model 7 EQ-5D index = Signiﬁcant items collapsed item levels.
Model 8 best performing mode selected from Models 1 to 7 above plus signiﬁcant patient and
disease characteristics.
Models 6 and 7 were not ﬁtted for splining as this is performed on continuous variables. Response
mapping ﬁtted models to each of the EQ-5D domains rather than the EQ-5D index. We assessed model
performance by assessing models across these speciﬁcations for each modelling technique to select the
best-ﬁtting model speciﬁcation. We then used the same criteria to compare the best-ﬁtting models across
the modelling techniques. LDVMM were ﬁtted only for the FACT-G dimension scores.
Representing for uncertainty in mapping methods
Probabilistic sensitivity analysis was used to allow for uncertainty in mapping coefﬁcients for the best
performing FACT-G model. Regression coefﬁcients were assumed to follow a normal distribution and the
covariance matrix for the model was used to allow for variability and correlations between variables. It was
necessary to run 100,000 simulations to obtain convergence to a mean across simulations. For each
simulation mean, the EQ-5D score was calculated and percentiles were used to summarise the variability
around the mean estimate.
Results
European Organization for Research and Treatment Quality-of-life
Questionnaire Core 30 Preliminary analysis
Table 16 shows the characteristics of the full sample and for each data set for those with complete data.
Mean age and proportion of males varied by data set. The breast cancer data set had the lowest mean
age and contained only females, and the MM data set had the highest mean age and the highest
proportion of males. The mean EQ-5D score also varied by data set, the MM data set had a mean EQ-5D
value of 0.519 whereas the breast and lung cancer data sets had higher mean EQ-5D values of 0.765 and
0.742, respectively. Only the MM data set covered the entire range of the EQ-5D and had fewer ceiling
effects than the other data sets, with 8% of responses at full health on EQ-5D, compared with 24% and
17% for the breast and lung cancer data sets, respectively. Figure 5 shows the histograms of the EQ-5D
index for each data set and the combined data set showing that the distributions differ by data set but
without further information we cannot conclude whether this is differences in the severity of the patients
in each data set or differences in the pattern of EQ-5D by condition. Separate assessment of the scores for
the EORTC QLQ-C30 scales most noticeably varied across the three data sets for physical functioning, role
functioning, pain, dyspnoea, constipation and global QoL (see Table 16).
Assessment of the correlations between the independent variables indicated that the highest correlations
were between role functioning, physical functioning and fatigue variables (see Appendix 12). Assessment
of the correlations between the EORTC QLQ-C30 summary scales and EQ-5D dimensions and utility score
indicated that overall physical functioning, role functioning, social functioning, fatigue, pain and global
QoL were most highly correlated with EQ-5D dimensions and score. However, as global QoL is likely to
encompass the other conceptual domains, it is theoretically preferable to exclude this from consideration
in the mapping function alongside the other summary scale variables. Correlations between the EORTC
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QLQ-C30 item levels by domains indicated that items within physical, role, emotional and social
functioning, QoL, fatigue and pain were highly correlated, suggesting that not all items within these
domains need to be selected for item level models.
European Organization for Research and Treatment Quality-of-life
Questionnaire Core 30 Mapping Analysis Results
Selecting models
We illustrate how the best performing model was selected using the OLS results for the EORTC QLQ-C30.
Table 17 summarises the predicted EQ-5D scores and model performance of the six models that were
undertaken. Physical, role and emotional functioning dimensions were statistically signiﬁcant and positive
as expected. Pain and sleep disturbance were statistically signiﬁcant and negative as expected but
dyspnoea was positive. Inclusion of squared terms improved the model (model 4) but interactions
(model 5) had no impact and results from these were therefore not reported. Items related to dimensions
TABLE 16 Characteristics of the patient samples
Variables
All cancers (n=771) Breast cancer (n= 100) Lung cancer (n=99) MM (n = 572)
Mean SD Mean SD Mean SD Mean SD
Age (years) 68 9.6 54 10.9 63 11 72 5.4
Male (%) 44 0 48 50
EQ-5D
EQ-5D utility score 0.579 0.342 0.765 0.202 0.742 0.199 0.519 0.360
Proportion reporting
EQ-5D = 1 (%)
11 24 17 8
Range of EQ-5D –0.594 to 1 –0.144 to 1 0.088 to 1 –0.594 to 1
EORTC QLQ-C30 dimensions
Physical functioning 65 25.6 78 19.9 70 19.6 62 26.5
Role functioning 59 33.2 73 27.7 68 27.0 55 34.2
Emotional functioning 70 24.9 73 22.7 76 21.5 68 25.6
Cognitive functioning 76 22.7 77 22.8 77 20.5 76 23.1
Social functioning 69 29.8 72 26.2 74 23.8 68 31.3
Fatiguea 45 26.2 39 20.9 43 23.1 47 27.3
Nauseaa 9 17.9 11 19.9 10 16.8 8 17.7
Paina 40 33.0 23 24.3 23 23.5 47 33.5
Dyspnoeaa 25 29.0 17 22.5 37 30.7 24 29.1
Sleep disturbancea 33 32.6 34 31.1 31 28.3 33 33.6
Appetite loss
a
27 32.5 20 28.5 29 32.3 29 33.1
Constipationa 23 30.7 12 23.4 23 30.0 25 31.6
Diarrhoeaa 10 19.9 16 27.0 11 20.3 8 18.4
Financial impacta 20 28.8 24 30.5 23 28.8 19 28.4
Global QoL 53 23.2 68 18.2 62 21.0 48 22.8
a Higher scores for symptom scales indicate worse symptoms. EORTC QLQ-C30 dimension score range 0–100, higher
scores indicate better functioning and QoL.
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of physical, role, cognitive, emotional and social functioning and fatigue, pain, sleep disturbance, appetite
loss and constipation symptoms were statistically signiﬁcant. Collapsing unordered levels (model 7) did not
improve the results; however, including age improved the results (model 8).
Model performance statistics indicate that item models consistently performed better than the
domain-level models. All the models tended to underpredict EQ-5D scores for those in near perfect or full
health and overpredicted those in poorer health (Figure 6). Dimension level models predicted individuals in
full health, with values above 1, but item-level models did not. At the severe end of health, item-level
models performed better (see Figure 6). The models were able to discriminate across severity (see
Table 17). There was some evidence that the error was associated with severity, with higher MAE for
poor health compared with excellent health.
Table 18 presents the ranking for each of the models performance statistics. Model 8, the item model with
age, was the best-ﬁtting model (mean rank = 2.08) although it did not predict any EQ-5D scores in full
health. Domain-level models without squared terms and interactions gave the poorest estimates.
Best-fitting models – European Organization for Research and Treatment
Quality-of-Life Questionnaire Core 30
The process described above for EORTC QLQ-C30 was repeated for the tobit, two-part, splining and response
mapping models, the results are presented in Appendix 12 and are summarised here (Table 19 and Figure 7).
The results for tobit models were similar to OLS models in terms of the dimensions that were signiﬁcant
and model performance statistics with item-level models performing better than the domain-level models.
The best performing model was model 8, which was the item-level model with age included. OLS and
tobit models were best at predicting the mean EQ-5D value. All the TPMs overpredicted mean scores and
median values were lower than the observed values (see Appendix 12). Model 8, i.e. the item-level model
(model 6) with age, was the best-performing model and was best at predicting the median EQ-5D values.
Only one splining mode was ﬁtted to EORTC QLQ-C30 data for signiﬁcant domain scores as identiﬁed in
OLS model 3 a single spline was included for physical functioning at a score of 47. This model did not
perform better than the best OLS (model 8), but had the least deviation from the shrinkage coefﬁcient of 1.
For response mapping, it was necessary to collapse EORTC QLQ-C30 items into two levels (no problem and
any problem). The mean and median EQ-5D predicted values were lower than the observed values
(see Appendix 12). Response mapping models were able to discriminate between different severity groups
and predicted scores were associated with level of severity. The best-ﬁtting model was model 8 (the domain
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TABLE 17 European Organization for Research and Treatment Quality-of-life Questionnaire Core 30 mean observed and predicted EQ-5D values per model and summary
model performance: OLS
Summary statistics
and model
performance tests n Observed values
OLS model 2 OLS model 3 OLS model 4 OLS model 6 OLS model 7 OLSmodel 8
All dimensions
Signiﬁcant
dimensions
Signiﬁcant +
squared terms
Signiﬁcant
items
Signiﬁcant
items + collapsed
Signiﬁcant
items + age
Mean (SD) 771 0.5793 (0.3423) 0.5793 (0.2797) 0.5793 (0.2792) 0.5793 (0.2830) 0.5793 (0.2863) 0.5793 (0.2844) 0.5793 (0.2866)
Median 0.6910 0.6281 0.6244 0.6451 0.6498 0.6557 0.6502
Range –0.5940 to 1 –0.1846 to 1.02 –0.1915 to 1.031 –0.3712 to 0.9419 –0.4078 to 0.9713 –0.3670 to 0.9430 –0.4046 to 0.9714
R2 0.668 0.665 0.684 0.700 0.691 0.701
Adjusted R2 0.662 0.662 0.681 0.689 0.683 0.690
AIC –286 –294 –340 –338 –330 –339
BIC –216 –257 –307 –207 –237 –205
Ramsey RESET F3,753 = 12.57,
p < 0.001
F3,761 = 13.09,
p < 0.001
F3,761 = 1.56,
p = 0.198
F3,737 = 1.00
p = 0.3945
F3,736 = 0.58,
p = 0.6310
F3,736 = 0.88,
p = 0.449
MAE 0.149 0.151 0.143 0.139 0.142 0.139
Shrinkage 0.836 0.996 0.997 1.060 1.072 1.042
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TABLE 17 European Organization for Research and Treatment Quality-of-life Questionnaire Core 30 mean observed and predicted EQ-5D values per model and summary
model performance: OLS (continued )
Summary statistics
and model
performance tests n Observed values
OLS model 2 OLS model 3 OLS model 4 OLS model 6 OLS model 7 OLSmodel 8
All dimensions
Signiﬁcant
dimensions
Signiﬁcant +
squared terms
Signiﬁcant
items
Signiﬁcant
items + collapsed
Signiﬁcant
items + age
Health status n Mean Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE
1 (very poor) 42 –0.0057 0.1213 0.221 0.1212 0.224 0.0638 0.201 0.0636 0.206 0.0685 0.210 0.0642 0.205
2 53 0.1763 0.2571 0.193 0.2631 0.194 0.2569 0.191 0.2471 0.181 0.2590 0.194 0.2470 0.179
3 144 0.4286 0.4403 0.193 0.4410 0.195 0.4577 0.189 0.4650 0.181 0.4684 0.183 0.4629 0.182
4 226 0.6220 0.5685 0.154 0.5661 0.155 0.5839 0.145 0.5829 0.137 0.5794 0.141 0.5823 0.138
5 186 0.7180 0.7145 0.112 0.7158 0.113 0.7179 0.108 0.7170 0.109 0.7147 0.109 0.7176 0.109
6 94 0.8321 0.8494 0.110 0.8470 0.109 0.8165 0.102 0.8145 0.100 0.8148 0.103 0.8181 0.098
7 (excellent) 26 0.9029 0.8958 0.073 0.9008 0.075 0.8538 0.086 0.8553 0.081 0.8504 0.080 0.8546 0.080
ANOVA F6 = 97,
p < 0.001
F6 = 126,
p < 0.001
F6 = 126,
p < 0.001
F6 = 118,
p < 0.001
F6 = 112,
p < 0.001
F6 = 109,
p < 0.001
F6 = 114,
p < 0.001
M
A
P
P
IN
G
T
O
E
Q
-5
D
8
2
N
IH
R
Jo
u
rn
a
ls
Lib
ra
ry
w
w
w
.jo
u
rn
a
lslib
ra
ry.n
ih
r.a
c.u
k
model including all the items, age and gender). In terms of predictive ability, the response mapping models
had the lowest MAEs on average. The best-ﬁtting response-mapping model differs from other model
techniques where the best-ﬁtting models were item models. This was a result of collapsing item levels in
order to estimate these models.
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FIGURE 6 European Organization for Research and Treatment Quality-of-life Questionnaire Core 30 Plots of
observed and predicted EQ-5D scores for OLS models.
TABLE 18 European Organization for Research and Treatment Quality-of-life Questionnaire Core 30 mean ranking
of summary statistics and model performance tests for OLS models
Ranking
components
OLS model 2 OLS model 3 OLS model 4 OLS model 6 OLS model 7 OLS model 8
All
dimensions
Signiﬁcant
dimensions
Signiﬁcant +
squared
terms
Signiﬁcant
items
Signiﬁcant
collapsed
items
Signiﬁcant
items + age
Mean (SD) 1 (6) 1 (5) 1 (4) 1 (2) 1 (3) 1 (1)
Median 5 6 4 3 1 2
Range 6 5 3 1 4 2
R2 5 6 4 2 3 1
Adjusted R2 5 5 4 2 3 1
AIC 6 5 1 3 4 2
BIC 6 2 1 4 3 5
MAE 5 6 4 1 3 1
Shrinkage 6 2 1 4 5 3
Health status Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE
1 (very poor) 4 4 6 5 3 3 2 2 5 5 1 1
2 6 5 5 6 2 1 1 3 4 4 3 2
3 1 5 2 6 3 4 5 1 6 3 4 2
4 5 5 6 6 1 4 2 1 4 3 3 2
5 6 5 4 6 1 1 3 2 5 2 2 2
6 4 6 2 5 3 3 6 2 4 4 1 1
7 (excellent) 2 1 1 2 5 6 3 5 6 3 4 3
Mean ranking 4.58 4.38 2.79 2.54 3.67 2.08
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TABLE 19 European Organization for Research and Treatment Quality-of-life Questionnaire Core 30 mean observed and predicted EQ-5D values per model and summary
model performance: best-ﬁtting model across modelling techniques
Summary statistics
and model
performance tests n Observed values
OLS model 8 Tobit model 8 TPM model 8 SPL model 3
Response
mapping model 8
Signiﬁcant
items + age
Signiﬁcant
items + age
Signiﬁcant
items + age (P1)
Signiﬁcant
dimensions
All dimensions +
age/gender
Mean (SD) 771 0.5793 (0.3423) 0.5793 (0.2866) 0.5792 (0.2891) 0.6066 (0.2997) 0.5793 (0.2833) 0.5726 (0.2914)
Median 0.6910 0.6502 0.6517 0.6892 0.6457 0.6569
Range –0.594 to 1 –0.4046 to
0.9714
–0.3937 to
0.9463
–0.3936 to
0.9898
–0.3718 to
0.9438
–0.3376 to
0.9416
MAE 0.139 0.139 0.140 0.143 0.134
Shrinkage 1.042 1.020 0.940 0.997 1.179
Health status Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE
1 (very poor) 42 –0.0057 0.0642 0.205 0.0638 0.203 0.0649 0.195 0.0660 0.245 0.0473 0.181
2 53 0.1763 0.2470 0.179 0.2433 0.177 0.2670 0.185 0.3345 0.236 0.2262 0.159
3 144 0.4286 0.4629 0.182 0.4602 0.183 0.4808 0.184 0.5166 0.142 0.4515 0.182
4 226 0.6220 0.5823 0.138 0.5816 0.139 0.6091 0.141 0.5694 0.143 0.5827 0.139
5 186 0.7180 0.7176 0.109 0.7205 0.109 0.7566 0.107 0.7353 0.084 0.7094 0.097
6 94 0.8321 0.8181 0.098 0.8195 0.099 0.8511 0.104 0.8151 0.072 0.8137 0.100
7 (excellent) 26 0.9029 0.8546 0.080 0.8546 0.081 0.8925 0.060 0.8660 0.134 0.8596 0.075
ANOVA F6=97,
p<0.001
F6=114,
p<0.001
F6=113,
p<0.001
F6=114,
p<0.001
F6=117,
p<0.001
F6=116,
p<0.001
SPL, splining.
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Table 20 presents ranking of model performance statistics and the mean ranking across the common
criteria for the best-ﬁtting models from the different techniques used. Response mapping was the best
performing model across all model performance statistics (mean ranking = 2.4) followed by OLS
(mean = 2.7) and the tobit model (mean = 2.75).
Table 21 presents the model coefﬁcients for the response-mapping model.
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FIGURE 7 Observed and predicted EQ-5D scores for best performing models for EORTC QLQ-C30. SPL, splining.
TABLE 20 European Organization for Research and Treatment Quality-of-life Questionnaire Core 30 mean ranking
of summary statistics and model performance tests: best performing model across techniques
Ranking
components
OLS model 8 Tobit model 8 TPM model 8 SPL model 3
Response
mapping
model 8
Signiﬁcant
items + age
Signiﬁcant
items + age
Signiﬁcant
items + age
(P1)
Signiﬁcant
dimensions
All
dimensions +
age/gender
Mean (SD) 1 (4) 3 (3) 5 (1) 1 (5) 4 (2)
Median 3 4 1 5 2
Range 2 3 1 4 5
MAE 2 2 4 5 1
Shrinkage 3 2 4 1 5
Health status Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE
1 (very poor) 3 4 2 3 4 2 5 5 1 1
2 3 3 2 2 4 4 5 5 1 1
3 3 2 2 4 4 5 5 1 1 2
4 3 1 4 2 1 4 5 5 2 2
5 1 4 2 4 5 3 4 1 3 2
6 2 3 1 2 5 5 3 1 4 4
7 (excellent) 4 3 4 4 1 1 2 5 3 2
Mean rank 2.7 2.75 3.2 3.65 2.4
SPL, splining.
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TABLE 21 European Organization for Research and Treatment Quality-of-life Questionnaire Core 30 Best-ﬁtting response-mapping model
Variables Mobility 2 Mobility 3 Self-care 2 Self-care 3 Usual acts 2 Usual acts 3 Pain 2 Pain 3
Anxiety/
depression 2
Anxiety/
depression 3
Physical
functioning (SE)
–0.072***
(0.010)
–0.167***
(0.037)
–0.049***
(0.008)
–0.099
(0.119)
–0.036***
(0.010)
–0.085***
(0.014)
–0.001
(0.009)
–0.013
(0.013)
–0.014**
(0.006)
–0.044***
(0.016)
Role
functioning (SE)
–0.011*
(0.006)
–0.007
(0.017)
–0.017***
(0.006)
–0.030
(0.023)
–0.032***
(0.007)
–0.055***
(0.010)
0.001
(0.007)
–0.001
(0.011)
0.005
(0.005)
0.019
(0.013)
Emotional
functioning (SE)
0.010
(0.006)
0.024
(0.019)
0.008
(0.006)
0.008
(0.015)
0.021***
(0.007)
0.028***
(0.010)
0.009
(0.008)
0.011
(0.011)
–0.078***
(0.008)
–0.148***
(0.017)
Cognitive
functioning (SE)
–0.011*
(0.006)
–0.006
(0.015)
–0.010*
(0.006)
–0.009
(0.029)
0.004
(0.007)
–0.001
(0.010)
0.003
(0.008)
0.015
(0.011)
–0.007
(0.006)
0.006
(0.014)
Social
functioning (SE)
0.003
(0.006)
0.011
(0.016)
–0.009*
(0.006)
–0.005
(0.017)
–0.021***
(0.007)
–0.034***
(0.009)
0.005
(0.008)
–0.001
(0.010)
0.006
(0.006)
0.008
(0.011)
Fatigue (SE) 0.006
(0.008)
0.002
(0.019)
–0.022***
(0.008)
–0.025
(0.027)
0.028***
(0.009)
0.033**
(0.013)
0.007
(0.008)
0.006
(0.013)
–0.006
(0.007)
0.007
(0.019)
Nausea and
vomiting (SE)
0.001
(0.007)
0.016
(0.018)
0.007
(0.008)
0.019
(0.029)
0.022**
(0.010)
0.022*
(0.013)
0.005
(0.017)
–0.004
(0.019)
–0.007
(0.008)
–0.009
(0.015)
Pain (SE) 0.023***
(0.005)
0.043***
(0.017)
0.016***
(0.005)
0.024*
(0.015)
0.020***
(0.006)
0.023***
(0.008)
0.100***
(0.012)
0.164***
(0.016)
0.002
(0.004)
–0.012
(0.012)
Dyspnoea (SE) 0.002
(0.005)
0.004
(0.012)
–0.005
(0.005)
–0.015
(0.014)
–0.005
(0.006)
–0.015**
(0.008)
0.010*
(0.006)
0.008
(0.008)
0.000
(0.004)
–0.018
(0.011)
Sleep
disturbance (SE)
0.002
(0.004)
0.010
(0.012)
0.002
(0.004)
–0.000
(0.010)
–0.001
(0.005)
–0.002
(0.007)
0.013***
(0.005)
0.021***
(0.008)
–0.003
(0.004)
0.012
(0.008)
Appetite loss (SE) –0.009*
(0.005)
0.004
(0.012)
–0.000
(0.004)
0.010
(0.013)
–0.010*
(0.006)
–0.011
(0.008)
–0.013*
(0.006)
–0.008
(0.009)
0.006
(0.004)
0.016*
(0.009)
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Variables Mobility 2 Mobility 3 Self-care 2 Self-care 3 Usual acts 2 Usual acts 3 Pain 2 Pain 3
Anxiety/
depression 2
Anxiety/
depression 3
Constipation (SE) –0.004
(0.005)
–0.012
(0.013)
–0.004
(0.005)
–0.009
(0.014)
–0.000
(0.005)
0.004
(0.007)
0.006
(0.006)
0.010
(0.008)
0.004
(0.004)
0.001
(0.009)
Diarrhoea (SE) –0.005
(0.006)
0.010
(0.016)
0.003
(0.006)
0.005
(0.024)
–0.009
(0.006)
–0.011
(0.009)
–0.004
(0.008)
–0.008
(0.012)
0.002
(0.006)
0.002
(0.013)
Financial
Impact (SE)
–0.001
(0.005)
–0.003
(0.010)
0.005
(0.004)
0.015
(0.010)
0.008
(0.006)
0.006
(0.008)
0.010*
(0.005)
0.012
(0.008)
0.012***
(0.004)
0.015*
(0.009)
Age (SE) 0.028**
(0.013)
–0.021
(0.056)
0.048***
(0.015)
0.131*
(0.069)
0.026**
(0.011)
0.008
(0.028)
Female (SE) –0.349
(0.251)
–1.397*
(0.831)
Constant (SE) 3.169**
(1.598)
3.542
(5.250)
0.498
(1.467)
–6.619
(5.120)
3.494**
(1.436)
5.675***
(1.835)
–3.255**
(1.410)
–9.819***
(2.086)
4.562***
(1.316)
6.024*
(3.123)
Observations 771 771 771 771 771 771 771 771 771 771
Pseudo
R squared
0.449 0.449 0.392 0.392 0.461 0.461 0.455 0.455 0.364 0.364
* Statistically signiﬁcant at the 10% level.
** Statistically signiﬁcant at the 5% level.
*** Statistically signiﬁcant at the 1% level.
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Functional Assessment of Cancer Therapy – General Scale
preliminary analysis
The mean EQ-5D index score for FACT-G data set was 0.721 (SD = 0.22) with a median of 0.735, scores
ranged from –0.135 to 1 and 18% of responders are in full health and 0.9% scored less than 0.
Figure 8 presents the distribution of the EQ-5D index which displays the usual characteristics: there is a
mass of observations at 1 (full health), there is a large gap between these observations and the next
allowable value according to the EQ-5D tariff score with two additional peaks in the distribution. Patients
with very poor HRQL were not included in the sample and, therefore, the data set does not span the full
range of EQ-5D. Table 22 shows that no responder had extreme problems for mobility and few responders
had extreme problems for self-care, usual activities, pain/discomfort or anxiety/depression.
Average FACT-G scores were 20, 23, 18 and 18 for the physical, social, emotional and functional
dimensions respectively (Table 23). The average overall score was 78 and ranged from 33 to 108, with no
responders at the worse end of the FACT-G score (0–32). This is similar to the EQ-5D, where there are no
respondents at the worst levels. The correlation between EQ-5D domains is presented in Appendix 13.
TABLE 22 Responses to EQ-5D dimensions
EQ-5D item levels Mobility Self-care
Usual
activities
Pain/
discomfort
Anxiety/
depression
No problems 316 (59.6%) 456 (86.0%) 206 (38.9%) 235 (44.3%) 260 (49.1%)
Some problems 214 (40.4%) 72 (13.6%) 292 (55.1%) 278 (52.5%) 260 (49.1%)
Unable/extreme problems 0 (0%) 2 (0.4%) 32 (6.0%) 17 (3.2%) 10 (1.9%)
0
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0.0 0.5 1.0
EQ-5D score
FIGURE 8 Distribution of EQ-5D scores for FACT-G data set.
TABLE 23 Summary of the FACT-G overall and domain scores
Summary statistics Physical Social Emotional Functional Total score
n 530 530 530 530 530
Mean (SD) 20 (5.7) 23 (4.8) 18 (4.5) 18 (5.9) 78 (15.2)
Median 21 24 18 18 79
IQR 17–25 20–26 15–21 13–22 68–89
Range 1–28 1–28 4–24 0–28 33–108
IQR, interquartile range.
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The only correlation of note is that between the physical domain and functional domain, which can be
regarded as a moderate correlation (p = 0.570); all other correlations were below 0.4.
There was a modest relationship between FACT-G overall score and EQ-5D (Spearman's rank-order
correlation = 0.575) (see Appendix 13). The EQ-5D also had a reasonable correlation with the physical and
functional domains of the FACT-G, EQ-5D usual activities correlate modestly with FACT-G physical and
functional scales and EQ-5D anxiety/depression correlates modestly with FACT-G emotion.
Best-fitting model Functional Assessment of Cancer Therapy – General Scale
The model selection process described above for EORTC QLQ-C30 was repeated for FACT-G and the
best-ﬁtting OLS, tobit, two-part, splining and response mapping models are summarised in Table 24 and
Figure9. Appendix 13 summarises individual OLS, tobit, two-part, splining and response mapping model results.
The best OLS and tobit models included signiﬁcant items (model 6). For OLS, these were ‘lack of energy’,
‘trouble meeting the needs of family’ and ‘pain’ from the physical domain, ‘feeling sad’ and ‘losing hope’
from the emotional domain and ‘able to work’ from the functional domain. Level 0 (very much) of ‘I feel
sad’ had fewer than 20 observations; therefore, these item levels were merged with level 1 and model 6
was then reﬁtted. Collapsing item levels did not improve the overall model ﬁt. Model 6 predicted the
overall mean, underestimated those in near perfect or full health and overestimated those in poorer health
states (see Figure 9). OLS gave the best mean estimates overall and by severity group, and had one of the
two largest ranges of predicted scores (the TPM covered the widest range). OLS was the poorest at
predicting the median and had the lowest shrinkage factor, suggesting it would be the most likely to
overpredict results in studies applying the mapping algorithm.
The tobit model included two items from the physical domain (lack of energy and pain) and two items
from the functional domain (able to work and enjoy life).
The best performing TPM included signiﬁcant domain and squared terms (model 4) and domain, squared,
interaction and gender and education (model 8). Females were less likely to report full health, whereas
those with college degrees or professional degrees were more likely to report full health. Level of
education was classiﬁed using an American system201 and not all studies collect educational information in
this way, meaning that this model may have limited generalisability to other studies. We therefore
recommend model 4 as the best-ﬁtting TPM as the estimates from models 4 and 8 were similar. Generally
TPMs resulted in poorer mean predictions than tobit and OLS models but did have a slightly wider
coverage of EQ-5D predicted scores.
Splining model 3 included signiﬁcant domain scores and produced better estimates than model 1 (global
FACT-G score model). Fractional polynomials identiﬁed cut-offs at a score of 25 for the physical domain and
a score of 15 for the emotional well-being domain – no cut-off was necessary for the functional domain.
The best response-mapping models for predicting EQ-5D were the simplest models using signiﬁcant
domain scores (model 3); this model was unable to predict the full range of EQ-5D scores owing to the
small proportion of responses at level 3, meaning that there were not enough data to obtain reliable
estimates at the lower level. The response-mapping model gave reasonable estimates of the mean and
median but the poorest MAE across severity groups.
A mean ranking of models across the different model performance statistics showed that OLS gave the
best predictions (mean = 2.08), followed by the tobit model (mean = 2.42), with response mapping
(mean = 3.5) and TPMs (mean = 3.58) giving the poorest predictions (Table 25). Table 26 presents model
coefﬁcients for the best-ﬁtting model. All models failed to predict anyone in full health, underpredicting
at the top of the EQ-5D scale and overpredicting at the bottom end of the scale. However, the
underprediction at the lower end of the scale is perhaps unsurprising given that few responders in the
FACT-G data set reported severe problems with QoL.
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TABLE 24 Summary of observed and predicted values for best performing models: FACT-G data set
Summary statistics
and model
performance tests
OLS model 6 Tobit model 6 TPM model 4 SPL model 3
Response
mapping model 3
Observed values
Signiﬁcant
item levels
Signiﬁcant
item levels
Signiﬁcant
domain scores,
squared and
square root terms
Signiﬁcant
domain scores
Signiﬁcant
domain scores
Mean (SD) 0.721 (0.223) 0.721 (0.163) 0.723 (0.161) 0.739 (0.154) 0.723 (0.144) 0.720 (0.133)
Median 0.735 0.755 0.738 0.753 0.736 0.737
Range –0.135 to 1 0.115 to 0.962 0.132 to 0.957 0.119 to 0.993 0.312 to 0.974 0.268 to 0.934
MAE 0.111 0.181 0.120 0.198 0.125
Shrinkage 0.850 0.962 0.944 0.982 1.019
Health states n Mean Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE
1 (best) 122 0.8645 0.8464 0.088 0.8498 0.088 0.8302 0.090 0.8460 0.097 0.7933 0.101
2 256 0.7219 0.7318 0.108 0.7320 0.111 0.7359 0.121 0.7277 0.121 0.7201 0.122
3 (worst) 152 0.6055 0.6033 0.135 0.6074 0.137 0.6713 0.141 0.6152 0.148 0.6601 0.149
ANOVA F2527 = 55,
p < 0.001
F2527 = 107,
p < 0.001
F2527 = 109,
p < 0.001
F2527 = 122,
p < 0.001
F2527 = 130,
p < 0.001
F2527 = 120,
p < 0.001
SPL, splining.
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Limited dependent variable mixture model: Functional Assessment of
Cancer Therapy – General Scale
A model with all four FACT-G domains was selected as a possible candidate for estimation. Gender and
age have been consistently shown to be important when estimating mapping functions. In addition, these
two variables are typically used as explanatory variables for a host of parameter values used to populate
decision analytic cost-effectiveness models and thus are also included. All four FACT-G domains are
allowed to determine the mean EQ-5D of each latent component directly as well as indirectly through the
probability of component membership. Gender and age determine the mean of EQ-5D in each class but
are excluded from the probabilities. Models with up to ﬁve different components were ﬁtted. Given the
difference in variable and model selection procedures in this section to those included in Best-fitting model
Functional Assessment of Cancer Therapy-General, a linear model with the same six covariates was also
ﬁtted for direct comparisons.
TABLE 25 FACT-G mean ranking of summary statistics and model performance tests: best performing model
across techniques
Ranking
components
OLS model 6 Tobit model 6 TPM model 4 SPL model 3
Response
mapping
model 3
Signiﬁcant
item levels
Signiﬁcant
item levels
Signiﬁcant
domain scores,
squared and
square root
terms
Signiﬁcant
domain scores
Signiﬁcant
domain scores
Mean (SD) 1 (1) 3 (2) 5 (3) 3 (4) 2 (5)
Median 5 3 4 1 2
Range 2 3 1 5 4
MAE 1 4 2 5 3
Shrinkage 5 3 4 2 1
Health states Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE
1 (best) 2 1 1 1 4 3 3 4 5 5
2 3 1 4 2 5 4 2 3 1 5
3 (worst) 2 1 1 2 5 3 3 4 4 5
Mean rank 2.08 2.42 3.58 3.25 3.5
SPL, splining.
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FIGURE 9 Summary of best FACT-G model predictions. SPL, splining.
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Table 27 presents summary measures of overall ﬁt and prediction for the linear model as well as the
LDVMM with three to ﬁve components. The AIC decreases steadily from the linear model to the
ﬁve-component LDVMM as more classes are added and it is lowest for the ﬁve-component LDVMM.
However, the BIC is lowest for the linear model, reﬂecting the much higher penalty for model complexity
TABLE 26 Coefﬁcients for best-ﬁtting mapping model from FACT-G: item level OLS
Domain Item Item level OLS model 6
Physical Lack of energy Very much (baseline level) F4505 = 3.62, p = 0.007
Quite a bit 0.045 (0.032)
Somewhat 0.036 (0.030)
A little bit 0.071 (0.033)*
Not at all 0.118 (0.033)***
Trouble meeting need of family Very much (baseline level) F4505 = 2.75, p = 0.028
Quite a bit 0.028 (0.056)
Somewhat 0.049 (0.050)
A little bit 0.088 (0.050)*
Not at all 0.098 (0.050)*
Pain Very much (baseline level) F4505 = 29.09, p < 0.001
Quite a bit 0.125 (0.073)*
Somewhat 0.219 (0.069)**
A little bit 0.240 (0.071)**
Not at all 0.342 (0.070)***
Emotional I feel sad Very much (baseline level) F4505 = 2.45, p = 0.045
Quite a bit –0.085 (0.105)
Somewhat –0.019 (0.101)
A little bit 0.006 (0.099)
Not at all 0.004 (0.099)
Losing hope Very much (baseline level) F4505 = 3.68, p = 0.006
Quite a bit –0.081 (0.122)
Somewhat –0.007 (0.079)
A little bit 0.013 (0.076)
Not at all 0.060 (0.075)
Functional Able to work Not at all (baseline level) F4505 = 10.22, p < 0.001
A little bit 0.113 (0.031)***
Somewhat 0.130 (0.028)***
Quite a bit 0.150 (0.028)***
Very much 0.152 (0.030)***
Constant 0.186 (0.0141)***
* Statistically signiﬁcant at the level of 10%.
** Statistically signiﬁcant at the level of 5%.
*** Statistically signiﬁcant at the level of 1%.
The values in brackets refer to SEs.
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of this information criterion given the size of the data set. Out of the three LDVMMs, BIC selects the
simplest model, a model with three components. Measures of in-sample predictions such as MAE and
RMSE are lowest for the LDVMM with ﬁve components.
Table 28(a) displays comparisons of the observed and predicted EQ-5D means by the ECOG performance
status, which measures the progression of the disease and its effect on the individual daily living activities.
There are no individuals in the last ECOG group corresponding to ‘completely disabled’ in this data set and
only 21 patients in the ‘capable of only limited self-care’ category, leaving only three groups of severity
with enough patients to make any kind of comparison and even these have relatively small sample sizes
across a broad range of severity. This prevents a more thorough analysis of systematic differences.
Table 28(b) and (c) present the MAE and RMSE for each ECOG category. The differences in absolute value
between the different LDVMMs are small as are their differences with the linear model. This is the typical
TABLE 27 Summary of overall model ﬁt and prediction measures
Model performance tests Linear model
LDVMM,
three classes
LDVMM,
four classes
LDVMM,
ﬁve classes
Log-likelihood 175.36 202.54 223.79 272.35
AIC –336.71 –337.07 –353.58 –424.70
BIC –306.80 –191.79 –152.76 –168.33
MAE 0.126 0.123 0.121 0.119
RMSE 0.174 0.171 0.170 0.168
TABLE 28 Comparisons of observed vs. predicted means and in sample predictions split by the ECOG
Statistic n
Observed
EQ-5D Linear model
LDVMM,
thee classes
LDVMM,
four classes
LDVMM,
ﬁve classes
(a) Mean
Health status (ECOG)
1 (best) 122 0.8645 0.8342 0.8375 0.8410 0.8423
2 256 0.7219 0.7334 0.7328 0.7339 0.7308
3 131 0.6301 0.6182 0.6194 0.6194 0.6262
4a (worst) 21 0.4517 0.5610 0.5537 0.5555 0.5527
(b) MAE
Health status (ECOG)
1 (best) 122 0.096 0.094 0.092 0.091
2 256 0.123 0.122 0.118 0.118
3 131 0.145 0.140 0.143 0.135
4a (worst) 21 0.205 0.207 0.199 0.195
(c) RMSE
Health status (ECOG)
1 (best) 122 0.124 0.121 0.122 0.122
2 256 0.177 0.174 0.172 0.171
3 131 0.186 0.181 0.183 0.180
4a (worst) 21 0.275 0.276 0.270 0.265
a Owing to the small sample size in this group, numbers are only reported for completeness and should be taken with caution.
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ﬁnding given the insensitivity of these measures when applied to individual level data sets and the small
range covered by the EQ-5D scale. In terms of the mean, the LDVMM with ﬁve components is closer to
the observed mean. Both the MAE and the RMSE are smallest for the LDVMM with ﬁve components with
the exception of the RMSE of the ﬁrst category of ECOG in which the smallest corresponds to the LDVMM
model with three components.
Figure 10 depicts the percentage distribution of EQ-5D in the data set on the top left corner as well as the
distributions of the simulated data from each model (100 replications per individual in the sample). The
accompanying Table 29 presents some descriptive statistics of the same simulated data sets. It is clear from
Figure 10 that the linear model is not capable of reproducing any of the characteristic features seen in
EQ-5D data. It generates points well above one in considerable numbers: 10.5% of the simulated data set
(see Table 29). The lack of observations at the bottom of the EQ-5D range allows a smaller estimated
variance of the error term in the linear model than it would have been otherwise without penalising the
likelihood excessively.
The key characteristics of EQ-5D are reﬂected in all three of the mixture models (see Figure 10). The mass
of observations at one, the gap to the next feasible values and the multimodal distribution are all clearly
generated by the use of this modelling method. There is a clear, separate peak in the observed data
around 0.8, which is replicated in the ﬁve-class model and to a lesser extent in the three-class model.
Of these models, and based on these various aspects of model suitability, the ﬁve-class model is the
optimal approach for estimating the index of EQ-5D from FACT-G domain scores, although that is based
on ﬁt for this particular data set which has features that may not be typical of the true relationship owing
to the small sample size such as the separate peak at around 0.8. If this is the case, the four-class model,
which offers similar performance, will be a better alternative. Table 30 presents the parameter estimates as
well as robust SE for these two LDVMMs.
0
5
10
15
20
P
e
r 
ce
n
t
0
5
10
15
20
P
e
r 
ce
n
t
0
5
10
15
20
P
e
r 
ce
n
t
0
5
10
15
20
P
e
r 
ce
n
t
0
5
10
15
20
P
e
r 
ce
n
t
0 0.5 1.0
EQ-5D EQ-5D EQ-5D
EQ-5D in FACT-G data set
0 0.5 1.0 1.5
EQ-5D in linear model
– 0.5 0 0.5 1.0
EQ-5D
– 0.5 0 0.5 1.0
EQ-5D
– 0.5 0 0.5 1.0
EQ-5D in LDVMM 3LC model
EQ-5D in LDVMM 4LC model EQ-5D in LDVMM 5LC model
FIGURE 10 Observed EQ-5D distribution vs. simulated distributions from the models.
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TABLE 30 Parameter estimates and robust SEs of the LDVMM models
Individual components Variables
LDVMM, four classes LDVMM, ﬁve classes
Parameter Robust SE Parameter Robust SEs
Component 1 Intercept 0.4404 0.0398 –0.1326 0.1690
Physical/10 0.0823 0.0125 0.0894 0.0488
Social/10 0.0079 0.0136 –0.0370 0.0410
Emotional/10 0.0534 0.0135 0.0741 0.0380
Functional/10 0.0531 0.0133 0.0834 0.0984
Female 0.0065 0.0107 –0.0700 0.0582
Age/10 –0.0106 0.0043 0.0262 0.0232
Variance –0.0084 0.0008 0.0096 0.0034
Component 2 Intercept 0.0475 0.0854 0.5255 0.0426
Physical/10 0.0277 0.0449 0.0694 0.0144
Social/10 0.0033 0.0172 0.0051 0.0128
Emotional/10 –0.3663 0.0290 0.0242 0.0140
Functional/10 0.3657 0.0420 0.0304 0.0142
Female –0.3006 0.0203 –0.0021 0.0109
Age/10 0.1210 0.0146 –0.0095 0.0046
Variance 0.0011 0.0009 0.0070 0.0008
Component 3 Intercept 0.2362 0.1543 0.9048 0.0500
Physical/10 0.0649 0.0459 –0.0284 0.0078
Social/10 0.0356 0.0415 –0.0022 0.0082
Emotional/10 0.0403 0.0379 0.0255 0.0152
Functional/10 –0.1298 0.0417 –0.0112 0.0121
Female –0.0814 0.0376 –0.0054 0.0065
Age/10 –0.0131 0.0179 0.0025 0.0020
Variance –0.0112 0.0036 0.0001 0.0001
continued
TABLE 29 Summary statistics of the observed EQ-5D distribution and simulated distributions from the models
Summary statistics
Observed
EQ-5D Linear model
LDVMM,
three classes
LDVMM
four, classes
LDVMM,
ﬁve classes
Mean (SD) 0.7213
(0.2226)
0.7224
(0.2230)
0.7216
(0.2214)
0.7235
(0.2261)
0.7251
(0.2235)
Median 0.735 0.7280 0.7436 0.7494 0.7422
Range –0.135–1 –0.176–1.605 –0.330–1 –0.544–1 –0.442–1
Percentage of values
equal to 1 (%)
17.55 0 17.51 19.91 19.28
Percentage of values
bigger than 1 (%)
0 10.48 0 0 0
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TABLE 30 Parameter estimates and robust SEs of the LDVMM models (continued )
Individual components Variables
LDVMM, four classes LDVMM, ﬁve classes
Parameter Robust SE Parameter Robust SEs
Component 4 Intercept 0.5016 0.0622 1.0421 0.0915
Physical/10 1.4330 0.0049 0.1591 0.0144
Social/10 0.2381 0.0063 –0.1523 0.0315
Emotional/10 –1.0314 0.0338 –0.0642 0.0160
Functional/10 0.3333 0.0129 –0.2793 0.0149
Female –0.3035 0.0048 –0.0645 0.0148
Age/10 –0.2678 0.0045 –0.0267 0.0069
Variance 0.0000 0.0000 –0.0008 0.0003
Component 5 Intercept 0.4723 0.0161
Physical/10 1.5171 0.0237
Social/10 0.2630 0.0056
Emotional/10 –1.0861 0.0168
Functional/10 0.3506 0.0060
Female –0.3354 0.0073
Age/10 –0.2845 0.0051
Variance 0.0000 0.0000
Probability of
component membership
Component 1 Intercept 26.3220 9.5991 28.7320 4.8843
Physical/10 –6.4481 2.0328 –7.7485 1.3572
Social/10 0.6283 0.5400 0.2088 0.7066
Emotional/10 –5.9957 3.1645 –5.3613 1.2930
Functional/10 1.0201 0.8806 –2.0401 0.6475
Component 2 Intercept 24.0409 9.7623 24.5811 4.5782
Physical/10 –6.9441 2.1127 –6.9610 1.3098
Social/10 –0.1360 0.9505 0.4083 0.4989
Emotional/10 –4.8344 3.2401 –3.7666 1.0400
Functional/10 1.3550 1.2704 –0.1056 0.4365
Component 3 Intercept 28.8196 9.6574 17.1879 4.3081
Physical/10 –7.4868 2.0489 –5.6688 1.3442
Social/10 0.8007 0.7136 0.6917 0.5661
Emotional/10 –6.8488 3.2067 –3.3006 1.0858
Functional/10 –0.3731 0.9861 0.8492 0.5185
Component 4 Intercept 20.2004 4.9627
Physical/10 –7.8089 1.3512
Social/10 1.4606 0.8702
Emotional/10 –2.3890 1.4754
Functional/10 –1.1400 0.6987
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Even though the models in this section are not directly comparable to those in the preceding section
owing to differing selection procedures, compared with the equivalent dimension models of the FACT G
(Appendix 13), the overall MAE of LDVMM is better than the three models with (signiﬁcant) domain
scores. Dropping insigniﬁcant terms from the components and from the probabilities of component
membership would increase both AIC and BIC for the LDVMM model and would tend to improve other
measures of ﬁt, making the LDVMM model appear to ﬁt better. However, in doing this, there is a risk of
ﬁtting the model to this particular data set in excess and has not been pursued here.
Uncertainty
After allowing for uncertainty, the mean EQ-5D estimates ranged from 0.541 to 0.944 (mean = 0.721).
Discussion
Different regression techniques were explored to develop mapping functions for two widely used cancer
measures, the EORTC QLQ-C30 and the FACT-G to the EQ-5D. In addition to methods such as OLS, which
are widely used in the literature, a newer method that takes into account the characteristics typically seen
in the distribution of the EQ-5D the LDVMMs were also applied for the FACT-G.
Response mapping gave the best predictions for the combined EORTC QLQ-C30 data sets. This model
used all dimension scores, age and gender to estimate the EQ-5D index. Compared with other models
ﬁtted to this data set, this was best at predicting the overall MAE and mean and MAE per health status
group. The mapping function is based on pooled data from three data sets, which was necessary in order
to give a large enough sample to produce more reliable and representative mapping estimates. The data
were from three different types of cancer and, therefore, could be argued to be more representative for
use in other populations of mixed cancer types than other published mapping models. We also explored a
range of models not previously examined in other studies.146,147,197–199,216
Only one previous study had mapped from FACT-G to EQ-5D and the mapping estimates were not
reliable.105 At this stage we do not know whether our ﬁndings are generalisable to other studies. Given
the small amount of patients in the severest levels of HRQL in the FACT-G data set, the generalisability of
those estimates are likely to be limited when compared with other populations containing patients at the
severe end of the HRQL scale. Of the models ﬁtted to the FACT-G data set, OLS and the tobit model using
signiﬁcant items gave the best estimates according to the mean predictions for the overall sample and the
subgroups deﬁned according to severity, and these models also performed well in the EORTC QLQ-C30
data sets. The model based on splining gave better median predictions and the response-mapping model
performed best in terms of shrinkage. Only one LDVMM speciﬁcation was ﬁtted for the FACT-G data set,
which included only dimension level information, gender and age. This model performed better than the
equivalent linear model for the FACT-G and was shown to generate the main characteristics of the original
distribution of EQ-5D in the data set. Even though the response mapping model results did not ﬁt the data
as well as other techniques, it is the only one, with the exception of the LDVMM, which can generate the
features observed in the distribution of EQ-5D data. It does, however, ignore the ordinality of the data,
and it is possible that more ﬂexible models for response mapping, such as those presented in Hernández
Alava et al.,213 or further developments will increase the predictive ability of this modelling approach.
When considering the development of mapping functions, we could consider the size of sample needed to
produce reliable functions. However, there are no rules for sample sizes in predictive modelling like
prognostic modelling and mapping modelling but a rule of thumb is to have at least 20 individuals per
independent variable.217 For simple models like OLS, this would mean that a model including four dimensions
would require a minimum of 80 individuals and a model including 27 items, each with ﬁve levels, would
require 2160 observations (4 × 27 × 20). For response mapping models, the number of variables would relate
to the smallest response category (usually level 3 for EQ-5D dimensions) and to work out sample size
requirements you could work backwards from the expected number of respondents in level 3.
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For example, if this was 3%, for a model including four dimensions you would need 2667 (80/0.03)
observations or 27 items with ﬁve levels 72,000 (2160/0.03) observations.
To our knowledge, this is the ﬁrst time that uncertainty has been accounted for in parameter (coefﬁcient)
estimates from mapping functions. At this stage we do not know what potential allowing for this
uncertainty will have on NICE decisions. Future research needs to build on this and allow for uncertainty in
the original EQ-5D estimates as well as the selection of appropriate models.
Generally, both OLS and tobit models using item level EORTC QLQ-C30 and FACT-G models gave some of
the best model estimates and for FACT-G produced the best models, while for TPMs, domain level models
gave better predictions. Other studies have ﬁtted CLAD and generalised linear models as mapping
functions. Like the tobit model, the CLAD model also deals with the limited nature of the data and
produces consistent estimates in the presence of heteroscedasticity and non-normality. Median based
models are not usually used for economic evaluation as, particularly when applied to costs, when
aggregated, may not accurately reﬂect the total cost or beneﬁt for the population.218 Therefore, this model
was not ﬁtted here. Generalised linear models were not ﬁtted either as they did not improve model ﬁt
over OLS models.
In terms of model selection, mapping studies in the literature report different model ﬁt and model
selection criteria, some focusing on model goodness of ﬁt, others on the predictive ability of the model.
Models should be selected mainly on their predictive ability, but other considerations may also be taken
into account. Even still, there are still a number of criteria from which a model can be selected and
different choices can result in alternative models being selection. In this chapter, rather than choosing one
performance statistic to select the best model, we have given equal weighting to the overall mean,
median, MAE, shrinkage and the mean and MAE per health status group. Further work should be
undertaken to examine whether the criteria we have included are the optimal criteria to be used when
judging mapping functions. For example, measures such as MAE and RMSE are not often used in other
analyses of individual level data because heterogeneity across individuals is considerable, making these
measures very insensitive to model improvements. This is an even greater problem when using dependent
variables that span an extremely small range such as EQ-5D. The ranking method used here does not
account for the magnitude of the predictions and how close they are to the observed data; further work
should be undertaken to incorporate this into selecting the best models.
One of the other methodological factors that should be taken into consideration when carrying out
mapping is the sample size used when producing the mapping functions. Response mapping produced
poor predictions for FACT-G, although it was the best-ﬁtting model for EORTC QLQ-C30. This was a result
of the sample not covering the poorer health states but is also a function of sample size. With a larger
sample, it would be possible to obtain more accurate predictions of the 3% of the sample being in level 3
for an EQ-5D dimension, for example. Further work is needed on sample size recommendations for the
more complex models such as response mapping and LDVMMs. However, given the typically small size of
cancer studies, it may be difﬁcult to ﬁnd studies with large enough samples to carry out the analysis.
Combining data sets, as carried out for the EORTC QLQ-C30, offers an alternative when available and
using mapping functions based on simpler techniques, such as OLS, may be the only option when these
are not available.
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Chapter 4 Developing ‘bolt-on’ items to EQ-5D
Background and aim
This chapter details the methods and results of the studies to develop ‘bolt-on’ items to the EQ-5D.
Bolt-ons are dimension(s) that can be appended to another instrument in order to overcome perceived
inadequacies of the parent instrument in a particular population. Utility values can then be obtained for
the health states described by the instrument with the bolt-on. The bolt-ons reported here have been
developed and tested with reference to the EQ-5D as the parent instrument. The EQ-5D was chosen for
this purpose as it is the most widely used GPBM for economic evaluation internationally, and is
recommended as the preferred GPBM by NICE in England and Wales. The systematic reviews of the
published literature reported in Chapter 2 found that the EQ-5D performed poorly in conditions affecting
hearing and in some vision impairments. Therefore, these two clinical areas were selected for development
of bolt-ons. In addition, energy was also selected as a potential bolt-on. Although the review of the
measures in cancer did not ﬁnd any particular problems related to cancer or cancer-related fatigue, it is an
area where concern has been raised by NICE and its stakeholders (as summarised in Wailoo et al.219).
This chapter describes the bolt-on items and two valuation studies. The ﬁrst study was an exploratory study
to test the impact of the three bolt-on items on EQ-5D health states chosen to reﬂect mild, moderate and
severe health states. Following from this study, the bolt-on having the largest impact was chosen for
further evaluation and the second study was designed to allow a full valuation of that bolt-on with
the EQ-5D.
Methods
Development of bolt-on items
The labels for the three bolt-on items were developed to be consistent with the labels of the three-level
version of the EQ-5D so that they include categories of ‘no problems’, ‘some problems’ and ‘extreme
problems’. In addition, the measures identiﬁed in the systematic reviews reported in Chapter 2 were
considered in the development of the descriptions of the condition-speciﬁc labels. The review highlighted
that some measures of vision and hearing give explicit reference to the use of supportive equipment, such
as hearing aids and glasses. The use and provision of equipment such as these are commonplace in
developed countries and, in most cases, easily address vision and hearing problems. A decision was taken
to include reference to the use of supportive equipment so that the bolt-on instrument captures vision
severity after taking into account the use of equipment. If the use of equipment was not explicitly
addressed, the bolt-on item would fail to distinguish more severe problems that cannot be corrected using
standard equipment. The references to equipment were developed to follow a similar format to that for
the ‘usual activities’ dimension of EQ-5D, which includes a clariﬁcation in parentheses in the heading of
the item. This referred to glasses or contact lenses in the vision bolt-on: ‘Vision (using glasses or contact
lenses if needed)’, and to hearing aids as an example in the hearing bolt-on: ‘Hearing (using equipment if
needed, e.g. hearing aids)’. The wording of the three bolt-on dimensions is shown in Box 1.
Methods of the exploratory study
Health state selection
The aim of the exploratory study was to test the impact of the three bolt-on items on EQ-5D health state
values. In brief, each possible level of severity of the bolt-ons was added to a selection of EQ-5D health
states, each of which also represented a different level of severity, the health states were valued and
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compared with values obtained for corresponding EQ-5D states without the bolt-ons. It was
hypothesised that:
l adding a mild level (no problems) of the bolt-on to a mild-state would have little impact compared
with a mild EQ-5D state without a bolt-on
l adding a moderate level (some problems) of the bolt-on to a moderate-state would have little impact
compared with a moderate EQ-5D state without a bolt-on
l adding a severe level (extreme problems) of the bolt-on to a severe-state would have little impact
compared with a severe EQ-5D state without a bolt-on.
It was, however, also recognised that other effects could logically occur. For example, it could be that people
assume no problems on the impairment or symptom reﬂected in the bolt-on if it is not presented. If this
were the case, adding on a ‘level 1’ (no problems) of the bolt-on would be expected to have no impact on
the EQ-5D health state regardless of the severity of that state. Therefore, we chose the study design for the
exploratory study to reﬂect our weak priors regarding the impact of the bolt-ons and to explore it further.
Three EQ-5D health states were chosen as ‘core’ states for valuation. The health states were selected
following consideration of three criteria: (1) to cover a range of severity levels, (2) to select from the set of
43 states that have previously been valued in a large UK general population study used to develop the UK
EQ-5D tariff,4,29 (3) to include combinations of problems that are not implausible or rare. This third criterion
was assessed by examining health states that occur with relative high frequency in the Health Survey for
England.220 The ﬁnal selection included three with a logically determined ordering of severity: a mild EQ-5D
state, a moderate state and a severe state. The notation used to describe the health states in this report
reﬂects the severity (level 1, 2, 3) on each of the ﬁve dimensions in the EQ-5D classiﬁcation in the order
presented in the questionnaire. The chosen mild state consists of no problems on the ﬁrst three and last
dimensions (mobility, self-care, usual activities and anxiety/depression) and moderate problems on the
fourth dimension (pain/discomfort); therefore, is represented by the classiﬁer 11121. The moderate state
included some or moderate problems on all ﬁve dimensions (22222). The severe state included moderate
problems on the ﬁrst three dimensions (mobility, self-care and usual activities) and severe problems on the
last two dimensions (pain/discomfort and anxiety/depression) and is represented by the classiﬁer 22233.
BOX 1 The three bolt-on items used in the exploratory study
Hearing (using equipment if needed, e.g. hearing aids)
Tiredness
I have no problems hearing □
I have some problems hearing □
I have extreme problems hearing □
Vision (using glasses or contact lenses if needed)
I have no problems seeing □
I have some problems seeing □
I have extreme problems seeing □
I am not tired □
I am moderately tired □
I am extremely tired □
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All three levels of the bolt-on item (with severity levels of 1, 2 or 3) were added to each EQ-5D state
resulting in nine states for valuation for each bolt-on dimension. The three core EQ-5D states without the
bolt-on items were also valued. In order to ensure consistency in the number of states valued between
groups and to allow a comparison of EQ-5D states with previous studies, six further EQ-5D states were
selected for valuation from the previous large UK valuation study. The ﬁnal selection of health states
valued is shown in Table 31.
Data collection
Respondents to the survey were allocated to one of the four questionnaire variants: EQ-5D with each of
the bolt-ons and EQ-5D alone. Five trained interviewers undertook the interviews. Interviewers were
instructed to use each questionnaire variant in turn, so their ﬁrst respondents completed questionnaire
one, the next questionnaire two and so on and then back to questionnaire one. This ensured an even
distribution of the variants between interviewers and minimised the risk of an interviewer effect biasing
the results. The interviews followed a similar format to the UK EQ-5D valuation study.4 After agreeing to
participate in the study, respondents were asked to describe their own health using the EQ-5D and the
bolt-on dimension they were about to value. Then the respondents rated their own health using the
EQ-VAS, which is bounded by 0 (‘worst imaginable health state’) and 100 (‘best imaginable health state’).
Respondents then ranked six hypothetical states described on separate cards as a ‘warm-up’ task to
familiarise respondents with the health state cards and with the process of stating their preferences
towards the health states. The six states consisted of four states randomly chosen by interviewers or
respondents from the nine states for each instrument, plus the best state described by the instrument and
‘immediate death’.
Respondents then completed the main valuation exercise using the TTO method.221 The best health state
(11111 or 11111 + 1) described by the EQ-5D with/without bolt-on was used as the upper anchor. The
respondent was asked to imagine 10 years of life in the health state under valuation, relative to a shorter
duration in the best state, followed by ‘immediate death’. A ‘TTO board’ was used as a visual aid to assist
respondents with one side for valuing health states better than dead and the other side for those health
states worse than dead. A conventional approach was taken to valuing states considered to be worse than
dead. If respondents indicated that they would rather die immediately than live in the imperfect health
state for any number of years, the TTO board was reversed as they were asked to state their preferred
option between the imperfect health state for t years followed by (10 – t) years in full health or immediate
death and the value of t was varied until the respondent was indifferent between the two options.
Respondents valued a practice health state and then each of the nine health states as described in
Table 31. Finally, respondents were asked to complete sociodemographic questions and their health status
described using the remaining bolt-on items.
TABLE 31 Health states selected for valuation in the exploratory study
EQ-5D EQ-5D + hearing EQ + vision EQ-5D + tiredness
11121 11121 + 1 11121 + 1 11121 + 1
22222 11121 + 2 11121 + 2 11121 + 2
22233 11121 + 3 11121 + 3 11121 + 3
11112 22222 + 1 22222 + 1 22222 + 1
11122 22222 + 2 22222 + 2 22222 + 2
21232 22222 + 3 22222 + 3 22222 + 3
22323 22233 + 1 22233 + 1 22233 + 1
33232 22233 + 2 22233 + 2 22233 + 2
33333 22233 + 3 22233 + 3 22233 + 3
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Analysis
The sample size was estimated to detect a difference of 0.1 in mean values for health states with and
without the bolt-on item using independent t-tests. Based on an assumed power of 0.8, signiﬁcance level
of 0.05 and SD of 0.3, based on a previously conducted study including a bolt-on item,19 73 respondents
were required in each bolt-on group. Therefore, study recruitment aimed to survey 300 people randomly
allocated to four groups of 75 people. Recruitment aimed to achieve a good spread across age, gender,
ethnicity and social class. The sample was selected on the basis of postal address within South Yorkshire
using the Names and Numbers software, AFD software (Ramsey, Isle of Man).
Time trade-off valuations were transformed using the transformation reported for the UK EQ-5D tariff to
ensure all health state values are bound between –1 and 1:4
for states valued as better than dead TTO = t/10 and
for states valued as worse than dead TTO = –t/10.
The number of observations, mean transformed TTO values, SDs, maximum and minimum values are
reported for all health states. Tests for differences in the sociodemographic characteristics between the
four groups were compared using a chi-square test for categorical variables, a chi-square gamma statistic
for ordered variables and ANOVA for continuous variables.
Paired t-tests were used to compare each health state with the bolt-on to the core EQ-5D state without
the bolt-on. Regression analyses were used to examine whether any differences between the groups could
explain any potential differences between the values for the bolt-on states. Random effects (RE) models
were used to take account of the clustering of data by respondents and allows for the fact that the error
term may not be independent of the respondent.
The general model is:
yij ¼ ðαþ βxij þ δqj þ θrj þ γziÞ þ εij ð4Þ
where:
yij = TTO utility values for health state j valued by respondent i
i = 1, 2, . . ., m represents individual respondents
j = 1, 2, . . ., n represents health states valued
x = vector of dummy variables for the three EQ-5D core health state
q = vector of dummy variables for each variant (including EQ-5D and three bolt-ons)
r = vector of dummy variables for the three severity levels of the bolt-ons
z = vector of sociodemographic characteristics, including respondent's gender, age, experience of the
bolt-on condition
εij = an error term whose autocorrelation structure and distributional properties depend on the
assumptions underlying the particular regression model used.
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Stata version 10 (StataCorp LP, College Station, TX, USA) was used for all regression analysis, and
SPSS v. 18 (SPSS Inc., Chicago, IL, USA) was used for the descriptive statistical analysis. A level of statistical
signiﬁcance was assumed where p < 0.05.
Methods of the full valuation study
The primary aim of the full valuation study was to develop a model for valuing all possible health states
described by EQ-5D with one of the bolt-ons. Secondary aims included assessing the impact of the bolt-on
to the coefﬁcients representing the ﬁve EQ-5D dimensions.
In order to choose a bolt-on for this study, the results of the exploratory study were examined to identify
the bolt-on with the most frequently statistically signiﬁcant and consistent impact on health state values.
Based on this assessment, the bolt-on for vision (EQ + vision) was selected for inclusion in the full valuation
study. No change was made to the labelling or format of the vision bolt-on.
Health state selection
Health states were selected based on an orthogonal design of EQ + vision states. This required values for
18 health states assuming a main effects additive model. As the orthogonal design included mainly severe
health states, two additional mild states were added to the orthogonal set. The set of EQ-5D only health
states was selected from dropping the sixth dimension of the 20 EQ + vision states. Both sets of 20 health
states were split in two in order to produce four groups of 10 states. The health states valued within the
survey are shown in Table 32.
Data collection
A further sample of 300 members of the general public in South Yorkshire was recruited to participate in
face-to-face interviews. The methods of sampling were the same as described for the exploratory study but
people who had previously participated in the exploratory study were excluded. Survey respondents were
allocated to one of four questionnaire variants and, as in the previous survey, each interviewer undertook
valuations of each questionnaire variant in turn. The interviews followed a similar format to the exploratory
study following amendments to take account of updated valuation methods for EQ-5D as recommended
by the EuroQol Group. Speciﬁcally these included referring to ‘dead’ rather than ‘immediate death’ and
‘full health’ rather than the description of state 11111. In summary, after agreeing to participate in the
study, respondents completed the EQ-5D for their own health (with the vision bolt-on if valuing EQ + vision
states), then completed a ‘warm up’ task of ranking four health states plus the state ‘dead’ and valuing a
TABLE 32 Health states selected to value in the full valuation survey
EQ-5D states EQ + vision states
Group 1 Group 2 Group 3 Group 4
23133 32231 23133 + 3 32231 + 1
13122 21221 13122 + 1 21221 + 2
23212 22323 23212 + 2 22323 + 1
21332 13331 21332 + 1 13331 + 2
31133 31312 31133 + 2 31312 + 3
12232 12313 12232 + 3 12313 + 2
22111 33321 22111 + 3 33321 + 3
32122 33213 32122 + 2 33213 + 1
11121 11223 11121 + 1 11223 + 3
33333 11112 33333 + 3 11112 + 2
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practice health state using the TTO method (22222/+ 2), and then valuing the 10 health states using the
TTO method using the same approach as described for the exploratory study. The ﬁnal task was for
respondents to complete sociodemographic questions and describe their health status using the vision
bolt-on (for those respondents valuing the EQ-5D only).
Analysis
The transformation of TTO valuations, statistical summaries of values, statistical software tests for
differences in the sociodemographic characteristics are the same as those reported above for the
exploratory study. Models were developed for both instruments separately using EQ-5D and EQ + vision.
RE models were used in analyses to account for repeated observations. The dependent variable in each
model was ‘1 – TTO value’ and dummy variables were used to represent the levels on each dimension. The
variables considered for inclusion in the analysis are shown in Table 33. The impact of the vision dimension
was assessed by its statistical signiﬁcance in the model after accounting for the EQ-5D dimensions.
Alternative model speciﬁcations were explored including models published for other large EQ-5D data sets
for the standard UK and USA EQ-5D value sets.4,222
The coefﬁcients of the EQ-5D dimension dummy variables in the ﬁnal model were compared using
the z-test in order to make an assessment of the impact of the vision bolt-on to the values given to the
EQ-5D dimensions.
TABLE 33 Variables considered for inclusion in the multivariate analysis of EQ-5D and EQ+vision
Variable Description
Mobility EQ-5D mobility dimension: level 1 (ref), level 2, level 3
Self-care EQ-5D self-care dimension: level 1 (ref), level 2, level 3
Activities EQ-5D usual activities dimension: level 1 (ref), level 2, level 3
Pain EQ-5D pain/discomfort dimension: level 1 (ref), level 2, level 3
Anxiety EQ-5D anxiety/depression dimension: level 1 (ref), level 2, level 3
Vision EQ + vision dimension: level 1 (ref), level 2, level 3
Gender Male (ref) or female
Age Age categories: (1) 18–24 years (ref), (2) 25–34 years, (3) 35–44 years, (4) 45–54 years, (5) 55–64 years,
(6) 65 + years
Marital Marital status: (1) single (ref), (2) married, (3) separated, (4) divorced, (5) widowed
Yourself Reporting experience serious of illness in yourself (0 reporting experience, 1 otherwise)
Family Reporting experience serious of illness in your family (0 reporting experience, 1 otherwise)
Carer Reporting experience serious of illness in caring for others (0 reporting experience, 1 otherwise)
Activity Main activity: (1) employed or self-employed (ref), (2) retired, (3) homemaker, (4) student,
(5) seeking work, (6) other
Education Educated beyond school leaving age (0 yes, 1 no)
Home Housing status: (1) own home (ref), (2) rent in public sector, (3) rent privately
SRVision Self-reported level vision problems: level 1 (ref), level 2, level 3
N3 1 if any level 3 problems included in the health state, 0 otherwise
I2 Number of dimensions at level 2 beyond the ﬁrst
I3 Number of dimensions at level 3 beyond the ﬁrst
D1 Number of dimensions not at level 1 beyond the ﬁrst
ref, reference level for dummy variables.
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Results of the exploratory study
Three hundred face-to-face interviews were successfully completed, evenly split (n = 75) across four
groups valuing each of the three bolt-ons and a group valuing EQ-5D alone. The characteristics of the
respondents are shown in Table 34. Overall the characteristics of the groups were well balanced with very
few statistically signiﬁcant differences between the groups. Statistically signiﬁcant differences were found
TABLE 34 Characteristics of respondents to the exploratory bolt-on valuation study
Characteristic
EQ-5D
(n = 75)
EQ + hearing
(n = 75)
EQ + vision
(n = 75)
EQ + tiredness
(n = 75)
χ
2 or t-statistic
(p-value)
Age group (%)
18–24 5 17 9 11 24.0 (0.065)
25–34 21 7 11 17
35–44 20 16 24 8
45–54 16 19 27 23
55–64 20 19 12 23
65 + 17 23 17 19
Male (%) 32 40 49 39 4.78 (0.189)
Relationship status (%)
Single 21 32 23 28 12.5 (0.408)
Married 53 40 60 48
Separated 3 7 6 5
Divorced 12 15 5 9
Widowed 11 5 5 9
Experience of serious illness (%)
In yourself 29 33 23 37 4.34 (0.223)
In your family 68 68 71 79 2.71 (0.439)
In caring for others 55 36 40 52 12.2 (0.007)
Main activity (%)
Employment 52 36 45 39 13.5 (0.563)
Retired 24 29 27 35
Housework 6 12 9 6
Student 3 5 5 6
Seeking work 6 12 6 3
Other 8 5 6 11
Educated after minimum school
leaving age (%)
64 60 56 55 1.48 (0.688)
Degree (%) 29 27 29 25 0.45 (0.930)
Home ownership (%)
Own home 71 65 75 69 5.01 (0.543)
Rent (local authority) 17 16 19 17
Rent (private sector) 12 19 7 12
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between the groups in terms of experience in caring for others, with more people in the EQ-5D and
EQ + tiredness groups reporting experience of this than those in the EQ + vision and EQ + hearing groups.
Self-reported health status is shown in Table 35. Few people reported severe problems on any of
the dimensions of health. The only differences in self-reported health between the groups were in the
number of respondents reporting problems with vision; fewer people in the group allocated to valuing the
EQ + vision reported current problems with vision. EQ-VAS scores and EQ-5D index values were similar
between the groups.
TABLE 35 Self-reported health of respondents in the exploratory study
EQ-5D
dimension
and level
EQ-5D (%)
(n = 75)
EQ + hearing
(%) (n = 75)
EQ + vision
(%) (n = 75)
EQ + tiredness
(%) (n = 75)
χ
2 or F-statistic
(p-value)
Mobility 1 62 59 58 48 11.4 (0.077)
2 13 15 17 27
3 0 1 0 0
Self-care 1 70 70 66 67 4.23 (0.646)
2 5 4 8 8
3 0 1 1 0
Usual activities 1 62 61 61 52 7.63 (0.266)
2 11 11 11 21
3 1 2 3 2
Pain/discomfort 1 46 48 53 41 4.36 (0.628)
2 24 22 18 27
3 5 5 4 7
Anxiety/depression 1 57 58 63 57 4.82 (0.567)
2 15 13 11 12
3 3 4 1 6
Hearing 1 64 63 61 63 2.65 (0.851)
2 11 11 14 11
3 0 1 0 1
Vision 1 44 43 61 45 13.3 (0.038)
2 30 30 13 29
3 1 2 1 1
Tiredness 1 39 40 42 40 6.17 (0.405)
2 28 29 31 25
3 8 6 2 10
Mean self-reported
VAS (SD)
77.1 (21.2) 80.9 (17.2) 78.9 (17.8) 74.7 (21.5) 1.38 (0.250)
Mean self-reported
EQ-5D index (SD)
0.83 (0.26) 0.80 (0.28) 0.84 (0.28) 0.75 (0.32) 13.36 (< 0.01)
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Comparison of health state values
A total of 2697 TTO values were elicited from the 300 respondents. On average, each state was valued
around 75 times. Summary statistics for the TTO values given to the EQ-5D health states (without bolt-on)
are shown in Table 36. Mean values from the Measurement and Valuation of Health (MVH) study29 used
to generate the social tariff of EQ-5D values for the UK are also presented for comparison.223,224
In general, the values given in the NICEQoL study were higher than those obtained through the MVH
study used to generate the social tariff of EQ-5D values for the UK. This is consistent with some
international valuation studies of EQ-5D health states conducted since the MVH study, which have also
reported higher mean TTO values compared with the original MVH study.223,224
The mean values for each of the bolt-on health states are presented in Table 37 alongside the values for
the ‘core’ EQ-5D states. The results of t-test comparing TTO values between the three core EQ-5D states
and the corresponding nine states with speciﬁc bolt-ons are also reported in Table 37.
TABLE 37 Comparison between mean TTO values for EQ-5D and EQ-5D with bolt-ons
EQ-5D state
EQ-5D
Bolt-on state
EQ-5D + hearing EQ + vision EQ-5D + tiredness
Mean Mean p-value Mean p-value Mean p-value
11121 0.94 111211 0.94 0.89 0.94 0.82 0.94 0.71
111212 0.90 0.07 0.90 0.01 0.90 0.06
111213 0.85 0.001 0.69 < 0.001 0.82 < 0.001
22222 0.71 222221 0.80 0.04 0.74 0.54 0.79 0.09
222222 0.77 0.18 0.76 0.25 0.74 0.54
222223 0.70 0.82 0.59 0.02 0.72 0.85
22233 0.41 222331 0.40 0.92 0.41 0.99 0.45 0.51
222332 0.45 0.56 0.41 0.99 0.45 0.52
222333 0.36 0.43 0.32 0.16 0.34 0.33
TABLE 36 Mean TTO values for all EQ-5D heath states (no bolt-on)
Values from valuation study
Values from
MVH study
State n Mean SD Median Minimum Maximum Mean
11121 76 0.94 0.11 1.00 0.50 1 0.85
22222 74 0.71 0.30 0.80 –0.30 1 0.50
22233 74 0.41 0.40 0.43 –0.80 1 –0.14
11112 75 0.93 0.14 1.00 0.40 1 0.83
11122 75 0.87 0.19 1.00 0.20 1 0.72
21232 76 0.52 0.40 0.50 –0.80 1 0.06
22323 75 0.46 0.43 0.50 –0.93 1 0.04
33232 74 0.11 0.40 0.01 –0.93 1 –0.33
33333 75 –0.02 0.40 0.00 –0.93 1 –0.54
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The ordering of the mean values of the three core EQ-5D states was consistent with the logical ordering of
these health states. Within each questionnaire variant, the TTO values were consistent with the domain
levels with the exception of levels 1 and 2 added to the severe health state, where level 2 was higher than
level 1 for the hearing bolt-on and there was no difference in values between bolt-on levels 1 and 2 in the
corresponding state for vision and tiredness.
For the mild state (11121), there were no differences between the mean value for the ‘core’ EQ-5D state
and for the states with the level 1 (no problems) bolt-on included. The states with a bolt-on level 2 added
to the mild state (111212) resulted in lower values for all three bolt-ons. This difference was statistically
signiﬁcant for vision and approached signiﬁcance for hearing (p = 0.07) and tiredness (p = 0.06). The
inclusion of the level 3 bolt-on to form state 111213 resulted in signiﬁcantly lower mean health state
values across all bolt-ons. Among the three bolt-ons, adding on a level 3 (severe problems) for vision
showed the greatest impact on the TTO value as the mean value decreased from 0.94 to 0.69, compared
with 0.85 for hearing and 0.82 for tiredness.
The pattern of values for the bolt-on items to the moderate (22222) and severe (22233) states was more
complex. For the moderate EQ-5D state (22222), including levels 1 or 2 of the bolt-ons increased the
health state values, although only the level 1 hearing bolt-on showed a statistically signiﬁcant difference.
There was little impact of adding a level 3 for hearing and tiredness, but there were signiﬁcantly lower
values for the level 3 vision bolt-on. SDs were consistently higher for the more severe health states (with or
without the bolt-ons).
For the severe state (22233), none of the bolt-on items had a statistically signiﬁcant impact on the TTO
value; however, the variance was also greater for these states. After adding level 1 and level 2 of the
bolt-ons, the mean TTO values showed no difference for vision, small increases for tiredness and a slight
increase for level 2 hearing, but none of the differences were statistically signiﬁcant. Although not
statistically signiﬁcant, the addition of level 3 led to a reduction in mean TTO values for all bolt-ons
(although it approached signiﬁcance at the 0.1 level).
Table 38 shows the results of the multivariate analysis using a RE model. The primary aim of this analysis was
to assess whether any of the differences in background characteristics between the groups had an impact
on the values given to the health states. A secondary aim was to assess the impact of background
characteristics on values more generally. The coefﬁcients representing the severity of the core EQ-5D states
were logically ordered and highly statistically signiﬁcant. Similarly, the coefﬁcients for the level of the
bolt-on were consistently ordered; however, only the most severe level was statistically different from level 1.
There were no signiﬁcant differences in the coefﬁcients for the type of bolt-on. Overall, the coefﬁcients are
difﬁcult to interpret as the impact of the bolt-on depends on the severity of the state to which it is added.
The results of the multivariate analysis show that those background characteristics that differed between
the groups (experience in caring for others and self-reported vision problems) had no signiﬁcant impact
upon the valuations given to the health states described by the instruments. Of the other background
characteristics, marital status signiﬁcantly impacted upon the values with single people giving lower values
to health states than some of the other groups. In addition, those seeking work and people who had no
further education after minimum school leaving age gave higher values to the health states.
Conclusions from the exploratory study
Each of the bolt-on items had a signiﬁcant impact on at least one EQ-5D health state. The extent and
direction of the impact of the bolt-on varied according to the level of severity of the bolt-on and the
severity of the state to which it was added. Adding a level 1 bolt-on to a mild state had no impact, but
adding more severe levels led to lower values. Adding a level one or two bolt-on to the moderate state led
to higher values, but this was only statistically signiﬁcant for the level 1 hearing bolt-on. Adding a level 3
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TABLE 38 Analysis of the impact of background characteristics on the health state values in the exploratory study
Explanatory variables Coefﬁcient SE p-value
Core states
11121 Ref
22222 –0.151*** 0.012 < 0.001
22233 –0.487*** 0.012 < 0.001
Bolt-ons
No bolt-on Ref
Hearing 0.055 0.036 0.132
Vision 0.005 0.12 0.902
Tiredness 0.037 1.05 0.292
Bolt-on levels
Level 1 Ref
Level 2 –0.015 0.013 0.235
Level 3 –0.114*** 0.013 < 0.01
Female –0.019 0.027 0.486
Age (years)
18–24 Ref
25–34 0.052 0.053 0.331
35–44 0.038 0.056 0.501
45–54 0.004 0.058 0.952
55–64 0.040 0.063 0.526
65 + 0.067 0.076 0.382
Marriage status
Single Ref
Married 0.091** 0.037 0.014
Separated 0.052 0.061 0.394
Divorced 0.094* 0.051 0.067
Widowed 0.153** 0.060 0.011
No experience of serious illness
In yourself 0.000 0.032 0.995
In your family –0.028 0.030 0.349
In caring for others –0.047 0.029 0.104
Main activities
Employed Ref
Retired –0.036 0.049 0.456
House work 0.013 0.045 0.769
Student 0.020 0.065 0.757
Seeking work 0.103** 0.052 0.048
Others 0.060 0.051 0.241
continued
continued
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bolt-on to the moderate state led to statistically signiﬁcant lower values for the vision bolt-on. Adding
a level 1 or 2 to the severe state has little impact or increased the health state values, though not
signiﬁcantly. Adding level 3 to the severe state reduced the value, but not signiﬁcantly. It should be noted
that the severe states had the highest SDs associated with the mean values and so the comparisons had
the lowest power.
Although there were a couple of statistically signiﬁcant differences in the sociodemographic composition
of the subgroups (speciﬁcally for experience in caring for others and vision problems), the regression
analysis conﬁrmed that these characteristics did not have a signiﬁcant impact upon valuations. There did
not appear to be substantial differences between the three bolt-ons, but overall, the impact appeared to
be stronger for the vision bolt-on, therefore, this was selected for the full valuation study.
Results of the full valuation study of EQ + vision
In total, 302 people completed the interviews: 155 for EQ-5D alone and 157 for EQ + vision. The
sociodemographic characteristics of respondents are presented in Table 39. There was a similar age and
gender balance between the two groups. A summary of the self-reported health status of the respondents
is shown in Table 40. There were no statistically signiﬁcant differences in the sociodemographic
characteristics or the self-reported health between the two groups.
TABLE 38 Analysis of the impact of background characteristics on the health state values in the exploratory
study (continued )
Explanatory variables Coefﬁcient SE p-value
Education (to minimum school leaving age only) 0.057** 0.026 0.031
House ownership
Rent from local authority 0.027 0.035 0.436
Rent from private sector 0.032 0.041 0.433
Self-reported health
Hearing1 Ref
Hearing2 –0.034 0.035 0.327
Hearing3 0.114 0.151 0.449
Vision1 Ref
Vision2 0.012 0.029 0.689
Vision3 –0.137 0.094 0.148
Tiredness1 Ref
Tiredness2 0.015 0.027 0.581
Tiredness3 –0.065 0.049 0.183
Constant 0.804*** 0.068 < 0.001
Observations 2219
Ref, reference value for dummy variables.
* p < 0.1.
** p < 0.05.
*** p < 0.01.
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The distribution of TTO values for each state is shown in Figure 11 and a summary is provided in Table 41.
Between 76 and 80 valuations were obtained for health state. Mean values ranged from 0.05 (state
33333) to 0.96 (state 11121) for the EQ-5D and from –0.04 (state 33333 + 3) to 0.95 (state 11112 + 2) for
the EQ + vision. The rank ordering of several of the EQ-5D ‘core’ states differed to the rank ordering of the
EQ + vision states. For example, for the EQ-5D, state 11121 was valued most highly followed by 11112;
however, the rankings of these two states were reversed when the vision bolt-on was included (the mean
value for 11112 + 2 was higher than that for 11121 + 1). SDs were generally higher for states considered
to be most severe and the range of values given for most states was large.
TABLE 39 Sociodemographic characteristics of respondents of the EQ+vision valuation study
Characteristic EQ-5D (n = 155) EQ + vision (n = 157) χ2 (p-value)
Age group (years) (%)
18–24 9.7 10.2 2.72 (0.742)
25–34 14.2 14.6
35–44 18.7 22.9
45–54 21.3 14.6
55–64 16.8 16.6
65+ 19.4 21.0
Male (%) 45.8 38.9 1.55 (0.214)
Relationship status (%)
Single 16.8 25.5 7.05 (0.133)
Married 57.4 59.2
Separated 3.2 1.9
Divorced 11.6 7.0
Widowed 11.0 6.4
Experience of serious illness (%)
In yourself 24.7 30.1 1.16 (0.282)
In your family 74.7 71.6 0.369 (0.544)
In caring for others 50.6 42.2 2.21 (0.137)
Main activity (%)
Employment 52.9 45.9 6.70 (0.244)
Retired 25.2 25.5
Housework 12.3 14.0
Student 0 1.9
Seeking work 3.9 8.3
Other 5.8 4.5
Educated after minimum school leaving age 56.1 57.3 0.05 (0.831)
Degree 32.9 36.5 0.45 (0.501)
Home ownership (%)
Own home 72.9 74.5 1.28 (0.527)
Rent (local authority) 18.7 14.6
Rent (private sector) 8.4 10.8
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Multivariate analysis
The regression models for the EQ-5D and EQ + vision (both excluding sociodemographic variables) are
presented in Tables 42 and 43, respectively.
The model speciﬁcations were estimated as below:
Model 1: including main effects only.
Model 2: including the N3 term to account for interactions as per the standard UK tariff (where N3 is a
dummy variable for any dimension at level 3).
Model 3: including the D1 terms to account for interactions as considered in the US tariff (where the D1
terms are a set of interaction terms representing moves away from full health and the number of
dimensions at level 3 beyond the ﬁrst).
Model 4: the preferred model including all sociodemographic characteristics.
The models speciﬁed for the regression analysis are reported in Tables 42 and 43 for the EQ-5D
and EQ + vision data, respectively. The terms representing interactions did not have statistically signiﬁcant
coefﬁcients in either of the models and so have been excluded from the ﬁnal models presented here.
TABLE 40 Self-reported health status of respondents in the EQ+vision study
EQ-5D dimension and level,
VAS and index
EQ-5D
(n = 155)
EQ + vision
(n = 157)
χ
2 or t-test
(p-value)
Mobility (%) Level 1 83.9 75.2 4.25 (0.119)
Level 2 16.1 24.2
Level 3 0.0 0.6
Self-care (%) Level 1 93.5 90.4 1.69 (0.431)
Level 2 6.5 8.9
Level 3 0.0 0.6
Usual activities (%) Level 1 81.9 76.4 1.55 (0.462)
Level 2 16.1 20.4
Level 3 1.9 3.2
Pain/discomfort (%) Level 1 66.5 61.1 1.63 (0.443)
Level 2 30.3 33.1
Level 3 3.2 5.7
Anxiety/depression (%) Level 1 80.0 77.7 3.73 (0.154)
Level 2 16.8 21.7
Level 3 3.2 0.6
Vision (%) Level 1 61.3 69.4 2.45 (0.294)
Level 2 35.5 28.7
Level 3 3.2 1.9
Mean self-reported VAS (SD) 79.2 (17.6) 75.8 (20.0) –1.58 (0.114)
Mean EQ-5D index (SD) 0.85 (0.24) 0.82 (0.26) –1.17 (0.244)
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FIGURE 11 Distribution of TTO values for EQ-5D and EQ+vision health states. (a) EQ-5D health states; (b) EQ+vision health states. (continued)
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FIGURE 11 Distribution of TTO values for EQ-5D and EQ+ vision health states. (a) EQ-5D health states; (b) EQ + vision health states. (continued)
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TABLE 41 Mean TTO values for EQ-5D and EQ+vision
Health state Mean n SD Minimum Maximum Median
EQ-5D states
11112 0.93 77 0.17 0.05 1 1.00
11121 0.96 78 0.10 0.53 1 1.00
11223 0.67 77 0.37 –0.73 1 0.78
12232 0.57 79 0.32 –0.5 1 0.63
12313 0.62 76 0.32 0 1 0.68
13122 0.75 78 0.30 0 1 0.85
13331 0.39 77 0.45 –0.73 1 0.40
21221 0.82 76 0.23 0.03 1 0.90
21332 0.55 77 0.30 –0.08 1 0.60
22111 0.90 77 0.15 0.35 1 1.00
22323 0.55 78 0.36 –0.6 1 0.51
23133 0.42 78 0.38 –0.83 1 0.43
23212 0.72 79 0.32 –0.5 1 0.80
31133 0.35 78 0.40 –0.98 1 0.38
31312 0.46 77 0.40 –0.93 1 0.50
32122 0.50 77 0.38 –0.98 1 0.53
32231 0.28 76 0.45 –0.93 1 0.38
33213 0.26 78 0.47 –0.98 1 0.35
33321 0.21 78 0.47 –0.93 1 0.20
33333 0.05 79 0.42 –0.98 1 0.00
EQ-5D + vision states
111122 0.95 79 0.10 0.55 1 1.00
111211 0.94 79 0.12 0.5 1 1.00
112233 0.59 77 0.40 –0.9 1 0.70
122323 0.53 77 0.34 –0.57 1 0.53
123132 0.63 76 0.36 –0.63 1 0.70
131221 0.80 79 0.23 0 1 0.90
133312 0.48 79 0.41 –0.93 1 0.50
212212 0.89 77 0.17 0.38 1 1.00
213321 0.60 79 0.35 –0.98 1 0.63
221113 0.77 79 0.25 0 1 0.83
223231 0.58 78 0.39 –0.98 1 0.70
231333 0.30 79 0.45 –0.98 1 0.33
232122 0.71 80 0.27 –0.03 1 0.75
311332 0.31 80 0.44 –0.98 1 0.30
313123 0.42 77 0.45 –0.88 1 0.50
continued
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TABLE 41 Mean TTO values for EQ-5D and EQ+vision (continued )
Health state Mean n SD Minimum Maximum Median
321222 0.43 79 0.41 –0.78 1 0.50
322311 0.35 79 0.43 –0.98 1 0.40
332131 0.34 80 0.46 –0.98 1 0.35
333213 0.24 78 0.48 –0.93 1 0.21
333333 –0.04 79 0.45 –0.98 1 0
TABLE 42 Models estimated for EQ-5D
Variable
Model 1: main effects only Model 2: including N3 term Model 3: including D1 term
Coefﬁcient SE p-value Coefﬁcient SE p-value Coefﬁcient SE p-value
Mobility 2 0.019 0.018 0.309 0.021 0.018 0.253 0.017 0.049 0.726
Mobility 3 0.315 0.017 < 0.001 0.308 0.018 < 0.001 0.293 0.083 < 0.001
Self-care 2 0.079 0.018 < 0.001 0.067 0.020 0.001 0.083 0.033 0.012
Self-care 3 0.185 0.018 < 0.001 0.170 0.022 < 0.001 0.166 0.069 0.016
Activities 2 0.076 0.020 < 0.001 0.066 0.022 0.002 0.091 0.035 0.011
Activities 3 0.150 0.021 < 0.001 0.136 0.024 < 0.001 0.136 0.071 0.056
Pain 2 0.071 0.018 < 0.001 0.060 0.020 0.003 0.082 0.030 0.006
Pain 3 0.236 0.020 < 0.001 0.221 0.024 < 0.001 0.220 0.078 0.005
Anxiety 2 0.036 0.020 0.070 0.014 0.027 0.610 0.039 0.031 0.206
Anxiety 3 0.120 0.018 < 0.001 0.100 0.025 < 0.001 0.101 0.062 0.103
Vision 2
Vision 3
N3 0.043 0.038 0.259
D1 0.020 0.041 0.635
I2 –0.029 0.069 0.675
I22 –0.001 0.022 0.970
I3 0.023 0.102 0.821
I32 –0.007 0.011 0.509
Constant 0.009 0.031 0.768 0.017 0.032 0.598
Number of
observations
1550 1550 1550
Number of groups 155 155 155
Log-likelihood –340 –339 –338
p-value from the
chi-squared test
< 0.001 < 0.001 < 0.001
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In the model for EQ-5D, all the coefﬁcients followed a logical order, the decrement in utility attributed to
level 3 problems was greater than that for level 2 problems. The coefﬁcients for all dimensions were
statistically signiﬁcant, except for the dummy variables representing some mobility problems and moderate
anxiety/depression. The largest impact on EQ-5D values was level 3 mobility problems (being conﬁned to
bed), followed by level 3 problems with pain/discomfort and self-care.
There were some similarities to the existing main UK data set for EQ-5D (level 3)4 that was based on a
large UK general population study. That study also found that level 3 mobility and pain/discomfort had the
largest impact on EQ-5D values; however, level 3 self-care problems had the ﬁfth largest impact. Overall,
the size of the utility decrements were smaller in this this study compared with the previous UK population
study and this reﬂects the higher TTO values reported by respondents in this study.
The model for EQ + vision demonstrated a similar pattern to that for EQ-5D. The coefﬁcients followed a
logical ordering, including the coefﬁcients for the vision bolt-on. The vision coefﬁcients were statistically
signiﬁcant, which indicates that vision has a signiﬁcant impact on EQ-5D values after taking into account
TABLE 43 Models estimated for EQ+vision
Variable
Model 1: main effects only Model 2: including N3 term Model 3: including D1 term
Coefﬁcient SE p-value Coefﬁcient SE p-value Coefﬁcient SE p-value
Mobility 2 0.034 0.018 0.062 0.032 0.018 0.079 0.025 0.039 0.533
Mobility 3 0.320 0.017 < 0.001 0.314 0.018 < 0.001 –0.069 0.354 0.846
Self-care 2 0.091 0.018 < 0.001 0.077 0.022 < 0.001 0.104 0.051 0.042
Self-care 3 0.158 0.018 < 0.001 0.147 0.021 < 0.001 –0.255 0.379 0.501
Activities 2 0.032 0.020 0.118 0.029 0.021 0.165 0.090 0.071 0.204
Activities 3 0.104 0.021 < 0.001 0.097 0.022 < 0.001 –0.209 0.306 0.495
Pain 2 0.062 0.019 0.001 0.062 0.019 0.001 0.071 0.038 0.062
Pain 3 0.219 0.020 < 0.001 0.216 0.020 < 0.001 –0.100 0.324 0.756
Anxiety 2 0.038 0.020 0.056 0.029 0.021 0.170 0.070 0.053 0.193
Anxiety 3 0.159 0.018 < 0.001 0.150 0.020 < 0.001 –0.161 0.319 0.612
Vision 2 0.037 0.018 0.040 0.039 0.018 0.031 0.030 0.034 0.389
Vision 3 0.130 0.018 < 0.001 0.127 0.018 < 0.001 –0.246 0.361 0.495
N3 0.035 0.033 0.293
D1 0.444 0.381 0.244
I2 –0.555 0.429 0.196
I22 0.026 0.017 0.128
I3 –0.236 0.168 0.160
I32 0.042 0.036 0.237
Constant –0.018 0.035 0.608 –0.026 0.036 0.477
Number of
observations
1570 1570 1570
Number of groups 157 157 157
Log-likelihood –361 –361 –361
p-value from the
chi-squared test
< 0.001 < 0.001 < 0.001
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the 5 standard EQ-5D dimensions. As with the model for EQ-5D, the coefﬁcients representing some
mobility problems and moderate anxiety/depression were not statistically signiﬁcant, which also
applied to the coefﬁcient representing some problems carrying out usual activities. The coefﬁcients with
the largest impacts were still level 3 mobility problems (being conﬁned to bed) and level 3 problems with
pain/discomfort; the coefﬁcient for level 3 vision problems was the ﬁfth largest, ahead of level 3 problems
performing usual activities.
Table 44 shows the results of the analysis including background characteristics. The values of people who
reported that they had some or extreme vision problems did not value the health states signiﬁcantly
differently from people who reported no vision problems. There were some statistically signiﬁcant
differences in the health state values according to age with the youngest age group giving lower
values than the other age groups. Some differences were also seen in the valuation of the EQ + vision
health states according to experience of caring for others and those seeking work compared with
employed respondents.
TABLE 44 Final models (with background characteristics)
Variable
EQ-5D EQ + vision
Coefﬁcient SE p-value Coefﬁcient SE p-value
Mobility 2 0.020 0.019 0.270 0.036 0.019 0.051
Mobility 3 0.318 0.017 < 0.001 0.320 0.017 < 0.001
Self-care 2 0.079 0.018 < 0.001 0.091 0.018 < 0.001
Self-care 3 0.185 0.018 < 0.001 0.163 0.018 < 0.001
Activities 2 0.076 0.020 < 0.001 0.033 0.021 0.105
Activities 3 0.149 0.021 < 0.001 0.108 0.021 < 0.001
Pain 2 0.072 0.018 < 0.001 0.060 0.019 0.002
Pain 3 0.238 0.020 < 0.001 0.216 0.020 < 0.001
Anxiety 2 0.039 0.020 0.051 0.037 0.020 0.062
Anxiety 3 0.122 0.018 < 0.001 0.158 0.018 < 0.001
Vision 2 0.033 0.018 0.068
Vision 3 0.127 0.018 < 0.001
Gender –0.040 0.043 0.352 –0.071 0.045 0.117
Age 1
Age 2 –0.104 0.090 0.248 –0.212 0.087 0.014
Age 3 –0.202 0.098 0.040 –0.316 0.088 < 0.001
Age 4 –0.188 0.103 0.069 –0.226 0.102 0.027
Age 5 –0.160 0.111 0.149 –0.208 0.105 0.048
Age 6 –0.147 0.132 0.264 –0.122 0.129 0.344
M_single
M_married 0.010 0.069 0.890 0.057 0.062 0.356
M_sep –0.001 0.124 0.991 0.449 0.148 0.002
M_div 0.078 0.091 0.390 0.058 0.097 0.549
M_widow 0.089 0.097 0.359 0.044 0.103 0.666
Yourself 0.022 0.052 0.681 –0.031 0.050 0.54
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The coefﬁcients for the ﬁve EQ-5D dimensions were compared between the EQ-5D model
and the EQ + vision model. A difference in the coefﬁcients would suggest that including the additional
vision dimension leads to different valuations of the ﬁve EQ-5D dimensions; for example, if having some
problems with self-care is valued differently depending on whether vision problems are present in the
health state. The results of the z-test are presented in Table 45. There were no statistical differences in the
coefﬁcients at the predeﬁned level for statistical signiﬁcance; however, some of the coefﬁcients appeared
to be qualitatively different and approached the level for signiﬁcance. In particular, the coefﬁcients for the
usual activities dimension differed by 0.045 and 0.046 for levels 2 and 3, respectively, each with p-values
of less than 0.1. The difference in the coefﬁcients for level 3 anxiety and depression was also of a similar
magnitude (0.039) that also had a p-value of less than 0.1.
Discussion
The results from the exploratory study and the main valuation study demonstrate that bolt-on items can
potentially have a signiﬁcant impact upon EQ-5D valuations. In these studies, bolt-ons representing vision
impairment, hearing impairment and tiredness all signiﬁcantly impacted on at least some health states.
The ﬁndings from both of the empirical studies presented here demonstrate that the relationship of the
bolt-ons to the EQ-5D state valuations is complex. The exploratory study shows that the impact of the
bolt-ons depends on the severity of the bolt-on item and the severity of the state to which they are added.
The inclusion of bolt-ons representing ‘no problems’ is not always of no consequence. When included
alongside severe health states, it can lead to higher valuations than not mentioning the absence of
problems. This has signiﬁcant implications for the valuation of bolt-ons as it suggests that including the
bolt-on valuation as a simple decrement in, for example, an additive model, is inadequate. This conﬁrms
ﬁndings in another bolt-on study looking at the addition of pain to a condition speciﬁc instrument.225
TABLE 44 Final models (with background characteristics) (continued )
Variable
EQ-5D EQ + vision
Coefﬁcient SE p-value Coefﬁcient SE p-value
Family 0.031 0.048 0.522 0.057 0.045 0.207
Carer –0.046 0.043 0.290 0.101 0.044 0.022
Activity_Emp
Activity_Retired 0.055 0.085 0.518 –0.123 0.087 0.159
Activity_home –0.076 0.066 0.247 0.013 0.063 0.839
Activity_student –0.027 0.149 0.856
Activity_seeking –0.046 0.103 0.653 –0.191 0.084 0.024
Activity_Other 0.058 0.087 0.505 0.032 0.105 0.759
Education –0.017 0.043 0.697 –0.045 0.046 0.331
Home_own
Home_rentLA –0.021 0.056 0.705 –0.031 0.064 0.626
Home_rentp –0.077 0.080 0.339 –0.142 0.072 0.047
Self-reported Vision 1
Self-reported Vision 2 0.008 0.047 0.860 –0.031 0.044 0.478
Self-reported Vision 3 –0.036 0.113 0.748 0.037 0.195 0.848
Constant 0.159 0.097 0.101 0.217 0.101 0.032
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The hearing and vision bolt-on items referred explicitly to the use of equipment and were designed to
detect more serious problems that cannot be corrected by the use of standard equipment such as
glasses. As a result, it is possible that the bolt-on items may not be responsive for some interventions that
remove the need for the use of that equipment; for example, laser eye surgery to remove the need for
wearing glasses. While accepting this limitation, this was considered preferable to the alternative of
excluding the use of equipment, as this could drive differences between levels of severity and would not
pick up the most severe levels of vision and hearing problems which are not readily correctable using
standard equipment.
Our results differ to an earlier study that investigated the impact of including ‘tiredness’ as a dimension
within the EQ-5D (i.e. a potential EQ-6D) using VAS.226 We found that the inclusion of a level of ‘no
tiredness’ on the bolt-on led to higher values compared with no bolt-on, as well as lower values reﬂecting
‘extreme tiredness’. One could hypothesise that the differences between the two studies could be the
result of the combinations of levels each has chosen to investigate. However, this appears not to be the
case as both studies included a common health state (11121). The study by Gudex226 found that the
inclusion of level 2 tiredness problems did not signiﬁcantly affect the valuations, whereas our study found
that it was associated with near signiﬁcantly lower values. There are notable differences between the two
studies that could perhaps explain the discrepancy, including the valuation methods and the number of
levels/labelling of the tiredness dimensions. Gudex226 used visual analogue ratings whereas this study used
the TTO method. In addition, the tiredness bolt-on consisted of two possible levels in the study by
Gudex,226 whereas the bolt-on in this study included three levels. On the other hand, similar results were
reported in a previous studying adding on a sleep dimension to EQ-5D.19 A signiﬁcant difference was
found after adding on level 1 to a moderate EQ-5D state (11233) but no statistically signiﬁcant differences
were found where various severity levels of the sleep dimension were added to ﬁve other relatively
moderate or severe EQ-5D states.
The complexities in the valuations were also found in the main valuation of the vision bolt-on, in which a
full valuation model was reported. One of the aims of the study was to establish whether the inclusion of
the bolt-on with the EQ-5D health state description had a signiﬁcant impact on the valuation of the ﬁve
EQ-5D dimensions. This is an important question as it affects whether future bolt-ons need to be valued
alongside the EQ-5D descriptions each time, which leads to substantial resources being required for the
TABLE 45 Comparison of the model coefﬁcients
Dimension and level EQ-5D model EQ + vision model p-value (z-test)
Mobility 2 0.019 0.0344 0.271
Mobility 3 0.315 0.320 0.428
Self-care 2 0.079 0.091 0.313
Self-care 3 0.185 0.158 0.140
Activities 2 0.076 0.032 0.059a
Activities 3 0.150 0.104 0.062a
Pain 2 0.071 0.062 0.367
Pain 3 0.236 0.219 0.285
Anxiety 2 0.036 0.038 0.468
Anxiety 3 0.120 0.159 0.062
a
Vision 2 0.0378
Vision 3 0.130
a p < 0.1.
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valuation of each bolt-on. Unfortunately, the results from the analysis were not conclusive. Although not
signiﬁcant at the predeﬁned level for statistical signiﬁcance, the project team were unable to conclude
that the impact was not qualitatively different. In particular, the vision bolt-on appeared to affect the
coefﬁcients for the usual activities dimension and the most severe level of anxiety and depression.
The EQ-5D was selected as the base measure for which bolt-ons were developed in this study. The EQ-5D
was chosen as the reference measure as it is the most commonly used GPBM in economic evaluation and
is recommended as the preferred GPBM by NICE in the UK.1 A similar approach could be employed for
other GPBMs if evidence were to suggest concerns regarding their responsiveness or validity. Indeed, one
of the early studies in this area included a generic bolt item with a condition-speciﬁc measure of HRQL.225
Developing bolt-ons to the other GPBMs considered in the review would require additional considerations
to those identiﬁed for EQ-5D. For example, the valuation methods for bolt-ons to the HUI systems would
need to be carefully considered. For the SF-6D, consideration would need to be given as to how the
bolt-on would be presented to respondents given that the SF-6D values are usually derived by applying the
SF-6D algorithm to responses from the SF-12 or SF-36 instruments.
The development of bolt-ons to EQ-5D could have signiﬁcant implications for researchers and
policy-makers who use QALY-based evaluations to inform their decision-making. Bolt-ons are likely to be
particularly useful where there has been concern about the psychometric properties of EQ-5D in speciﬁc
conditions, such as for hearing and some vision impairments as identiﬁed in the review presented here.
Inclusion of the bolt-on items could improve the performance of generic measures, such as EQ-5D,
for speciﬁc conditions, for example by increasing their responsiveness. This could be very attractive for
policy-makers who require a degree of consistency in decision making, for example if they want to compare
results with a common threshold value or to studies using the same outcome measure. The degree of
consistency with the ‘standard’ EQ-5D value set is essentially an empirical issue, and needs to be considered
relative to the alternative approaches or instruments. The results presented for the valuation of the
EQ + vision bolt-on suggest that there are likely to be differences in EQ-5D values depending on the bolt-on
included. While acknowledging this, one would expect the use of a common valuation methodology and a
very similar descriptive system to produce more consistent valuations than an entirely different descriptive
system and/or valuation method, although this needs to be conﬁrmed empirically. The development of
bolt-on items should not be viewed as an ‘easy option’ for those wishing to improve on the responsiveness
or validity of EQ-5D or other GPBMs. A substantial amount of research has been conducted to develop and
validate the EQ-5D and the other GPBMs included in the review presented here. If this approach is taken
forward, it will be important to ensure that appropriate high-quality research underpinning each individual
bolt-on is conducted and for EQ-5D, the valuation methods to be comparable to other EQ-5D valuation
studies. This is a substantial and resource-intensive exercise. It should also include validation of the bolt-on
measure, which is an area of further research for the bolt-on items developed for this study.
The main weakness of the studies presented is that the sample sizes were limited by the constraints of the
costs of conducting face-to-face interviews with respondents. Many of the differences appeared potentially
important and approached the 0.05 level of signiﬁcance. Further research needs to be conducted using
larger sample sizes.
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Chapter 5 Discussion
The project had three main related objectives: (1) to establish where EQ-5D and other commonly usedGPBMs are appropriate for measuring HRQL for economic evaluation, (2) to develop mapping functions
to predict EQ-5D outcomes from condition-speciﬁc or clinical measures and to compare the performance
of alternative model speciﬁcations, and (3) to investigate the development and valuation of bolt-ons to the
EQ-5D descriptive system for those conditions in which EQ-5D is not sufﬁcient. We have systematically
reviewed the evidence and provided a narrative analysis of the performance of EQ-5D and two other
widely used GPBMs (SF-6D and HUI3) in four broadly deﬁned conditions: cancers, hearing impairments,
skin conditions and vision impairment. We have tested alternative model speciﬁcations to map from
cancer-speciﬁc measures of HRQL to EQ-5D. Finally, we have developed three potential bolt-ons to EQ-5D
and estimated a full value set for a bolt-on for vision (EQ + vision). While the framing for this research has
been to inform the methods of assessment used by NICE in its decision-making, the results are
generalisable to other jurisdictions and/or uses of GPBMs.
Psychometric properties of the generic preference-based
measures
Overall, the number of studies that use the EQ-5D is much larger than for HUI3 or SF-6D, with the
exception of hearing-related conditions. The systematic reviews indicated that EQ-5D performs well in
most cancers but performs poorly in hearing-related conditions. The evidence from studies of skin
conditions suggested that EQ-5D performs well; however, most of the data relate to psoriasis and psoriatic
arthritis. The results were mixed for conditions affecting vision and the performance depends on the
nature and aetiology of the condition; speciﬁcally, the evidence showed good performance in cataracts
and conjunctivitis but poor ability to assess severity in AMD and diabetic retinopathy, and mixed evidence
for glaucoma. The evidence suggested that HUI3 is able to assess severity of HRQL for hearing impairments
and some cancers and there was some evidence, albeit limited, that HUI3 captures HRQL for vision
impairment with the exception of diabetic retinopathy. However, there was no evidence from HUI3 for
skin conditions. There was very little evidence available to make an assessment of the performance of
SF-6D in these conditions. There was also a complete lack of evidence on the reliability of all of the
measures in vision, hearing and skin conditions.
A limitation of the assessment of validity and responsiveness of the GPBMs is that there is no gold
standard of HRQL with which to compare the measures and, therefore, there will always be an element of
subjectivity in this type of analysis. This limitation is not unique to the measures chosen here or to the
focus on preference-based instruments. The literature review presented here utilised psychometric tests to
evaluate the ability the GPBMs to reﬂect the impact of the conditions assessed on HRQL.227 While many of
the studies were not speciﬁcally designed to test the psychometric properties of the instruments, most
reported data in sufﬁcient detail to allow an assessment to be made of how well an instrument seems to
capture the impact of a condition or treatment on HRQL. This approach to assessment relies on the
measures used as comparators to adequately reﬂect HRQL. Some of the measures, particularly clinical
indicators (such as VA) do not measure HRQL speciﬁcally and may only give a narrow representation of the
disease and even where broader condition-speciﬁc measures are used, these do not reﬂect preferences or
the relative values placed on different symptoms or health effects. Unfortunately, it was possible to
extract only very limited information on the reliability and acceptability of the instruments from the
studies identiﬁed.
With these limitations in mind, we were able to form an overall assessment on the performance of the
GPBMs by considering the totality of the data reported by other instruments within the same studies.
We have taken a systematic approach to reviewing and summarising the data. The conclusions from these
assessments have been tabulated in terms of consistency in the direction of measures and statistical
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signiﬁcance. It is not clear from the ﬁndings whether the poor performance of EQ-5D in hearing and some
vision impairments are due to the inadequacies in the description of the ﬁve dimensions or in the number
of levels for each dimension. Currently, the evidence points to the EQ-5D not properly capturing the
impact of sensory impairments generally; however, there was some evidence that EQ-5D could distinguish
between the most extreme differences in these conditions (for example, from the case–control studies).
If this is the case, it is possible that increasing the number of levels of the instrument could improve
performance; however, whether increasing the number of levels to ﬁve, as in the new version of EQ-5D,
will be sufﬁcient to overcome the problems of EQ-5D in sensory impairments remains to be seen.
Research to establish whether the new descriptive system and the forthcoming new valuation set improve
the performance of EQ-5D in these conditions would be helpful to understand the full impact of the
additional levels.
The review of the performance of EQ-5D has focused on the three-level version of the instrument, as this
is the most widely used version. A new version of the EQ-5D has been developed with the number of
levels increased to ﬁve;3 however, reported data from the new version are currently limited. This could
improve the ability of EQ-5D to differentiate between levels of disease severity or assess responsiveness in
hearing and vision impairments and further research in this area would be helpful.
Mapping to predict EQ-5D outcomes when data are unavailable
The results of the systematic review found that EQ-5D performed well in relation to cancers and skin
conditions. Of these, cancer was chosen to be the focus of the mapping analyses and data sets containing
EQ-5D and one or more condition-speciﬁc or clinical indicator were obtained. The data sets obtained
included one of two commonly used cancer-speciﬁc QoL questionnaires: FACT-G or EORTC QLQ-C30.
There is little consensus in the published literature about how to select the best model from a mapping
exercise, different criteria (AIC/BIC) will select different models as they give importance to different issues.
Different measures of accuracy of predictions (e.g. MAE, RMSE) typically used in mapping studies were not
developed for use in this situation where we are faced with individual level data. They are very insensitive
given the high level of individual heterogeneity and the small range of the utility scale. Even after this,
different measures will lead to different models being selected since they weight errors in different ways.
There is no test for what model is best so a range of criteria need to be considered and a judgement
made. A range of alternative model speciﬁcations were explored using both measures and data sets, and
included different standard modelling approaches, explanatory variables and different representations of
the dependent variable (EQ-5D index or dimensions). A variety of statistics were reported with some
focusing on model goodness of ﬁt and others on the predictive ability of the model. As the purpose of
mapping is to predict values, it could be argued that we should give more weight to predictive ability;
however, there are still a number of criteria that can be used to assessed predictive performance such as
mean predictions, MAE and shrinkage, which we have reported here. Where mapping is used in practice,
the aim is usually to estimate mean values for a set of health states, often deﬁned in terms of severity,
included within an economic model. Reviews of published mapping functions have found that they
frequently do not give accurate predictions at the lower and upper end of the utility scale. In the analyses
presented here, we have examined the accuracy of predictions for subgroups of responses deﬁned
according to different levels of severity using an external reference measure of health. Ideally, we would
assess the deﬁne severity according to the measure(s) of severity included in the economic model for which
the mapping has been conducted and then assess the predicted values relative to an external sample
representative of the population of interest. The response mapping models to predict responses at the
dimension level for EQ-5D performed best for the EORTC QLQ-C30 data. This was not the case for the
FACT-G data set, which included a more limited range of EQ-5D data and few patients reporting very
severe levels of health. Therefore, it was not possible to reliably map to all of the EQ-5D dimension levels.
In that analysis, the linear regression models using OLS performed the best of the standard models
according to the mean predictions and MAE for the overall sample and the subgroups deﬁned according
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to severity; however, the model based on splining gave better median predictions and the response
mapping model performed best in terms of shrinkage.
It is now widely observed, and has been further demonstrated in the analyses presented here, that the
distribution of EQ-5D values observed in patient data are typically not normally distributed when the UK
tariff is applied. The distribution is usually bimodal or multimodal and usually exhibits a large peak at 1 (full
health) for all but the most severe of health conditions. In addition, there is a sizable gap in the values
between the largest value (1) and the next largest (0.88). This is likely to cause problems for some of the
standard statistical models. Response mapping has the capability of reﬂecting these features. Similarly, the
limited dependent mixture model, reported here in illustrative analyses, is designed taking such features
into account. For individual patient sampling models, these features are critical and also ensure that values
outside the feasible range are not predicted. For cohort models, where the interest is in estimating the
mean (and its uncertainty) for subgroups of patients, these models also offer the advantage that neither
mean estimates nor their sampled values taking into account uncertainty lie outside the feasible range.
When the number of subgroups is large and/or lie at the extremes of the EQ-5D range, then these
features are of particular importance given how they are to be used in economic evaluation. When
compared against an equivalent linear model, the LDVMM performs better on almost all relevant measures
both for the sample as a whole and for severity deﬁned subgroups. Ideally, all the mapping functions
would be estimated in bigger data sets spanning the full spectrum of disease and then validated against
an external, but similar, sample. Unfortunately, such data were not available for us to conduct this analysis
but it would be a useful piece of further research if such data sets exist. The generalisability of the
mapping algorithm predicting from the FACT-G study to populations including patients in the severest
levels of health is limited as the data set only included few observations at the lower end of the
HRQL scale.
The bolt-on studies
Mapping is not an effective solution to the problem of measuring and valuing HRQL where EQ-5D has
been found to be inappropriate. There may be a preference for using the EQ-5D to maintain
consistency between analyses and, therefore, adaptations to the questionnaire may be a potential solution.
We examined a new approach of bolt-ons and developed and tested three bolt-on items in an exploratory
study valuing nine health states from each descriptive system. We focused on the two areas where the
EQ-5D was identiﬁed to have some problems in the literature review: hearing and vision. Furthermore,
although the review found that EQ-5D performs well in cancer, there have been concerns about the
face validity regarding the lack of an energy dimension in EQ-5D and this was also included in the
exploratory analysis.
All three of the bolt-on items had an impact on TTO values for the EQ + bolt-on states, but the results
suggested that the relationship may not be straightforward. The extent and direction of the impact of the
bolt-on varied according to the level of severity of the bolt-on and the severity of the core EQ-5D state to
which it was added. In most cases, including a level 1 bolt-on resulted in no difference or higher values,
the addition of level 2 was mixed and the addition of level 3 led to lower values.
The results for the tiredness bolt-on differed to those from a previous study assessing the inclusion of a
similar dimension within the EQ-5D.226 However, this disagreement could be attributed to any number of
differences in study design including the method of valuation (VAS compared with TTO) and the number
and labelling of the bolt-on levels. All three of the bolt-ons in the exploratory study showed some impact.
There did not appear to substantial differences between the three bolt-ons, although the impact appeared
to be marginally strongest for the vision bolt-on and this was selected for full valuation. However, we
believe that based on the results of the exploratory analysis, the tiredness and hearing bolt-on items
warrant further investigation and development.
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Given the results of the exploratory study, a full valuation of the vision bolt-on was conducted using
face-to-face TTO interviews with members of the general public. The results of this study show that the
vision bolt-on had a signiﬁcant impact on EQ-5D state valuations. As with the exploratory analysis, the
results suggest a somewhat complex relationship between the bolt-on and EQ-5D. Health states with a
level 3 (extreme) vision problems included are unsurprisingly lower than the corresponding EQ-5D health
state; however, the values given to severe EQ-5D states are higher if ‘no problems’ on vision are explicitly
mentioned (EQ + vision) compared with if vision is not mentioned at all (EQ-5D only). This could be due to
people focusing on the positive aspect of the health state or considering the absence of vision problems to
be ‘ray of light’ in an otherwise severe health state. Some qualitative exploration of what people consider
when responding would be informative.
It would be easier and less resource-intensive if future bolt-on items could be valued separately rather than
conducting a valuation of the full bolt-on classiﬁcation including the EQ-5D. In addition, it could potentially
be advantageous for decision-makers if the values of the bolt-on items could be related back to a standard
tariff. However, based on the results presented here, a model with a simple decrement for each of the
bolt-on levels is not appropriate. A more sophisticated analysis that takes into account both the severity of
the bolt-on and the severity of the core EQ-5D state to which it is added may be feasible. Whether a full
valuation of the EQ + bolt-on instrument is required for each new bolt-on item is not clear. Unfortunately,
the analysis comparing the coefﬁcients of the models with and without the bolt-on was not conclusive.
It showed that there were no statistically signiﬁcant differences between the coefﬁcients at the 5% level.
However, the size of some differences in coefﬁcients was not trivial and the lack of signiﬁcant differences
could have been due to the sample size. There is also the possibility that the impact is speciﬁc to the
condition to which the bolt-on relates.
The limitations of the study include that the interviews were based in a speciﬁc region of the UK and may not
be generalisable to other countries or indeed regions in the UK, although there is no clear reason to suppose
that the pattern of results would be different elsewhere. Some differences in reported problems with vision
were found between the groups in the exploratory study; however, the regression analysis showed that these
characteristics did not signiﬁcantly impact on values and the same ﬁnding was observed in the full valuation of
EQ + vision. Another limitation is the lack of qualitative research to investigate acceptability and alternative
phrasing of the bolt-ons; however, the labelling builds on the framework of the EQ-5D and the qualitative
research that has been used to develop it. Finally, this study has focused on the three-level version for
the EQ-5D and it is not clear if similar results would be seen with the ﬁve-level version.
A key feature of the EQ-5D is that it can be used across a range of conditions or diseases. This has a
substantial advantage for economic evaluation and healthcare decision-making as it means decisions can
be based on a common measure and applied consistently across evaluations. For speciﬁc conditions, where
EQ-5D has been demonstrated to lack validity, the development of bolt-on instruments can offer a solution
by improving the sensitivity of the instrument. While this may be at the expense of a level of consistency
in the measurement and valuation of HRQL between conditions, retaining the EQ-5D as the basis for
measurement may be beneﬁcial. By retaining the EQ-5D as the core basis for measurement and by using a
common valuation methodology, the degree of inconsistency in the estimates of HRQL is likely to be less
than if alternative GPBMs or condition-speciﬁc PBMs are used instead.
Conclusion
This report has presented three substantial pieces of research. We have considered when speciﬁc GPBMs
are appropriate for the measurement of HRQL, alternative methods for predicting outcomes when GPBMs
have been found to be appropriate but data are unavailable and a method for developing bolt-ons
to EQ-5D to improve its sensitivity. We have systematically reviewed the evidence on the performance
of EQ-5D and two other commonly used GPBMs in four, very broadly deﬁned, clinical areas. We
found that EQ-5D performs well in most cancers and skin conditions, although evidence on reliability
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was lacking for the latter. We also found that EQ-5D shows mixed results in vision impairment and
performs poorly in hearing-related conditions. Even where EQ-5D appears to be an appropriate measure of
HRQL, data are not always collected within clinical studies. We have developed algorithms to predict
EQ-5D outcomes from two commonly used cancer-speciﬁc measures of QoL and explored a range of
alternative model speciﬁcations. Models predicting EQ-5D dimension-level responses performed best for
one of the measures (EORTC QLQ-C30); however, this approach did not work well in an alternative data
set including the FACT-G as it included patients with a narrower range of disease severity. In this latter
data set, when considering standard models, the OLS regression performed best in terms of the accuracy
of mean predictions for the whole sample and the subgroups deﬁned according to severity. The LDVMM
outperformed the linear model in illustrative analysis of a selected model. Three bolt-on items to EQ-5D
were developed and tested in an exploratory study and a bolt-on for vision was tested further and a full
set of valuations for EQ + vision obtained. The results of these studies show that the inclusion of a bolt-on
item has a complex impact on EQ-5D values and the results have important implications for that valuation
of future bolt-ons.
Recommendations for further research
Generic preference-based measures are widely used in the economic evaluation of health interventions
and are used to inform the decision-making of bodies such as NICE in the UK. The research presented
here has consolidated some of the existing research in this area and presented new areas of methodology.
In order to ensure the most appropriate use of generic and condition-speciﬁc measures in HTA and
health-care decision-making, further research is required. We have highlighted the areas that we consider
to be priorities for further research below.
Psychometric properties of the generic preference-based measures in
different conditions
The reviews of the psychometric properties of the GPBMs focused on four broadly deﬁned conditions: hearing
impairment, vision impairment, skin conditions and cancers. We recommend extending these reviews of the
psychometric literature to more conditions. This would provide useful information and lead to recommendations
on the use of the GPBMs for researchers conducting HTAs of interventions in other conditions.
Given the widespread use of the measures in HTA, the amount of evidence on psychometric properties of
the instruments was limited and, in most cases, the studies had not been speciﬁcally designed to examine
these issues. We recommend that more primary research or analyses of primary data sets into the
psychometric properties of GPBMs is undertaken, particularly in cancer, and particularly of the reliability of
the measures in the other conditions.
Mapping
It was not possible to validate the mapping functions estimated in this project using an external data set,
but this is recommended to assess the external validity of the functions.
In addition, we recommend comparing alternative statistical models in larger data sets, including those for
EORTC QLQ-C30 and FACT-G.
The development and use of bolt-ons to EQ-5D
The development and use of bolt-ons to EQ-5D is still a new but growing area of methodological research.
The research presented in this report offers insights that can be used when developing future bolt-ons.
Further research to validate the EQ + vision measure presented here would be useful. The results of the
exploratory study of the hearing and tiredness bolt-ons suggest that these measures would also beneﬁt
from validation and further valuation. There are still methodological issues relating to bolt-on development
that require further investigation. We recommend that the best way to undertake this is to develop a
systematic programme of research into bolt-ons for EQ-5D.
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Appendix 1 Project protocol
Aims and objectives
The National Institute for Health and Care Excellence (NICE) Technology Appraisals (TA) Methods Guide
recommends the use of GPBMs of HRQL (speciﬁcally naming the EQ-5D) for its economic evaluations.
Generic measures have been criticised for being insensitive or failing to capture important aspects of
health. The NICE TA Guide recognises that EQ-5D data may not always be available and/or appropriate
and offers some advice for these circumstances. However, it does not identify those areas where
EQ-5D is inappropriate nor does it provide criteria to determine when a measure is appropriate for a
particular condition or treatment. Information from condition-speciﬁc measures can be incorporated
into the standard framework of analysis adopted by NICE using techniques such as mapping from
condition-speciﬁc or clinical measures to the generic measure, modifying the generic HRQL instrument
(e.g. creating ‘add-on’ dimensions) and valuing condition-speciﬁc measures directly (i.e. creating
preference-based condition-speciﬁc measures).
The overall aim of the proposal will be to develop methods for systematically incorporating
condition-speciﬁc and other non-reference case measures into the NICE decision-making framework.
Research objectives:
1. To examine where commonly used generic HRQL measures are not appropriate for use in calculating
QALYs for NICE decision-making by undertaking a review of the published literature on the use of
generic measures (EQ-5D, SF-6D and HUI) for different conditions and treatments.
2. To consider the use of condition-speciﬁc measures when data from generic instruments are not
available by mapping from condition-speciﬁc and clinical measures to generic measures. Speciﬁcally, to
generate functions to map from three key condition-speciﬁc or clinical measures to EQ-5D and conduct
exploratory analysis around the incorporation of uncertainty in the predicted estimates.
3. To explore new methods for developing new preference-based measures. Speciﬁcally, by investigating
the use of new ‘add-on’s to expand the EQ-5D descriptive system for those conditions in which EQ-5D
is not appropriate (as determined by part 1).
Description of the project methodology
Stage 1: Review of the appropriateness of generic measures of
health-related quality of life
A review of the published literature will identify studies in which generic instruments (EQ-5D, HUI 3 and
SF-6D) have been used to obtain health-state utility values (HSUVs) in four key areas: visual impairment,
aural impairment, cancer and skin conditions. The review will be conducted using MEDLINE, EMBASE, NHS
Economic Evaluation Database (EED) and HTA and OHE Health Economic Evaluations Database (HEED).
The records from these databases will be supplemented by a review of a database held by the EuroQol
Group containing more than 1500 references of studies relating to the use of the EQ-5D. The papers
identiﬁed from the search will be sifted to identify papers that report data on the use of generic
instruments or systematic reviews related to the use of generics. Systematic reviews will be assessed for
quality and relevance to the study. Where good quality systematic reviews exist, these will be used to
guide the subsequent review for that particular condition/treatment. Studies will then be grouped into
condition groups based on ICD-9 codes. Papers that report the use of EQ-5D from another study will be
reviewed, and the original articles considered for inclusion. Papers reporting primary data collection will be
included in the review if they report data on the use of EQ-5D, SF-6DF or HUI 3 in sufﬁcient detail to allow
an assessment of their validity. Therefore empirical papers must include data on the resulting health
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classiﬁcation systems or utility values and include data on other measures of health outcomes (e.g. visual
analogue scale data, disease speciﬁc-measures and/or clinical measures of severity). Papers reporting
qualitative studies on the use of the generic instruments will also be included.
The assessment of the validity of a preference-based measure of health such as the EQ-5D is fraught with
conceptual and empirical problems owing to the lack of a gold standard.228 A common mistake is to
assume that because a condition speciﬁc measure ﬁnds a difference, then a generic measure should reﬂect
that difference, when the general population may not regard the difference as sufﬁciently important in the
valuation task. The approach adopted here follows that suggested in Brazier and Deverill,33 that
distinguishes the validity of the descriptive system from that of the preference-based index. It will examine
the descriptive validity of the EQ-5D as a descriptive system in terms of its content, face and construct
validity. Contact and face validity will be examined using evidence from qualitative studies. Construct
validity of the descriptive system will be assessed in terms of whether the distribution of responses by
dimension level agrees with other measures of those dimensions and other relevant indicators. The
empirical validity of the index will be based on the convergence with other measures of stated preferences
and hypothetical preferences (other indicators of likely preferences). The former will use GPBMs and
directly elicited preferences (e.g. time trade-off or standard gamble). Hypothetical preferences will be
assessed by looking at convergence with other measures and clinical indicators, but care will be taken in
the interpretation to ensure that these are likely to reﬂect genuine differences in preferences. These tests
will be applied to cross sectional data to examine validity and the longitudinal data to examine the
responsiveness of the measure.
Stage 2: Mapping from condition-specific and clinical measures to EQ-5D
The results of the literature review and existing research conducted in ScHARR11,229,230 will form the basis
for this section of the current project. This comprehensive literature review identiﬁed some methodological
issues in the use mapping to predict health-related utility values. Most published papers have focused
upon mapping between alternative generic instruments (e.g. SF-12 to EQ-5D209) or from existing
condition-speciﬁc instruments to generic instruments (e.g. Asthma quality of life questionnaire to EQ-5D16).
Relatively few published studies have focused on mapping from clinical measures of disease activity or
severity.12,231 However, these severity indices may form the basis of health outcomes estimation included in
submissions to NICE (e.g. Psoriasis Area and Severity Index and Crohn's Disease Activity Index). A key issue
is arising from the literature review is that the uncertainty around the resulting predictions is usually
ignored when the mapping algorithms are applied, and thus the estimates do not reﬂect that the health-
state utility values are estimated and not observed.
At least three mapping functions will be developed during this stage of the project, including at least one
using clinical scales rather than patient-reported outcomes. This stage will also include exploratory work
around some methodological issues, speciﬁcally the incorporation of uncertainty into the predicted
estimates and an assessment of whether methods differ for mapping from clinical outcome measures.
Data sets held within ScHARR will be considered for use to generate the mapping functions. In addition
members of the EuroQol Group will be approached for access to data sets that include EQ-5D data and
responses to a condition-speciﬁc measure and to clinical measures of severity. (One of the terms and
conditions for the use of the EQ-5D is that data should be made available to other EuroQol Group
members if requested.) Data sets will include those that include data from the EQ-5D and other
condition-speciﬁc measures and/or clinical measures of severity.
The mapping functions will be made publicly available at no charge via the ScHARR website, where the
predictive ability is considered adequate for use by others, along with guidance on incorporating the
uncertainty in the estimates.
Phase 1: A potential list of mapping functions will be drawn up based on the availability of datasets of
sufﬁcient size to undertake the mapping exercise. This ‘long list’ will be reduced to a recommended list of
possible mapping functions based on how widespread the use of a condition-speciﬁc or clinical measure is
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and whether good quality mapping functions have already been published for that measure. We will
consult with representatives from NICE before making the ﬁnal decision about which condition-speciﬁc
and clinical measures to create mapping functions from, however at least one will be derived from a
condition-speciﬁc measure and at least one will be developed from clinical measure/s of severity. It is
anticipated that at least 3 mapping functions will be developed.
Phase 2: The mapping function will be estimated. The datasets will be randomly split into two subsets in
order to provide a subset for model estimation and a subset for assessing the predictive ability of the models.
Alternative models will be considered to estimate the mapping function. Simple OLS models will be explored
as these have been most frequently used in published studies.11 However simple OLS models ignore the
bounded nature of health-state utility data (i.e. the maximum value is 1) will result in biased and inconsistent
estimates. Tobit and censored least absolute deviations (CLAD) models will also be explored as appropriate
alternatives.230 Both the tobit and the CLAD models use the same structure to generate both the continuous
and the censored observations. Rejection of this assumption would render the asymptotic properties of the
CLAD model invalid. Therefore, we will ﬁrst explore the validity of this assumption by estimating different
two-part models. In addition, there is also an issue of efﬁciency loss of the CLAD estimator when compared
to maximum likelihood if the assumed distribution of the errors is correct. Consideration will also be given to
Generalised Linear Models with RE, Adjusted Least Square Regression Model (ALS), and Weighted Least
Squares models. Most published mapping models predict the single index utility value from the generic
instrument. However, there are advantages to predicting the responses to the health state classiﬁcation
system (e.g. the descriptor 12112 on the EQ-5D) as this better reﬂects the data that would have collected
had the relevant generic instrument been included in the study and enables alternative sets of utility data or
‘tariffs’ to be applied to the health state descriptions. Models that map to the single index utility value and
those which map to descriptive classiﬁcation will be considered.
Phase 3: The goodness of ﬁt and predictive ability of the alternative models will be assessed in order to
recommend a preferred model for each condition-speciﬁc or clinical measure.
The goodness of ﬁt of the models obtained will be assessed using standard statistics (variance explained,
range, mean and SE). The predictive abilities will be compared by charting the observed and predicted
preference-based scores together with the residuals. The mean error, mean absolute error, RMSE and the
proportion of predicted values within the minimum clinically important difference for the preference-based
index will also be reported.
Phase 4: The literature describing results of mapping exercises rarely report the full range of statistics
required to independently assess the functions. Analysts who wish to use the results of the mapping
functions are not provided with the data required to estimate uncertainties in the predicted values. In
addition, there are no clear recommendations of methods to incorporate the uncertainty arising from the
predicted values into their application when estimating QALYs. Exploratory work into the appropriate
methods for incorporating uncertainty in the predicted values into practical analyses will be conducted.
This will include using probabilistic simulation; however this requires the underlying distribution of the
values to be appropriately speciﬁed. For example, if the tobit model is found to be the most appropriate
model speciﬁcation it will be necessary to ensure that the distribution takes into account the censoring of
the dependent variable is properly taken into account when incorporating the uncertainty into
practical analyses.
Stage 3: Developing new measures by extending existing generic measures:
‘add-on’s to the EQ-5D
The review conducted in Stage 1 will identify those conditions in which generic instruments, and
speciﬁcally the EQ-5D, are not appropriate. In these cases it is not meaningful to map from a
condition-speciﬁc measure to the generic because the generic measure does not adequately capture the
important aspects of health for that condition. Previous work has been conducted on taking existing
condition-speciﬁc measures and deriving preference-based measures15,16 and a further study is currently
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investigating some of the methods around this (COSMeQ study).14 Problems associated with this approach
include a loss of information when condensing the original measure into a new measure for which
preferences can be obtained, the introduction of labelling effects and the failure to reﬂect side effects and
co-morbidities. An alternative approach is ‘add-on’ additional dimensions to existing generic measures.
The focus of this part of the study will be to the EQ-5D due to its prominence in the NICE Methods Guide.
A new 5 level version of the EQ-5D has recently become available however empirical data, including data
on value set of corresponding utility estimates, aren't currently available to allow its routine use in
decision-making. Therefore evidence from this review will relate to the 3 level version of the EQ-5D. The
focus for this element of the project will focus on adding additional dimensions to the 3 level version of
the EQ-5D. The proposed approach will be similar to that adopted in a recent study to investigate the
addition of a sleep dimension to the EQ-5D.19
Phase 1: Approximately 3 conditions will be selected where the EQ-5D has been shown to be insufﬁcient
for capturing changes on HRQL from those identiﬁed in the review of the literature described in stage 1 of
the proposal. Six EQ-5D health states will be selected covering a range of severity (2 mild, 2 moderate and
2 severe), plus full health (11111) and the worst possible health state (33333). The same states with the
addition of an extra ‘add-on’ dimension relating to the condition of interest will be described. The
description of the add-on will be based on the results of review described in section 1. The description of
levels will follow the approach used for the EQ-5D (no problems, some problems and extreme problems).
There will be four variants of the questionnaire to avoid contamination between them (original EQ-5D,
plus 3 versions with add-ons).
The effect of including the additional dimension will be assessed by comparing mean valuations with and
without the additional dimension using an independent t-test. Assuming a power of 0.8, signiﬁcance level
of 0.05, SD of 0.3 and a difference of 0.1, then this requires a sample of 73 interviews in each group for
each instrument. In order to obtain 75 valuations per variant of the questionnaire, this will require a
sample of 300 people (4 × 75 people). A sample of 300 members of the general public in South Yorkshire
will be selected randomly from the electoral register. Three groups will each be allocated to one of the
add-on instruments and one will be allocated to the original EQ-5D questionnaire. The methods of
valuation will be compatible with the original EQ-5D valuation study29 and will use the time trade-off
method using full health as the top anchor and using a time board for visual props. The recruitment of
patients and conduct of the interviews will be commissioned from Shefﬁeld Hallam University who have
extensive experience of conducting this kind of study.14
Phase 2: Based on the results of phase 1, the new ‘add-on’ instrument that is found to add the most
additional information will be selected for further study in order to develop a valuation system and to
generate a set of methods that can be used by others when considering expanding the descriptive system
of a generic instrument. Based on an orthogonal design for an instrument with six dimensions, values for
18 health states are required for an additive model. For ﬁve dimensions, 16 states are required. Therefore
it will be necessary to obtain valuations for 34 states. A sample of 300 members of the general public in
South Yorkshire will be selected randomly from the electoral register and recruited to the study (to get
75 valuations per state; 4 groups each valuing 8 or 9 states). They will be split into four groups: two
groups will each value 9 health states from the new add-on instrument and two groups will each value
8 health states from the standard EQ-5D. The recruitment of people and methods of valuation will be the
same as described in Phase 1.
A model will be developed to estimate a tariff of values for all health states. The impact of the inclusion of
the add-on will be assessed in two ways: 1) examining the signiﬁcance of the co-efﬁcient of the extra
dimension and 2) examining the impact on the other dimensions from having a new dimension added to
the descriptive system. The model developed for the add-on instrument and the descriptive system will be
made publicly available at no charge.
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Appendix 2 Search strategies for literature review
MEDLINE Search strategy for vision review (ﬁrst search)
1. (vision disorder$ or micropsia$ or metamorphopsia$ or hemeralopia$ or day blindness or macropsia$).mp.
2. [mp=title, original title, abstract, name of substance word, subject heading word, unique identiﬁer]
(18729)
3. vision disorders/ or visually impaired persons/ (18807)
4. 1 or 2 (19258)
5. (euroqol or euro qol or eq5d or eq 5d or eq-5d or (euro adj qol) or (eur adj qual) or (eq adj 5d)).mp.
[mp=title, original title, abstract, name of substance word, subject heading word, unique identiﬁer] (1868)
6. (hui3 or hui 3 or health utilities index mark 3 or health utilities mark three or hui III or huiIII).mp. [mp=title,
original title, abstract, name of substance word, subject heading word, unique identiﬁer] (207)
7. (sf6D or sf 6D or short form 6D or shortform 6D or sf six D or sfsixD or shortform six D or short form
sixD or sf-6d or 6d or 6-d or 6 dimension).mp. [mp=title, original title, abstract, name of substance
word, subject heading word, unique identiﬁer] (4204)
8. 4 or 5 or 6 (6114)
9. 3 and 7 (14)
10. from 8 keep 1-14 (14)
Search strategy including speciﬁc visual disorders
(second search)
amblyopia
acuity
age related macular degeneration
anisometropia
astigmatism
blurred vision
cataracts
conjunctivitis
corneal opacities
cytomegalovirus
cytomegalovirus retinitis
day blindness
diabetic retinopathy
diplopia
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double vision
dry eye
dystrophy
edema
far sightedness
glaucoma
hemeralopia*
hemianopia
hypermetropia
lazy eye
macropsia*
macular degeneration
metamorphopsia*
micropsia*
near sightedness
night blindness
nystagmus
ocular hypertension
Oedema
onchocerciasis
phaco
phacoemulisiﬁcation
quandrantanopia
retinitis pigmentosa
retinopathy
river blindness
strabismus
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trachoma
vision
vision disorder*
visual*
visually impaired persons
disorder adj (eyelid or lacrimal system or orbit or conjunctiva or sclera or cornea or iris or ciliary body or
lens or choriod or retina or vitreous body or globe or optic nerve or visual pathways or ocular muscles or
binocular movement or accomadation or refraction or eye or adnexa)
(euroqol or euro qol or eq5d or eq 5d or eq-5d or (euro adj qol) or (eur adj qual) or (eq adj 5d)).mp.
(hui3 or hui 3 or health utilities index mark 3 or health utilities mark three or hui III or huiIII).mp.
(sf6D or sf 6D or short form 6D or shortform 6D or sf six D or sfsixD or shortform six D or short form sixD
or sf-6d or 6d or 6-d or 6 dimension).mp.
MEDLINE search strategy used for hearing review
1. (euroqol or euro qol or eq5d or eq 5d or eq-5d or (euro adj qol)Or eur adj qual) or (eq adj 5d).mp.
2. (hui3 or hui 3 or health utilities index mark 3 or health utilities mark three or hui III or huiIII).mp.
3. (sf6D or sf 6D or short form 6D or shortform 6D or sf six D or sfsixD or shortform six D or short form
sixD or sf-6d or 6d or 6-d or 6 dimension).mp.
4. (hearing disorder or dysacusis or paracousis or paracusis or Distorted hearing).mp.
5. (hearing loss or hearing complaints or hearing aids or cochlearimplants).mp.
[mp=title, original title, abstract, name of substance word, subject heading word, unique identiﬁer]
6. hearing disorders/
7. 1 or 2 or 3
8. 4 or 5 or 6
9. 7 and 8
MEDLINE search strategy used for skin review
1. (euroqol or euro qol or eq5d or eq 5d or eq-5d or (euro adj qol) or (eur adj qual) or (eq adj 5d)).mp.
(2151)
2. (hui3 or hui 3 or health utilities index mark 3 or health utilities mark three or hui III or huiIII).mp. (231)
3. (sf6D or sf 6D or short form 6D or shortform 6D or sf six D or sfsixD or shortform six D or short form
sixD or sf-6d or 6d or 6-d or 6 dimension).mp. (4538)
4. 1 or 2 or 3 (6722)
5. Staphylococcal scalded skin syndrome.mp. or Staphylococcal Scalded Skin Syndrome/ (414)
6. Impetigo.mp. or Impetigo/ (1457)
7. boil.mp. or Furunculosis/ (1278)
8. furunculosis.mp. (1165)
9. Cutaneous abscess.mp. (66)
10. Cellulitis/ or Cellulitis.mp. (8369)
11. Acute lymphadenitis.mp. (30)
12. Pilonidal cyst.mp. (116)
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13. Pyoderma/ or Pyoderma.mp. (3928)
14. Erythrasma.mp. or Erythrasma/ (175)
15. Pemphigus/ or Pemphigus.mp. (7253)
16. Pemphigoid.mp. or Pemphigoid, Bullous/ (4942)
17. Dermatosis.mp. or Skin Diseases/ (46511)
18. Acantholysis/ or Acantholytic disorder.mp. (660)
19. Dermatitis/ or Dermatitis.mp. (59308)
20. Eczema/ or eczema.mp. (13886)
21. prurigo.mp. or Prurigo/ (1207)
22. Pruritus.mp. or Pruritus/ (13152)
23. Lichen simplex chronicus.mp. or Neurodermatitis/ (1396)
24. Dyshidrosis.mp. (104)
25. Erythema intertrigo.mp. (2)
26. Pityriasis alba.mp. (79)
27. Papulosquamous.mp. (861)
28. Psoriasis.mp. or Psoriasis/ (27853)
29. Acrodermatitis/ or Acrodermatitis continua.mp. (1813)
30. Pustulosis.mp. (1302)
31. Urticaria/ or Urticaria.mp. (12733)
32. erythema.mp. or Erythema/ (25199)
33. Sunburn.mp. or Sunburn/ (2693)
34. Dermatitis, Phototoxic/ (528)
35. Dermatitis, Photoallergic/ or Photoallergic.mp. (700)
36. Solar urticaria.mp. (228)
37. Actinic keratosis.mp. or Keratosis, Actinic/ (944)
38. Actinic reticuloid.mp. (139)
39. Cutis rhomboidalis nuchae.mp. (12)
40. Poikiloderma of Civatte.mp. (36)
41. Cutis laxa senilis.mp. (0)
42. Actinic granuloma.mp. (49)
43. Acne.mp. (11465)
44. Rosacea.mp. or Rosacea/ (2084)
45. Vitiligo.mp. or Vitiligo/ (4053)
46. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or
23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39
or 40 or 41 or 42 or 43 or 44 or 45 (212215)
47. 4 and 46 (60)
MEDLINE search strategy used for cancer review
1. (euroqol or euro qol or eq5d or eq 5d or eq-5d or (euro adj qol) or (eur adj qual) or (eq adj 5d)).mp.
2. (hui3 or hui 3 or health utilities index mark 3 or health utilities mark three or hui III or huiIII).mp.
3. (sf6D or sf 6D or short form 6D or shortform 6D or sf six D or sfsixD or shortform six D or short form
sixD or sf-6d or 6d or 6-d or 6 dimension).mp.
4. 1 or 2 or 3
Adenocarcinoma
Astrocytoma
Blastoma
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Cancer
carcinoma
Cytoma
Cytosis
Ependymoma
Glioblastoma
heavy chain disease
hepatoma
hogkin’s disease
Kahler’s disease
Leiomyoma
Leukaemia
lymphoma
Lymphosarcoma
Malignant glioma
Malignant neoplasm
melanoma
mesothelioma
Multiple myeloma
myeloma
Myelomatosis
Myelosis
neoplasms
Neuroblastoma
Non-Hodgkin lymphoma
Non-Hodgkin’s Lymphoma
Oligodendroglioma
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Osteosarcoma
Retinoblastoma
sarcoma
Thymoma
Tumour/Tumor
Waldenström’s macroglobulinaemia
5. 4 and 5 (270)
6. from 6 keep 1-270 (270)
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Appendix 3 Summary of validity for utility 
measures: visual disorders
Study reference 
grouped by condition 
(author, year)
Utility 
measures Methods Results
Glaucoma
Aspinall et al., 200844 EQ-5D Known groups 
(severity)
Convergence
EQ-index stratified by mild, moderate and severe visual field loss. 
EQ-index, mobility, self-care and anxiety statistically significantly 
correlated with VA. Mobility and self-care correlated with severity 
of visual field loss
Kobelt et al., 200645 EQ-5D Known groups 
(severity) 
EQ-5D utility decreased with increased severity, but difference 
between groups only statistically significant for severe disease 
after controlling for co-morbidity
Mittmann et al., 200134 HUI3 Known groups 
(case–control)
Mean HUI3 values (SD): glaucoma patients 0.924 (0.086);  
no condition patients 0.953 (0.068) 
Montemayor et al., 
200146
EQ-5D Convergence EQ-5D correlated with age (health status only) and VFA score. Not 
correlated with diagnosis, VA, mean deviation in the better or 
worse eye, corrected pattern standard deviation in the better or 
worse eye. VFA was the best predictor of EQ-5D
Thygesen et al., 200854 EQ-5D Convergence
Known groups 
(severity)
Better VA is correlated with higher EQ-5D (p = 0.005). EQ-5D was 
consistent with the severity groups defined by Snellen scores
AMD
Cruess et al., 200747 EQ-5D Known groups 
(case–control)
Convergence
EQ-5D not significantly lower in subjects compared with control 
(14% relative difference, p = 0.064). Moves in the right direction. 
No association between EQ-5D and VA stratification found
Espallargues et al., 
200522
EQ-5D, 
SF-6D and 
HUI3
Convergence
Known groups 
(severity)
All preference-based measures were correlated and significant to 
1% level with VF-14. EQ-5D was not correlated to a significant 
level with CS or VA. VAS was correlated with 5% significant level 
with CS and VA. SF-6D was correlated with CS (1% level) and VA 
(5% level). HUI3 and TTO were correlated with both CS and VA 
to 1% level. VA and CS were consistent with HUI3, SF-6D, TTO 
and VAS but not with the EQ-5D
Lotery et al., 200748 EQ-5D Known groups 
(severity)
Convergence
EQ-5D and VFQ-25 differentiated between groups (statistically 
significant). No apparent relationship was found between EQ-5D 
and severity of vision loss. This was found for the NEI-VFQ-25  
(no p-value reported)
Payakachat et al., 
200949
EQ-5D Known groups 
(severity)
Subjects reported full health in EQ-5D but had visual problems, as 
elicited by the NEI-VFQ-25
Ruiz-Moreno et al., 
200856
EQ-5D Known groups 
(case–control)
Adjusted mean scores 0.68 vs. 0.79 p < 0.05 for neovascular-
AMD vs. control
Soubrane et al., 200743 EQ-5D Known groups 
(case–control 
and severity)
Adjusted mean scores of EQ-5D 0.65 vs. 0.75 p < 0.001 for 
neovascular-AMD vs. control.
No significant difference across VA levels of neovascular-AMD 
(and does not follow degree of severity)
Kim et al., 201055 EQ-5D Known groups 
(severity)
Significant differences were found in EQ-5D scores for people 
with unilateral and bilateral AMD
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Study reference 
grouped by condition 
(author, year)
Utility 
measures Methods Results
Cataracts
Asakawa et al., 200836 HUI3 Known groups 
(case–control, 
gender)
Adjusted mean differences in single-attribute vision utility scores 
for cataracts were negative, quantitatively important (difference 
> 0.05) and statistically significant
Datta et al., 200853 EQ-5D Convergence No visual variables were significantly associated with EQ-5D.  
VF-14 was strongly associated with acuity, stereopsis and contrast 
sensitivity. Acuity was less important than either stereopsis or 
contrast sensitivity for EQ-5D, which may suggest that acuity is 
required for function tasks, but stereopsis and contrast sensitivity 
were more important determinant of generic QoL
Polack et al., 200737 EQ-5D Known groups 
(case–control)
Convergence
Cases were significantly more likely to report problems with 
mobility, self-care, usual activities and anxiety than controls
No significant association between VA and EQ-5D across all 
dimensions, except for self-care which has a borderline (p = 0.05) 
association
Polack et al., 200838 EQ-5D Known groups 
(case–control)
Convergence
Significant difference (p < 0.001) across all EQ-5D dimensions 
between cases and controls. Poorer VA was associated with 
higher odds or reporting any problem with mobility, self-care, 
usual activities and pain. There was no significant association  
for depression
Polack et al., 201039 EQ-5D Known groups 
(case–control)
Convergence
Significant difference between cases and controls using VF20 
and self-rated health scale. Cases were significantly more likely 
to report problems with all five EQ-5D domains compared with 
controls after adjustment for age, gender and socioeconomic 
status. Inconsistent association between EQ-5D and VA level. 
Borderline trend with VA shown with self-care (p = 0.05), driven 
by the higher prevalence of reported problems among cases with 
perception of light compared with those with moderate visual 
impairment. The lack of association with the remaining domains 
may reflect the fact that relatively few cases (< 25%) reported no 
problem, resulting in a lack of variation in the data
Diabetic retinopathy
Lloyd et al., 200842 EQ-5D 
and HUI3
Known groups 
(severity)
Convergence
EQ-5D index, EQ-VAS and HUI3 all show some inconsistency 
when compared with degree of severity. Pattern on VFQ-25 
consistent. Between each level of VA, not every difference in 
utility was significant or consistent. Results show a significant 
trend with EQ-5D and HUI3 worsening as VA worsens. A 
regression was undertaken and VFQ-25 and LogMAR were 
identified as independent significant predictors of utility. The data 
from the EQ-5D, HUI and VFQ-25 suggest that relatively mild 
vision loss (6/12 to 6/18) can be associated with very substantial 
declines in utility, with lower scores than people with worse vision
Smith et al., 200850 Convergence 
(through 
regressions)
Known groups 
(severity)
No clear pattern from mean values. OLS model used to estimate 
the impact on utility of a doubling of the visual angle. Utility 
values dropped by approximately seven points for each doubling 
(assuming linear relationship between acuity and utility). Doubling 
visual angle results in utility loss of about 0.03. A non-parametric 
ordinal logistic model was fitted and this estimated that anyone 
who suffered any degree of visual impairment were more likely 
to report non-perfect utility values (OR 1.44, 95% confidence 
interval 1.08 to 1.91)
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Study reference 
grouped by condition 
(author, year)
Utility 
measures Methods Results
Conjunctivitis
Pitt et al., 200460 EQ-5D Known groups 
(case–control)
Inconsistent results comparing SAC to controls. Only the pain 
domain and the EQ-5D were significantly worse in the SAC group 
compared with the control. In some cases, the remaining domains 
were worse in the control (but non-significant). RQLQ was 
statistically significant across all domains. VFQ-25 was statistically 
significant across the mean vision score and the general  
health score
Rajagopalan et al., 
200551
EQ-5D Known groups 
(severity) 
EQ-5D showed significant differences in scale scores across the 
varying severity levels (EQ-5D, p < 0.05, and VAS, p < 0.0001). 
Significant differences were seen across all IDEEL scales except 
treatment satisfaction. EQ-5D and IDEEL were consistent in their 
ranking of severity. Strength of difference analysis was provided 
and the IDEEL outperformed EQ-5D and SF-36 across all severity 
levels. Mean (SD) EQ-5D scores: control 0.87 (0.03), non-SS KCS 
0.82 (0.02) and SS 0.74 (0.03). Mean (SD) EQ-5D VAS score: 
88.93 (2.06), non-SS KCS 82.45 (1.19) and SS 66.94 (2.43)
Smith et al., 200561 EQ-5D Known groups 
(case–control)
EQ-VAS and all EQ-5D dimensions, except mobility, are statistically 
significant (p < 0.02) between SAC and control groups. 
Interestingly, VFQ-25 showed significantly lower scores in all 
domains in the SAC group, except for the general health domain, 
which returned a lower (non-significant) value for the  
control group
Other visual disorders
Boulton et al., 200640 HUI3 Known groups 
(severity) 
Statistically different (unknown to what level) mean HUI3 scores 
between groups
Clark et al., 200862 EQ-5D Known groups 
(case–control)
Significant differences between cases and controls using NEI 
VFQ-25, but not with EQ-5D or TTO. Only the mobility domain 
had a significant difference. Patients had a significant difference 
using the VFQ-25; however, no difference was significant when 
stratified by visual impairment. Postoperation VA was statistically 
significantly different
Kempen et al., 200363 EQ-5D Known groups 
(severity) 
Does not distinguish between groups (non-significant) and 
direction of trend is counter-intuitive. VAS distinguished  
newly-diagnosed group. No statistically significant difference in 
EQ-5D and borderline between VAS
Langelaan et al., 
200741
EQ-5D Known groups 
(severity) 
None were statistically significant at the 5% level. VA saw an 
appropriate movement in EQ-5D; however, VF moved in the 
wrong direction
Quinn et al., 200464 HUI3 Known groups 
(severity) 
HUI3 mean (SD) scores: All 0.59 (0.39). Blind or low vision  
in better eye 0.25 (0.37). Sighted in better eye 0.78 (0.25).  
No-ROP subjects 0.90 (0.16). Statistical significance of VA not 
given but appears to be statistically significant and appropriate. 
HUI3 showed a significantly lower score (p < 0.001) for the blind 
group compared with the sighted group and the non-ROP group 
compared with the sighted group (p < 0.001)
van Nispen et al., 
200952
EQ-5D Convergence 
(through 
regression) 
LogMAR VA is a significant risk factor for lower QoL
IDEEL, impact of dry eyes on everyday life questionnaire; KCS, Keratoconjunctivitis sicca; LogMAR, logarithm of the 
minimum angle of resolution; NEI-VFQ-25, National Eye Institute Visual Functioning Questionnaire – 25; ROP, retinopathy 
of prematurity; RQLQ, rhinoconjunctivitis QoL questionnaire; SS, Sjögren’s syndrome.
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Appendix 4 Summary of responsiveness for 
utility measures: visual disorders
Study (author, year)
Utility 
measures Method Results
Cataracts 
Conner-Spady et al., 
200558
EQ-5D Pre–post treatment comparison 
of VFA, EQ-VAS and EQ-5D
EQ-VAS and EQ-5D show a non-significant  
improvement. Mean difference (SD): EQ-VAS 1.93  
(13.27) and EQ-5D 0.03 (0.17). Per cent better/ 
worse: EQ-VAS 49/33, EQ-5D 38/23
Black et al., 200957 EQ-5D Pre–post treatment comparison 
of VF-14 and EQ-5D
Statistically significant improvement in both EQ-5D 
and VF-14 (p = 0.003). Mean (SD) VF-14 scores:  
preoperation 82.7 (17.3), postoperation 93.7  
(13.2); mean EQ-5D scores: preoperation 0.82,  
postoperation 0.79
AMD 
Kim et al., 201055 EQ-5D Pre–post treatment comparison 
of VF-4D and EQ-5D
Statistically significant improvement in both EQ-5D 
and VF-14 (p < 0.001). Mean VF-4D scores: before 
treatment 0.411, after treatment 0.353. Mean  
EQ-5D scores: before treatment 0.729, after  
treatment 0.793
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Appendix 5 Summary of validity for utility 
measures: hearing impairments
Study 
(author, 
year) Instrument Assessment Methods Summary of results 
Barton 
et al., 
200521
HUI3/EQ-
5D/SF-6D
Convergence Correlations between 
measures 
Moderate to strong correlations were found between 
HUI3, EQ-5D and SF-6D
Barton 
et al., 
200665
HUI3 Known 
groups 
(severity)
Convergence 
HUI3 scores and severity 
groups defined by AHL 
level
HUI3 mean scores were different between moderate, 
severe, profound1, profound2 and implanted groups 
(significance not reported). Cochlear implant (grouped 
by age at implantation and duration of use), AHL and 
gender were significant predictors of HUI3 (p < 0.01)
Bichey 
et al., 
200268
HUI3 Known 
groups 
(severity)
HUI3 scores and PTA 
(presented by cochlear 
implant and hearing aid 
group)
HUI3 mean scores: 0.82 (cochlear implant) vs. 0.62 
(hearing aid), consistent with PTA. No statistical test 
reported
Damen 
et al., 
200769
HUI3 Convergence Spearman’s rank 
correlations between 
mean score of different 
measures at the  
follow-up
Correlation coefficients: 0.33 (HUI3 and AN test, 
p < 0.05), 0.39 (HUI3 and NVA test, p <0.05),  
0.48 (NCIQ and AN test, p < 0.05), 0.32 (NCIQ and 
NVA test, p < 0.05) 
Lovett 
et al., 
201066
HUI3 Known 
groups 
(severity) 
HUI3 index scores 
and SSQ, VAS 
scores presented by 
unilateral and bilateral 
implantation groups
A significant difference (p < 0.05) was detected 
in favour of the bilateral group using the SSQ; no 
significant (p = 0.2) differences detected (HUI3  
and VAS) 
Palmer 
et al., 
199975
HUI3 Known 
groups 
(severity)
HUI3 index scores 
presented by Cochlear 
implant and non- 
Cochlear implant 
groups at enrolment, 
6 and 12 months after 
cochlear implant
Difference between cochlear implant and non-
cochlear implant groups by HUI3: not significant 
(baseline), significant (p < 0.1) difference (0.76 for 
cochlear implant and 0.58 for non-cochlear implant) 
at both 6 and 12 months after intervention
Smith-
Olinde 
et al., 
200867
HUI3 Known 
groups 
(severity) 
HUI3 utility index 
presented by four 
groups defined by 
degree of hearing loss 
Both HUI3 and QWB scores declined with the degree 
of hearing loss, the decline was greater for HUI3 than 
QWB. No statistical significance were presented
Grutters 
et al., 
200723
EQ-5D (UK 
and Dutch 
tariff), HUI3
Known 
groups (age, 
gender and 
severity)
Convergence 
Utility scores compared 
between age, gender 
(EQ-5D) and clinically 
distinctive groups (HUI3)
Agreements between 
utility scores by Kendall’s 
tau correlation and ICC 
Significant differences detected: age and gender (by 
EQ-5D) and clinically distinctive groups (by HUI3). 
Kendall’s Tau correlations: 0.36 to 0.41 (between  
EQ-5D with UK or Dutch tariff and HUI2, HUI3) ICC: 
0.44 to 0.51 (between utility measures) 
Sach 
and 
Barton, 
200776
EQ-5D Known 
groups 
(through 
regressions) 
Multiple linear 
regression were 
estimated between the 
child’s EQ-5D scores and 
CAP, as well as other 
variables
Statistically significant coefficients (p < 0.05) for 
children with or without additional disabilities, gender, 
a more severe deaf condition (measured by CAP); 
non statistical significant coefficients (p > 0.05) for 
children with a mild deaf condition (in the top three 
levels of the CAP) and other socioeconomic factors
AHL, average hearing level; AN test, Antwerp-Nijmegen hearing test battery; CAP, categories of auditory perception;  
ICC, intraclass correlation; NCIQ, the Nijmegen Cochlear Implant questionnaire; NVA test, Dutch Audiological Society 
open speech recognition test; SSQ, speech, spatial and qualities of hearing scale for parents.
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Appendix 6 Summary of responsiveness for 
utility measures: hearing impairments
Study 
(author, 
year) Instruments Assessment methods Results summary
Barton 
et al., 
200521
EQ-5D, SF-6D and HUI3 Correlation between 
change scores of 
different measures
Statistically significant difference (p < 0.001) 
between score changes of the HUI compared with 
SF-6D or EQ-5D, but not between the EQ-5D and  
SF-6D. Pearson correlation coefficients between 
score changes were small (around or below 0.2)
Grutters 
et al., 
200723
EQ-5D (UK and Dutch 
tariff), HUI2 and HUI3
Mean change of scores 
after hearing aid fitting, 
ES and SRM
Mean change score of HUI2 and HUI3 were 
significantly different from E-5D (UK or Dutch tariff); 
ES and SRM of EQ-5D were small (0.02–0.05), ES 
and SRM of HUI2 and HUI3 were large (around 0.6)
Lee et al., 
200679
EQ-5D, QWB, VAS, HUI3 Paired t-test for change 
of scores after cochlear 
implant for EQ-5D, 
QWB, VAS, HUI and its 
dimensions
Mean change scores were statistically significant 
(p < 0.05) for EQ-5D,VAS, QWB, HUI3, HUI hearing 
and emotion dimensions
Hol et al., 
200470
EQ-5D, EQ-5D 
responses, VAS, HHDI 
and SF-36 
Change and ES of  
EQ-5D, EQ-5D 
responses, VAS,  
HHDI domains and  
SF-36 domains after 
bone-anchored  
hearing aid fitting
For both air-conduction hearing aid and : 
conventional bone-conduction hearing aid groups, 
mean change scores of EQ-5D and EQ-5D index and 
its five dimensions, VAS, SF-36 and subdomains were 
small and not significant. ESs were also small at 0.05 
for EQ-5D and 0.1 for VAS. ES for mobility, self-care 
and pain dimension of EQ-5D and role limitation 
(emotional), mental health and pain domains were 
larger at around 0.3. Mean change ES for HHDI 
disability and handicap dimensions were large at 
1.42 and 0.79 
Joore et al., 
2002a,71 
2002b,74
2003a72
EQ-5D responses,  
EQ-VAS, ADPI,  
hearing VAS,  
SF-36 social domain, 
Amsterdam Inventory
Change of scores of 
different measures after 
hearing aid fitting
After a hearing aid fitting, the mean scores on the 
first five questions of ADPI, Amsterdam Inventory 
and hearing VAS showed a significantly significant 
reduction. The largest improvements were found in 
‘detection of sounds’ and ‘intelligibility in quiet’ and 
the smallest improvement was in ‘intelligibility in 
noise’. This change maintained to the second  
follow-up. Change in ADPI from baseline to T2 
and hearing loss (BEPTA) were not correlated 
(r = –0.066); the correlation between gain in ADPI 
and reported degree of satisfaction with the hearing 
aid at the second follow-up measurement was 
higher (r = 0.389, p < 0.01).
EQ-5D VAS showed slight improvement after the 
hearing aid fitting (paired differences = 0.02,  
non-significant). The correlation between change 
in EQ-5D VAS and ADPI scores was low at –0.039. 
Response to EQ-5D dimensions showed little change 
over time with only the feeling dimension improving 
significantly from baseline to T1
Vuorialho 
et al., 
2006a,77
2006b78
EQ-5D, VAS, HHIE, SRT 
and WRS
Mean change and 
statistical test (paired 
t-test or Wilcoxon 
signed ranks tests) for 
different measures after 
hearing aid
The hearing aid improved the mean SRT and also 
slightly improved the mean WRS. The mean HHIE-S 
scores changed from 28.7 to 12.7 6 months after 
fitting the hearing aid for the first time. The  
EQ-VAS score changed significantly 6 months after 
the hearing aid fitting. No change was detected for 
the EQ-5D index 
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Study 
(author, 
year) Instruments Assessment methods Results summary
Cheng 
et al., 
200080
HUI3, VAS, TTO Perceived change 
scores and correlations 
between change scores
VAS: 92% perceived improvement of QoL, 4% no 
change, 4% decrease (one required reimplantation; 
one encountered difficulty during rehabilitation). 
HUI: 95% improved and 5% decreased. TTO: 78% 
improved and 22% no change. Pearson correlations: 
VAS/TTO: 0.57 (n = 49); VAS/HUI: 0.44 (n = 22);  
TTO/HUI: 0.48 (n = 15)
Damen 
et al., 
200769
HUI3, NCIQ Statistically significant 
difference between 
scores of different 
instruments and their 
subdomains pre and 
post cochlear implant
Where significant changes in five of the NCIQ 
domains (speech perception advanced, speech 
perception basic, speech production, self-esteem, 
activities) were found, HUI3 index also showed 
significant improvement
Lovett 
et al., 
201066
HUI3, VAS, SSQ Gain in scores of 
different measures
SSQ demonstrated significant difference between 
gains of unilateral and bilateral groups but HUI3  
and VAS did not show this
ADPI, Audiological Disabilities Preference Index; BEPTA, better ear PTA; HHDI, hearing handicap and disability index; 
HHIE, Hearing Handicap Inventory for the Elderly; HHIE-S, Hearing Handicap Inventory for the Elderly – Screening;  
NCIQ, Nijmegen Cochlear Implant questionnaire; SRM, standardised response mean; SRT, Speech reception thresholds; 
SSQ, Speech, Spatial and Qualities of hearing scale for parents; WRS, Word Reception Scores.
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Appendix 7 Summary of validity for utility 
measures: skin conditions
Study reference 
grouped by 
condition 
(author, year) Assessment methods Results 
Psoriasis and psoriatic arthritis 
Bansback et al., 
200683
Known groups (regression 
model predicts EQ-5D from 
HAQ-DI)
Convergent validity
Coefficient: –0.31 (p = 0.03)
Brodszky et al., 
201092
Known groups (other)
Convergent validity
All groups: standard mean differences of EQ-5D were comparably 
lower than PsAQoL and HAQ. Significant differences were found for 
two groups for EQ-5D, three groups for PsAQoL and four groups 
for HAQ. Strong Spearman’s rank-order correlation (> 0.5) between 
EQ-5D and HAQ, PsAQoL, the patient pain VAS, the patient global 
VAS and the BASDAI 
Christophers 
et al., 201093
Known groups (severity)
Psoriasis and psoriatic arthritis
EQ-5D of psoriatic arthritis is lower than psoriasis patients (0.56 vs. 
0.82, p < 0.0005). Psoriasis effects on every day tasks [lower than 
psoriatic arthritis patients (2.34 vs. 2.85 p < 0.001)]
Daudén et al., 
200984
Known groups (severity)
Continuous vs. paused therapy 
After treatment, difference (p < 0.05) found for EQ-5D, EQ-VAS and 
DLQI, but not for HAD-D, HAD-A or SF-36 vitality and satisfaction 
survey
Van de Kerkhof, 
200482
Known groups (case–control)
Psoriasis patients vs. general 
population
Psoriasis patients reported greatest problems on EQ-5D pain and 
anxiety than general population (no significant data reported)
Luger et al., 
200996
Known groups (Severity)
Patients with/without joint pain; 
with/without nail psoriasis
Joint pain groups: differences (p < 0.1) for EQ-5D, EQ-VAS, 
PASI, DLQI, SF-36 vitality and HADS but no significant difference 
(p > 0.10) for BSA. Nail psoriasis group: differences (p < 0.1) for 
EQ-5D, EQ-VAS, BSA, PASI and HADS-depression but no significant 
difference (p > 0.1) for SF-36 vitality scores and HADS-anxiety 
subscale
Reich et al., 
200985
Known groups (case–control) 
Psoriasis patients and the UK 
general population
The EQ-5D, EQ-VAS, FACIT-F and DLQI scores of people with 
psoriasis were lower than those of UK population
Shikiar et al., 
200695
Convergent validity EQ-5D showed moderate to strong correlations with DLQI, PASI, 
PGA EQ-VAS and SF-36 domains. EQ-5D and DLQI more highly 
correlated with the PASI and PGA than any of the SF-36 domains
Weiss et al., 
200287
Known groups (case–control)
Psoriasis patients vs. population 
with no chronic conditions
EQ-5D and SF-36 of psoriasis patients were lower (p < 0.01) than a 
population of healthy subjects
Convergent validity Patient’s SWLS scores were correlated with EQ-5D (0.46, p = 0.006) 
and VAS (0.48, p = 0.004) and all eight dimensions of SF-36  
(0.34–0.65, p < 0.05). EQ-5D (0.62–0.78, p < 0.001) and EQ-VAS 
(0.48–0.76, p d 0.003) correlated with the eight dimensions  
of SF-36
Acne
Klassen et al., 
200081
Known groups (case–control)
Acne patients vs. population 
sample (20–39 years)
Acne patients reported higher proportions of moderate or severe 
problems for most EQ-5D dimensions (especially pain and anxiety) 
than population sample
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Study reference 
grouped by 
condition 
(author, year) Assessment methods Results 
Hidradenitis suppurativa
Matusiak et al., 
201089
Known group (severity)
Hurley classification I, II and III
Differences (p < 0.01) between Hurley’s classification groups were 
found for EQ-5D, EQ-VAS, DLQI, BDI-SF, FACIT-F, QLES-Q and the 
GQ 6-item scale
Convergent validity Moderate correlations were found between the number of sites 
affected and the EQ-5D, DLQI and FACIT-F (correlations ranged from 
0.28 to 0.39, p < 0.05)
Hand eczema 
Moberg et al., 
200990
Known groups (severity): with/
without hand eczema
Known groups (others): age, 
gender
Hand eczema: EQ-5D and EQ-VAS differ (p < 0.05) between groups, 
as well as between age and gender subgroups. The proportions of 
people reporting problems in EQ-5D dimensions were significantly 
larger in the group with hand eczema compared with patients 
without hand eczema
Convergent validity Strong correlations were found between EQ-5D and EQ-VAS
Venous leg ulcers 
Walters et al., 
199991
Known groups (non severity 
and severity): age, Mobility, 
Initial ulcer size
Current and maximum ulcer 
duration
Age group: ES of EQ-5D and SF-MPQ were less than 0.2. Difference 
(p < 0.05) detected by SF-36 (PF, GHP and MH) and the FAI. Mobility 
group: differences (p < 0.05) detected by five dimensions of the  
SF-36 (PF, RL, Pain, VT and SF), EQ-5D, FAI and EQ-VAS. Initial leg 
ulcer size group: small ES for four measures. Current ulcer duration 
and maximum ulcer duration: small ESs observed for four measures 
Convergent validity EQ-5D achieved moderate to high correlations with SF-36 
dimensions, FAI and SF-MPQ (larger than between other measures)
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; FACIT-F, Functional Assessment of Chronic Illness Therapy –  
Fatigue; GHP, general health profile; GQ, Global question index; MH, mental health; PF, physical functioning;  
PGA, Physician Global Assessment of psoriasis; QLES-Q, Quality of Life Enjoyment and Satisfaction Questionnaire;  
RL, role limitations; SF, social functioning; SWLS, Satisfaction With Life Scale; VT, vitality.
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Appendix 8 Summary of responsiveness for utility 
measures: skin conditions 
Study reference 
grouped by 
condition 
(author, year) Method of assessment Responsiveness results
Psoriasis and psoriatic arthritis
Daudén et al., 
200984
Examine changes between 
baseline and 54 weeks’ follow-
up for two treatment groups
EQ-5D, EQ-VAS, DLQI, HADS-anxiety and SF-36 vitality improved 
statistically (p < 0.05) and clinically meaningfully from baseline for 
both treatment groups
Van de Kerkhof, 
200482
Examine change between 
baseline and end of treatment 
at 4 weeks
Significant improvement detected by psoriasis disability index, 
EQ-VAS, VAS (p < 0.01) and EQ-5D pain/discomfort and anxiety/
depression (no significant information)
Luger et al., 
200996
Examine change before and 
after treatments in 54 weeks
Joint pain patients: DLQI improved by 8.86 (61%), EQ-5D by 0.17 
(29%), EQ-VAS by 12.87 (23%), SF-36 vitality by 5.55 (11%), 
HADS-depression scores by 1.9 (29%) and HADS-anxiety sores by 
2.27 (28%) (all p < 0.001). Patients with joint pain had greater 
improvement than patients without joint pain in DLQI, EQ-5D utility 
index and HADS-depression and HADS-anxiety after treatment. 
Nail psoriasis patients: NAPSI improved by 2.38 (51%). Significant 
improvement observed for DLQI and EQ-VAS but not EQ-5D
Reich et al., 
200985
Test improvement after 
treatments 
At week 12, treatment group achieved significant improvement 
than placebo in total DLQI (–7.4 vs. –1.2, p < 0.0001), six DLQI 
domains (p < 0.01), EQ-5D (17% vs. 3%, p < 0.05), EQ-VAS (11% 
vs. 8%, p < 0.01) and moderate improvement in FACT-F (1.3 vs. 
0.3, no significant difference between groups). A total of 37.5% 
of treatment group and 2.2% placebo group achieved a PASI 75 
response (p < 0.0001). At week 24, both treatment and placebo 
groups DLQI total and domain scores improved (–9.6 vs. –7.1),  
EQ-5D (23% vs. 19%), VAS (29% vs. 3.9%) and FACT-F (3.7 vs. 
2.9). A total of 71.1% of the treatment group and 44% of the 
placebo achieved PASI 75 response (p < 0.05)
Revicki et al., 
200894
Examine change of scores  
over time 
At week 16, DLQI improved by 9.1 (adalimumab), 3.4 (methotrexate), 
5.7 (placebo) and differences between improvements in groups was 
statistically significant. Statistically significant improvement for the 
adalimumab group detected by EQ-5D, DLQI, PASI and significantly 
different with placebo (p < 0.001)
Shikiar et al., 
200695
Examine correlations between 
changes of patient-reported 
outcomes with changes in 
clinical measures (PASI and 
PGA);
Compare improvements 
between two groups (defined 
as PASI responder and non 
responder) 
Correlations 0.69 (p < 0.001) for changes of DLQI with PASI, 0.71 
(p < 0.001) for DLQI with PGA, 0.57 (p < 0.001) for EQ-5D PASI and 
–0.44 (p < 0.001) for EQ-5D and PGA. EQ-5D, DLQI, PASI, PGA, 
EQ-VAS and most SF-36 domains detected significant differences 
between responders and non-responders. DLQI was the most 
responsive (ES 0.4) and EQ-5D and EQ-VAS were similar with several 
SF-36 domain scores (ES 0.12)
Shikiar et al., 
200786
Examine changes of measures 
between baseline and 12 weeks 
follow-up by treatment groups
Two treatment groups improved greater than placebo in DLQI 
(10 vs. 1.3), EQ-5D (p < 0.01), EQ-VAS (p < 0.01) and most SF-36 
domains (p < 0.05, except physical functioning)
Weiss et al., 
200688
Examine change of scores after 
treatment
At the end of 2 weeks of therapy, PASI achieved 35% improvement 
(p < 0.001), EQ-5D 11.5% improvement (p = 0.007), BSA improved 
20.4%(p < 0.001), DLQI improved 40.2% (p < 0.001) and EQ-VAS 
improved 8.2% (p < 0.001). The patient’s perception of disease 
severity by SAPASI improved 26.2% (p = 0.04)
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Study reference 
grouped by 
condition 
(author, year) Method of assessment Responsiveness results
Acne
Klassen et al., 
200081
Examine change after 
treatment (4 and 12 months) 
and ES of change
After treatment, the proportion of subjects to report a moderate 
problem on EQ-5D dimensions dropped greatly. EQ-5D, SF-36 PCS, 
DLQI, and acne grade changed significantly at 4 months. Change 
was small for EQ-VAS. ESs were 1.57 (the acne grades), 0.98 (DLQI), 
0.3–0.45 (SF-36 summary score) and 0.44 and 0.53 (EQ-5D)
Venous leg ulcers 
Walters et al., 
199991
Assess change over time and 
SRM against patient’s group by 
leg ulcer healed status or by 
response to the self-perceived 
question (item two of SF-36)
By leg ulcer healed status: at 3 months, EQ-5D detected 
deterioration of health status for both groups, which was agreed 
by SF-36 but conflicted with SF-MPQ and VAS. There were small 
and insignificant SRMs for EQ-5D, SF-36 and FAI but moderate 
to large SRMs for SF-MPQ. There was no different health change 
between the healed and no healed groups except for Pain Rating 
Index (sensory) of SF-MPQ and VAS. After 12 months, changes 
in EQ-5D and most SF-36 domains were detected over time and 
the differences were significant between groups. By the transition 
question: at 3 months, a significant pattern (ANOVA) found for all 
instruments, except PF and RL dimensions of SF-36, with a worse 
response of the transition question associated with negative scores 
but a better response not associated with positive changes 
PF, physical functioning; PCS, physical component score; PGA, Physician Global Assessment of psoriasis; RL, role 
limitations; SRM, standardised response mean.
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Appendix 9 Summary of reliability for utility 
measures: cancers 
Study reference 
grouped by 
condition 
(author, year) Instrument
Assessment 
methods Results
Brain cancer
Le Gales et al., 
1999163
HUI3 Internal 
consistency
Inter-rater reliability
Multitrait analysis was used to assess internal reliability. 
Correlations of questions within the attribute to which they 
contribute were examined to check that they were higher than 
correlations with other attributes. The authors confirmed that this 
was the case, except for questions 11 and 12 and the cognition 
attribute when completed by the parent; however, the authors 
also noted that numerous unexpected correlations were found to 
be statistically significant
There were significant correlations between patient, parent and 
physician assessments. The hearing dimension demonstrated the 
greatest amount of agreement between raters. This was followed 
by speech, ambulation and dexterity. The weakest agreement was 
between raters of the emotion, cognition and pain dimensions
Hodgkin’s lymphoma 
Klaassen et al., 
2010186
HUI3 Inter-rater reliability Fair to substantial agreement
Kidney/renal cancer 
Cella et al., 
2010168
EQ-5D Stability across 
treatment groups
EQ-5D, VAS and FACT scores do not differ between the country 
cohorts, which provides some evidence for the reliability of the 
instruments in multinational trials
Leukaemia 
Barr et al., 
1997174
HUI3 Inter-rater reliability No differences were found on other measures. No significant 
effect of assessor on HUI3 score was found. This was also 
apparent at the dimension level (for the mobility, emotion and 
pain dimensions)
Hahn et al., 
2003176
EQ-5D Stability across 
treatment groups 
at baseline
No differences were found on other measures. As expected, no 
significant differences between the treatment groups as baseline 
for EQ-5D
Lymphoma 
van Agthoven 
et al., 2001177
EQ-5D Stability across 
treatment groups 
at baseline
As expected, no significant differences between the treatment 
groups as baseline for EQ-5D and EORTC QLQ-C30
Witzens-Harig 
et al., 2009192
EQ-5D Stability across 
treatment groups 
at follow-up
As expected, no significant difference in QoL scores between the 
groups at follow-up for EQ-5D, EORTC QLQ-C30
ML/AML
Banks et al., 
2008178
HUI2/HUI3 Inter-rater reliability The HUI2 showed substantial accordance between the child 
and parent report, whereas, for the HUI3, the concordance was 
moderate. The concordance for the PedsQL was lower. Indicates 
reliability of HUI assessments across raters
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Study reference 
grouped by 
condition 
(author, year) Instrument
Assessment 
methods Results
Musculoskeletal cancer 
Lee et al., 
2003184
EQ-5D Internal 
consistency
The authors examined the validity and reliability of a condition-
specific system (Musculoskeletal Tumor Society functional 
evaluation system) relative to EQ-5D and SF-36. They examined 
the internal consistency of EQ-5D dimensions relative to the 
overall score and of individual SF-36 questions to summary scores. 
The authors concluded that internal consistency was in the range 
defined as high for both measures
Cancer survivors 
Barr et al., 
2000133
HUI3 Inter-rater reliability At least 81% agreement across the HUI2/3 domains for both 
Wilm’s tumour and neuroblastoma
Boman et al., 
2009134
HUI3 Inter-rater reliability Agreement range across the dimensions 60% (pain) to 95.5% 
(hearing) for survivors/parents. ICC’s in the range of 0.40 (pain) to 
0.96 (self-care)
Felder-Puig et al., 
2000131 
HUI3 Inter-rater reliability Percentage agreement between the three raters ranged from 
56% to 100%. Kappa estimates ranged from 0.14 to 1, 
exhibiting a broader range
Fu et al., 2006130 HUI3 Inter-rater reliability Substantial agreement across the raters for the vision, hearing 
and ambulation domains and low agreement across the raters for 
the emotion domain. Patients are more likely to report moderate 
or severe emotion (p < 0.001) and cognition (p < 0.003) than 
parents/physicians, and patients and parents are more likely to 
report moderate or severe pain than physicians (p < 0.001)
Barr et al., 
1999127
HUI2 Inter-rater reliability Inter-rater reliability was higher for the more observable 
attributes of mobility and self-care. Pain also displayed reasonable 
agreement at a higher level than emotion. ICCs indicate that 
there is a strong agreement between raters for HUI2 utility scores
ICC, intraclass correlation.
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Appendix 10 Summary of validity for utility 
measures: cancers 
Study reference 
grouped by 
condition 
(author, year) Measure
Assessment 
methods Results 
Brain cancer
Le Gales et al., 
1999163
HUI3 Known-group 
validity (severity)
Face validity 
Difference in the number of impaired HUI attributes is 
significantly different between levels of health status as assessed 
by physicians. No significant differences across groups defined 
according to levels of radiation therapy received were found. 
Approximately 70% of children and 80% of parents concluded 
that all of the important aspects of health status were covered. 
Physicians were more ambivalent
McCarter et al., 
2006162
HUI3 Known-group 
validity (case–
control and 
severity)
Convergent validity
All of the HUI3 dimensions were significantly different except 
emotion with the patient sample reporting lower utility scores. 
The utility scores differ between the tumour groups but no 
statistical tests of significance were reported. The majority of 
correlations between the KPS, MMSE and HUI dimensions were 
moderate or strong (> 0.35)
Breast cancer 
Chang et al., 
2004143
HUI3 Convergent validity A strong and significant correlation was observed for HUI3 and 
FACT-An and FACT-F. A less strong correlation was observed 
between three subscales of HUI3 (ambulation, emotion, 
cognition) and FACT-An and FACT-F
Crott et al., 
2010146
EQ-5D Convergent 
validity (through 
regression)
A statistical relationship was estimated between EORTC 
QLQ-C30 and EQ-5D. Individual EORTC QLQ items better 
explained EQ-5D values than the total EORTC QLQ-C30 score. 
The preferred model showed good fit (adjusted R2 of 0.801 and 
RMSE of 0.096). The statistically significant items were physical, 
emotional and social functioning, pain, constipation and 
diarrhoea. Items that were not included (not significant) were 
role and cognitive function, fatigue, nausea-vomiting, dyspnoea, 
appetite and financial problems
Freedman et al., 
2010145
EQ-5D Convergent validity Strong correlations were observed between EQ-5D index and 
EQ-VAS 
Jansen et al., 
2004137
EQ-5D Convergent 
validity (through 
regression)
The pattern of results for EQ-5D was consistent with other 
measures. None of the measures, including EQ-5D index, 
VAS, HADS-anxiety and HADS-depression, had a significant 
relationship with perceived choice or chemotherapy (p > 0.05) 
but did for interactions of choice and chemotherapy (p < 0.05) 
and age (p < 0.05)
Kimman et al., 
2009144
EQ-5D Convergent validity Correlation coefficients: 0.423 (EQ-5D index vs. EROTC) and 
0.634 (EQ-VAS vs. EORTC). EQ-VAS and EQ-5D index both 
moved in the expected direction with EORTC
Lidgren et al., 
2007138
EQ-5D Known-group 
validity (severity)
Convergent validity
The EQ-5D index differentiated between groups categorised 
according to those in their first year after primary breast cancer 
(state P) and those in the metastatic disease (state M) compared 
with patients in their second or more years after primary cancer 
or recurrence (state S), but did not differentiate patients in their 
first year after recurrence (state R) compared with state S. The TTO 
differentiated group M with S, but not groups P and R with S. For 
all breast cancer states except ‘state R’, TTO values were significantly 
higher than EQ-5D indices with the correlation being 0.44
APPENDIX 10
174
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Study reference 
grouped by 
condition 
(author, year) Measure
Assessment 
methods Results 
Breast cancer 
Lovrics et al., 
2008141
HUI3 Convergent validity Most Pearson correlations between HUI3 and SF-36 were 
statistically significant (p < 0.01). HUI3 showed moderate to very 
strong positive correlations to SF-36 PCS scores and moderate to 
substantial positive correlations to SF-36 MCS scores
Cervical cancer
Korfage et al., 
2010164
EQ-5D Known-group 
validity (severity)
Convergent validity
The EQ-5D scores indicate that the borderline/mild dyskaryosis 
group has worse HRQL than the healthy population but 
the difference is not statistically significant. In contrast, 
the differences in the SF-12 PCS and MCS, and STAI are all 
significant. Mixed patterns were observed the EQ-5D, which 
did not find the group differences that were found using other 
generic (SF-12) and condition specific (STAI/PCQ) measures. 
Perceived risk of being diagnosed with cervical cancer was 
associated with EQ-5D (p = 0.004) and PCQ (p < 0.005) score, 
but not with MCS (p = 0.12) or STAI (p = 0.18)
Maissi et al., 
2005167
EQ-5D Known-group 
validity (severity)
EQ-5D is as sensitive to HRQL issues in cervical cancer (around 
anxiety and distress) as measured by the STAI and General 
Health Questionnaire
Whynes et al., 
2008a165
EQ-5D Convergent validity A range of significant validity results demonstrating that the  
EQ-5D is correlated with both the EQ-5D VAS and the HADS, 
which is a widely used measure of anxiety and depression
Whynes et al., 
2008b166
EQ-5D Known-group 
validity (severity) 
At post-study follow-up, the EQ-5D, HADS-anxiety and  
HADS-depression do not discriminate between the control and 
intervention groups, but the chance dimension of the  
MHLCS does
Colon cancer
Doornebosch 
et al., 2007115
EQ-5D Known-group 
validity (severity)
Mean EQ-VAS scores were similar after treatments (TEM, 
TME and controls), EQ-5D indices did not differ between the 
three groups, sores of EORTC QLQ-C30 subscales showed no 
differences across between groups and EORTC QLQ-CR38 
showed a significant difference between TEM and TME groups 
regarding defecation problems with TEM patients having less 
defection problems than TME patients (p < 0.05)
Gosselink et al., 
2006121
EQ-5D Known-group 
validity (case–
control, severity)
Mean EQ-5D index of CPA was significantly higher than the 
gender-age matched general population whereas LRA and APR 
groups were similar with general population. EQ-5D indices did 
not differ between the three treatment groups. EQ-VAS scores 
of CPA were significantly higher than the gender matched 
general population whereas LRA and APR groups were similar 
to the general population. Significant differences were found 
between the groups who had CPA and LRA, and between the 
CPA and LRA groups. Significant differences between the three 
groups were found on five subscales of the EORTC measures
Hamashima, 
2002117
EQ-5D Known-group 
validity (case–
control)
No significant differences were revealed between with and 
without stoma groups on the basis of EQ-5D index, EQ-VAS  
and stoma-specific QoL questions relating to outing and  
travel question
Janson et al., 
2007122
EQ-5D Known-group 
validity (severity)
EQ-5D index, EQ-VAS and EORTC QLQ-C30 revealed no 
differences between study groups at baseline
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Study reference 
grouped by 
condition 
(author, year) Measure
Assessment 
methods Results 
Colon cancer
Ramsey et al., 
1998190
HUI3 Known-group 
validity
FACT-C summary scores showed little variation over time by 
tumour stage at diagnosis. The smoothed curves of HUI3 values 
suggested that the pattern of scores over time differs depending 
on the initial stages at diagnosis. HUI3 values did not different 
significantly by tumour stage at diagnosis. FACT-C scores 
showed a non-significant trend toward declining health for more 
advanced stages of disease and showed little variation over time 
by tumour stage at diagnosis. The smoothed curves of HUI3 
values suggested that the pattern of scores over time differs 
depending on the initial stages at diagnosis. HUI3 values did not 
differ significantly by tumour stage at diagnosis. FACT-C scores 
showed a non-significant trend toward declining health for more 
advanced stages of colorectal carcinoma
Sharma et al., 
2007123
EQ-5D Convergent validity Only HADS-anxiety scores, positive and negative affect schedule 
score and FACT emotional well-being subscale score were 
moderately significantly correlated with TNM stage. Other 
measures, including EQ-5D index and EQ-VAS, were not 
significant and had low correlation to the TNM stages
Siena et al., 
2007118
EQ-5D Known-group 
validity (severity)
Results for the FACT colorectal symptom index and EQ-5D for all 
treatment groups were similar regardless of imputation method. 
Similar results for panitumumab and best supportive care 
patients stratified by tumour progress status were observed for 
EQ-VAS and EORTC global scale
Wilson et al., 
2006120
EQ-5D Known-group 
validity (severity)
Except the SF-12 MCS score, EQ-5D index, EQ-VAS, SF-12 
general health, SF-12 PCS, QLQ general health, FACT-C total 
scores declined with advancing preoperative ECOG performance 
status. Multivariate analysis demonstrated that EQ-5D, EQ-VAS, 
SF-12 GH, SF-12 PCS and QLQ-GH scores were significantly 
different between ECOG performance status groups
Gastric (and related) cancer
Homs et al., 
2004149
EQ-5D Known-group 
validity (case–
control)
Large difference in EQ-5D scores between the general and study 
population groups, with those in the study population reporting 
lower EQ-5D utility scores at baseline
Kontodimopoulos 
et al., 2009147
EQ-5D/ 
SF-6D
Convergent 
validity (through 
regression) 
EORTC physical and emotional functioning and global health 
status significantly predicted EQ-5D utility scores. Indicates 
relationship between some EORTC dimensions and EQ-5D
EORTC social and emotional functioning, pain, constipation, 
dyspnoea and global health status predicted SF-6D utility score 
(significant predictor). Indicates relationship between some 
EORTC dimensions and SF-6D
O’Gorman et al., 
1998151
EQ-5D Known-group 
validity (severity)
Convergent validity
EQ-5D scores and most of the EORTC subscales are significantly 
lower in the weight-losing group. Within the weight-losing 
group, no significant difference in EQ-5D or EORTC values 
but KPS significantly lower in the inflammatory response 
group. Significant correlations between appetite scores and 
EQ-5D (0.43)/EORTC (0.61)/KPS (0.55) scores. Overall, EQ-5D 
is demonstrating validity in comparison to condition specific 
measures
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Study reference 
grouped by 
condition 
(author, year) Measure
Assessment 
methods Results 
Gastric (and related) cancer
Rogers et al., 
2006148
EQ-5D 
(dimensions)
Known-group 
validity (case–
control, severity)
Convergent validity
Higher percentage of patients reporting problems in the EQ-5D  
dimensions than a general population reference group but 
significance not reported. Patients having radiotherapy report 
significantly lower VAS and higher EQ-5D mobility/usual 
activity dimension scores than those not having radiotherapy. 
University of Washington QoL questionnaire overall QoL score 
significantly correlated with EQ-5D mobility/usual activity and 
anxiety/depression dimensions. University of Washington QoL 
questionnaire activity/recreation and EQ-5D usual activity/
mobility/self-care dimensions are significantly correlated. 
University of Washington QoL questionnaire is correlated with 
anxiety/depression, pain and usual activities dimensions
Shenfine et al., 
2009150
EQ-5D Known-group 
validity (severity)
EQ-5D significantly discriminates between the treatment groups 
at follow-up
Wildi et al., 
2004152
EQ-5D Known-group 
validity (severity)
Those at stage 0 (low severity) display higher EQ-5D utility scores 
than stages 1–3. However, the overall difference between the 
stages is not significant and the EQ-5D scores do not decrease as 
expected between stages 1–3. This provides limited evidence for 
the known-group validity of EQ-5D
Hodgkin’s lymphoma
Klaassen et al., 
2010185
HUI3 Convergent validity Strong correlation between HUI3 and other measures
Kidney/renal cancer
Castellano et al., 
2009171
EQ-5D Convergent validity EQ-5D index scores are significantly correlated with the FACT-G 
and FACT kidney symptom index at 0.6 or above. The EQ-5D 
and EQ-5D VAS are more highly correlated with the condition 
specific instruments than with each other
Cella et al., 
2008169
EQ-5D No formal tests 
but pattern was 
observed
EQ-5D, VAS and FACT scores follow a similar pattern across the 
study follow-up period
Cella et al., 
2010168
EQ-5D No formal tests 
but pattern was 
observed
EQ-5D, VAS and FACT scores do not differ between the country 
cohorts, which provides some evidence for the validity of the 
instruments in multinational trials
Sternberg et al., 
2010193
EQ-5D No formal tests 
but pattern was 
observed
EQ-5D, VAS and EORTC global health follow the same pattern 
across the study period
Yang et al., 
2010170
EQ-5D No formal tests 
but pattern was 
observed
EQ-5D and VAS scores follow the same pattern which indicates 
agreement between the measures
Leukaemia 
Cox et al., 
2005187
HUI3 Acceptability
Missing data/
ceiling effects/
proxy completer 
comments
A significant quantity of data were missing, despite the fact 
that proxies had undergone extensive orientation to the HUI. 
Speech was the only category with no missing data. There is a 
high ceiling effect across all HUI attributes, with vision, hearing 
and dexterity displaying the highest levels. Comments that there 
is missing data because attribute was not able to be observed. 
Comments that measures functional performance, not QoL. 
Limited evidence for the acceptability of HUI3
Hahn et al., 
2003176
EQ-5D Known-group 
validity (severity) 
EQ-5D demonstrated treatment differences at all follow-up  
time points
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Study reference 
grouped by 
condition 
(author, year) Measure
Assessment 
methods Results 
Liver metastases 
Langenhoff et al., 
2006180
EQ-5D Known-group 
validity (severity)
Both the EQ-5D and EORTC QLQ-C30 are sensitive to differences 
between patient treatment groups
Mendez Romero 
et al., 2008172
EQ-5D Known-group 
validity (case–
control)
Both the EQ-5D and EORTC are sensitive to differences between 
a metastatic liver tumour patient group and a general population 
group similar in terms of age in the expected direction
Krabbe et al., 
2004179
EQ-5D Known-group 
validity (severity)
The EQ-5D/VAS and EORTC global health scale discriminated 
well between the three treatment groups, and followed a similar 
pattern across the study period
Lung cancer
Pickard et al., 
2007103
EQ-5D Known-group 
validity (severity)
Minimally important differences for the EQ-5D index by FACT 
quintile subgroups reveal that the EQ-5D is able to distinguish 
between the patients at the various FACT quintiles. However, the 
results should be interpreted with caution owing to the small 
sample size
Trippoli et al., 
2001173
EQ-5D Known-group 
validity (severity)
Convergent validity
The EQ-5D significantly distinguishes between patients with 
metastasis and those without
There are significant correlations between the EQ-5D index score 
and VAS and also between the EQ-5D and SF-36
Lymphoma 
Doorduijn et al., 
2005188
EQ-5D Known-group 
validity (severity)
EQ-5D significantly discriminates between clinical indicator 
severity levels, with those at a more severe level reporting lower 
EQ-5D index scores
ML/AML
Banks et al., 
2008178
HUI2/HUI3 Convergent validity There were correlations of at least 0.2 between all pairs of 
measures used at baseline. The proxy HUI2/3 was substantially 
correlated with the PedsQL generic scores. The proxy HUI2/3 
and the PedsQL generic showed substantial correlations with the 
CHQ physical score. Indicates concurrent validity of HUI
Slovacek et al., 
2007181
EQ-5D Known-group 
validity (severity)
Difference between ML and AML EQ-5D scores index and 
dimension scores, with ML indicating significantly higher scores. 
Indicates that EQ-5D can discriminate between the level of HRQL 
associated with different types of cancer. However, sample size 
was small
MM
Slovacek et al., 
2008175
EQ-5D Known-group 
validity (others)
EQ-5D significantly decreases as age increases and non-smokers 
have significantly higher EQ-5D scores. Indicates known-group 
validity of EQ-5D across demographic variables
MM/ML
Slovacek et al., 
2007182
EQ-5D Known-group 
validity (severity)
Difference between MM and ML EQ-5D scores, with ML 
indicating significantly higher scores. Indicates that EQ-5D can 
discriminate between the level of HRQL associated with different 
types of cancer
Musculoskeletal cancer
Lee et al., 2003184 EQ-5D Convergent validity EQ-5D dimensions were significantly correlated with all 
dimensions of MSTS. Results discussed in terms of MSTS. Limited 
evidence for convergent validity of EQ-5D dimensions
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Study reference 
grouped by 
condition 
(author, year) Measure
Assessment 
methods Results 
Pancreatic cancer
Muller-Nordhorn 
et al., 2006183
EQ-5D Known-group 
validity (case–
control, other)
Male cancer patients were significantly more likely to report 
any problems on all five EQ-5D dimensions than the general 
population reference sample. However, female patients were 
only significantly more likely to report problems on the anxiety/
depression domain
EQ-5D VAS significantly discriminates between the cancer 
patient and general population samples for both males and 
females. There were no significant differences in EQ-5D and 
EORTC scores between males and females or patients with or 
without metastases
Prostate cancer 
Albertsen et al., 
1998155
HUI3 Convergent validity The association between HUI3 and the self-administered 
questionnaire was not significant
Krahn et al., 
2007160
HUI3 Convergent validity Low ICC between HUI3 and SG utilities
Sandblom et al., 
2004158
EQ-5D Known-group 
validity (severity)
EQ-5D scores discriminate between survival groups
Shimizu et al., 
2008156
EQ-5D/SF-
6D
Known-group 
validity (severity) 
EQ-5D and SF-6D discriminate between severity groups as 
indicated by the number of symptoms. A higher number of 
symptoms resulted in lower utility scores, as expected
Sullivan et al., 
2007157
EQ-5D Known-group 
validity (severity)
The change in HRQL seemed worse for patients undergoing 
chemotherapy and TURP than those who did not. Some 
evidence that generic and condition specific instruments 
discriminate between different treatment groups
Weinfurt et al., 
2005159
EQ-5D Known-group 
validity
The generic and condition specific instruments are able to pick 
up effects by patients groups experiencing the different types  
of SRE
Spinal metastases 
Falicov et al., 
2006101
EQ-5D/HUI3 Convergent validity Low/moderate correlation between the utility measures
Non-specific cancer
Capuano et al., 
2008107
EQ-5D Convergent validity Anaemia (p = 0.031) and weight loss (p = 0.002) were 
significantly influenced EQ-5D scores. Inflammation was not 
statistically significant and relationship with fatigue was not 
directly tested, but both anaemia and weight loss significantly 
impacted on fatigue
Pickard et al., 
2007103
EQ-5D Known groups 
(severity)
A trend was seen in line with expectations according to severity. 
Statistical significance not presented. EQ-5D scores decrease 
as ECOG increases (i.e. as performance status worsens) and as 
functional assessment (FACT) increases. This applies to both US 
and UK tariffs, although is more pronounced with the UK tariff
Ravasco et al., 
2003104
EQ-5D Known groups 
(severity)
High-risk patients had statistically significantly worse scores than 
low risk patients on all dimensions at baseline (p = 0.001) and at 
the end of the study (p = 0.01)
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Study reference 
grouped by 
condition 
(author, year) Measure
Assessment 
methods Results 
Non-specific cancer
Wang et al., 
200897
EQ-5D Known groups 
(case–control)
The likelihood of reporting any problem was statistically 
significantly higher for cancer patients compared with other 
patients for the usual activities dimension (p < 0.01) but not 
for the other dimensions. On the SF-36, there were statistically 
significant differences on the physical functioning and general 
health domains but not any of the others. Cancer was a 
significant explanatory variable for EQ-VAS scores, but not for 
SF-36 summary scores
Pickard et al., 
2007114
EQ-5D Correlations
Known groups 
(severity) 
All dimensions statistically significant at varying strengths. Crude 
summary score decreases as ECOG scores increase as expected. 
EQ-5D summary scores: ECOG 0 = 89.7 (n = 98), ECOG 1 = 76.0 
(n = 205); ECOG 2 = 68.6 (n = 100) and ECOG 3 = 57.0 (n = 20)
Barton et al., 
200898
EQ-5D/ 
SF-6D
Known groups 
(case–control)
Significant differences between cancer and non-cancer groups 
were found for EQ-VAS (p < 0.05) but not EQ-5D or SF-6D
Bowker et al., 
200699
HUI3 Known-group 
validity (case–
control) 
Mean difference in scores, adjusted for sociodemographics, were 
statistically significantly different (p < 0.001) for cancer, cancer 
and diabetes, and diabetes only compared with no cancer 
or diabetes. Unadjusted mean (SD) scores were statistically 
significantly different (ANOVA p < 0.001) for cancer, cancer and 
diabetes, diabetes only and no cancer
Cheung et al., 
2009105
EQ-5D Known group 
(severity)
Convergent 
(through 
regression) 
At baseline/follow-up, ECOG 0 = 0.899/0.921, ECOG 
1 = 0.791/0.773, ECOG 2 = 0.718/0.737 and ECOG 
3 = 0.596/0.530
Social domain of FACT-G was not statistically significant in any 
of the models, but all other dimensions and total score were. R2 
ranged from 0.345 to 0.451
Lathia et al., 
2008 (abstract 
only)102
EQ-5D Convergent 
(through 
regression)
Strongest relationship with FACT-N was with pain/discomfort 
(p = 0.18). Model fit was poor R2 = –0.04
Chow et al., 
2010106
EQ-5D Known group 
(severity) (stage 
and treatment 
group) 
Appropriate trend found in EQ-5D scores by stage (statistical 
significance between stages not reported). Similar pattern was 
found for VAS scores. Mean (SE) HUI3 scores for CAM users: 
cancer stages 0, I and complete responders 0.82 (0.03); stages 
II/III: 0.80 (0.02); and stage IV: 0.77 (0.02). Mean (SE) HUI3 
scores for non-CAM users: Cancer stages 0, I and complete 
responders 0.86 (0.04); stages II/III: 0.80 (0.03) and; stage IV: 
0.56 (0.06). Multivariate regression analysis found that there 
was no statistically significant difference in EQ-5D or VAS scores 
between treatment groups after adjusting for covariates
Norum, 1996100 EQ-5D Convergent All three measures were highly correlated with each other (all 
p < 0.0001) based on Persons correlation and Mantel–Haenszel 
test
Sung et al., 
2003108
HUI3 Convergent validity
Acceptability
Significant correlations between CHQ pain and HUI pain, 
CHQ physical and HUI mobility, CHQ mental health and HUI2 
emotion. HUI utility significantly correlated with the CHQ 
physical scale but not the psychosocial scale. A total of 89% 
reported that the CHQ and HUI were easy to complete
Trudel et al., 
1998109
HUI3 Convergent validity
Known-group 
validity
Content validity
The correlations between the HUI3 utility and dimension scores 
and the other measures included are in the moderate range. The 
difference between the groups is statistically significant for the 
HUI3 emotion, pain, self-care and overall utility score. HUI3 was 
adequate as a descriptive health system but does not include 
neuropsychological or psychosocial aspects
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Study reference 
grouped by 
condition 
(author, year) Measure
Assessment 
methods Results 
Cancer survivors 
Barr et al., 
2000133
HUI3 Known-group 
validity
The hearing (p = 0.01) and speech (p = 0.02) dimensions 
significantly discriminate between the samples but no other 
dimension reaches significance
Boman et al., 
2009134
HUI3 Known-group 
validity (case–
control)
All HUI3 attributes display significant difference between 
survivors and controls (survivors better health) except emotion 
and pain. Range of significant differences between the tumour 
diagnoses and controls
Felder-Puig et al., 
2000131
HUI3 Known-group 
validity (severity)
Significant relationship between degree of severity and HUI2 
scores for the majority of groups (p < 0.05). For attributes, 
difference significant for pain and emotion
Fu et al., 2006130 HUI3 Group differences 
(other, severity)
The HUI3 score for the vision dimension was higher in the 
Hodgkin’s group compared with acute lymphoblastic leukaemia 
(p < 0.01). The difference between the emotion (p < 0.01) 
and HRQL (p < 0.05) scores are significantly different with the 
Canadian group displaying higher mean scores. As expected, 
the differences in mean single attribute scores between acute 
lymphoblastic leukaemia and Hodgkin’s disease patients were 
not statistically significant
Grant et al., 
2006135
HUI3 Group differences 
(severity)
As expected, the attribute and overall utility scores were not 
statistically different between the two diagnosis groups
Korfage et al., 
2009129
EQ-5D Known-group 
validity (case–
control)
When controlling for differences in background variables, 
neither the EQ-5D nor the majority of the SF-36 dimensions 
display significant group differences between the survivors and 
control group (only the mental health domain of the SF-36 is 
significant). The STAI score is significantly different between  
the groups
Nijdam et al., 
2008128
EQ-5D Known-group 
validity (severity)
The EQ-5D and QLQ-C30 do not differ between the treatment 
groups, providing evidence that the measures are performing in 
the same way
Nixon Speechley 
et al., 1999136
HUI3 Convergent validity Significant correlations between the HUI and CHQ across a 
range of similar dimensions
Barr et al., 
1999127
HUI2 Known-group 
validity (severity)
HUI2 can discriminate between radiotherapy treatment and 
disease status groups
Pogany et al., 
2006132
HUI3 Known-group 
validity (case–
control, severity)
HUI3 utility scores discriminate between survivors and controls. 
There are significant differences between survivors and controls 
across the HUI3 dimensions and some significant discrimination 
by treatment groups
Shimoda et al., 
2005126
HUI3 Known-group 
validity (severity)
Acceptability
Mean HUI scores significantly decreased in line with global 
health ratings for nurse and physician assessors (p < 0.02). 
For patients, the HUI3 significantly decreased (p = 0.05) but 
the HUI2 did not (p = 0.117). No assessor reported problems 
understanding and answering the questions
APR, abdominoperineal resection; CAM, complementary and alternative medicine; CPA, coloanal J-pouch anastomosis; 
ICC, intraclass correlation; KPS, Karnofsky performance score; LRA, low colorectal anastomosis; MCS, mental component 
score; MHLCS, multidimensional health locus of control scale; MMSE, mini mental state examination; PCS, physical 
component score; SRE, skeletal-related events; TEM, transanal endoscopic microsurgery; TME, total mesorectal excision.
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Appendix 11 Summary of responsiveness for 
utility measures – cancers
Study reference 
grouped by 
condition 
(author, year) Instrument 
Assessment 
methods Results 
Breast cancer 
Chang et al., 
2004143
EQ-5D and 
HUI3
Mean change over 
time between 
groups.
Correlations 
between change 
scores of HUI3 and 
condition-specific 
measures over time
Over time, HUI3 overall scores improved in the epoetin alfa 
group (mean 0.018, SD 0.024) but decreased in the standard of 
care group (mean –0.041, SD 0.254, p = 0.036). The difference 
of change score between the two groups was significant 
(p = 0.036). Emotion, ambulation and cognition of HUI3 also 
detected significant improvement in the epoetion alfa group 
compared with the standard of care group. A strong and 
significant correlation was observed between change scores 
of HUI3 and FACT-An and FACT-F scores. Less strong but 
significant correlations were observed for emotion, ambulation 
and cognation subscales of HUI3 with FACT-An and FACT-F. 
Over time, EQ-5D detected improvement in the epoetin alfa 
group: base line mean 0.71 (SD 0.22) to follow-up mean 0.78 
(SD 0.15); standard of care group: baseline mean 0.72 (SD 0.23) 
to follow-up mean 0.76 (SD 0.19). The difference of change 
scores between the two groups was not significant (p = 0.639). 
Over time, for the epoetin alfa group, EQ-VAS improved from 
62.13 at baseline to 70.05 at follow-up; for the standard of care 
group, EQ-VAS decreased from 62.88 to 60.83. The difference 
between two groups was significant (p = 0.018)
Conner-Spady 
et al., 2001139
EQ-5D ES, paired groups 
t-test; ANOVA; 
Friedman test
All ES EQ-5D over time was large, except EQ-5D index (T3–T4) 
what was 0.66. There was no significant differences in ES 
between EQ-5D and FLIC at T1–T3 and T3–T4. EQ-5D was 
consistent with other measures: significant changes in mean 
scores over time for EQ-5D, VAS, FLIC and FLIC subscales 
(physical well-being, social well-being, hardship, and nausea 
subscales). EQ-5D dimensions of mobility, self-care and usual 
activities showed significant change over time
Conner-Spady 
et al., 2005140
EQ-5D Friedman test, one-
way ANOVA to 
assess differences 
in HRQL over time
EQ-5D, FLIC and QoL VAS showed a similar pattern of change. 
They all decreased following high-dose chemotherapy and 
returned to baseline level after high-dose chemotherapy. There 
was a significant decrease in HRQL from T1 to T3 and a return 
to baseline level by T8. From T4 to T7, FLIC showed a significant 
improvement and EQ-5D and QoL VAS showed a non-significant 
improvement. The Friedman test showed significant changes 
over time for EQ-5D mobility, self-care, usual activity and anxiety 
but not for pain
Kimman et al., 
2009144
EQ-5D Correlations 
between anchor 
scores and 
measures of 
interests, SRM 
for subgroups, 
Games–Howell 
post hoc procedure 
to compare mean 
change scores 
between ‘no 
change’ subgroup 
and other 
subgroups
In the subgroup of patients with no changed global health, 
neither SRM of EQ-5D index nor EQ-VAS indicated an effect. For 
subgroups with a small deterioration or improvement, SRMs of 
EQ-5D index were too small to be considered as an effect, SRMs of 
EQ-VAS indicated a small effect. For subgroups with moderate and 
large improvements or deteriorations, SRMs indicated a moderate 
effect (> 0.5) on EQ-5D index and a large effect (> 0.8) on  
EQ-VAS. For the EQ-5D index, mean change scores of subgroups 
reporting moderate and large improvement that differed 
significantly from ‘no change’ group, the subgroups reporting 
small improvements or a small or moderate and large deterioration 
could not be differentiated from the ‘no change’ group. EQ-VAS 
differed significant between ‘no change’ and ‘moderate and large 
improvement’ and ‘moderate and large deterioration’
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Study reference 
grouped by 
condition 
(author, year) Instrument 
Assessment 
methods Results 
Breast cancer 
Polsky et al., 
2002142
HUI3 Test for change 
over time
Significant differences were found in VAS and HUI3 5 months 
after surgery. Emotion attribute of HUI3 was the only one of 
significance. Differences were non-significant 1 and 2 years 
after surgery. Choice has a short-term impact on health state 
preferences but no long-term benefits
Lovrics et al., 
2008141
HUI3 ANOVA and paired 
comparisons ES 
Significant changes over time were demonstrated (p < 0.01) 
for both measures. Both scores decrease after surgery and 
improve over time but remain below normative values at all 
postoperative time points (p < 0.01). The HUI3 multiattribute, 
pain and ambulation scores and the SF-36 PCS, BP, PF, RP, VT 
and social functioning scores all showed a large downward ES 
from intensive care to the postoperative time. By 24 months, the 
ES for these physical variables were small or trivial
Cervical cancer
Maissi et al., 
2005167
EQ-5D Mean change 
across the study 
period
Mean change on EQ-5D, General Health Questionnaire and STAI 
is small but no significance testing is reported
Whynes et al., 
2008a165
EQ-5D Regression 
predicting decrease 
in VAS scores 
between baseline 
and follow-up
VAS score decreases were significantly predicted (p < 0.01) 
by EQ-5D dimension increases (worsening health), decreases 
(improving health) and HADS increases (worsening health). 
Regression demonstrates that change over the study period for 
EQ-5D is apparent
Colon cancer
Anderson and 
Palmer, 1998119
EQ-5D OR for responses 
of EQ-5D 
dimensions 
between baseline 
and weeks 5 and 
15 over the two 
groups
ANOVA was used 
to assess RSCL in 
weeks 2, 5, 10 
and 15
At week 2, there were significant differences between Raltitrexed 
and 5-FU + LV in changes from baseline for all dimensions and 
subdimensions of the RSCL, with the exception of the psychological 
symptoms and disease categories, which fell just outside the 
significant range. At week 2, there was a highly significant 
difference in favour of Raltitrexed in four EQ-5D dimensions and 
general health question. Patients (Raltitrexed) were three times 
less likely to have problems with mobility and usual activities than 
patients in the 5-FU + LV group (OR 2.9 and p < 0.02). They were 
also at least twice as likely to have a better general health  
(OR 2.3, p < 0.001) and they were two to three times as capable 
of self-care as patients in the 5-FU + LV group, but not significantly. 
Subsequently, the differences between the two treatment groups 
diminished but there were still some statistically non-significant 
trends in favour of reltitrexed on the EQ-5D scale and in total 
symptom advantages that were maintained to week 10
Doornebosch 
et al., 2008116
EQ-5D Wilcoxon signed-
rank test and 
Mann-Witney 
U-test for change 
scores within or 
between groups. 
Spearman’s rank-
order correlation 
coefficient 
between change 
scores 
Six months after surgery, mean Faecal Incontinence Severity Index 
scores decreased significantly, depicting an improvement in faecal 
continence. Reduction of Faecal Incontinence Severity Index was 
significantly greater in patients with a tumour location within 
7 cm from the denatate line (p = 0.01) (significant correlations). 
EQ-VAS was significantly higher 6 months after TEM (p < 0.02). 
The observed change in EQ-VAS showed no correlation with the 
postoperative alterations in Faecal Incontinence Severity Index 
scores or tumour characteristics. Both pre and postoperative 
EQ-5D index scores were similar to those of the gender-age 
matched general population. The EQ-5D index was not affected 
by age and gender of the patients, surgical aspects and tumour 
characteristics. FIQL showed a significant improvement in two 
of the four domains (embarrassment and lifestyle). The domains 
of lifestyle, coping and behaviour and embarrassment were 
correlated with the Faecal Incontinence Severity Index. FIQL scores 
were not affected by age and gender of the patients and surgical 
aspects and tumour characteristics
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Study reference 
grouped by 
condition 
(author, year) Instrument 
Assessment 
methods Results 
Colon cancer
Janson et al., 
2007122
EQ-5D Mean changes of 
scores between 
groups
ANOVA analysis of change over time of the EQ-5D index 
indicated no significant differences. For EORTC QLQ-C30, 
there was a significant benefit of LCR at the 2- and 4-week 
assessments. At the 12-week assessment, a borderline 
significance was found. In role function, there was a significant 
benefit of LCR at the 2-week assessment
Sharma et al., 
2007123
EQ-5D Mean changes of 
scores before and 
after surgery
Depression measured by the HADS scale was significantly higher 
in the 6-week postdischarge measure (3.6 vs. 4.8, p < 0.05). 
There was no statistically significant difference in the other 
scores
Gastric (and related) cancer
Homs et al., 
2004149
EQ-5D Mean change Stent group shown to have significantly reduced QoL on EORTC 
role/emotional/cognitive/social scales (p < 0.05). The EQ-5D 
and VAS show a decrease but the scores for each group are not 
significantly different. Limited evidence for the responsiveness of 
EQ-5D at a lower level than selected dimensions of the condition 
specific EORTC
McMillan et al., 
1999153
EQ-5D Mean change EQ-5D index demonstrating significant improvement in the 
intervention arm at follow-up. EQ-5D is responding to change in 
the intervention group
Verschuur et al., 
2009154
EQ-5D Mean change Both EQ-5D and EORTC display mean change in the expected 
direction over time, with both measures displaying improvement 
at follow-up. This provides some evidence for the responsiveness 
of EQ-5D in gastric cancer
Hodgkin’s lymphoma 
Klaassen et al., 
2010185
HUI3 t-Tests, ES and 
area under 
receiver operating 
characteristic curve
All measures showed a significant change in summary scores 
between Time 1 and Time 4. All of the ESs were large and 
clinically relevant. The HUI had negligible to small ESs between 
Time 2–3 and Time 3–4, whereas the PedsQl, Lanksy Play-
Performance scale and VAS had moderate to large ESs
Kidney/renal cancer
Castellano et al., 
2009171
EQ-5D ES/significance 
level
The difference between the treatment groups is statistically 
significant overall, demonstrating that the EQ-5D index and VAS 
respond to treatment effects across the study period. However, 
the ESs are in the range defined as small
Cella et al., 
2008169
EQ-5D ES The difference between the treatment groups is statistically 
significant overall, demonstrating that the EQ-5D index and VAS 
respond to treatment effects across the study period. However, 
the ESs are in the range defined as small
Cella et al., 
2010168
EQ-5D No formal 
statistical tests
The EQ-5D and VAS results indicate that the measures respond 
to change in treatment groups but no formal tests have been 
conducted
Sternberg et al., 
2010193
EQ-5D No formal 
statistical tests
It is not clear whether QoL differences between the treatment 
groups were not picked up by the instruments because they 
were not present or because of the lack of responsiveness of the 
questionnaires
Yang et al., 
2010170
EQ-5D No formal 
statistical tests
There is some evidence that EQ-5D and VAS are able to 
distinguish between treatments over time but no formal tests 
have been conducted
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Study reference 
grouped by 
condition 
(author, year) Instrument 
Assessment 
methods Results 
Leukaemia 
Barr et al., 
1997174
HUI2 Change over the 
study period
The HUI2 proves to be responsive across a range of indicators 
and in comparison to four temporary health states for which 
utility scores are available
Hahn et al., 
2003176
EQ-5D Mean change over 
the study period
EQ-5D is picking up differences in mean change over time 
between the treatment groups. At three of four follow-up time 
points, the reduction in the EQ-5D score reflects the proportion 
of the sample that is showing a clinically relevant decline 
on the trial outcome index. This provides evidence for the 
responsiveness of EQ-5D
Liver metastases 
Langenhoff et al., 
2006180
EQ-5D ES of change over 
the study period
Both the EORTC and EQ-5D are responding over time and 
demonstrating sensitivity to change in HRQL following 
different surgical procedures across three groups. The EORTC 
is responding to improvement following surgery and also a 
subsequent change in two groups who receive chemotherapy. 
However, the EQ-5D is not picking up this change as clearly
Mendez Romero 
et al., 2008172
EQ-5D Statistical 
significance 
between baseline 
scores and follow-
up scores 
The EQ-5D and EORTC findings are consistent as, overall, neither 
measure demonstrates significant differences in responsiveness 
apart from one EORTC dimension at one of the three follow-up 
points
Krabbe et al., 
2004179
EQ-5D ES of change over 
the study period
ESs of comparable magnitude across the EQ-5D index, 
dimensions, and EORTC scores. Evidence for responsiveness of 
the EQ-5D/EORTC in comparison to each other
Lymphoma 
Doorduijn et al., 
2005188
EQ-5D Mean change over 
study period
Most EQ-5D mean change scores are not significant. Some 
EORTC dimensions are significant. EORTC may be more 
responsive than EQ-5D
Van Agthoven 
et al., 2001177
EQ-5D Mean change over 
study period
EQ-5D index scores decrease after treatment and then improve 
after discharge but significance not reported. Limited evidence 
for EQ-5D responsiveness
Witzens-Harig 
et al., 2009192
EQ-5D Mean change over 
study period
Change within the intervention group over the study period is 
being captured by both the EQ-5D and EORTC. Evidence for the 
responsiveness of both measures
ML/AML
Banks et al., 
2008178
HUI2/HUI3 Mean change in 
proxy report
The HUI displays a low level of change over the study period in 
comparison to the PedsQL but change is at a similar level to  
the CHQ
MM
Uyl-de-Groot 
et al., 2005124
EQ-5D Mean change over 
study period
Significant mean change for EQ-5D index score and a range of 
EORTC QLQ-C30 dimensions at selected follow-up time points. 
There is some evidence for the responsiveness of EQ-5D in 
comparison to the condition specific EORTC QLQ-C30, but this is 
not consistent across time points
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Study reference 
grouped by 
condition 
(author, year) Instrument 
Assessment 
methods Results 
Prostate cancer 
Krahn et al., 
2007160
EQ-5D/HUI3 Standardized ES, 
standardized mean 
response
Mean change in 
utility
Area under 
receiver operator 
curve
Differential 
responsiveness
Internal responsiveness: generic instruments were less responsive 
to treatments as shown by smaller effects compared with 
disease specific instruments
External responsiveness: utility measures – generic and disease 
specific – were able to discriminate between those whose 
health changed and those whose health did not. EQ-5D most 
consistently reported a high area under receiver operator curve 
Sullivan et al., 
2007157
EQ-5D Mean change 
across study period
Patients underwent rapid deterioration in FACT-P, EQ-5D and 
10 out of 14 EORTC domains over the 9-month follow-up. This 
provides some evidence of responsiveness of the instruments
Weinfurt et al., 
2005159
EQ-5D ES The ESs for radiation to bone are larger in comparison. There 
is evidence to suggest that for radiation to bone SRE, ESs are 
significant for the total FACT-G score and the EQ-5D utility score. 
For pathological fracture type SRE, the ES is significant for the 
EQ-5D utility score
Spinal metastases 
Falicov et al., 
2006101
HUI3 (pain 
dimension)
Mean change over 
study period
The HUI3 pain dimension and EORTC QLQ-C30 significantly 
respond to changes in QoL/pain over the study period. 
Responsiveness of one dimension of the HUI3 is good
Non-specific cancer
Mantovani et al., 
2004111
EQ-5D Change over time 
compared with 
external measure 
(up to 4 months)
EQ-5D shows a trend of improvement over time, with slight 
reduction in utility between months 2 and 4. The improvement 
at 4 months was statistically significant compared with baseline 
(p = 0.029). EQ-5D mean (SD): baseline: 0.33 (0.4), 1 month: 
0.45 (0.3), 2 month: 0.59 (0.3) and 4 month: 0.54 (0.3). The 
EORTC QLQ-C30, EQ-VAS and MFSI-SF fatigue showed similar 
trends in scores over time and were all statistically significant at 
months 1 and 2, but not at month 4. MFSI-SF vigour showed a 
small non-statistically significant improvement at all time points
Vaghela et al., 
2007112
EQ-5D Change over time 
compared with 
external measure 
(up to 6 weeks)
Statistically significant improvements were found on the first 
two stated concerns of MYCaW, the overall MYCAW profile and 
the EQ-VAS but not on the well-being measure. A statistically 
significant improvement was only seen on the anxiety and 
depression dimension of EQ-5D
Ravasco et al., 
2003104
EQ-5D EQ-5D domains 
and VAS scores 
presented 
before and after 
radiotherapy
All dimensions improved following radiotherapy (except for 
pain and discomfort) but this was only statistically significant 
for high-risk patients (p = 0.004). Pain worsened; however, 
severe symptoms also worsened (anorexia, diarrhoea, dysphagia, 
odynophagia). Mobility, usual activities and anxiety/depression 
were associated with presence of malnutrition and reduced 
energy intake. The VAS scores showed an increase following 
radiotherapy in all groups, but this was only statistically 
significant for high-risk patients (p = 0.001)
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Study reference 
grouped by 
condition 
(author, year) Instrument 
Assessment 
methods Results 
Non-specific cancer
Weze et al., 
2004110
EQ-5D EQ-5D and VAS 
data presented 
before and after 
therapy
Statistically significant improvement on the anxiety/depression 
dimension (p = 0.005) and borderline on the pain dimension 
(p = 0.058). No changes on the other dimensions
Mean EQ-VAS score increased by 12.5 (p = 0.008). Other 
improvements in VAS scores that were statistically significant 
(p < 0.05) were: stress, fear, pain, sleep, relaxation and coping. 
Non-statistically significant VAS scores included: panic, anger, 
disability and immobility
Kim et al., 
2008113
EQ-5D EQ-5D domains 
(summed) and VAS 
scores presented 
before and after 
mirtazapine
Statistically significant differences found in sum of levels found 
on pain/discomfort and anxiety/depression dimensions after 
treatment. No differences were found for mobility or self-care. 
Usual activities: mean 2.1/2.0, pain/discomfort: mean 2.1/1.9, 
anxiety/depression: mean 2.3/1.8. Statistically significant 
differences found on all other outcome measures
BP, bodily pain; FACT-P, Functional Assessment of Cancer Therapy – Prostate Scale; FIQL, Faecal Incontinence QoL; 
LCR, laparoscopic colon resection; MFSI-SF, Multidimensional Fatigue Symptom Inventory-Short Form; OR, odds ratio; 
PCS, physical component score; PF, physical functioning; RP, role physical; SRE, skeletal-related events; SRM, standardised 
response mean; TEM, transanal endoscopic microsurgery; VT, vitality. 
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Appendix 12 Results from mapping from 
European Organization for Research and Treatment 
Quality-of-Life Questionnaire Core 30 to EQ-5D
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 TABLE 46 Spearman’s rank-order correlation coefficients among EORTC QLQ-C30 summary scales for all data
EORTC 
QLQ-C30 
scale pf rf ef cf sf fa nv pa ql dy sl ap co di fi
pf 1
rf 0.7470** 1
ef 0.3412** 0.3938** 1
cf 0.3861** 0.3819** 0.3835** 1
sf 0.5824** 0.6450** 0.4251** 0.4023** 1
fa –0.6839** –0.7023** –0.5018** –0.4971** –0.5813** 1
nv –0.2811** –0.2758** –0.2867** –0.2739** –0.2683** 0.3319** 1
pa –0.6127** –0.6454** –0.4177** –0.3487** –0.4871** 0.5747** 0.2698** 1
ql 0.6266** 0.6387** 0.4268** 0.3199** 0.5147** –0.6237** –0.2731** –0.6021** 1
dy –0.3396** –0.2875** –0.2370** –0.2550** –0.2601** 0.4104** 0.2634** 0.1976** –0.2590** 1
sl –0.2082** –0.2907** –0.4069** –0.2848** –0.2550** 0.3817** 0.1876** 0.2954** –0.2880** 0.2412** 1
ap –0.4350** –0.4474** –0.3992** –0.3526** –0.4321** 0.5442** 0.4294** 0.4017** –0.4769** 0.2583** 0.2730** 1
co –0.3091** –0.3042** –0.2821** –0.2707** –0.2780** 0.3218** 0.2353** 0.3091** –0.3224** 0.1519** 0.2181** 0.3265** 1
di –0.0731 –0.0825 –0.1332** –0.1435** –0.1044** 0.1041** 0.2191** 0.1017** –0.0669 0.1570** 0.1109** 0.1665** 0.0255 1
fi –0.2785** –0.2588** –0.2365** –0.2459** –0.3745** 0.2260** 0.0975** 0.2088** –0.2134** 0.1335** 0.1760** 0.2004** 0.1410** 0.0643 1
ap, appetite loss; cf, cognitive functioning; co, constipation; di, diarrhoea; dy, dyspnoea; ef, emotional functioning; fa, fatigue; fi, financial difficulties; nv, nausea and vomiting; pa, pain; 
pf, physical functioning; ql, QoL; rf, role functioning; sf, social functioning; sl, sleep disturbance.
** p < 0.05.
Correlations > |0.5| are highlighted.
APPENDIX 12
190
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 47 Spearman’s rank-order correlation coefficients among EORTC QLQ-C30 summary scales
Data set
EQ-5D index, 
dimension or 
term pf rf ef cf sf fa
All EQ-5D 0.7001** 0.6875** 0.4862** 0.3935** 0.5649** –0.6245**
eq1 –0.6923** –0.5845** –0.2344** –0.3116** –0.4272** 0.5121**
eq2 –0.5806** –0.5403** –0.2311** –0.2822** –0.4281** 0.3795**
eq3 –0.7086** –0.7218** –0.2803** –0.3369** –0.5932** 0.6011**
eq4 –0.4708** –0.4845** –0.3066** –0.2527** –0.3704** 0.4397**
eq5 –0.3111** –0.2963** –0.6674** –0.3159** –0.3213** 0.3747**
N3 –0.5324** –0.5391** –0.3821** –0.3037** –0.4581** 0.4729**
Breast EQ-5D 0.4980** 0.3450** 0.4236** 0.3547** 0.3270** –0.4447**
eq1 –0.6431** –0.4769** –0.0342 –0.1702 –0.253 0.4321**
eq2 –0.2564 –0.1135 –0.0847 –0.0992 –0.2008 0.1279
eq3 –0.5227** –0.6129** –0.0626 –0.2992** –0.5064** 0.5070**
eq4 –0.3105** –0.1578 –0.1608 –0.2075 –0.086 0.2031
eq5 –0.1705 –0.1129 –0.6216** –0.2497 –0.2789** 0.3022**
N3 –0.1076 –0.1486 –0.3386** –0.3262** –0.22 0.2721**
Lung EQ-5D 0.5790** 0.6098** 0.3810** 0.3116** 0.5209** –0.6029**
eq1 –0.5609** –0.3125** –0.0925 –0.1678 –0.3241** 0.3835**
eq2 –0.4686** –0.2664** 0.0243 –0.1864 –0.2855** 0.3173**
eq3 –0.5586** –0.5831** –0.2364 –0.1939 –0.5133** 0.5753**
eq4 –0.2386 –0.4029** –0.2255 –0.2113 –0.2979** 0.3649**
eq5 –0.2810** –0.3519** –0.5505** –0.1972 –0.2812** 0.2655**
N3 –0.2269 –0.3667** –0.2227 –0.0684 –0.226 0.3057**
Multiple EQ-5D 0.7287** 0.7206** 0.4979** 0.4304** 0.6214** –0.6472**
Myeloma eq1 –0.6890** –0.6006** –0.2592** –0.3648** –0.4745** 0.5275**
eq2 –0.6050** –0.5817** –0.2490** –0.3223** –0.4738** 0.3974**
eq3 –0.7310** –0.7344** –0.2994** –0.3691** –0.6232** 0.6028**
eq4 –0.4946** –0.5097** –0.3247** –0.2723** –0.4242** 0.4674**
eq5 –0.3191** –0.2932** –0.6776** –0.3441** –0.3315** 0.3933**
N3 –0.5907** –0.5796** –0.3932** –0.3381** –0.5090** 0.5062**
ap, appetite loss; cf, cognitive functioning; co, constipation; di, diarrhoea; dy, dyspnoea; ef, emotional functioning;  
eq1, EQ-5D mobility; eq2, EQ-5D self-care; eq3, EQ-5D usual activities; eq4, EQ-5D pain/discomfort; eq5, EQ-5D anxiety/
depression; fa, fatigue; fi, financial difficulties; N3, EQ-5D N3 term; nv, nausea and vomiting; pa, pain; pf, physical 
functioning; ql, QoL; rf, role functioning; sf, social functioning; sl, sleep disturbance.
** p < 0.05.
Correlations > |0.5| are highlighted.
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nv pa ql dy sl ap co di fi
–0.2709** –0.7348** 0.6687** –0.2340** –0.3518** –0.4326** –0.3302** –0.0726 –0.2713**
0.1935** 0.5602** –0.5436** 0.2419** 0.1920** 0.3037** 0.2402** 0.0471 0.1653**
0.1949** 0.5044** –0.4716** 0.1296** 0.1560** 0.3006** 0.2274** 0.0598 0.2225**
0.2447** 0.5869** –0.5883** 0.2170** 0.2081** 0.3723** 0.2956** 0.0423 0.2582**
0.1865** 0.7244** –0.4790** 0.1815** 0.2983** 0.2762** 0.2664** 0.0597 0.2016**
0.1887** 0.3227** –0.3991** 0.1758** 0.2831** 0.3408** 0.2388** 0.0876 0.2222**
0.2225** 0.5172** –0.5310** 0.1326** 0.2628** 0.3844** 0.2920** 0.0705 0.2060**
–0.2945** –0.6974** 0.4318** –0.3227** –0.3391** –0.3290** –0.1919 –0.2701** –0.0658
0.3358** 0.5192** –0.3258** 0.3859** 0.1322 0.2971** 0.1464 0.3179** –0.0213
0.2534 0.2285 –0.1047 0.1692 0.0278 0.2273 0.0559 0.0394 0.0515
0.3145** 0.5480** –0.4500** 0.3725** 0.0818 0.3299** 0.2669** 0.2571** 0.2187
0.2555 0.6696** –0.2656** 0.2933** 0.2975** 0.0842 0.0176 0.1387 0.0123
0.0677 0.2375 –0.3017** 0.0633 0.1518 0.2932** 0.2301 0.1487 0.0695
0.0597 0.15 –0.1187 0.0538 0.3189** 0.2735** 0.2163 0.1999 0.0621
–0.2733** –0.6294** 0.5297** –0.2453 –0.3190** –0.4577** –0.2479 0.048 –0.2735**
0.0848 0.3159** –0.3370** 0.3334** 0.2034 0.2425 0.2191 –0.0549 0.1297
0.1449 0.1538 –0.2484 0.0325 –0.1316 0.2624** 0.1356 –0.0253 –0.0501
0.1884 0.1954 –0.4579** 0.2860** 0.1463 0.4168** 0.2404 0.0927 0.1667
0.1963 0.7295** –0.2994** 0.1229 0.2849** 0.2675** 0.1911 –0.0071 0.2718**
0.2069 0.2691** –0.3799** 0.0342 0.2557 0.3276** 0.1185 –0.0257 0.2792**
0.0349 0.2397 –0.1911 –0.0021 0.2256 0.1989 –0.082 –0.0266 0.01
–0.3320** –0.7282** 0.6833** –0.2627** –0.3819** –0.4598** –0.3398** –0.1187** –0.3630**
0.2420** 0.5389** –0.5436** 0.2388** 0.2196** 0.3099** 0.2223** 0.0663 0.2485**
0.2454** 0.5139** –0.4756** 0.1639** 0.2074** 0.3165** 0.2264** 0.1197** 0.3179**
0.2824** 0.6032** –0.5897** 0.1951** 0.2435** 0.3646** 0.2819** 0.039 0.3171**
0.2122** 0.7095** –0.5071** 0.1944** 0.3164** 0.3030** 0.2887** 0.0959 0.2574**
0.2331** 0.3157** –0.3849** 0.2397** 0.3158** 0.3522** 0.2470** 0.1223** 0.2687**
0.2995** 0.5509** –0.5752** 0.1752** 0.2817** 0.4238** 0.3199** 0.1096** 0.2820**
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TABLE 48 European Organization for Research and Treatment Quality-of-Life Questionnaire Core 30 mean observed and predicted EQ-5D values per model and summary 
model performance: OLS
Summary statistics and 
model performance tests n
Observed 
values OLS 2 OLS 3 OLS 4 OLS 6 OLS 7 OLS 8
Mean (SD) 771 0.5793 
(0.3423)
0.5793 (0.2797) 0.5793 (0.2792) 0.5793 (0.2830) 0.5793 (0.2863) 0.5793 (0.2844) 0.5793 (0.2866)
Median 0.6910 0.6281 0.6244 0.6451 0.6498 0.6557 0.6502
Range –0.5940–1 –0.1846–1.02 –0.1915–1.031 –0.3712–0.9419 –0.4078–0.9713 –0.3670–0.9430 –0.4046–0.9714
R2 0.668 0.665 0.684 0.700 0.691 0.701
Adjusted R2 0.662 0.662 0.681 0.689 0.683 0.690
AIC –286 –294 –340 –338 –330 –339
BIC –216 –257 –307 –207 –237 –205
Ramsey RESET F
3,753
 = 12.57, 
p = 0.000
F
3,761
 = 13.09, 
p = 0.000
F
3,761
  = 1.56, 
p = 0.198
F
3,737
 = 1.00, 
p = 0.3945
F
3,736
 = 0.58, 
p = 0.6310
F
3,736
 = 0.88, 
p = 0.449
MAE 0.149 0.151 0.143 0.139 0.142 0.139
Shrinkage 0.836 0.996 0.997 1.060 1.072 1.042
Health status
(EORTC QLQ-C30 item 29) n Mean Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE
1 (very poor) 42 –0.0057 0.1213 0.221 0.1212 0.224 0.0638 0.201 0.0636 0.206 0.0685 0.210 0.0642 0.205
2 53 0.1763 0.2571 0.193 0.2631 0.194 0.2569 0.191 0.2471 0.181 0.2590 0.194 0.2470 0.179
3 144 0.4286 0.4403 0.193 0.4410 0.195 0.4577 0.189 0.4650 0.181 0.4684 0.183 0.4629 0.182
4 226 0.6220 0.5685 0.154 0.5661 0.155 0.5839 0.145 0.5829 0.137 0.5794 0.141 0.5823 0.138
5 186 0.7180 0.7145 0.112 0.7158 0.113 0.7179 0.108 0.7170 0.109 0.7147 0.109 0.7176 0.109
6 94 0.8321 0.8494 0.110 0.8470 0.109 0.8165 0.102 0.8145 0.100 0.8148 0.103 0.8181 0.098
7 (excellent) 26 0.9029 0.8958 0.073 0.9008 0.075 0.8538 0.086 0.8553 0.081 0.8504 0.080 0.8546 0.080
ANOVA F
6
 = 97, 
p = 0.000
F
6
 = 126,  
p = 0.000
F
6
 = 126,  
p = 0.000
F
6
 = 118,  
p = 0.000
F
6
 = 112,  
p = 0.000
F
6
 = 109,  
p = 0.000
F
6
 = 114,  
p = 0.000
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TABLE 49 Best-fitting EORTC QLQ-C30 OLS model
OLS model 8
Domain Item Item level Regression coefficient (SE)
Physical functioning Trouble strenuous activities Not at all (base) F2
3
 = 6.77, p = 0.080
A little –0.0460** (0.018)
Quite a bit –0.0375* (0.021)
Very much –0.0326 (0.029)
Short walk Not at all (base) F2
3
 = 22.92, p = 0.000
A little –0.0551*** (0.021)
Quite a bit –0.0975*** (0.033)
Very much –0.2160*** (0.047)
Need help eating/dressing Not at all (base) F2
3
 = 42.39, p = 0.000
A little –0.1199*** (0.027)
Quite a bit –0.2516*** (0.051)
Very much –0.3118*** (0.069)
Role functioning Limited work/housework Not at all (base) F2
3
 = 21.34, p = 0.000
A little –0.0245 (0.017)
Quite a bit –0.0938*** (0.027)
Very much –0.1546*** (0.037)
Emotional functioning Irritable Not at all (base) F2
3
 = 9.47, p = 0.024
A little –0.0442*** (0.016)
Quite a bit –0.0416 (0.030)
Very much –0.1086* (0.062)
Depressed Not at all (base) F2
3
 = 22.03, p = 0.000
A little –0.0517*** (0.016)
Quite a bit –0.0839*** (0.029)
Very much –0.1601*** (0.046)
Social functioning Not at all (base) F2
3
 = 7.74, p = 0.052
A little –0.0317* (0.017)
Quite a bit –0.0140 (0.025)
Very much –0.0765** (0.034)
Pain Pain Not at all (base) F2
3
 = 86.11, p = 0.000
A little –0.0574*** (0.016)
Quite a bit –0.1473*** (0.022)
Very much –0.2958*** (0.035)
Constipation Constipation Not at all (base) F2
3
 = 8.85, p = 0.031
A little –0.0150 (0.016)
Quite a bit –0.0753*** (0.028)
Very much 0.0244 (0.038)
continued
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TABLE 49 Best-fitting EORTC QLQ-C30 OLS model (continued )
OLS model 8
Domain Item Item level Regression coefficient (SE)
Age (years) F2
1
 = 3.98, p = 0.046
–0.0014** (0.001)
Constant 1.0458*** (0.048)
Observations 771
R2 0.701
Adjusted R2 0.690
MAE 0.139
AIC –339
BIC –205
Ramsey RESET F
3,736
 = 0.88, p = 0.449
  * Statistically significant at the 10% level.
 ** Statistically significant at the 5% level.
*** Statistically significant at the 1% level.
FIGURE 12 Summary of performance of all OLS models.
– 0.6
– 0.4
– 0.2
0.0
0.2
0.4
0.6
0.8
1.0
– 0.6 – 0.4 – 0.2 0.0 0.2 0.4 0.6 0.8 1.0
EQ-5D mean observed
EQ-5D mean (OLS model 2)
EQ-5D mean (OLS model 3)
EQ-5D mean (OLS model 4)
EQ-5D mean (OLS model 6)
EQ-5D mean (OLS model 7)
EQ-5D mean (OLS model 8)
EQ-5D mean observed
E
Q
-5
D
 m
e
a
n
 p
re
d
ic
te
d
D
O
I: 1
0
.3
3
1
0
/h
ta
1
8
0
9
0
 
H
E
A
LT
H
 T
E
C
H
N
O
L
O
G
Y
 A
S
S
E
S
S
M
E
N
T
 2
0
1
4
 
V
O
L
. 
1
8
 
N
O
. 
9
1
9
5
©
 Q
u
e
e
n
’s P
rin
te
r a
n
d
 C
o
n
tro
lle
r o
f H
M
S
O
 2
0
1
4
. T
h
is w
o
rk
 w
a
s p
ro
d
u
ce
d
 b
y Lo
n
g
w
o
rth
 e
t a
l. u
n
d
e
r th
e
 te
rm
s o
f a
 co
m
m
issio
n
in
g
 co
n
tra
ct issu
e
d
 b
y th
e
 S
e
cre
ta
ry o
f S
ta
te
 fo
r  
H
e
a
lth
. T
h
is issu
e
 m
a
y b
e
 fre
e
ly re
p
ro
d
u
ce
d
 fo
r th
e
 p
u
rp
o
se
s o
f p
riva
te
 re
se
a
rch
 a
n
d
 stu
d
y a
n
d
 e
xtra
cts (o
r in
d
e
e
d
, th
e
 fu
ll re
p
o
rt) m
a
y b
e
 in
clu
d
e
d
 in
 p
ro
fe
ssio
n
a
l jo
u
rn
a
ls 
p
ro
vid
e
d
 th
a
t su
ita
b
le
 a
ck
n
o
w
le
d
g
e
m
e
n
t is m
a
d
e
 a
n
d
 th
e
 re
p
ro
d
u
ctio
n
 is n
o
t a
sso
cia
te
d
 w
ith
 a
n
y fo
rm
 o
f a
d
ve
rtisin
g
. A
p
p
lica
tio
n
s fo
r co
m
m
e
rcia
l re
p
ro
d
u
ctio
n
 sh
o
u
ld
 b
e
 
a
d
d
re
sse
d
 to
: N
IH
R
 Jo
u
rn
a
ls Lib
ra
ry, N
a
tio
n
a
l In
stitu
te
 fo
r H
e
a
lth
 R
e
se
a
rch
, E
va
lu
a
tio
n
, Tria
ls a
n
d
 S
tu
d
ie
s C
o
o
rd
in
a
tin
g
 C
e
n
tre
, A
lp
h
a
 H
o
u
se
, U
n
ive
rsity o
f S
o
u
th
a
m
p
to
n
 S
cie
n
ce
 
P
a
rk
, S
o
u
th
a
m
p
to
n
 S
O
1
6
 7
N
S
, U
K
.
TABLE 50 European Organization for Research and Treatment Quality-of-Life Questionnaire Core 30 mean observed and predicted EQ-5D values per model and summary 
model performance: tobit
Summary 
statistics 
and model 
performance 
tests n Observed
Tobit model 2
All dimensions
Tobit model 2
Significant 
dimensions
Tobit model 2
Significant and 
squared terms
Tobit model 2
Significant items
Tobit model 2
Significant items 
collapsed
Tobit model 2
Significant items +  
age
Mean (SD) 771 0.5793 (0.3423) 0.5769 (0.2804) 0.5768 (0.2797) 0.5786 (0.2850) 0.5792 (0.2887) 0.5790 (0.2866) 0.5792 (0.2891)
Median 0.6910 0.6419 0.6393 0.6570 0.6551 0.6581 0.6517 
Range –0.5940–1 –0.2201–0.94 –0.2297–0.948 –0.3574–0.9143 –0.3971–0.9408 –0.3622–0.9286 –0.3937–0.9463
Pseudo R2 1.024 1.019 1.044 1.094 1.066 1.101
Log-likelihood 9.83 7.53 17.92 63.57 26.53 40.66
AIC 12 3 –19 –18 –11 –21
BIC 87 45 17 117 87 118
MAE 0.147 0.148 0.143 0.139 0.142 0.139
Sigma 0.214 0.215 0.210 0.197 0.208 0.204
Shrinkage 0.921 0.999 0.989 1.04 1.06 1.02
Health status 
(EORTC 
QLQ-C30  
item 29) n Mean Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE
1 (very poor) 42 –0.0057 0.1021 0.211 0.1014 0.213 0.0578 0.198 0.0631 0.204 0.0676 0.209 0.0638 0.203
2 53 0.1763 0.2476 0.188 0.2534 0.189 0.2498 0.188 0.2433 0.179 0.2551 0.193 0.2433 0.177
3 144 0.4286 0.4418 0.191 0.4423 0.193 0.4555 0.189 0.4630 0.181 0.4664 0.183 0.4602 0.183
4 226 0.6220 0.5737 0.152 0.5715 0.153 0.5851 0.146 0.5821 0.138 0.5784 0.141 0.5816 0.139
5 186 0.7180 0.7163 0.108 0.7172 0.110 0.7201 0.107 0.7198 0.108 0.7174 0.108 0.7205 0.109
6 94 0.8321 0.8327 0.110 0.8304 0.110 0.8154 0.105 0.8158 0.101 0.8154 0.103 0.8195 0.099
7 (excellent) 26 0.9029 0.8693 0.083 0.8718 0.085 0.8491 0.091 0.8548 0.082 0.8498 0.083 0.8546 0.081
ANOVA F
6
 = 97, 
p = 0.000
F
6
 = 124,  
p = 0.000
F
6
 = 123,  
p = 0.000
F
6
 = 119,  
p = 0.000
F
6
 = 112,  
p = 0.000
F
6
 = 109,  
p = 0.000
F
6
 = 113,  
p = 0.000
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TABLE 51 European Organization for Research and Treatment Quality-of-Life Questionnaire Core 30 best-fitting 
tobit model
Domain Item Item level
Tobit model 8
Regression coefficient (SE)
Physical Trouble strenuous activities Not at all (base) F2
3
 = 8.22 p = 0.042
A little –0.0675*** (0.024)
Quite a bit –0.0581** (0.026)
Very much –0.0549* (0.033)
Short walk Not at all (base) F2
3
 = 23.65 p = 0.000
A little –0.0607*** (0.021)
Quite a bit –0.0974*** (0.034)
Very much –0.2215*** (0.048)
Need help eating/dressing Not at all (base) F2
3
 = 42.40 p = 0.000
A little –0.1158*** (0.027)
Quite a bit –0.2477*** (0.051)
Very much –0.3096*** (0.069)
Role Limited work/housework Not at all (base) F2
3
 = 22.72 p = 0.000
A little –0.0344* (0.021)
Quite a bit –0.1048*** (0.028)
Very much –0.1649*** (0.038)
Emotional Irritable Not at all (base) F2
3
 = 10.46 p = 0.012
A little –0.0519*** (0.018)
Quite a bit –0.0481 (0.032)
Very much –0.1212* (0.067)
Depressed Not at all (base) F2
3
 = 23.28 p = 0.000
A little –0.0629*** (0.017)
Quite a bit –0.0921*** (0.030)
Very much –0.1683*** (0.047)
Social functioning Interfered social activities Not at all (base) F2
3
 = 9.71 p = 0.021
A little –0.0435** (0.018)
Quite a bit –0.0211 (0.026)
Very much –0.0849** (0.035)
Pain Pain Not at all (base) F2
3
 = 101.35 p = 0.000
A little –0.0896*** (0.020)
Quite a bit –0.1788*** (0.025)
Very much –0.3252*** (0.035)
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TABLE 51 European Organization for Research and Treatment Quality-of-Life Questionnaire Core 30 best-fitting 
tobit model (continued )
Domain Item Item level
Tobit model 8
Regression coefficient (SE)
Constipation Been constipated Not at all (base) F2
3
 = 8.59, p = 0.035
A little –0.0165 (0.018)
Quite a bit –0.0785*** (0.029)
Very much 0.0209 (0.039)
Age (years) F2
1
 = 5.50, p = 0.019
–0.0020** (0.001)
Constant 1.1677*** (0.061)
Observations 771
Sigma 0.204
Pseudo R2 1.101
MAE 0.139
AIC –21
BIC 118
  * Statistically significant at the 10% level.
 ** Statistically significant at the 5% level.
*** Statistically significant at the 1% level.
Linear predictions using the above predictions need to be adjusted to take into account upper and lower limits.
FIGURE 13 Summary of performance of all tobit models.
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TABLE 52 European Organization for Research and Treatment Quality-of-Life Questionnaire Core 30 mean observed and predicted EQ-5D values per model and summary 
model performance: TPM (continued )
Summary statistics 
and model 
performance tests n
Observed 
values
TPM model 2 TPM model 3 TPM model 4 TPM model 6 TPM model 7 TPM model 8
All dimensions
Significant 
dimensions
Significant and 
squared terms Collapsed items
Significant 
collapsed items
Significant 
collapsed  
items + age
Mean (SD) 771 0.5793 
(0.3423)
0.6102  
(0.3025)
0.6108  
(0.3021)
0.6066  
(0.2994)
0.6073  
(0.2987)
0.6074  
(0.2985)
0.6066  
(0.2997)
Median 0.6910 0.6788 0.6851 0.6797 0.6897 0.6892 0.6892
Range –0.5940–1 –0.2463–
0.9896
–0.2636–
0.9889
–0.3997–
0.9731
–0.3915–
0.9747
–0.4109–
0.9744
–0.3936–
0.9898
Part 1 Part 2 Part 1 Part 2 Part 1 Part 2 Part 1 Part 2 Part 1 Part 2 Part 1 Part 2
Pseudo R2 0.437 0.411 0.411 0.376 0.376 0.406
AIC 334 –369 326 –379 326 –384 351 –390 351 –390 336
BIC 403 –294 344 –341 344 –356 383 –283 383 –287 373
Model goodness of fit F2
753
 = 421,
p = 1.000
F2
422
 = 237,
p = 1.000
F2
422
 = 237,
p = 1.000
F2
51
 = 79,
p = 0.008
F2
51
 = 79,
p = 0.008
F2
429
 = 519,
p = 0.002
Log likelihood –151.85 200.25 –158.76 197.27 –158.76 198.17 –168.38 217.86 –168.38 216.83 –160.14 217.86
Sigma 0.232 0.234 0.226 0.216 0.217 0.216
MAE 0.147 0.150 0.146 0.140 0.140 0.140
Shrinkage 0.920 0.923 0.936 0.942 0.943 0.940
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Summary statistics 
and model 
performance tests n
Observed 
values
TPM model 2 TPM model 3 TPM model 4 TPM model 6 TPM model 7 TPM model 8
All dimensions
Significant 
dimensions
Significant and 
squared terms Collapsed items
Significant 
collapsed items
Significant 
collapsed  
items + age
Health status (EORTC 
QLQ-C30 item 29) n Mean Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE
1 (very poor) 42 –0.0057 0.0996 0.203 0.0992 0.207 0.0603 0.207 0.0675 0.196 0.0663 0.200 0.0649 0.195
2 53 0.1763 0.2562 0.186 0.2652 0.196 0.2666 0.202 0.2689 0.186 0.2649 0.185 0.2670 0.185
3 144 0.4286 0.4637 0.192 0.4655 0.195 0.4824 0.193 0.4835 0.186 0.4838 0.186 0.4808 0.184
4 226 0.6220 0.6071 0.152 0.6069 0.153 0.6103 0.145 0.6102 0.141 0.6111 0.140 0.6091 0.141
5 186 0.7180 0.7605 0.112 0.7607 0.114 0.7514 0.113 0.7565 0.107 0.7567 0.107 0.7566 0.107
6 94 0.8321 0.8855 0.116 0.8842 0.115 0.8577 0.102 0.8473 0.106 0.8475 0.106 0.8511 0.104
7 (excellent) 26 0.9029 0.9234 0.065 0.9203 0.067 0.8928 0.072 0.8934 0.061 0.8939 0.061 0.8925 0.060
ANOVA F
6
 = 97, 
p = 0.000
F
6
 = 123, 
p = 0.000
F
6
 = 120, 
p = 0.000
F
6
 = 116, 
p = 0.000
F
6
 = 112, 
p = 0.000
F
6
 = 114, 
p = 0.000
F
6
 = 114, 
p = 0.000
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TABLE 53 European Organization for Research and Treatment Quality-of-Life Questionnaire Core 30 TPM 
best-fitting model
TPM model 8 part 1 TPM model 8 part 2
Domain Item Item level Regression coefficient (SE) Regression coefficient (SE)
Logistic Truncated regression
Physical Strenuous activity Not at all (base) –0.9099*** (0.326)
A little
Quite a bit
Very much
Short walk Not at all (base) F2
3
 = 31.53, p = 0.000
A little –0.0739*** (0.025)
Quite a bit –0.1299*** (0.036)
Very much –0.2585*** (0.048)
Stay in bed/chair Not at all (base) –0.6943*** (0.392)
A little
Quite a bit
Very much
Need help eating/
dressing
Not at all (base) F2
3
 = 44.11, p = 0.000
A little –0.0315 (0.026)
Quite a bit –0.1194*** (0.033)
Very much –0.1833*** (0.043)
Role Limited work Not at all (base) –0.7200* (0.380) F2
3
 = 22.28, p = 0.000
A little –0.0315 (0.026)
Quite a bit –0.1194*** (0.033)
Very much –0.1833*** (0.043)
Depressed Not at all (base) –1.5256*** (0.374) F2
3
 = 19.04, p = 0.000
A little –0.0671*** (0.022)
Quite a bit –0.0928*** (0.032)
Very much –0.1750*** (0.050)
Interfered social 
activities
Not at all (base) –1.0215*** (0.380)
A little
Quite a bit
Very much
Pain Pain Not at all (base) –1.9394*** (0.333) F2
3
 = 63.60, p = 0.000
A little –0.0429 (0.029)
Quite a bit –0.1405*** (0.034)
Very much –0.2933*** (0.042)
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TABLE 53 European Organization for Research and Treatment Quality-of-Life Questionnaire Core 30 TPM  
best-fitting model (continued )
TPM model 8 part 1 TPM model 8 part 2
Domain Item Item level Regression coefficient (SE) Regression coefficient (SE)
Sleep 
disturbance
Trouble sleeping Not at all (base) F2
3
 = 10.98, p = 0.0012
A little –0.0545** (0.023)
Quite a bit –0.0628** (0.029)
Very much –0.1082*** (0.038)
Appetite loss Lacked appetite Not at all (base) F2
3
 = 9.36, p = 0.025
A little 0.0089 (0.023)
Quite a bit –0.0812*** (0.031)
Very much –0.0285 (0.043)
Age (years) –0.0549*** (0.014)
Constant 4.8139*** (0.992) 0.9625*** (0.031)
Observations 771 685
Log-likelihood –160.14 217.86
Pseudo R2 0.406
Sigma 0.217
MAE 0.140
AIC 336 –389
BIC 373 –283
  * Statistically significant at the 10% level.
 ** Statistically significant at the 5% level.
*** Statistically significant at the 1% level.
FIGURE 14 Summary of performance of all TPM models.
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TABLE 54 European Organization for Research and Treatment Quality-of-Life Questionnaire Core 30 mean 
observed and predicted EQ-5D values per model and summary model performance: splining
Summary statistics and model performance tests n Observed values
SPL model 3
Significant dimensions
Mean 
(SD)
771 0.5793 (0.3423) 0.5793 (0.2833)
Median 0.6910 0.6457
Range –0.5940 to 1 –0.3718 to 0.9438
R2 0.685
AIC –343
BIC –310
MAE 0.143
Shrinkage 0.997
Ramsey RESET F
3,761
 = 1.17, p = 0.321
Health status (EORTC QLQ-C30 item 29) n Mean Mean MAE
1 (very poor) 42 –0.0057 0.0660 0.245
2 53 0.1763 0.3345 0.236
3 144 0.4286 0.5166 0.142
4 226 0.6220 0.5694 0.143
5 186 0.7180 0.7353 0.084
6 94 0.8321 0.8151 0.072
7 (excellent) 26 0.9029 0.8660 0.134
ANOVA F
6
 = 117, p = 0.000
SPL, splining.
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TABLE 55 European Organization for Research and Treatment Quality-of-Life Questionnaire Core 30 best-fitting 
OLS dimension model with splines
Domain
SPL model 3
Regression coefficient (SE)
Physical functioning 1 0.1197*** (0.013)
Physical functioning 2 0.0528*** (0.007)
Role functioning 0.0012*** (0.000)
Emotional functioning 0.0020*** (0.000)
Pain –0.0035*** (0.000)
Sleep disturbance –0.0007** (0.000)
Constant 0.5339*** (0.044)
Observations 771
Pseudo R2 0.685
SPL, splining.
 ** Statistically significant at the 5% level.
*** Statistically significant at the 1% level.
FIGURE 15 Summary of performance of splining model. SPL, splining.
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TABLE 56 European Organization for Research and Treatment Quality-of-life Questionnaire Core 30 mean observed and predicted EQ-5D values per model and summary 
model performance: response mapping
Summary statistics and 
model performance 
tests n Observed values
Response mapping 2 Response mapping 3 Response mapping 4 Response mapping 6 Response mapping 8
All dimensions Significant dimensions
Significant and 
squared terms
Significant collapsed 
items
Significant collapsed  
items + age/gender
Mean (SD) 0.5793 (0.3423) 0.5726 
(0.2913)
0.5715 
(0.2891)
0.5724 
(0.2883)
0.5363 
(0.2734)
0.5726 
(0.2914)
Median 0.6910 0.6605 0.6552 0.6518 0.6066 0.6569
Range –0.5940–1 –0.3420–
0.9405
–0.3371–
0.9406
–0.3846–
0.9516
–0.1170–
0.9332
–0.3376–
0.9416
MAE 0.134 0.138 0.138 0.192 0.134
Shrinkage 1.065 0.997 0.998 0.962 1.179
Health status (EORTC 
QLQ-C30 item 29) n Mean Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE
1 (very poor) 42 –0.0057 0.0473 0.183 0.0408 0.196 0.0370 0.201 0.1833 0.291 0.0473 0.181
2 53 0.1763 0.2314 0.162 0.2295 0.177 0.2346 0.176 0.3026 0.241 0.2262 0.159
3 144 0.4286 0.4506 0.181 0.4513 0.183 0.4548 0.182 0.4296 0.239 0.4515 0.182
4 226 0.6220 0.5836 0.139 0.5801 0.144 0.5785 0.144 0.5193 0.187 0.5827 0.139
5 186 0.7180 0.7088 0.097 0.7106 0.102 0.7106 0.104 0.6488 0.162 0.7094 0.097
6 94 0.8321 0.8120 0.102 0.8094 0.099 0.8121 0.097 0.7313 0.149 0.8137 0.100
7 (excellent) 26 0.9029 0.8585 0.077 0.8621 0.075 0.8674 0.068 0.8122 0.097 0.8596 0.075
ANOVA F
6
 = 97, p = 0.000 F
6
 = 114, p = 0.000 F
6
 = 120, p = 0.000 F
6
 = 122, p = 0.000 F
6
 = 57, p = 0.000 F
6
 = 116, p = 0.000
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Appendix 13 Results from mapping from 
Functional Assessment of Cancer Therapy – 
General Scale to EQ-5D
TABLE 57 Spearman’s rank correlation coefficients among the FACT-G summary scales
FACT-G summary scale Physical Social/family Emotional Functional
Physical 1
Social/family 0.185 1
Emotional 0.378 0.321 1
Functional 0.570 0.290 0.442 1
Correlations > |0.5| are highlighted.
TABLE 58 Spearman’s rank correlation coefficients between EQ-5D and FACT-G summary scales and total score
EQ-5D index and dimensions Physical Social/family Emotional Functional Total
EQ-5D 0.566 0.178 0.382 0.501 0.575
eq1 –0.383 –0.083 –0.172 –0.341 –0.353
eq2 –0.323 –0.085 –0.118 –0.303 –0.300
eq3 –0.504 –0.128 –0.214 –0.504 –0.487
eq4 –0.460 –0.116 –0.227 –0.304 –0.396
eq5 –0.309 –0.245 –0.560 –0.349 –0.493
n3 –0.310 –0.067 –0.198 –0.297 –0.310
Correlations > |0.5| are highlighted.
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TABLE 59 Summary of observed and predicted values per model: OLS
Summary 
statistics 
and model 
performance 
tests
Observed 
values
OLS model 1 OLS model 2 OLS model 3 OLS model 4 OLS model 5 OLS model 6 OLS model 7
Total score Domain scores
OLS significant 
domains
OLS significant 
domains and 
squared terms
OLS significant 
domains, squared 
and interaction 
terms
OLS item levels: 
significant levels 
only
OLS item levels: 
significant levels 
only, collapse 
unordered items
Mean (SD) 0.721 (0.223) 0.721 (0.128) 0.721 (0.138) 0.721 (0.138) 0.721 (0.144) 0.721 (0.146) 0.721 (0.163) 0.721 (0.161)
Median 0.735 0.730 0.735 0.735 0.738 0.744 0.755 0.750
Range –0.135–1 0.319–0.975 0.357–0.971 0.357–0.972 0.198–0.981 0.161–0.946 0.115–0.962 0.169–0.961
R2 0.331 0.383 0.383 0.417 0.432 0.535 0.524
Adjusted R2 0.330 0.378 0.379 0.413 0.425 0.513 0.507
AIC –298.40 –335.20 –337.12 –365.34 –374.98 –445.43 –443.38
BIC –289.86 –313.84 –320.11 –343.97 –345.07 –338.60 –357.92
Ramsey RESET F
3,525
 = 3.19, 
p = 0.024
F
3,522
 = 0.83, 
p = 0.477
F
3,525
=0.84, 
p = 0.471
F
3,524
 = 2.96, 
p = 0.032
F
3,521
 = 2.06, 
p = 0.104
F
3,502
 = 0.72,  
p = 0.539
F
3,507
 = 1.17, 
p = 0.320
MAE 0.129 0.126 0.126 0.124 0.122 0.111 0.112
Shrinkage 1.005 0.992 0.996 0.995 0.991 0.850 0.909
n Mean Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE
ECOG
Normal, no symptoms 122 0.8645 0.8156 0.1113 0.8339 0.0958 0.8339 0.0958 0.8429 0.0966 0.8404 0.0973 0.8464 0.0868 0.8464 0.0870
Some symptoms 256 0.7219 0.7280 0.1220 0.7325 0.1237 0.7325 0.1236 0.7263 0.1227 0.7281 0.1214 0.7318 0.1080 0.7319 0.1087
Require some bed 152 0.6055 0.6344 0.1568 0.6121 0.1540 0.6121 0.1540 0.6154 0.1465 0.6143 0.1451 0.6033 0.1353 0.6032 0.1343
ANOVA F
2,527
 = 55, 
p < 0.001
F
2,527
 = 92,  
p < 0.001
F
2,527
 = 134,  
p < 0.001
F
2,527
 = 135,  
p < 0.001
F
2,527
 = 125,  
p < 0.001
F
2,527
 = 117,  
p < 0.001
F
2,527
 = 107,  
p < 0.001
F
2,527
 = 108,  
p < 0.001
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TABLE 60 Model coefficients for best performing OLS model (model 6)
Domain Item Item level
OLS model 6
Regression coefficient (SE)
Physical Lack of energy Very much (baseline level) F
4,505
 = 3.62, p = 0.007
Quite a bit 0.045 (0.032)
Somewhat 0.036 (0.030)
A little bit 0.071 (0.033)*
Not at all 0.118 (0.033)***
Trouble meeting need of family Very much (baseline level) F
4,505
 = 2.75, p = 0.028
Quite a bit –0.028 (0.056)
Somewhat 0.049 (0.050)
A little bit 0.088 (0.050)*
Not at all 0.098 (0.050)*
Pain Very much (baseline level) F
4,505
 = 29.09, p < 0.001
Quite a bit 0.125 (0.073)*
Somewhat 0.219 (0.069)**
A little bit 0.240 (0.071)**
Not at all 0.342 (0.070)***
Emotional I feel sad Very much (baseline level) F
4,505
 = 2.45, p = 0.045
Quite a bit –0.085 (0.105)
Somewhat –0.019 (0.101)
A little bit –0.006 (0.099)
Not at all –0.004 (0.099)
Losing hope Very much (baseline level) F
4,505
 = 3.68, p = 0.006
Quite a bit –0.081 (0.122)
Somewhat –0.007 (0.079)
A little bit 0.013 (0.076)
Not at all 0.060 (0.075)
Functional Able to work Not at all (baseline level) F
4,505
 = 10.22, p < 0.001
A little bit 0.113 (0.031)***
Somewhat 0.130 (0.028)***
Quite a bit 0.150 (0.028)***
Very much 0.152 (0.030)***
Constant –0.597 (0.0141)***
  * Statistically significant at the 10% level.
 ** Statistically significant at the 5% level.
*** Statistically significant at the 1% level.
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FIGURE 17 Summary of performance of all OLS models.
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TABLE 61 Summary of observed and predicted values per model: tobit models
Summary 
statistics 
and model 
performance 
tests
Observed 
values
Tobit model 1 Tobit model 2 Tobit model 3 Tobit model 4 Tobit model 5 Tobit model 6 Tobit model 8
Total score Domain scores
Significant 
domains
Significant 
domains and 
squared terms
Significant 
domains, 
squared and 
interaction terms
Item levels: 
significant items 
only
Item levels: 
significant 
items only 
and significant 
patient 
characteristics
Mean (SD) 0.721 (0.223) 0.723 (0.133) 0.724 (0.143) 0.724 (0.143) 0.723 (0.147) 0.723 (0.151) 0.723 (0.161) 0.723 (0.159)
Median 0.735 0.743 0.750 0.750 0.736 0.739 0.738 0.735
Range –0.135–1 0.264–0.939 0.322–0.939 0.322–0.939 0.201–0.953 0.191–0.992 0.132–0.957 0.188–0.963
Pseudo R2 0.826 0.976 0.976 1.093 1.178 1.367 1.338
Log-likelihood –23.06 –3.18 –3.18 12.28 23.57 48.71 44.97
AIC 52.12 18.35 16.35 –12.82 –27.14 –61.42 –55.94
BIC 64.93 43.99 37.72 17.09 15.58 15.49 16.70
MAE 0.130 0.127 0.127 0.124 0.122 0.113 0.116
Sigma 0.211 0.202 0.202 0.196 0.192 0.181 0.182
Shrinkage 0.965 0.948 0.952 0.967 0.958 0.962 0.953
n Mean Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE
ECOG
Normal, no symptoms 122 0.8645 0.8167 0.119 0.8345 0.0976 0.8345 0.0976 0.8466 0.0953 0.8494 0.0930 0.8498 0.0878 0.8713 0.0890
Some symptoms 256 0.7219 0.7331 0.1210 0.7385 0.1233 0.7385 0.1233 0.7218 0.1226 0.7271 0.1229 0.7320 0.1108 0.7224 0.1137
Require some bed 152 0.6055 0.6325 0.1598 0.6100 0.1566 0.6100 0.1567 0.6155 0.1479 0.6155 0.1454 0.6074 0.1365 0.6057 0.1409
ANOVA F
2,527
 = 55, 
p < 0.001
F
2,527
 = 87,  
p < 0.001
F
2,527
 = 126,  
p < 0.001
F
2,527
 = 126,  
p < 0.001
F
2,527
 = 122,  
p < 0.001
F
2,527
 = 116,  
p < 0.001
F
2,527
 = 109,  
p < 0.001
F
2,527
 = 146,  
p < 0.001
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TABLE 62 Coefficients for best performing tobit model (model 6)a
Domain Item Item level
Tobit model 6
Regression coefficient (SE)
Physical Lack of energy Very much (baseline level)
Quite a bit 0.055 (0.034)
Somewhat 0.053 (0.033)
A little bit 0.113 (0.037)**
Not at all 0.200 (0.044)***
Pain Very much (baseline level)
Quite a bit 0.164 (0.075)*
Somewhat 0.255 (0.070)***
A little bit 0.293 (0.071)***
Not at all 0.431 (0.072)***
Functional Able to work Not at all (baseline level)
A little bit 0.097 (0.033)**
Somewhat 0.110 (0.031)***
Quite a bit 0.149 (0.032)***
Very much 0.151 (0.036)***
Enjoy life Not at all (baseline level)
A little bit –0.098 (0.092)**
Somewhat –0.012 (0.088)*
Quite a bit –0.010 (0.087)
Very much –0.057 (0.088)
Constant 0.231 (0.115)*
Sigma 0.181 (0.009)
a A Stata programme (do) file is available from the authors on request.
  * Statistically significant at the 10% level.
 ** Statistically significant at the 5% level.
*** Statistically significant at the 1% level.
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FIGURE 18 Summary of performance of all tobit models.
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TABLE 63 Summary of observed and predicted values per model: TPMs
Summary 
statistics 
and model 
performance 
tests
Observed 
values
Model 1 Model 2 Model 3
Total score Domain scores
Two-part significant 
domains
Mean (SD) 0.721 (0.223) 0.744 (0.139) 0.741 (0.150) 0.743 (0.148)
Median 0.735 0.755 0.758 0.760
Range –0.135–1 0.314–0.977 0.350–0.980 0.336–0.975
MAE 0.129 0.125 0.125
Shrinkage 0.922 0.911 0.930
Part 1 Part 2 Part 1 Part 2 Part 1 Part 2
Model goodness 
of fit
F2
153
 = 131, 
p = 0.896
F2
518
 = 826, 
p < 0.001
F2
256
 = 662, 
p < 0.001
F F F F F
Log-likelihood –189 170 –177 184 –179 182
Sigma N/A 0.203 N/A 0.194 N/A 0.195
Pseudo R2 0.234 N/A 0.280 N/A 0.272 N/A
AIC 381 –333 364 –356 364 –356
BIC 390 –321 386 –330 377 –339
n Mean Mean MAE Mean MAE Mean MAE
ECOG
Normal, no 
symptoms
122 0.8645 0.8144 0.1035 0.8265 0.0906 0.8279 0.0895
Some 
symptoms
256 0.7219 0.7444 0.1219 0.7420 0.1249 0.7437 0.1252
Require 
some bed
152 0.6055 0.6857 0.1593 0.6721 0.1534 0.6735 0.1531
ANOVA F
2,527
 = 55,  
p < 0.001
F
2,527
 = 91,  
p < 0.001
F
2,527
 = 135,  
p < 0.001
F
2,527
 = 145,  
p < 0.001
N/A, not applicable. 
a Model 6 would not converge for logistic regression (some levels were dropped owing to having no observations 
reducing the sample size n = 404). This model is not compared with the other models as it is based on a  
different sample.
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Model 4 Model 5 Model 6a Model 7 Model 8
Two-part significant 
domains and 
squared terms
Two-part significant 
domains, squared 
and interaction 
terms
Two-part item levels: 
significant levels 
only
Two-part item 
levels: significant 
levels only, collapse 
unordered items
Two-part significant 
domains, squared 
terms, interaction 
terms and 
significant patient 
characteristics
0.739 (0.154) 0.739 (0.153) 0.791 (0.132) 0.744 (0.149) 0.739 (0.154)
0.753 0.763 0.809 0.735 0.759
0.119–0.993 0.106–0.971 0.321–0.992 0.476–0.987 0.106–0.988
0.120 0.120 0.093 0.122 0.118
0.944 0.946 0.589 0.917 0.953
Part 1 Part 2 Part 1 Part 2 Part 1 Part 2 Part 1 Part 2 Part 1 Part 2
F F F F2
479
 = 451, 
p < 0.001
F2
255
 = 215, 
p = 0.967
F2
348
 = 517, 
p < 0.001
F2
41
 = 56, 
p = 0.058
F2
463
 = 444, 
p = 0.733
–165 200 –170 203 –131 260 –175 188 –160 203
N/A 0.184 N/A 0.182 N/A 0.154 N/A 0.195 N/A 0.182
0.328 N/A 0.307 N/A 0.399 N/A 0.288 N/A 0.350 N/A
343 –389 350 –390 332 –444 364 –360 336 –390
369 –363 367 –355 482 –281 394 –326 370 –310
Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE
0.8302 0.0896 0.8269 0.0907 0.8470 0.0764 0.8313 0.0871 0.8278 0.0876
0.7359 0.1211 0.7374 0.1205 0.7665 0.0919 0.7401 0.1204 0.7375 0.1185
0.6713 0.1410 0.6716 0.1435 0.7028 0.1161 0.6797 0.1513 0.6706 0.1412
F
2,527
 = 122,  
p < 0.001
F
2,527
 = 117,  
p < 0.001
F
2,401
 = 62,  
p < 0.001
F
2,527
 = 112,  
p < 0.001
F
2,527
 = 112,  
p < 0.001
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TABLE 64 Coefficients for modelling to FACT-G domain scores: TPMs
Domains
TPM model 4
Significant summary scores and squared terms (SE)
Part 1 Part 2
Physical –0.458 (0.161)**
Social
Emotional –0.105 (0.022)***
Functional 0.420 (0.178)*
Physical2 0.016 (0.004)*** 0.0005 (0.00007)***
±Emotion 1.540 (0.455)** 0.825 (0.163)***
±Functional –2.76 (1.431)* 0.075 (0.015)***
Constant –2.574 (3.482) –1.369 (0.308)***
Number of observations 530 437
  * Statistically significant at the 10% level.
 ** Statistically significant at the 5% level.
*** Statistically significant at the 1% level.
FIGURE 19 Summary of performance of all TPMs.
– 0.6
– 0.4
– 0.2
0.0
0.2
0.4
0.6
0.8
1.0
– 0.6 – 0.4 – 0.2 0.0 0.2 0.4 0.6 0.8 1.0
EQ-5D mean observed
EQ-5D predicted − model 1
EQ-5D predicted − model 2
EQ-5D predicted − model 3
EQ-5D predicted − model 4
EQ-5D predicted − model 5
EQ-5D predicted − model 6
EQ-5D predicted − model 7
EQ-5D predicted − model 8
EQ-5D mean observedE
Q
-5
D
 m
e
a
n
 p
re
d
ic
te
d
DOI: 10.3310/hta18090 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 9
217
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Longworth et al. under the terms of a commissioning contract issued by the Secretary of State for  
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
TABLE 65 Summary of observed and predicted values per model: splining
Summary statistics and model  
performance tests Observed values
SPL model 1 SPL model 3
Total score Significant domains
Mean (SD) 0.721 (0.223) 0.724 (0.134) 0.723 (0.144)
Median 0.735 0.745 0.736
Range –0.135–1 0.250–0.937 0.312–0.974
Pseudo R2 0.827 1.079
Log-likelihood –23.02 10.45
AIC 54.04 –6.91
BIC 71.13 23.00
MAE 0.130 0.123
Sigma 0.210 0.198
Shrinkage 0.961 0.982
n Mean Mean MAE Mean MAE
ECOG
Normal, no symptoms 122 0.8645 0.8163 0.112 0.8460 0.097
Some symptoms 256 0.7219 0.7334 0.121 0.7277 0.121
Require some bed 152 0.6055 0.6325 0.160 0.6152 0.148
ANOVA F
2,527
 = 55, p < 0.001 F
6,527
 = 87, p < 0.001 F
6,527
 = 130, p < 0.001
SPL, splining.
TABLE 66 Coefficients for modelling to FACT-G significant domain scores
Summary statistics and model performance tests SPL: model 2 (SE)
Physical (0–25) 0.013 (0.002)***
Physical score (> 25) 0.079 (0.016)***
Emotional (0–15) 0.020 (0.005)***
Emotional (> 15) 0.001 (0.004)
Functional 0.010 (0.002)***
Constant –0.006 (0.075)
Number of observations 530
SPL, splining.
*** Statistically significant at the 1% level.
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FIGURE 20 Summary of performance of all splining models.
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TABLE 67 Summary of observed and predicted values per model: response mapping
Summary statistics and model 
performance tests Observed values
Response mapping 1 Response mapping 2 Response mapping 3 Response mapping 4 Response mapping 5
Total score
Significant domain 
scores
Significant domain 
scores, squared and 
square root terms
Significant domain 
scores, squared, 
square root and 
interaction terms
Significant domain 
scores, squared, 
square root, 
interaction terms 
and characteristics
n 530 530 530 530 530 530
Mean (SD) 0.721 (0.223) 0.715 (0.126) 0.720 (0.133) 0.677 (0.122) 0.732 (0.175) 0.762 (0.178)
Median 0.735 0.728 0.737 0.695 0.780 0.817
Range –0.135 to 1 0.223–0.930 0.268–0.934 0.194–0.848 0.214–0.960 0.157–0.975
MAE 0.130 0.125 0.136 0.131 0.138
Shrinkage 1.027 1.019 1.968 1.146 0.981
n Mean Mean MAE Mean MAE Mean MAE Mean MAE Mean MAE
ECOG
Normal, no symptoms 122 0.8645 0.7784 0.1161 0.7933 0.1009 0.7439 0.1273 0.8265 0.0882 0.8509 0.0913
Some symptoms 256 0.7219 0.7160 0.1216 0.7201 0.1219 0.6761 0.1289 0.7336 0.1288 0.7694 0.1355
Require some bed rest 152 0.6055 0.6635 0.1565 0.6601 0.1485 0.6241 0.1539 0.6537 0.1700 0.6798 0.1786
ANOVA F
2,527
 = 55, p < 0.001 F
2,527
 = 87, p < 0.001 F
2,527
 = 120, p < 0.001 F
2,527
 = 112, p < 0.001 F
2,527
 = 127, p < 0.001 F
2,527
 = 251, p < 0.001
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TABLE 68 Model 3: coefficients for FACT-G significant domain scores
Summary statistics 
and model 
performance tests
Mobility Self-care Usual activities Pain Anxiety/depression
Some 
problems
Extreme 
problems
Some 
problems
Extreme 
problems
Some 
problems
Extreme 
problems
Some 
problems
Extreme 
problems
Some 
problems
Extreme 
problems
Physical –0.111  
(0.023)***
N/A –0.100  
(0.024)***
–0.244  
(2.191)
–0.237  
(0.044)***
–0.285  
(0.056)***
–0.206  
(0.030)***
–0.319  
(0.051)***
Emotional N/A –0.331  
(0.036)***
–0.607  
(5.147)
Functional –0.074  
(0.020)***
N/A –0.104  
(0.027)***
–0.307  
(6.663)
–0.124  
(0.030)***
–0.266  
(0.053)***
–0.057  
(0.023)*
0.010  
(0.053)
–0.047  
(0.021)*
–0.197  
(1.465)
Constant 3.089  
(0.418)***
N/A 1.633  
(0.427)***
2.017  
(60.731)
7.737  
(0.895)***
8.239  
(1.210)***
5.499  
(0.574)***
3.510  
(1.045)**
6.773  
(0.660)***
8.839  
(47.729)
Log-likelihood –310.22 –189.70 –338.3 –346.92 –302.08
Pseudo R2 0.132 0.151 0.263 0.191 0.263
AIC 626.44 391.39 688.27 705.84 616.16
BIC 639.26 417.03 713.91 731.48 641.80
  * Statistically significant at the 10% level.
 ** Statistically significant at the 5% level.
*** Statistically significant at the 1% level.
N/A, not applicable as there is no one with extreme problems for mobility.
Values in brackets are the standard errors of regression coefficients.
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FIGURE 21 Mean predicted EQ-5D scores and observed scores.
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Appendix 14 Summary of time trade-off values 
for all health states included in the exploratory 
bolt-on study
Count Mean SD Median Minimum Maximum
EQ-5D
11121 (mild) 76 0.94 0.11 1.00 0.50 1
22222 (moderate) 74 0.71 0.30 0.80 –0.30 1
22233 (severe) 74 0.41 0.40 0.43 –0.80 1
11112 75 0.93 0.14 1.00 0.40 1
11122 75 0.87 0.19 1.00 0.20 1
21232 76 0.52 0.40 0.50 –0.80 1
22323 75 0.46 0.43 0.50 –0.93 1
33232 74 0.11 0.40 0.01 –0.93 1
33333 75 –0.02 0.40 0.00 –0.93 1
EQ-5D + hearing
111211 76 0.94 0.13 1.00 0.40 1
111212 75 0.90 0.18 1.00 0.10 1
111213 75 0.85 0.24 0.98 0.00 1
222221 74 0.80 0.25 0.90 0.00 1
222222 75 0.77 0.27 0.90 –0.30 1
222223 75 0.70 0.30 0.75 –0.05 1
222331 75 0.40 0.44 0.47 –0.98 1
222332 74 0.45 0.44 0.50 –0.98 1
222333 76 0.36 0.41 0.45 –0.98 1
EQ + vision 
111211 74 0.94 0.11 1.00 0.45 1
111212 74 0.90 0.13 0.93 0.47 1
111213 75 0.69 0.28 0.75 0.00 1
222221 75 0.74 0.23 0.75 0.20 1
222222 75 0.76 0.21 0.75 0.20 1
222223 75 0.59 0.29 0.60 0.00 1
222331 75 0.41 0.35 0.46 –0.63 1
222332 76 0.41 0.34 0.43 –0.50 1
222333 75 0.32 0.33 0.35 –0.50 1
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Count Mean SD Median Minimum Maximum
EQ-5D + tiredness
111211 74 0.94 0.14 1.00 0.35 1
111212 73 0.90 0.15 1.00 0.38 1
111213 77 0.82 0.26 0.93 –0.38 1
222221 75 0.79 0.26 0.93 –0.17 1
222222 75 0.74 0.30 0.80 –0.38 1
222223 75 0.72 0.27 0.80 –0.43 1
222331 75 0.45 0.43 0.50 –0.90 1
222332 77 0.45 0.42 0.50 –0.80 1
222333 75 0.34 0.45 0.40 –0.90 1
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